
    <!DOCTYPE html>
    <html>
    <head>
        <title>CSV to HTML Table</title>
        <style>
            table {
                width: 100%;
                border-collapse: collapse;
            }
            table, th, td {
                border: 1px solid black;
            }
            th, td {
                padding: 8px;
                text-align: left;
            }
            th {
                background-color: #f2f2f2;
            }
        </style>
    </head>
    <body>
        <h2>CSV to HTML Table</h2>
        <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>names_of_medicines</th>
      <th>Generic_name</th>
      <th>pregnancy_safety</th>
      <th>sec_title</th>
      <th>main_title</th>
      <th>explanation_medicine</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>amikacin</td>
      <td>Amikin</td>
      <td>D</td>
      <td>Aminoglycosides</td>
      <td>ANTIBIOTICS</td>
      <td>amikacin (Amikin)-[Amp 100mg/2ml, 500mg/2ml] IM IV 15mg/kg/d in 2-3 divided doses up to 7-10d. Total &lt;15mg/kg/d. Individualization is critical because of low therapeutic index. Peak: 20-35µg/ml, trough: &lt;5µg/ml. Neonate: 15mg/kg/d q8h. ¶D. *L2. S.E: Ototoxicity, nephrotoxicity, neuromuscular blockade, respiratory paralysis.</td>
    </tr>
    <tr>
      <td>gentamicin</td>
      <td>Gentamicin-Ika</td>
      <td>D</td>
      <td>Aminoglycosides</td>
      <td>ANTIBIOTICS</td>
      <td>gentamicin (Gentamicin-Ika)-[Amp 80mg] (Isotonic Gentamicin)-[Infusion 100, 300mg/100ml] IM IV 3-6mg/kg/d divided in 1-2 doses up to 7-10d. Individualization is critical because of low therapeutic index. Peak: 4-6μg/ml, trough: &lt;2μg/ml. Alt: 5-7mg/kg 1x/d. Peds: 6-7.5mg/kg/d in 3 divided doses. ¶D. *L2. S.E: Ototoxicity, nephrotoxicity, respiratory paralysis.</td>
    </tr>
    <tr>
      <td>neomycin</td>
      <td>Neomycin</td>
      <td>C</td>
      <td>Aminoglycosides</td>
      <td>ANTIBIOTICS</td>
      <td>neomycin (Neomycin)-[Tab 500mg] PO Surgical prophylaxis: 1G at 1, 2, and 11 PM on day preceding 8 AM surgery. Hepatic encephalopathy: 4-12G/d every 4-6h for 5-6d. Chronic hepatic insufficiency: 4G/d indefinitely. Peds: Diarrhea 50mg/kg/d in 6 divided doses for 2-3d. ¶C. S.E: Nephrotoxicity, ototoxicity, respiratory paralysis</td>
    </tr>
    <tr>
      <td>tobramycin</td>
      <td>Tobi</td>
      <td>C</td>
      <td>Aminoglycosides</td>
      <td>ANTIBIOTICS</td>
      <td>tobramycin (Tobi)-[Inh Soln 300mg/5ml] Neb 30ind0mg 2x/d. Individualization is critical because of low therapeutic index. ¶C. S.E: Ototoxicity, nephrotoxicity, neuromuscular blockade.</td>
    </tr>
    <tr>
      <td>ertapenem</td>
      <td>Invanz</td>
      <td>B</td>
      <td>Carbapenems</td>
      <td>ANTIBIOTICS</td>
      <td>ertapenem (Invanz)-[Amp 1G] IV IM Adult: 1G/d. Peds (3m-12y): 15mg/kg 2x/d. ¶B. S.E: Anaphylaxis, seizure.</td>
    </tr>
    <tr>
      <td>imipenem+cilastatin</td>
      <td>Tienam</td>
      <td>C</td>
      <td>Carbapenems</td>
      <td>ANTIBIOTICS</td>
      <td>imipenem+cilastatin (Tienam)-[Soln 500+500mg] IV 125-500mg (over 30-60min) and 750-1000mg (over 40-60min). Max 4G for 4-7d Peds: 15-25mg/kg/d q6h. Peak 21-58μg/ml. cilastatin prevents renal metabolism of imipenem. ¶C. *L2. S.E: Anaphylaxis, seizure, hypotension, pseudomembranous colitis.</td>
    </tr>
    <tr>
      <td>meropenem</td>
      <td>Meronem</td>
      <td>B</td>
      <td>Carbapenems</td>
      <td>ANTIBIOTICS</td>
      <td>meropenem (Meronem)-[Amp 0.5, 1G] IV 1G 3x/d. CF/Meningitis: 2G 3x/d. Peds (3m-12y): 10-20mg/kg 3x/d. Peds CF/meningitis: 40mg/kg 3x/d. ¶B. *L3. S.E: Anaphylaxis, seizure, hepatic toxicity, pseudomembranous colitis.</td>
    </tr>
    <tr>
      <td>cefadroxil</td>
      <td>Biodroxil</td>
      <td>B</td>
      <td>Cephalosporins – 1st generation</td>
      <td>ANTIBIOTICS</td>
      <td>cefadroxil (Biodroxil)-[Cap 500mg] (Duracef)-[Cap 500mg; Susp 250mg/5ml] PO 0.5-1G 2x/d for 10d. Peds: 30mg/kg/d 2x/d. Peak: 16μg/ml. ¶B. *L1. S.E: Anaphylaxis, pseudomembranous colitis, Stevens-Johnson syndrome, serum sickness.</td>
    </tr>
    <tr>
      <td>cefazolin</td>
      <td>Cefamezin, Kefazin, Kefzol, Totacef</td>
      <td>B</td>
      <td>Cephalosporins – 1st generation</td>
      <td>ANTIBIOTICS</td>
      <td>cefazolin (Cefamezin, Kefazin, Kefzol, Totacef)-[Amp 1G] IM IV 2-6G/d 2-4x/d for 4-7d. Peds: 25-100mg/kg/d in 3-4 divided doses. ¶B. *L1. S.E: Anaphylaxis, pseudomembranous colitis, Stevens-Johnson syndrome, hypotension.</td>
    </tr>
    <tr>
      <td>cefaclor</td>
      <td>Ceclor, Cefalor</td>
      <td>B</td>
      <td>Cephalosporins – 2nd generation</td>
      <td>ANTIBIOTICS</td>
      <td>cefaclor (Ceclor, Cefalor)-[Cap 250, 500mg; Susp 125, 250mg/5ml) (Cefaclor-Teva)-[Susp 250mg/5ml] PO 250-500mg 3x/d for 7-10d. Peds: 20-40mg/kg/d in 3 divided doses. Max 4G/d. ¶B. *L1. S.E: Pseudomembranous colitis, eosinophilia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>cefonicid</td>
      <td>Cefonicid-Teva</td>
      <td>B</td>
      <td>Cephalosporins – 2nd generation</td>
      <td>ANTIBIOTICS</td>
      <td>cefonicid (Cefonicid-Teva)-[Amp 1G] IM IV 1-2G/d. Surgical prophylaxis: 1hr prior. ¶B. S.E: Pseudomembranous colitis, eosinophilia, leukopenia, AKI, hypersensitivity.</td>
    </tr>
    <tr>
      <td>cefuroxime</td>
      <td>Cefuroxime-Teva</td>
      <td>B</td>
      <td>Cephalosporins – 2nd generation</td>
      <td>ANTIBIOTICS</td>
      <td>cefuroxime (Cefuroxime-Teva)-[Pwdr for IV 1500, 750mg] (Zinacef, Kefurim, Pan-Cefuroxime)-[Amp 0.75G] (Zinnat)-[Tab 125, 250, 500mg; Susp 125, 250mg/5ml] PO 125-500mg 2x/d for 7-10d. IM IV 750-1.5mg 3x/d. Max 6G. Peds: 50-100mg/kg/d in 3-4 divided dose 5-10d. ¶B. *L2. S.E: Anaphylaxis, pseudomembranous colitis, Stevens-Johnson syndrome, hypotension, disulfiram-like reaction with alcohol ingestion and block synthesis of vitamin K-dependent coagulation factors.</td>
    </tr>
    <tr>
      <td>cefixime</td>
      <td>Supran</td>
      <td>B</td>
      <td>Cephalosporins – 3rd generation</td>
      <td>ANTIBIOTICS</td>
      <td>cefixime (Supran)-[Cap 200, 400mg; Susp 100mg/5ml] PO 400mg/d 1x/d or 200mg 2x/d. Peds 8mg/kg/d or 4mg/kg/d 2x/d. ¶B. *L2. S.E: Anaphylaxis, pseudomembranous colitis, reduced prothrombin activity, AKI.</td>
    </tr>
    <tr>
      <td>cefotaxime</td>
      <td>Claforan, Kefotam</td>
      <td>B</td>
      <td>Cephalosporins – 3rd generation</td>
      <td>ANTIBIOTICS</td>
      <td>cefotaxime (Claforan, Kefotam)-[Amp 1G] IM IV 0.5-8G/d in 2-4 divided dose. Max 12G/d. ¶B. *L2. S.E: Pseudomembranous colitis, anaphylaxis, neutropenia, leukopenia.</td>
    </tr>
    <tr>
      <td>ceftazidime</td>
      <td>Fortrum, Ceftazide, Ceftazidime-Teva, Septax</td>
      <td>B</td>
      <td>Cephalosporins – 3rd generation</td>
      <td>ANTIBIOTICS</td>
      <td>ceftazidime (Fortrum, Ceftazide, Ceftazidime-Teva, Septax)-[Amp 1, 2G] IV 1-6G/d. Peds: 30-50mg/kg/d. Max 6G/d. ¶B. *L1. S.E: Eosinophilia, thrombocytosis, leukopenia, phlebitis.</td>
    </tr>
    <tr>
      <td>ceftriaxone</td>
      <td>Ceftriaxone</td>
      <td>B</td>
      <td>Cephalosporins – 3rd generation</td>
      <td>ANTIBIOTICS</td>
      <td>ceftriaxone (Ceftriaxone)-[Amp 1193mg] (Pan-Ceftriaxone)-[Pwdr for Inj 1G] IM IV 1-4G/d. ¶B. *L1. S.E: Cholestatic hepatitis, AKI, eosinophilia, thrombocytopenia, leukopenia, neutropenia.</td>
    </tr>
    <tr>
      <td>ceftaroline fosamil</td>
      <td>Zinforo</td>
      <td>B</td>
      <td>Cephalosporins – 5th generation</td>
      <td>ANTIBIOTICS</td>
      <td>ceftaroline fosamil (Zinforo)-[Pwdr 600mg] IV 600mg every 12hr administered over 5-60min. 2-18yrs: ≤ 33 kg: 12mg/kg every 8hr. &gt; 33 kg: 400mg every 8hr or 600mg every 12hr. &lt;2yrs: 8mg/kg every 8hr. ¶B. *L3. S.E: Diarrhea, nausea, rash, vomiting, pyrexia.</td>
    </tr>
    <tr>
      <td>ciprofloxacin</td>
      <td>Ciprodex</td>
      <td>C</td>
      <td>Fluoroquinolones</td>
      <td>ANTIBIOTICS</td>
      <td>ciprofloxacin (Ciprodex)-[Tab 0.25, 0.5, 0.75G] (Ciprofloxacin-Teva)-[Tab 0.25, 0.5, 0.75G; Soln 2mg/ml] (Giroflox)-[Soln 200mg/100ml] PO 0.25G 2x/d. Severe: 0.5-0.75G/d. IV 100mg 2x/d. Severe: 200-400mg 2x/d. Gonorrhea: 100mg 1x/d. CF: 20mg/kg 2x/d. Max 1.5G. ¶C. *L3. S.E: Tendinopathy, eosinophilia. Avoid in patients with myasthenia gravis, increased ICP, prolongation of QT Interval.</td>
    </tr>
    <tr>
      <td>levofloxacin</td>
      <td>Levofloxacin-Teva, Tavanic, Tavanic IV</td>
      <td>C</td>
      <td>Fluoroquinolones</td>
      <td>ANTIBIOTICS</td>
      <td>levofloxacin (Levofloxacin-Teva, Tavanic, Tavanic IV)-[FC Tab 500mg; Soln 5mg/ml] (Levo)-[Tab 500mg] PO 250-750mg/d. IV 250-750mg 1-2x/d. Slow IV. ¶C. *L3. S.E: Cartilage damage, tendon rupture, peripheral neuropathy, increased ICP, seizure, hypersensitivity.</td>
    </tr>
    <tr>
      <td>moxifloxacin</td>
      <td>Megaxin</td>
      <td>C</td>
      <td>Fluoroquinolones</td>
      <td>ANTIBIOTICS</td>
      <td>moxifloxacin (Megaxin)-[Tab 0.4G; Amp 400mg/250ml] PO IV 0.4G/d for 5-14d. ¶C. *L3. S.E: Cartilage damage, tendon rupture, peripheral neuropathy, increased ICP, seizure, severe hypersensitivity.</td>
    </tr>
    <tr>
      <td>ofloxacin</td>
      <td>Oflodex, Ofloxacin-Teva</td>
      <td>C</td>
      <td>Fluoroquinolones</td>
      <td>ANTIBIOTICS</td>
      <td>ofloxacin (Oflodex, Ofloxacin-Teva)-[Tab 200mg] (Tarivid)-[Tab 200mg; Amp 2mg/ml] (Ofloxacina)-[Amp 2mg/ml] PO 200-750mg 1-2x/d (simple UTI 3d). IV 200-400mg 2x/d. ¶C. *L2. S.E: Cartilage damage, tendon rupture, peripheral neuropathy, increased ICP, seizure, hypersensitivity.</td>
    </tr>
    <tr>
      <td>azithromycin</td>
      <td>Azenil</td>
      <td>B</td>
      <td>Macrolides</td>
      <td>ANTIBIOTICS</td>
      <td>azithromycin (Azenil)-[Cap 250mg; Susp 200mg/5ml] (Azithromycin-Teva)-[Amp 200mg/5ml] (Zeto 250)-[Tab 250mg] (Zitromax)-[Amp 524.1mg] (Zmax)-[Susp 2.096G] PO 1G 1-3d or 0.5G on 1st day, then 0.25G/d for 4d. IV 500mg 1x/d for at least 2d. STD: 1G single dose. Peds: 10mg/kg on 1st day, then 5mg/kg for 2-5d. ¶B. *L2. S.E: Pseudomembranous colitis, hypersensitivity, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>clarithromycin</td>
      <td>Karin</td>
      <td>C</td>
      <td>Macrolides</td>
      <td>ANTIBIOTICS</td>
      <td>clarithromycin (Karin)-[Tab 250, 500mg] (Klacid)-[FC Tab 500mg; Susp 125mg/5ml] (Klaridex)-[Cap 250mg] PO 250-500mg 2-3x/d for 7-14d. Peds: 15mg/kg/d in 2 divided doses for 10d. ¶C. *L1. S.E: Hepatotoxicity, hypersensitivity, arrhythmia, leukopenia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>erythromycin base</td>
      <td>Eryc</td>
      <td>B</td>
      <td>Macrolides</td>
      <td>ANTIBIOTICS</td>
      <td>erythromycin base (Eryc)-[EC Cap 250mg] PO 250mg 4x/d or 500mg 2x/d. Max 4G/d. Before meal. IV 1-4G/d in divided doses. ¶B. *L2. S.E: Acute cholestatic hepatitis, ototoxicity.</td>
    </tr>
    <tr>
      <td>erythromycin lactobionate</td>
      <td>Erythrocin Lactobionate</td>
      <td>B</td>
      <td>Macrolides</td>
      <td>ANTIBIOTICS</td>
      <td>erythromycin lactobionate (Erythrocin Lactobionate)-[Amp 1G] (Erythromycin Merck)-[Amp 1G] IV 15-20mg/kg/d or 2G/d. Up to 4G. Peds: 30-40mg/kg/d. ¶B. *L3. S.E: Eosinophilia, arrhythmia, deafness, pancreatitis, hepatobiliary disorders, anaphylaxis, seizures, interstitial nephritis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, hypotension.</td>
    </tr>
    <tr>
      <td>erythromycin stearate</td>
      <td>Erythro-Teva, Erythro-Teva</td>
      <td>B</td>
      <td>Macrolides</td>
      <td>ANTIBIOTICS</td>
      <td>erythromycin stearate (Erythro-Teva, Erythro-Teva)-[Tab 250, 500mg] PO 250mg 4x/d. Max 4G/d. Peds: 30-50mg/kg/d in divided dose. ¶B. S.E: Eosinophilia, arrhythmia, deafness, pancreatitis, hepatobiliary disorders, interstitial nephritis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, hypotension.</td>
    </tr>
    <tr>
      <td>erythromycin+sulfisoxasole</td>
      <td>Pediazole</td>
      <td>C</td>
      <td>Macrolides</td>
      <td>ANTIBIOTICS</td>
      <td>erythromycin+sulfisoxasole (Pediazole)-[Susp 200+600mg/5ml] Not prescribed for adults. PO 50mg/kg/d in 3-4 divided dose for 10d. ¶C. S.E: Severe stomach pain, deafness.</td>
    </tr>
    <tr>
      <td>roxithromycin</td>
      <td>Roxo 150, Rulid 150</td>
      <td>B</td>
      <td>Macrolides</td>
      <td>ANTIBIOTICS</td>
      <td>roxithromycin (Roxo 150, Rulid 150) -[Tab 150mg] PO 150mg 2x/d. Peds: 12-23kg: 50mg 2x/d. 24-40kg: 100mg 2x/d. ¶B. S.E: QT prolongation, myasthenia, severe bullous skin reactions.</td>
    </tr>
    <tr>
      <td>spiramycin</td>
      <td>Rovamycin</td>
      <td>C</td>
      <td>Macrolides</td>
      <td>ANTIBIOTICS</td>
      <td>spiramycin (Rovamycin)-[Tab 1.5MU; Syrp 0.375MU/5ml; Amp 1.5MU] PO 3Tab 2x/d 1st day then 2Tab 2x/d. Peds: 0.75-1.125MU 2-3x/d. IV 1.5-3.0MU 3x/d or 4.5MU/d slow continuous. ¶C. S.E: Hypersensitivity, cholestatic hepatitis.</td>
    </tr>
    <tr>
      <td>amoxicillin</td>
      <td>Moxypen, Moxyvit</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>amoxicillin (Moxypen, Moxyvit)-[Cap 250, 500mg; Susp 250mg/5ml] PO 250-1000mg 3x/d. Peds: 25-45mg/kg/d in 3 divided doses. ¶B. *L1. S.E: Seizures, pseudomembranous enterocolitis, eosinophilia, hemolytic anemia, neuropathy, interstitial nephritis, anaphylaxis.</td>
    </tr>
    <tr>
      <td>amoxicillin+clavulanic acid</td>
      <td>Amoxiclav-Teva</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>amoxicillin+clavulanic acid (Amoxiclav-Teva)-[Tab 875+125mg] (Augmentin)-[Tab 250+125mg, 500+125mg; Susp 125+31.25mg/5ml, 250+62.5mg/5ml, 400+57mg/5ml, 600+42.9mg/5ml; Amp 500+100mg, 1000+200mg] (Augmentin 875)-[Tab 875+125mg] (Maclivan)-[Tab 500+125mg; Susp 250+62.5mg/5ml, 400+57mg/5ml] (Claventin)-[Susp 250+62.5mg/5ml] (Clavenir)-[Amp 1000+200mg/vial] PO 250-500mg 3x/d or 875mg 2x/d. Peds: 30mg/kg/d in 2 divided dose. IV 1G 2-4x/d. Peds: 25mg/kg 2-4x/d. ¶B. *L1. S.E: Seizures, pseudomembranous enterocolitis, eosinophilia, hemolytic anemia, neuropathy, interstitial nephritis, anaphylaxis.</td>
    </tr>
    <tr>
      <td>ampicillin</td>
      <td>Ampisulvenir</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>ampicillin (Ampisulvenir)-[Amp 1500, 3000mg] (Penibrin)-[Amp 500, 1000, 2000mg] IV 1000-2000mg 4x/d for 7-10d. Peds: 50mg/kg/d q6h. ¶B. *L1. S.E: Hypersensitivity.</td>
    </tr>
    <tr>
      <td>ampicillin+sulbactam</td>
      <td>Unasyn</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>ampicillin+sulbactam (Unasyn)-[Amp 500+250, 1000+500, 2000+1000mg] IV 1500-3000mg/d in 4 divided doses for 7-10d. Peds: 100-300mg/kg/d in 4 divided doses for 7-10d. ¶B. *L1. S.E: Hypersensitivity, thrombophlebitis.</td>
    </tr>
    <tr>
      <td>cloxacillin</td>
      <td>Orbenil</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>cloxacillin (Orbenil)-[Amp 500, 2000mg] IV 250-500mg 4x/d for 7-10d. Max 6G/d. Peds: IV 50-100mg/kg/d in 4 divided doses. ¶B. *L2. S.E: Hypersensitivity, cholestatic hepatitis, neutropenia, leukopenia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>penicillin G benzathine</td>
      <td>Durabiotic</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>penicillin G benzathine (Durabiotic)-[Amp 1.2MU/vial]. IM Strep: 1.2MU single dose. Peds: 0.3-0.6MU single dose. Prophylaxis of Rheumatic Fever and Glomerulonephritis: 1.2MU/month. ¶B. *L1. S.E: Seizures, eosinophilia, hemolytic anemia, neuropathy, interstitial nephritis, anaphylaxis.</td>
    </tr>
    <tr>
      <td>penicillin G sodium</td>
      <td>Penicillin G</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>penicillin G sodium (Penicillin G)-[Amp 5, 10MU/vial]. IV Strep, pneumoc, staph: 5-24MU q6h for 7-10d. Meningococcal Meningitis/Septicemia: 1-2MU q2h x24. ¶B. *L1. S.E: Seizures, eosinophilia, hemolytic anemia, neuropathy, interstitial nephritis, anaphylaxis.</td>
    </tr>
    <tr>
      <td>phenoxymethylpenicillin, penicillin V</td>
      <td>Rafa-Pen VK</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>phenoxymethylpenicillin, penicillin V (Rafa-Pen VK)-[Syrp 250mg/5ml] PO Strep, staph, pneumoc: 250-500mg q6h for 7-10 days. Peds: 50-75mg/kg/d q6-8h. ¶B. S.E: Seizures, eosinophilia, hemolytic anemia, neuropathy, interstitial nephritis, anaphylaxis.</td>
    </tr>
    <tr>
      <td>piperacillin</td>
      <td>Pipracin</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>piperacillin (Pipracin)-[Amp 4G] IM IV 2-3G q6-12h or 3-4G q4-6h. Gonorrhea: IM 2G single dose. ¶B. *L2. S.E: Anaphylaxis.</td>
    </tr>
    <tr>
      <td>piperacillin+tazobactam</td>
      <td>Fresenius, Piperacillin/Tazobactam-Panpharma</td>
      <td>B</td>
      <td>Penicillins</td>
      <td>ANTIBIOTICS</td>
      <td>piperacillin+tazobactam (Fresenius, Piperacillin/Tazobactam-Panpharma)-[Amp 2000+250, 4000+500mg/vial] (Tazocillin, Tazocin, Tazopip, Tazo-pip Avenir, Tazorex)-[Amp 4000+500mg/vial] IM IV 2.5-4.5G q6h for 7-10d. ¶B. *L2. S.E: Hypersensitivity.</td>
    </tr>
    <tr>
      <td>sulfamethoxazole+trimethoprim</td>
      <td>Resprim</td>
      <td>C</td>
      <td>Sulfonamides</td>
      <td>ANTIBIOTICS</td>
      <td>sulfamethoxazole+trimethoprim (Resprim)-[Susp 200+40mg/5ml] (Septrin)-[Amp 400+80mg/5ml] (Diseptyl)-[Susp 0.8%, 4%] (Diseptyl forte)-[Cap 800+160mg] PO 240-960mg q12h. Peds: 48mg/kg q12h. Pneumocystis treatment: 120mg/kg. Prophylaxis: 240mg/d. ¶C. *L3. S.E: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, blood dyscrasia.</td>
    </tr>
    <tr>
      <td>doxycycline</td>
      <td>Doxy 100, Doxylin 100</td>
      <td>D</td>
      <td>Tetracyclines</td>
      <td>ANTIBIOTICS</td>
      <td>doxycycline (Doxy 100, Doxylin 100)-[Cap 100mg]  PO 200mg initial dose and 100mg maintenance q12h. Peds: Not recommended (Tooth discoloration enamel hypoplasia). ¶D. *L3. S.E: Nephrotoxicity, hypersensitivity, thrombocytopenia, ICP.</td>
    </tr>
    <tr>
      <td>minocycline</td>
      <td>Arestin</td>
      <td>D</td>
      <td>Tetracyclines</td>
      <td>ANTIBIOTICS</td>
      <td>minocycline (Arestin)-[Pwdr sublingual 1mg] (Minoclin, Minocycline)-[Cap 50, 100mg] PO 200mg followed by 100mg q12h. Peds: Not recommended (Tooth discoloration, enamel hypoplasia). ¶D. *L3(acute use) L4(chronic use) S.E: Convulsions, eosinophilic pneumonia, hypersensitivity, lupus like reactions, pancytopenia, rhabdomyolysis, papillary thyroid cancer.</td>
    </tr>
    <tr>
      <td>aztreonam</td>
      <td>Cayston</td>
      <td>B</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>aztreonam (Cayston)-[Pwdr for inhalation 75mg/vial]. CF: 75mg 3x/d (4hr apart) for 28 days, Peds: as adults. ¶B. *L2. S.E: Bronchospasm.</td>
    </tr>
    <tr>
      <td>chloramphenicol</td>
      <td>Phenicol</td>
      <td>C</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>chloramphenicol (Phenicol)-[Eye Drops 0.55%] (Phenimixin)-[Eye Drops 0.2%] (Synthomycine)-[Ophthalmic Cream 3% ,5%] (Tarocidin D)-[Eye Drops 2mg/ml] (Threolone)-[Oint 3%]. Apply 3-4x/d for few days. ¶C. *L4. S.E: Bone marrow hypoplasia.</td>
    </tr>
    <tr>
      <td>clindamycin phosphate</td>
      <td>Clindamycin</td>
      <td>B</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>clindamycin phosphate (Clindamycin)-[Amp 150mg/ml] (Dalacin)- [Vaginal Cream 2%; Ovul 100mg] (Dalacin C)-[Cap 150, 300mg] (Dalagis T Lotion)-[Lot 1%] (Duac)-[Gel 1%] (Zindaclin)-[Gel 1%] PO 150-450mg 4x/d. IM IV 600-2700mg/d in 2-4 divided dose (not to exceed 4.8G/d). Topical: apply 2x/d. Ovul: 1x/d for 3d. Peds: 9-40mg/kg/d 3-4x/d. ¶B. *L2. S.E: Cardiac arrest, neutropenia, thrombocytopenia, renal insufficiency.</td>
    </tr>
    <tr>
      <td>colistimethate</td>
      <td>Coliracin</td>
      <td>C</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>colistimethate (Coliracin)-[Pwdr for Inj 1MU/vial] IV IM 2.5-5mg/kg/d in 2-4 divided dose. Peds: as adults. ¶C. S.E: Neurotoxicity, nephrotoxicity, apnea, pulmonary toxicity.</td>
    </tr>
    <tr>
      <td>fosfomycin</td>
      <td>Monurol</td>
      <td>B</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>fosfomycin (Monurol)-[Pwdr 3G] PO UTI: 3G once with 90-120ml water. Repeat every 2-3d up to 3 doses. Prostatitis: 3G every 3d for 21d. ¶B. *L3. S.E: Anaphylaxis, aplastic anemia, deafness, hepatic necrosis.</td>
    </tr>
    <tr>
      <td>fusidate</td>
      <td>Fucidin lEO</td>
      <td>C</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>fusidate (Fucidin lEO)-[Tab 250mg] (Fucidin Ointment)-[Oint 2%] Topical 3-4x/d for 2wks. PO 2x/d. Peds: 50mg/kg/d divided in 3 doses. ¶C (for Tab). S.E: Myopathy, renal failure, arrhythmias, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>linezolid</td>
      <td>Zyvoxid</td>
      <td>C</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>linezolid (Zyvoxid)-[Tab-600mg; Soln 2mg/ml] PO IV 600mg 2x/d for 10-14d. Peds: &lt;11yr 10mg/kg (Max 600mg/dose) 3x/d. &gt;12yr as adult dosing. ¶C. S.E: Pancytopenia.</td>
    </tr>
    <tr>
      <td>metronidazole</td>
      <td>Flagyl, Flagyl Injectable</td>
      <td>B</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>metronidazole (Flagyl, Flagyl Injectable)-[Tab 250mg; Susp 2.5%, 40mg/ml] (Metrogyl)-[Tab 250mg] (Metronidazole)-[Soln 500mg/100ml] (Noritate)-[Cream 1%] (Rozex)-[Gel 0.75%] (Zidoval)-[Gel 0.75%] Anaerobic infections: PO 750mg 3x/d IV 500mg 4x/d (Peds 30mg/kg/d). Pelvic inflammatory disease: PO 500mg 2x/d 2wks. Trichomoniasis: PO 250mg 3x/d for 7d (Peds 15mg/kg/d). Amebiasis: PO 500-750mg 3x/d for 5-10d (Peds 35-50mg/kg/d). Topical Apply a thin layer 1-2x/d. ¶B. *L2. S.E: Aseptic meningitis, peripheral neuropathy, leukopenia, thrombocytopenia, optic neuropathy.</td>
    </tr>
    <tr>
      <td>nitrofurantoin</td>
      <td>NaN</td>
      <td>B</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>nitrofurantoin ((29 ג' (Apo-Nitrofurantion, Macrodantin)-[Tab 100mg] PO UTI: 50-100mg 4x/d for 7d and for 3d after urine is sterile. UTI prophylaxis: 50-100mg 1x/d at bedtime. Peds-UTI: &gt;1month 5-7mg/kg/d divided q6h. &gt;12yrs as adult. Peds-UTI-prophylaxis: &gt;1month 1-2mg/kg/day divided 1-2x/d. ¶B. *L2. S.E: ECG changes, pseudomembranous colitis, pancreatitis, anemia, leukopenia, hepatic necrosis, pulmonary fibrosis.</td>
    </tr>
    <tr>
      <td>rifampicin</td>
      <td>NaN</td>
      <td>C</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>rifampicin (29 ג') (Rifadin)-[Cap 150, 300mg; Syrp 100mg/5ml; Inj 600mg] (Eremafat)-[Cap 150 ,300mg; Inj 600ml] PO IV Tuberculosis: 10mg/kg/d 1x/d for 4 months. Max 600mg/d (Peds 10-20mg/kg/d 1x/d for 6 months). H.influenza prophylaxis: 600mg/d for 4d. Meningitis (Pneumoc or Staph): 600mg/d. ¶C. *L2. S.E: Pancreatitis, ataxia, psychosis, adrenal insufficiency, acute renal failure.</td>
    </tr>
    <tr>
      <td>teicoplanin</td>
      <td>Targocid</td>
      <td>B</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>teicoplanin (Targocid)-[Amp 200mg] PO 100-200mg 2x/d, IV Initial: 400-800mg (6-12mg/kg) every 12h for 3-5 doses; maintenance: IV IM 6-12mg/kg 1x/d. Peds: &lt;2months IV 16mg/kg q12h for 3 doses followed by 8mg/kg 1x/d, &gt;2 months IV 10mg/kg q12h for 3 doses followed by 6-10mg/kg 1x/d. ¶B. S.E: Renal insufficiency.</td>
    </tr>
    <tr>
      <td>tinidazole</td>
      <td>Fasigyn, Protocide</td>
      <td>C</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>tinidazole (Fasigyn, Protocide)-[Tab 500mg] PO Amebiasis, intestinal: 2G/d for 3d. Bacterial vaginosis: 2G/d for 2d or 1G/d for 5d. Giardiasis: 2G 1x/d. Trichomoniasis: 2G as a single dose; sexual partners should be treated at the same time. Peds Amebiasis, intestinal: &gt;3 years 50mg/kg/day for 3-5d. Max 2G/d. Peds Giardiasis: &gt;3 years 50mg/kg 1x/d. ¶C. *L3. S.E: Ataxia, leukopenia, neutropenia, bronchospasm.</td>
    </tr>
    <tr>
      <td>vancomycin</td>
      <td>Vancomycin, Vanco-Teva, Vancovir</td>
      <td>B</td>
      <td>Other Antibiotics</td>
      <td>ANTIBIOTICS</td>
      <td>vancomycin (Vancomycin, Vanco-Teva, Vancovir)-[Amp 0.5, 1G] IV 0.5G q6h or 1G q12h (infuse over 1hr, not to exceed 10mg/min). Peds: 10mg/kg 4x/d. ¶B. *L1. S.E: Red Man syndrome, hematuria, ototoxicity.</td>
    </tr>
    <tr>
      <td>acyclovir</td>
      <td>Acyclo-V, Supra-Vir</td>
      <td>B</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>acyclovir (Acyclo-V, Supra-Vir)-[Tab 200, 400mg] (Acyclovenir)-[Cap 250mg] (Zovirax)-[Tab 200, 400, 800mg; Susp 200mg/5ml; Amp 250mg] PO HSV/VZV: 800mg q4h for 7-10d. Prophylaxis: 400mg q12h. IV 10mg/kg infused over 1h q8h. Peds: VZV: 2y and up 20mg/kg q6h for 5d. Children over 40kg: 800mg 4x/d for 5d. ¶B. *L2. S.E: Renal failure (IV administration), encephalopathic changes, purpura / hemolytic uremic syndrome in immunocompromised patients.</td>
    </tr>
    <tr>
      <td>famciclovir</td>
      <td>NaN</td>
      <td>B</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>famciclovir (29 ג') (Famciclovir)-[Tab 125mg] PO Genital HSV: 1000mg 2x/d for 1d. Labial HSV 1500mg for 1d. ¶B. *L2. S.E: Erythema multiforme.</td>
    </tr>
    <tr>
      <td>foscarnet</td>
      <td>Foscavir</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>foscarnet (Foscavir)-[Amp 24mg/ml] IV HSV and CMV: 40-60mg/kg 2-3x/d slow. Maint: 90-120mg/kg/d. ¶C. *L4. S.E: Nephrotoxicity, seizures, electrolyte disturbances, anemia.</td>
    </tr>
    <tr>
      <td>lamivudine</td>
      <td>Zeffix</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>lamivudine (Zeffix)-[Tab 100mg; Susp 5mg/ml] (Lamivudine TEVA)-[Tab 100, 150, 300mg] (Epivir)-[Tab 150, 300mg; Soln 10mg/ml] PO HBV: 100mg 1x/d. ¶C. *L2. S.E: Neutropenia, anemia, pancreatitis, lactic acidosis, hepatomegaly with steatosis, optic neuritis, peripheral neuropathy, hypersensitivity.</td>
    </tr>
    <tr>
      <td>oseltamivir</td>
      <td>Tamiflu</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>oseltamivir (Tamiflu)-[Cap 75mg] PO Influenza: 75mg 2x/d for 5d. Prophylaxis: 75mg 1x/d for at least 10d. ¶C. *L2. S.E: Bronchospasm, respiratory depression.</td>
    </tr>
    <tr>
      <td>ribavirin</td>
      <td>Copegus, Rebetol</td>
      <td>X</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>ribavirin (Copegus, Rebetol)-[Tab/Cap 200mg] PO ≤75kg 400mg AM and 600mg PM. &gt;75kg 600mg AM and 600mg PM. ¶X. *L4. S.E: Bradyarrhythmia, hypotension, pancreatitis, hemolytic anemia, thrombotic thrombocytopenic purpura, hepatotoxicity, bacterial infection.</td>
    </tr>
    <tr>
      <td>valaciclovir</td>
      <td>Valtrex, Valaciclovir TEVA, Valaciclovir MEDITEC, Valaciclovir TRIMA, Valovir</td>
      <td>B</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>valaciclovir (Valtrex, Valaciclovir TEVA, Valaciclovir MEDITEC, Valaciclovir TRIMA, Valovir)-[FC Tab 500mg] PO HZV: 1G 3x/d for 7d. Genital HSV: 1G 2x/d for 7-10d. Labial HSV: 2G 2x/d total. ¶B. *L1. S.E: Renal failure (IV administration), purpura / hemolytic uremic syndrome in immunocompromised patients, encephalopathic changes.</td>
    </tr>
    <tr>
      <td>valganciclovir</td>
      <td>Valcyte</td>
      <td>D</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>valganciclovir (Valcyte)-[Tab 450mg] PO CMV Retinitis: 900mg 1-2x/d for 21d. ¶D. S.E: Pancytopenia, bone marrow aplasia, impairment of fertility, carcinogenesis.</td>
    </tr>
    <tr>
      <td>zanamivir</td>
      <td>Relenza</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>zanamivir (Relenza)-[Inhaler 5mg] Inh Influenza: 2 puffs q12h for 5d. ¶C. *L3. S.E: Bronchospasm, respiratory depression.</td>
    </tr>
    <tr>
      <td>amantadine</td>
      <td>PK-Merz</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>amantadine (PK-Merz)-[Infus 0.2G/500ml] PO 200mg/d. ¶C. *L3. S.E: Neuroleptic malignant syndrome, exacerbation of mental disorder.</td>
    </tr>
    <tr>
      <td>rimantadine</td>
      <td>Flumadine</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>rimantadine (Flumadine)-[Tab 100mg; Syrp 50mg/5ml] PO Influenza: 100mg 2x/d. ¶C. *L3. S.E: Neuroleptic malignant syndrome, exacerbation of mental disorder.</td>
    </tr>
    <tr>
      <td>interferon alpha-2B</td>
      <td>Intron A</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>interferon alpha-2B (Intron A)-[Amp 10MIU, 15MIU/ml] SC IM Hepatitis B: 30-35MIU 1x/wk or 10MIU 3x/wk or 5MIU/d q24h for 16wks. Hepatitis C: 3MIU 3x/wk for 18-24mnth. ¶C. *L2. S.E: Gastric hemorrhage, pancytopenia, autoimmune diseases, psychotic disorder.</td>
    </tr>
    <tr>
      <td>peginterferon alfa-2A</td>
      <td>Pegasys</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>peginterferon alfa-2A (Pegasys)-[Amp/Prefill Syringe 135, 180µg/0.5ml] SC Hepatitis C: 180µg 1x/wk. ¶C. *L3. S.E: Aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.</td>
    </tr>
    <tr>
      <td>palivizumab</td>
      <td>Abbosynagis</td>
      <td>C</td>
      <td>Anti -virals</td>
      <td>ANTIBIOTICS</td>
      <td>palivizumab (Abbosynagis)-[Amp 50, 100mg] IM RSV: 15mg/kg 1x/mnth. During RSV season. ¶C. S.E: Hypersensitivity, coagulation disorders.</td>
    </tr>
    <tr>
      <td>abacavir</td>
      <td>Ziagen</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>abacavir (Ziagen)-[Tab 300mg; Soln 20mg/ml] PO 300mg 2x/d. Peds: PO 14-20kg: 150mg 2x/d. 20-25kg: up to max 450mg/d. ≥25kg: 300mg 2x/d. ¶C. *L3. S.E: Hypersensitivity, severe hepatomegaly with steatosis, fat redistribtution, MI.</td>
    </tr>
    <tr>
      <td>didanosine</td>
      <td>Videx</td>
      <td>B</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>didanosine (Videx)-[EC Tab 125, 200, 250, 400mg; Susp 2gr] PO 400mg 1x/d. &lt;60kg 250mg 1x/d. Peds: 200mg 1x/d. ¶B. *L5. S.E: Pancreatitis, severe hepatomegaly with steatosis, lactic acidosis, peripheral neuropathy, optic neuritis, fat redistribution.</td>
    </tr>
    <tr>
      <td>efavirenz</td>
      <td>Stocrin</td>
      <td>D</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>efavirenz (Stocrin)-[Cap 50,100, 200mg; Tab 600mg] PO &gt;50kg Increase efavirenz dose to 800mg 1x/d. Peds: 3.5-5kg: 100mg 1x/d. 5-7.5kg: 150mg 1x/d. 7.5-15kg: 200mg 1x/d. 15-20kg: 250mg 1x/d. 20-25kg: 300mg 1x/d. 25-32.5kg: 350mg 1x/d. 32.5-40kg: 400mg 1x/d. ≥40kg: 600mg 1x/d. ¶D. *L4. S.E: Psychiatric and nervous system symptoms, fertility risk, hepatotoxicity, fat redistribution.</td>
    </tr>
    <tr>
      <td>efavirenz+emtricitabine+tenofovir disoproxil</td>
      <td>Atripla</td>
      <td>D</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>efavirenz+emtricitabine+tenofovir disoproxil (Atripla)-[Tab 600+200+245mg] PO 1Tab 1x/d taken on an empty stomach, preferably at bedtime. Should not be administered in patients with creatinine clearance &lt;50ml/min. ¶D. *L4. S.E: Dizziness, depression, insomnia, abnormal dreams, and rash.</td>
    </tr>
    <tr>
      <td>ganciclovir</td>
      <td>Cymevene</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>ganciclovir (Cymevene)-[Amp 500mg; Caps 500mg] For CMV: PO 1gr 3x/d or 0.5gr 6x/d with meals. ¶C. *L4. S.E: Agranulocytosis, thrombocytopenia, carcinogenesis, fertility risk.</td>
    </tr>
    <tr>
      <td>indinavir</td>
      <td>Crixivan</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>indinavir (Crixivan)-[Cap 200, 400mg] PO 800mg 3x/d. With water. ¶C. S.E: Nephrolithiasis, hemolytic anemia, hepatitis, hyperglycemia.</td>
    </tr>
    <tr>
      <td>lamivudine</td>
      <td>Epivir</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>lamivudine (Epivir)-[Caps 150mg; Soln 10mg/ml] PO 300mg 1x/d or 150mg 2x/d. Peds: 4mg/kg up to max 150mg 2x/d. ¶C.*L2. S.E: Pancreatitis.</td>
    </tr>
    <tr>
      <td>nelfinavir</td>
      <td>Viracept</td>
      <td>B</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>nelfinavir (Viracept)-[Tab 250, 625mg; Pwdr 50mg/1G scoopful] PO 1250mg 2x/d or 750mg 3x/d with meals. Peds: 45-55mg/kg 2x/d or 25-35mg/kg 3x/d. ¶B. S.E: Pancytopenia, hepatitis, arrhythmia, hyperlipidemia, hyperuricemia, hyperglycemia, hypoglycemia, kidney calculus, immune reconstitution/reactivation syndrome.</td>
    </tr>
    <tr>
      <td>nevirapine</td>
      <td>Viramune</td>
      <td>B</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>nevirapine (Viramune)-[Tab 200mg; Susp 10mg/ml] PO 200mg 1x/d for 14d followed by 200mg 2x/d. Peds: &lt;15d: 150mg/m2 1x/d for 14d, then 2x/d. ¶B. *L3. S.E: Hepatic disorders, Steven-Johnson syndrome, toxic epidermal necrolysis, hypersensitivity.</td>
    </tr>
    <tr>
      <td>ritonavir</td>
      <td>Norvir</td>
      <td>B</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>ritonavir (Norvir)-[Cap, Soft Cap 100mg; Soln 80mg/ml] PO Begin 300mg 2x/d with food. Peds: &lt;1m 400mg/m2 2x/d up to max 600mg 2x/d with food. ¶B. *L3. S.E: Pancreatitis, hypersensitivity, AV block.</td>
    </tr>
    <tr>
      <td>ritonavir+lopinavir</td>
      <td>Kaletra</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>ritonavir+lopinavir (Kaletra)-[Cap 25+100, 50+200mg; Soln 20+80mg/ml] PO 100mg or 5ml 2x/d. Peds: 15-40kg: 2.5+10mg/kg 2x/d. &lt;15kg: 3+12mg/kg 2x/d. ¶C. S.E: Pancreatitis, hepatotoxicity, PR and QT interval prolongation.</td>
    </tr>
    <tr>
      <td>saquinavir</td>
      <td>Invirase</td>
      <td>B</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>saquinavir (Invirase)-[Cap 200mg; Coated Tab 500mg] PO 500mg 2x/d or 200mg 5x/d 2hr after meal. ¶B. S.E: PR and QT interval prolongation, hemophilia, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>stavudine</td>
      <td>Zerit</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>stavudine (Zerit)-[Cap 15, 20, 30, 40mg; Susp 1mg/ml] PO ≥60kg: 40mg 2x/d. &lt;60kg: 30mg 2x/d. Peds:&lt;13d: 0.5mg/kg. &gt;14d: 1mg/kg 2x/d. ¶C. S.E: Hepatotoxicity, neurologic symptoms, pancreatitis.</td>
    </tr>
    <tr>
      <td>trimetrexate</td>
      <td>Trimetrexate</td>
      <td>D</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>trimetrexate (Trimetrexate)-[Amp 25, 200mg] IV P.carinii in AIDS: 45mg/m2 1x/d 21d. With leucoverin 24d. ¶D. S.E: Bone marrow suppression, bronchospasm, hypotension, hyponatremia, hypocalcemia.</td>
    </tr>
    <tr>
      <td>zidovudine</td>
      <td>Retrovir</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>zidovudine (Retrovir)-[Cap 100, 300mg; Syrp 50mg/5ml; Amp 10mg/ml] PO 300mg 2x/d. Peds: 240mg/m2 2x/d or 160mg 3x/d. IV 1mg/kg 6x/d. ¶C. *L3. S.E: Bone marrow suppression, myopathy.</td>
    </tr>
    <tr>
      <td>zidovudine+lamivudine</td>
      <td>Combivir</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>zidovudine+lamivudine (Combivir)-[Tab 300+150mg] PO 1 Tab 2x/d. ¶C. *L3. S.E: Bone marrow suppression, myopathy, pancreatitis.</td>
    </tr>
    <tr>
      <td>zidovudine+lamivudine+abacavir</td>
      <td>Trizivir</td>
      <td>C</td>
      <td>Aids</td>
      <td>ANTIBIOTICS</td>
      <td>zidovudine+lamivudine+abacavir (Trizivir)-[FC Tab 300+150+300mg] PO 1Tab 2x/d. ¶C. S.E: Hypersensitivity, bone marrow suppression, myopathy, MI.</td>
    </tr>
    <tr>
      <td>albendazole</td>
      <td>Eskazole</td>
      <td>C</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>albendazole (Eskazole)-[Tab 400mg] PO Hydatid cyst (echinococcus): 400mg 2x/d for 28d. Peds: 15mg/kg/d in 2 divided dose. ¶C. *L3. S.E: Agranulocytosis, leukopenia, pancytopenia, thrombocytopenia, hepatotoxicity, acute renal failure.</td>
    </tr>
    <tr>
      <td>doxycycline</td>
      <td>Doxybiotic, Doxy100, Doxylin</td>
      <td>D</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>doxycycline (Doxybiotic, Doxy100, Doxylin)-[Tab/Cap 100mg] PO Malaria prophylaxis: 100mg 1-2d before entering area, 100mg/d in area, continue for 4wks after leaving. Do not take with milk. ¶D. *L3. S.E: Bulging fontanelle, discoloration and hypoplasia of teeth and temporary stunting of growth, hepatotoxicity, pseudotumor cerebri.</td>
    </tr>
    <tr>
      <td>hydroxychloroquine</td>
      <td>Plaquenil</td>
      <td>C</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>hydroxychloroquine (Plaquenil)-[Tab 200mg] PO Malaria suppression: 400mg/d. Acute attack: 800mg followed by 400mg/d q6-8h and 400mg on each of two consecutive day. ¶C. *L2. S.E: Psychiatric disorders, nervous system disorders, eye disorders.</td>
    </tr>
    <tr>
      <td>mebendazole</td>
      <td>Vermox</td>
      <td>C</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>mebendazole (Vermox)-[Tab 100mg; Susp 20mg/ml] PO 100mg 2x/d 3d. Enterobiasis: 100mg 1x1d. ¶C. *L3. S.E: Agranulocytosis, pancytopenia, hepatotoxicity, acute renal failure.</td>
    </tr>
    <tr>
      <td>mefloquine</td>
      <td>Lariam</td>
      <td>B</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>mefloquine (Lariam)-[Tab 250mg] PO Malaria treatment: 1250mg single dose. Prophylaxis: 250mg 1wk before entering area, then 250mg/wk until for 4wks after leaving. ¶B. *L2. S.E: Seizure, neuropsychiatric symptoms, cardiac conduction abnormalities.</td>
    </tr>
    <tr>
      <td>metronidazole</td>
      <td>Flagyl</td>
      <td>B</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>metronidazole (Flagyl)-[Tab 250mg; Susp 40mg/ml; Vag Tab 500mg] Amebiasis: 500-750mg/d 3x/d for 5-10d. Peds: 35-50mg/kg/d 3x/d for 10d. Trichomoniasis: PO 2G 1x/d for 1d or 1G 2x/d for 1d or 250mg 3x/d for 7d. Vag tab 1x/d at bedtime for 10-20d. ¶B (do not use 1st trimester). *L3. S.E: Anorexia, cystitis, dysuria, insomnia, leukopenia, thrombocytopenia, ototoxicity, peripheral neuropathy, polyuria, seizures.</td>
    </tr>
    <tr>
      <td>pentamidine</td>
      <td>Pentacarinet</td>
      <td>C</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>pentamidine (Pentacarinet)-[Amp 300mg] IM IV Pneumocystis: 4mg/kg/d for 14d. ¶C. S.E: Severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias, nephrotoxic.</td>
    </tr>
    <tr>
      <td>proguanil</td>
      <td>Malarone</td>
      <td>C</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>proguanil (Malarone)-[Tab 25+62.5, 100+250mg] PO Malaria: 1Tab started at least 1d prior and continued 7d after leaving area. Acute malaria: 4Tab together for 3d. Peds: 11-20kg=100mg/d, 21-30kg=200mg/d, 31-40kg=300mg/d, 1x/d for 3d. ¶C. S.E: Anorexia, pancytopenia, granulocytopenia.</td>
    </tr>
    <tr>
      <td>pyrantel pamoate</td>
      <td>NaN</td>
      <td>N</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>pyrantel pamoate (29 ג') (Combantrin) -[Susp 125mg/2.5ml] PO 11mg/kg single dose 2x/wk. Max 1G. Pinworm, roundworm, hookworm, threadworm, whipworm. ¶Not established. S.E: Diarrhea, dizziness, increases in liver enzymes, insomnia, skin rashes.</td>
    </tr>
    <tr>
      <td>quinine sulfate</td>
      <td>Quinine</td>
      <td>C</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>quinine sulfate (Quinine)-[Tab 300mg] PO 600mg 3x/d for 3-7d. Peds: &lt;16 years: 9mg/kg (Max: 600mg) 3x/d for 3-7d. ¶C. *L2. S.E: Cinchonism, tinnitus, deafness, headaches, nausea, vomiting, visual disturbances, prolonged QT interval, DIC, thrombocytopenia, hepatotoxicity, hemolytic uremic syndrome, interstitial nephritis.</td>
    </tr>
    <tr>
      <td>stibogluconate</td>
      <td>NaN</td>
      <td>N</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>stibogluconate (ג' 29) (Pentostam)-[Soln 10g/100ml] IM IV Leishmaniasis: 20mg/kg/d for 28d. ¶Not established. S.E: Myelosuppression, chemical pancreatitis, prolonged QT interval, renal dysfunction.</td>
    </tr>
    <tr>
      <td>tinidazole</td>
      <td>Proctocide</td>
      <td>C</td>
      <td>Antimalaria/Antihelminth/Antiparasitic</td>
      <td>ANTIBIOTICS</td>
      <td>tinidazole (Proctocide)-[Tab 500mg] PO Amebiasis: 2G 1x/d for 2-3d. Giardia, Trichomonas: 2G single dose. ¶C. *L3. S.E: Leukopenia, thrombocytopenia, ototoxicity</td>
    </tr>
    <tr>
      <td>cycloserine</td>
      <td>NaN</td>
      <td>C</td>
      <td>Antimycobacterial</td>
      <td>ANTIBIOTICS</td>
      <td>cycloserine (29 ג')(Cycloserine) -[Cap 250mg] PO 0.5-1G/d. 1st 2 weeks: 250mg 2x/d. ¶C. *L3. S.E: Aggression, anorexia, coma, CHF, hyperirritability, seizures, tremors.</td>
    </tr>
    <tr>
      <td>ethambutol</td>
      <td>Myambutol</td>
      <td>C</td>
      <td>Antimycobacterial</td>
      <td>ANTIBIOTICS</td>
      <td>ethambutol (Myambutol)-[Tab 400mg] PO 15-25mg/kg 1x up to 2.5G. ¶C. *L2. S.E: Optic neuritis, blindness, peripheral neuropathy, neutropenia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>Isoniazid</td>
      <td>NaN</td>
      <td>C</td>
      <td>Antimycobacterial</td>
      <td>ANTIBIOTICS</td>
      <td>Isoniazid (29 ג') (Isoniazid) -[Tab 300mg] PO 5mg/kg 1x up to 300mg single dose or 15mg/kg up to 900mg 2-3/wks. Consider supplemental pyridoxine 25-50mg/d 1xd. 9mnths duration. ¶C. *L3. S.E: Hepatitis, neurotoxicity (paresthesias, peripheral neuropathy, ataxia), systemic lupus erythematosus, seizure, hematologic abnormalities.</td>
    </tr>
    <tr>
      <td>rifabutin</td>
      <td>Mycobutin</td>
      <td>B</td>
      <td>Antimycobacterial</td>
      <td>ANTIBIOTICS</td>
      <td>rifabutin (Mycobutin)-[Cap 150mg] PO 300mg 1x/d or 150mg 2x/d. ¶B. S.E: Thrombocytopenia, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>rifampicin</td>
      <td>Rimactan</td>
      <td>C</td>
      <td>Antimycobacterial</td>
      <td>ANTIBIOTICS</td>
      <td>rifampicin (Rimactan)-[Cap 150, 300mg; Syrp 100mg/5ml; Amp 600mg] PO IV 300mg/d. ¶C. *L2. S.E: Rash, anorexia, diarrhea, ataxia, dizziness, pruritis, adrenal insufficiency, agranulocytosis, DIC, jaundice, myalgia, acute renal failure, hematuria, flu-like syndrome.</td>
    </tr>
    <tr>
      <td>amphotericin B</td>
      <td>Abelcent</td>
      <td>B</td>
      <td>Antifunga-1</td>
      <td>ANTIBIOTICS</td>
      <td>amphotericin B (Abelcent)-[Amp 5mg/ml] (Ambisome)-[Amp 50mg] IV 5mg/kg/d infusion rate 2.5mg/kg/hr. If exceed 2hr shake the bag every 2hr. ¶B. *L3. S.E: Renal toxicity, renal tubular acidosis, cylindruria, hypokalemia, cytokine storm, fever, chills, hypotension, anemia.</td>
    </tr>
    <tr>
      <td>caspofungin</td>
      <td>Cancidas</td>
      <td>C</td>
      <td>Antifunga-1</td>
      <td>ANTIBIOTICS</td>
      <td>caspofungin (Cancidas)-[Amp 50, 70mg] IV Aspergillosis/Candida: 70mg 1st day then 50mg/d. Slow infusion. ¶C. *L3. S.E: Anemia, blurred vision, diarrhea, fever, hypotension, seizures, tachycardia, tachypnea.</td>
    </tr>
    <tr>
      <td>fluconazole</td>
      <td>Diflucan</td>
      <td>C</td>
      <td>Antifunga-1</td>
      <td>ANTIBIOTICS</td>
      <td>fluconazole (Diflucan)-[Susp 50mg/5ml, 200mg/5ml] (Flucanol)-[Cap 50, 100, 150, 200mg] (Fluconazole Taro 150)-[Cap 150mg] (Fluco-Avenir)-[Soln 2mg/ml]. (Fluconazole Teva)-[Cap 150mg] (Stabilanol)-[Soln 2mg/ml] (Trican)-[Cap 50, 150, 200mg] (Triflucan)-[Amp 2mg/ml] Systemic Candidiasis: PO IV Not established up to 400mg/d. Oral candidiasis: PO 200mg on day 1 then 100mg/d for 7-14d. Esophagitis: PO 200mg on day 1 then 100mg/d up to 400mg/d for 21d. Vaginal Candida: PO 150mg single dose. Peds: PO 3-12mg/kg/d 1x/d. ¶C(single dose for vaginal candidiasis)/D(all other indications). *L2. S.E: Hepatic toxicity, Stevens-Johnson syndrome, gastrointestinal disturbance, rash.</td>
    </tr>
    <tr>
      <td>itraconazole</td>
      <td>Sporanox</td>
      <td>C</td>
      <td>Antifunga-1</td>
      <td>ANTIBIOTICS</td>
      <td>itraconazole (Sporanox)-[Cap 100mg; Soln 10mg/ml] (Itranol)-[Cap 100mg] PO Onychomycosis: 200mg 1x/d 12wk (toenails). 2 courses of 200mg 2x/d 3wks (fingernails). Aspergillosis: 200-400mg 1x/d. Blastomycosis &amp; Histoplasmosis: 200mg/d increase 100mg/d to max 400mg/d in 2 divided doses. Neutropenia: 200mg 1x/d. ¶C. *L2. S.E: Hepatotoxicity, CHF, cardiac dysrhythmias, drug interactions.</td>
    </tr>
    <tr>
      <td>ketoconazole</td>
      <td>Nizoral</td>
      <td>C</td>
      <td>Antifunga-1</td>
      <td>ANTIBIOTICS</td>
      <td>ketoconazole (Nizoral)-[Cream 20mg/g; Shampoo 20mg/g] (Ketozol)-[shampoo 20mg/g] 2x/d 4wks. ¶C. *L2. S.E: Erythema, irritation, paresthesia, pruritus, rash and warmth.</td>
    </tr>
    <tr>
      <td>nystatin</td>
      <td>Dermacombin Cream</td>
      <td>C</td>
      <td>Antifunga-1</td>
      <td>ANTIBIOTICS</td>
      <td>nystatin  (Dermacombin Cream)-[Cream 100000IU/g] (Dermacombin Ointment)-[Oint 100,000IU/g] (Nystatin Ready Mix)-[Susp 100,000IU/ml] Dermal 1-2x/d. PO adults &amp; children: 4-6ml 4x/d. infants: 2ml 4x/d. ¶C. *L1. S.E: Rare allergic reactions, burning, itching, rash, eczema, pain on application.</td>
    </tr>
    <tr>
      <td>terbinafine</td>
      <td>Dermasil</td>
      <td>B</td>
      <td>Antifunga-1</td>
      <td>ANTIBIOTICS</td>
      <td>terbinafine (Dermasil)-[cream 1%] (Lamisil)-[Tab 250mg; Cream 1%; Gel 1%; Spray 1%] (Lamisil Once)-[Soln 10mg/g] (Patir)-[Cream 1%] (Terbinafine-Teva)-[Cap 250mg] PO Onychomycosis: 250mg 1x/d for 6wks (fingernails) or 12wks (toenails). Dermal 1-2x/d for 1wk. ¶B. *L2. S.E: Hepatotoxicity, Stevens-Johnson syndrome, neutropenia, exacerbation of psoriasis or subacute cutaneous lupus erythematosus (oral terbinafine).</td>
    </tr>
    <tr>
      <td>voriconazole</td>
      <td>Vfend</td>
      <td>D</td>
      <td>Antifunga-1</td>
      <td>ANTIBIOTICS</td>
      <td>voriconazole (Vfend)-[FC Tab 50, 200mg; Susp 40mg/ml; Pwdr 200mg/vial] (Voriconazole Teva)-[Tab 50, 200mg] (Voriconazole Trima)-[Tab 200mg] PO invasive aspergillosis, deep tissue candidiasis, scedosporiosis and fusariosis start 6mg/kg IV 2x/d for first 24h (loading dose), then 200mg PO 2x/d. Esophageal candidiasis: 200mg 1x/d. ¶D. S.E: Hepatotoxicity, Stevens-Johnson syndrome, GI disturbance, rash.</td>
    </tr>
    <tr>
      <td>amlodipine</td>
      <td>Amlodipine-Teva, Norvasc, Amlodipine Pharmaswiss, Amlow</td>
      <td>C</td>
      <td>Calcium Channel Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>amlodipine (Amlodipine-Teva, Norvasc, Amlodipine Pharmaswiss, Amlow)-[Tab 5, 10mg] PO Start 5mg/d. Max 10mg/d. ¶C. *L3. S.E: Increased angina, rare MI.</td>
    </tr>
    <tr>
      <td>amlodipine+valsartan</td>
      <td>Duplex, Exforage</td>
      <td>D</td>
      <td>Calcium Channel Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>amlodipine+valsartan (Duplex, Exforage)-[FC Tab 10+160, 5+160 5mg+180mg] PO start 5mg+160mg 1x/d. Max 10mg+320mg 1x/d. ¶D. S.E: Rare blurred or loss of vision.</td>
    </tr>
    <tr>
      <td>diltiazem</td>
      <td>Adizem</td>
      <td>C</td>
      <td>Calcium Channel Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>diltiazem (Adizem)-[CR Cap 120, 180, 240mg] (Dilatam)-[SR Tab 120mg] (Dilitiazem Teva)-[Tab 30, 60mg] PO Hypertension: 180-480mg 1x/d. Angina: 120-480mg 1x/d. ¶C. *L3. S.E: Rare cardiac arrhythmia, atrioventricular block, bradyarrhythmia, exacerbation of heart failure.</td>
    </tr>
    <tr>
      <td>felodipine</td>
      <td>Penedil</td>
      <td>C</td>
      <td>Calcium Channel Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>felodipine (Penedil)-[SR Tab 2.5, 5, 10mg] PO start 5mg/d, recommended range is 2.5-10mg 1x/d. ¶C. *L3. S.E: Increased angina, rare MI.</td>
    </tr>
    <tr>
      <td>lercanidipine</td>
      <td>Vasodip, Lercanidipine Teva</td>
      <td>C</td>
      <td>Calcium Channel Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>lercanidipine (Vasodip, Lercanidipine Teva)-[Tab 10, 20mg] (Lercappess)-[FC Tab 10, 20mg] PO 10mg 1x/d. Max 20mg/d. ¶C. S.E: Rare angina pectoris, fall in BP.</td>
    </tr>
    <tr>
      <td>lercanidipine+enalapril</td>
      <td>Vasodip Combo</td>
      <td>D</td>
      <td>Calcium Channel Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>lercanidipine+enalapril (Vasodip Combo)-[Tab 10+10, 10mg+20mg] PO 10 PO 1Tab/d 15min before meal, preferably in the morning. Avoid grapefruit juice. ¶D. S.E: Vertigo, cough, peripheral edema.</td>
    </tr>
    <tr>
      <td>nifedipine</td>
      <td>Pressolat</td>
      <td>C</td>
      <td>Calcium Channel Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>nifedipine (Pressolat)-[MR Tab 10mg] (Osmo-Adalat)-[CR Tab 20, 30, 60mg] (Nifedil)-[CR Tab 30, 60mg] PO 10mg 3x/d up to 120mg/d. Avoid sublingual. Controlled release: 30-60mg/d. Max 90mg/d. ¶C. *L2. S.E: Increased angina, rare MI.</td>
    </tr>
    <tr>
      <td>verapamil</td>
      <td>Ikacor</td>
      <td>C</td>
      <td>Calcium Channel Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>verapamil (Ikacor)-[Tab 40, 80, 120mg.] (Ikapress)-[SR Tab 180, 240mg] (Verapress)-[Cap 240mg] PO Angina: 80-120mg 3x/d Arrhythmia: 240-320mg/d in divided doses. Hypertension: 80mg 3x/d. Sustained release: PO 180-240mg/d up to max 480mg/d. ¶C. *L2. S.E: Rare cardiac arrhythmia, atrioventricular block, bradyarrhythmia, exacerbation of HF.</td>
    </tr>
    <tr>
      <td>benazepril</td>
      <td>Benazepril-Teva</td>
      <td>C</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>benazepril (Benazepril-Teva)-[Tab 20mg] PO Hypertension: Start 2.5mg 1x/d. May increase slowly to 20-40mg single or divided dose. ¶C-1st trimester, D-2-3rd trimester. *L2. S.E: Angioedema (more frequent in black patients), agranulocytosis, neutropenia.</td>
    </tr>
    <tr>
      <td>captopril</td>
      <td>Aceril</td>
      <td>D</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>captopril (Aceril)-[Tab 12.5, 25, 50mg] PO Hypertension: 25-150mg 2-3x/d. Max 450mg/d. CHF: 6.25-25mg 3x/d. Max 450mg/d. Diabetic nephropathy: 25mg 3x/d. ¶D. *L2. S.E: Angioedema (more frequent in black patients), agranulocytosis, neutropenia.</td>
    </tr>
    <tr>
      <td>cilazapril</td>
      <td>Cilaril, Cilaril Plus, Cilaril Plus-Teva</td>
      <td>D</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>cilazapril (Cilaril, Cilaril Plus, Cilaril Plus-Teva)-[Tab 1, 2.5, 5mg] PO HTN: Start 1.25mg 1x/d. Maint: 2.5-5mg/d. Max 10mg/d. HF:2.5-20mg 2x/d. ¶D. S.E: Angioedema, cholestatic jaundice, cough, hyperkalemia, anaphylaxis, hypotension, agranulocytosis.</td>
    </tr>
    <tr>
      <td>cilazapril+hydrochlorothiazide</td>
      <td>Cilazapril Plus Teva</td>
      <td>D</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>cilazapril+hydrochlorothiazide (Cilazapril Plus Teva)-[Tab 5mg+12.5mg] PO 1Tab 1x/d. ¶D. S.E: Angioedema, cholestatic jaundice, cough, hyperkalemia, anaphylaxis, hypotension, agranulocytosis, gout, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>enalapril</td>
      <td>Enalapril, Enaladex</td>
      <td>D</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>enalapril (Enalapril, Enaladex)-[Tab 5, 10, 20mg] PO Hypertension: Start 5mg/d single or divided dose. Max 40mg/d. HF: 2.5-20mg 2x/d. Max 40mg/d. ¶D. *L2. S.E: Angioedema (more frequent in Black patients), agranulocytosis, neutropenia.</td>
    </tr>
    <tr>
      <td>enalapril+ hydrochlorothiazide</td>
      <td>Naprizide</td>
      <td>D</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>enalapril+ hydrochlorothiazide (Naprizide)-[Tab 5mg+12.5mg, 10mg+25mg] PO 10-40mg/d in a single or two divided doses of 12.5-50mg daily of hydrochlorothiazide. ¶D. S.E: Fetal toxicity.</td>
    </tr>
    <tr>
      <td>lercanidipine+enalapril</td>
      <td>Vasodip Combo</td>
      <td>D</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>lercanidipine+enalapril (Vasodip Combo)-[Tab 10+10, 10mg+20mg] PO 1Tab/d 15min before meal, preferably in the morning. Avoid grapefruit juice. ¶D. S.E: Vertigo, cough, peripheral edema.</td>
    </tr>
    <tr>
      <td>lisinopril</td>
      <td>Tensopril</td>
      <td>C</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>lisinopril (Tensopril)-[Tab 5mg] PO Hypertension: Start 10mg 1x/d. Max 80mg/d. CHF, acute MI: Start 5mg/d. Usual 10-20mg/d. ¶C-1st trimester, D-2nd-3rd. *L3. S.E: Angioedema (more frequent in black patients), agranulocytosis, neutropenia.</td>
    </tr>
    <tr>
      <td>moexipril</td>
      <td>Perdix</td>
      <td>D</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>moexipril (Perdix)-[Tab 7.5, 15mg] PO HTN: Start 7.5mg 1x/d recommended: 7.5-30mg/d. ¶D. S.E: Angioedema (more frequent in Black patients), agranulocytosis, neutropenia.</td>
    </tr>
    <tr>
      <td>ramipril</td>
      <td>Tritace, Tritace Comp, Ramipril Plus Teva, Ramipril Teva, Ramitens</td>
      <td>C</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>ramipril (Tritace, Tritace Comp, Ramipril Plus Teva, Ramipril Teva, Ramitens)-[Cap 1.25, 2.5, 5, 10, 12.5, 25mg] PO Hypertension: start 2.5mg 1x/d. Maintenance dosage is 2.5-20mg/d. ¶C 1st trimester, D-2-3rd. *L3. S.E: Angioedema (more frequent in black patients), agranulocytosis, neutropenia.</td>
    </tr>
    <tr>
      <td>ramipril+hydrochlorothiazide</td>
      <td>Ramipril Plus Teva 2.5mg/12.5mg and 5mg/25mg</td>
      <td>C</td>
      <td>Angiotensin Converting Enzyme Inhibitors</td>
      <td>CARDIOVASCULAR</td>
      <td>ramipril+hydrochlorothiazide (Ramipril Plus Teva 2.5mg/12.5mg and 5mg/25mg)-[Tab 2.5,12.5, 5, 25mg] PO 1x/d. May increase slowly to max 4Tab/d. ¶C 1st trimester, D 2-3rd. S.E: Angioedema, cholestatic jaundice, cough, hyperkalemia, anaphylaxis, hypotension, agranulocytosis, gout, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>candesartan</td>
      <td>Atacand, Candesartan Plus Teva, Candor, Cancor Plus</td>
      <td>D</td>
      <td>Angiotensin Receptor Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>candesartan (Atacand, Candesartan Plus Teva, Candor, Cancor Plus)-[Tab 4, 8, 12.5 16mg] PO Hypertension: total daily dose 8-32mg 1-2x/d. Adult HF: 4mg/d. Target dose is 32mg/d in 2 week intervals. ¶D-2-3rd trimester.*L3. S.E: Rare thrombocytopenia, rhabdomyolysis, rare angioedema.</td>
    </tr>
    <tr>
      <td>candesartan+hydrochlorothiazide</td>
      <td>Atacand Plus</td>
      <td>D</td>
      <td>Angiotensin Receptor Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>candesartan+hydrochlorothiazide (Atacand Plus)-[Tab 16+12.5mg] PO Hypertension: 16mg/d total daily dosage 8-32mg and 12.5-50mg/d of hydrochlorothiazide. Effect usually attained 4wks. ¶D. S.E: Fetal toxicity.</td>
    </tr>
    <tr>
      <td>losartan</td>
      <td>Ocsaar, Loserta</td>
      <td>D</td>
      <td>Angiotensin Receptor Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>losartan (Ocsaar, Loserta)-[Tab 12.5, 50mg] (Losardex, Losartan Teva)-[FC Tab 12.5, 50mg] (Lotan)-[Cap 100mg; Tab 12.5, 50mg] PO Hypertension: Start 50mg 1x/d or 25mg if volume depleted. Max 100mg/d. ¶D. *L3. S.E: Vertigo, orthostatic hypotension, hyperkalemia.</td>
    </tr>
    <tr>
      <td>losartan+hydrochlorothiazide</td>
      <td>Ocsaar Plus, Losardex Plus, Losarta Plus, Losartan Plus Teva, Lotan Plus</td>
      <td>D</td>
      <td>Angiotensin Receptor Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>losartan+hydrochlorothiazide (Ocsaar Plus, Losardex Plus, Losarta Plus, Losartan Plus Teva, Lotan Plus)-[Tab 50+12.5mg] PO Hypertension: 1-2 Tab 1x/d. ¶D. S.E: Fetal toxicity, palpitation, dizziness, anemia, dyspnea, blurred vision, impotence, renal dysfunction.</td>
    </tr>
    <tr>
      <td>valsartan</td>
      <td>Diovan, Valsartan Dexcel</td>
      <td>D</td>
      <td>Angiotensin Receptor Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>valsartan (Diovan, Valsartan Dexcel)-[FC Tab 40, 80, 160mg] (Vector)-[FC Tab 40, 60mg; Tab 160mg] PO Hypertension: 80-320mg 1x/d. HF: start 40mg 2x/d, titration 80-160mg 2x/d. Post MI: start 20mg 2x/d, uptitrate within 7 days to 40mg 2x/d. ¶D. *L3. S.E: Rare thrombocytopenia, rhabdomyolysis, rare angioedema, fetal toxicity.</td>
    </tr>
    <tr>
      <td>valsartan+hydrochlorothiazide</td>
      <td>Co-Diovan, Vector Plus</td>
      <td>D</td>
      <td>Angiotensin Receptor Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>valsartan+hydrochlorothiazide (Co-Diovan, Vector Plus)-[FC Tab 80+12.5mg, 160+12.5mg, 160+25mg] (Duplex, Exoforge)-[FC Tab 160+10mg, 160+5mg, 80+5mg] PO Start 160+12.5mg 1x/d. Increase dosage by response up to 320+25mg. ¶D. S.E Fetal toxicity, palpitations, tachycardia, dizziness, dyspnea, hypotension.</td>
    </tr>
    <tr>
      <td>acebutolol</td>
      <td>Sectral</td>
      <td>B</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>acebutolol (Sectral)-[Tab 200, 400mg] β1 PO Start 400mg 1x/d or 200mg 2x/d. Max 1200mg/d. ¶B. *L3. S.E. Fatigue, dizziness, diarrhea, constipation, dyspepsia, abnormal vision.</td>
    </tr>
    <tr>
      <td>atenolol</td>
      <td>Normalol, Normiten</td>
      <td>D</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>atenolol (Normalol, Normiten)-[Tab 25, 50, 100mg] β1 PO Hypertension: 50-100mg 1x/d. Angina pectoris: 50-200mg 1x/d. ¶D. *L3. S.E: Atrioventricular block, bradyarrhythmia.</td>
    </tr>
    <tr>
      <td>betaxolol</td>
      <td>Betoptic-S</td>
      <td>C</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>betaxolol (Betoptic-S)-[Soln 2.8mg/ml] β1 Ocular Glaucoma: 2 drops 2x/d. ¶C. *L3. S.E: Rare bradycardia, heart block, CHF, pulmonary distress.</td>
    </tr>
    <tr>
      <td>bisoprolol</td>
      <td>Concor</td>
      <td>C</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>bisoprolol (Concor)-[Tab 5, 10mg] (Cardiloc)-[FC Tab 1.25, 2.5, 5, 10mg] (Bisoprolol Fumarate Inovamed)-[FC Tab 2.5, 5, 10mg]β1 PO Start 2.5-5mg 1x/d. Max 20mg/d. ¶C. *L3. S.E: Headache, cough, edema, thrombocytopenia, bradycardia.</td>
    </tr>
    <tr>
      <td>carvedilol</td>
      <td>Carvedexxon</td>
      <td>C</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>carvedilol (Carvedexxon)-[Tab 6.25, 12.5mg] (Carvedilol Teva)-[Tab 3.25, 12.5mg] α1β1β2 PO Hypertension: Start 6.25mg 2x/d. Max 50mg/d. LV dysfunction after MI: start 6.25mg 2x/d increase until 25mg 2x/d. ¶C. *L3. S.E: Bronchospasm, atrioventricular block, bradyarrhythmia, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>esmolol</td>
      <td>NaN</td>
      <td>C</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>esmolol (29 ג') (Esmolol 10MG/ML)-[Soln 100mg/10ml] β1 IV SVT: loading dose 500mcg/kg over 1min, maintenance dose 50-200mcg/kg/min. Surgical Tachycardia and Hypertension: loading dose 500mcg/kg over 1min, maintenance infusion of 50mcg/kg/min for 4min. ¶C. *L3. S.E: Atrioventricular block, bradyarrhythmia.</td>
    </tr>
    <tr>
      <td>labetalol</td>
      <td>Trandate</td>
      <td>C</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>labetalol (Trandate)-[Tab 100, 200mg; Soln 5mg/ml] α1β1β2 PO IV Hypertension: Start 100mg 2x/d. Max 400mg 2x/d. Emergency: IV start 20mg slow, then 40-80mg every 10min as needed up to 300mg. Maint: 1-2mg/min. ¶C. *L2. S.E: Bronchospasm, atrioventricular block, bradyarrhythmia, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>metoprolol</td>
      <td>Neobloc</td>
      <td>C</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>metoprolol (Neobloc)-[Tab 100mg] (Lopressor Divitabs)-[SR Tab 200mg] β1 PO HTN, angina: start 25-100mg 1x/d. Max 400mg/d. ¶C. *L3. S.E: Atrioventricular block, bradyarrhythmia.</td>
    </tr>
    <tr>
      <td>propranolol hydrochloride</td>
      <td>Deralin, Prolol</td>
      <td>C</td>
      <td>Beta Blockers</td>
      <td>CARDIOVASCULAR</td>
      <td>propranolol hydrochloride (Deralin, Prolol)-[Cap 10, 40mg] (Slow Deralin)-[SR Cap 80, 160mg] β1β2 PO Hypertension: Start 40mg 2-3x/d, increase to 80mg 2x/d to max 640mg/d. Sustained release: Start 80mg 1x/d. Migraine: The usual effective dose range is 160-240mg 1x/d. Peds: &lt;12yrs 20mg 2-3x/d. IV Start 1-3mg. Administration rate should not exceed 1mg/min. If necessary, a second dose may be given after 2min. ¶C. *L3. S.E: CHF hypotension, intensification of AV block, bradycardia, thrombocytopenic purpura, arterial insufficiency, mental depression, weakness, fatigue, hallucinations, visual disturbances, vivid dreams, ischemic colitis, bronchospasm.</td>
    </tr>
    <tr>
      <td>adenosine</td>
      <td>Adenocor</td>
      <td>C</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>adenosine (Adenocor)-[Amp 6mg/2ml] IV SVT Adult: Initial dose 6mg bolus, then 12mg rapid (may be repeated a second time if required). Peds: &lt;50kg initial dose: 0.05-0.1mg/kg bolus, then increase by 0.05 to 0.1mg/kg. Peds: &gt;50kg - adult dose. Max 12mg. ¶C.*L1. S.E: Palpitations, chest pain, hypotension, dyspnea, VT, VF, bronchospasm, seizures.</td>
    </tr>
    <tr>
      <td>amiodarone</td>
      <td>Amiocor</td>
      <td>D</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>amiodarone (Amiocor)-[Tab 200mg] (Amiodacore)-[Tab 200mg; Amp 150mg] (Procor)-[Tab 200mg] IV Load 150mg over 10min, then 1mg/min for 6hr, then 0.5mg/min for 18hr (Mix in Glu5%). PO Start 600-1600mg 1x/d for 1-3wks then reduce to 400-800mg 1x/d for 4wks, then reduce to lowest effective dose, usually 200-400mg 1x/d. Life-threatening ventricular arrhythmias: 800-1600mg 1-2X2x/d for 1-3wks until adequate arrhythmia control is achieved, decrease to 600-800mg/d in 1-2 doses for 1 month; maintenance: 400mg/d. Pulseless VT or VF: IV push, I.O.: Initial: 300mg rapid bolus; if pulseless VT or VF continues after subsequent defibrillation attempt or recurs, administer supplemental dose of 150mg. Upon return of spontaneous circulation, follow with an infusion of 1mg/minute for 6hrs, then 0.5 mg/minute for 18hr (mean daily doses &gt;2.1G/d have been associated with hypotension). Stable VT: IV 150mg over 10min, then 1mg/min for 6 hourshrs, followed by 0.5mg/min; continue this rate for at least 18hrs (total infusion duration: 24 hours) or until complete transition to oral. Breakthrough stable VT: 150mg supplemental doses in 100ml D5W or NS over 10min (mean daily doses &gt;2.1G/d have been associated with hypotension) Atrial Fibrillation: Pharmacologic cardioversion (off-label use): Oral: 600-800mg/d in divided doses until 1G total, then 200mg/d as maintenance. 800mg/d x14/d, followed by 600mg/d for the next 14d, then 300mg/d for the remainder of the first year, then 200mg/d thereafter or 10mg/kg/d for 14d, followed by 300mg/d for 4wks, followed by maintenance dosage of 200mg/d. IV: 150mg over 10min, then 1mg/min for 6hrs, then 0.5mg/min for 18hrs or change to oral maintenance dosing (eg 100 to 200mg 1x/d). Recommendations for conversion to oral amiodarone after IV administration: Use the following as a guide:&lt;1wk IV infusion: 800-1600mg/d. 1-3wks IV infusion: 600-800mg/d. &gt;3wks IV infusion: 400mg. ¶D. *L5. S.E: Optic neuropathy, peripheral neuropathy, photosensitivity, pulmonary toxicity digoxin toxicity, prolonged INR.</td>
    </tr>
    <tr>
      <td>digoxin</td>
      <td>Digoxin-Zori</td>
      <td>C</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>digoxin (Digoxin-Zori)-[Tab 0.25mg] (Digoxin Kern Pharma)-[Tab 0.25mg] (Lanoxin PG Elixir)-[0.25mg/5ml] (Lanoxin PG Elixir)-[Syrp 50µg/ml; Amp 0.5mg/2ml] PO Loading dose: 10-15mcg/kg as following: First 1/2 of the loading dose, then 1/4 of the loading dose every 6-8h twice. Maintenance: 3.4-5.1mcg/kg 1x/d (Doses may be increased every 2 weeks). Peds: 5-10yrs loading dose: 20-45mcg/kg (administrated as for adults). Maintenance: 3.2-6.4mcg/kg 2x/d (Doses may be increased every 2 weeks). IV Loading dose: 8-12mcg/kg (First 1/2 of the loading dose, then ¼ of the loading dose every 6-8h). Maintenance dose: 2.4-3.3mcg/kg 1x/d. Maintenance Dose 3.4-5.1mcg/kg 1x/d. IM administration leads to sever pain.  For adults, no more than 500mcg of Digoxin should be injected into a single site. Administer the dose over a period of 5 minutes or longer and avoid bolus administration to prevent systemic and coronary vasoconstriction. Mixing of Digoxin Injection with other drugs in the same container or simultaneous administration in the same intravenous line is not recommended. ¶C. *L2. S.E: Cardiac toxicity, CNS toxicity, intestinal ischemia, hemorrhagic necrosis of the intestines, delirium, hallucinations, gynecomastia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>disopyramide</td>
      <td>Rythmical</td>
      <td>C</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>disopyramide (Rythmical)-[Tab 100, 150mg] PO Start 400-800mg/d. Body weight &gt;50kg then 150mg 4x/d. Body weight &lt;50kg then 100mg 4x/d. For cardiomyopathy a loading dose should not be given, initial dosage up to 100mg 3-4X4x/d. For patients with moderate renal insufficiency (GFR&gt;40), the recommended dosage is 100mg 4X4x/d. For patient with severe renal insufficiency, recommended dosage is 100mg 4X4x/d (GFR&lt;40), 100mg 3X3x/d (30&lt;GFR&lt;40), 100mg 2X2x/d (15&lt;GFR&lt;30),and 100mg 1X1x/d (GFR&lt;15). Ventricular Arrhythmia: Loading dose 300mg (when no response/toxicity 200mg 4X4x/d). Peds: &lt;1yr 10-30mg/kg/d, 1-4yrs 10-20mg/kg/d, 4-12yrs 10-15mg/kg/d, &gt;12yrs 6-15mg/kg/d . ¶C. *L2. S.E: Blurred vision, hypotension with or without HF, dyspnea, syncope, hypokalemia, AV block.</td>
    </tr>
    <tr>
      <td>flecainide</td>
      <td>Tambocor</td>
      <td>C</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>flecainide (Tambocor)-[Tab 50, 100mg; Amp 10 mg/ml] PO PSVT\PAF: 50mg/d in 2 divided doses. Doses may be increased in increments of 50mg 2x/d every 4d. Max for SVT 300mg/d. Sustained VT: 100mg 2x/d. Doses may be increased in increments of 50mg 2x/d every 4d. Max 400mg/d. IV bolus: Administer 2mg/kg over no less than 10min, or in divided doses, for SVT or HF give initial dose over 30min. Max 150mg/bolus. IV infusion: Slow injection of 2mg/kg over 30min, then first hour: 1.5mg/kg/h, later hours: 0.1-0.25mg/kg/h. Max 600mg/d. ¶C. *L3. S.E: Dyspnea, palpitations, tremor, arrhythmia, hypertension, hypotension, blood dyscrasia, neuropathy, amnesia.</td>
    </tr>
    <tr>
      <td>lidocaine</td>
      <td>Esracain</td>
      <td>B</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>lidocaine (Esracain)-[Amp 1, 2%] (Lidocaine HCL)-[Amp 2%+ epinephrine 1:100,000] IV Load 1mg/kg, then 0.5mg/kg every 8-10min as needed to max 3mg/kg. Maint: 1-4mg/min. Peds: 20-50µg/kg/min. Autoinjector as per instructions. Adult dose: VF or pulseless VT (after defibrillation attempts, CPR, and vasopressor administration), alternative to amiodarone: IV, intraosseous (I.O.): Initial: 1-1.5mg/kg. If refractory VF or pulseless VT, repeat 0.5-0.75mg/kg bolus q5-10min (max cumulative dose: 3mg/kg). Follow with continuous infusion (1-4mg/min) after return of perfusion. Reappearance of arrhythmia during constant infusion: 0.5mg/kg bolus and reassessment of infusion. Hemodynamically stable monomorphic VT: IV 1-1.5mg/kg; repeat with 0.5-0.75mg/kg q5-10min as necessary (max cumulative dose: 3mg/kg). Follow with continuous infusion of 1-4mg/min (or 14-57mcg/kg/min). Note: Reduce maintenance infusion in patients with CHF, shock, or hepatic disease; initiate infusion at 10mcg/kg/min (max: 1.5mg/min or 20mcg/kg/min). Pediatric dose: Antiarrhythmic: IV, intraosseous (I.O.): Note: For use in VF or pulseless VT if amiodarone is not available; give after defibrillation attempts, CPR, and epinephrine: Loading dose: 1mg/kg (max: 100mg); follow with continuous infusion; may administer second bolus of 0.5mg/kg if delay between bolus and start of infusion is &gt;15min. Continuous Infusion: 20-50mcg/kg/minute. Per the manufacturer, do not exceed 20mcg/kg/minute in patients with shock, hepatic disease, cardiac arrest, or CHF. Endotracheal 2-3mg/kg; flush with 5ml of NS and follow with 5 assisted manual ventilations. ¶B. *L2. S.E: Arrhythmia, cardiovascular collapse, edema, confusion, coma, euphoria, hallucinations, thrombophlebitis, paresthesia, tinnitus, bronchospasm, anaphylaxis.</td>
    </tr>
    <tr>
      <td>mexiletine hydrochloride</td>
      <td>Mexiletine</td>
      <td>C</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>mexiletine hydrochloride (Mexiletine)-[Cap 150, 200, 250mg] (Mexitil)-[Cap 200mg] (Novo-Mexiletine HCL)-[Cap 200mg] PO Start 200mg 3x/d (Dose may be adjusted in 50 or 100mg increments up or down). Max 1200mg/d. ¶C. S.E: Ventricular arrhythmia, PVC’s, tremor, dyspnea.</td>
    </tr>
    <tr>
      <td>procainamide</td>
      <td>Procainamide</td>
      <td>C</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>procainamide (Procainamide)-[Amp 100mg/ml 5x10ml] IV IM Antiarrhythmic: Initial dose of 50mg/kg/d 3-4x/d. Arrhythmias associated with anesthesia or surgery: 100-500mg . Adult dose: Must be titrated to patient's response. Antiarrhythmic: IM 50mg/kg/d divided q3-6h or 0.5-1G q4-8h. IV Loading dose: 15-18mg/kg administered as slow infusion over 25-30min or 100mg/dose at a rate not to exceed 50mg/minute repeated q5min as needed to a total dose of 1G. Hemodynamically stable monomorphic VT or pre-excited atrial fibrillation: Loading dose: Infuse 20-50mg/min or 100mg q5min until arrhythmia controlled, hypotension occurs, QRS complex widens by 50% of its original width, or total of 17mg/kg is given. Follow with a continuous infusion of 1-4mg/minute. Note: Not recommended for use in ongoing ventricular fibrillation (VF) or pulseless VT due to prolonged administration time and uncertain efficacy. Maintenance dose: 1-4mg/minute by continuous infusion. Maintenance infusions should be reduced by one-third in patients with moderate renal or cardiac impairment and by two-thirds in patients with severe renal or cardiac impairment. PO Sustained release formulation: Maintenance: 50mg/kg/24hours given in divided doses q6h. Suggested maintenance dose: &lt;55kg 500mg q6h. 55-91kg 750mg q6h, &gt;91kg 1000mg q6h. Peds: Must be titrated to patient's response: Arrhythmias: IM 20-30mg/kg/day divided 4-6x/d to max 4G/day. IV Load: 3-6mg/kg/dose over 5min not to exceed 100mg/dose; repeat every 5-10min to max 15mg/kg/load. Maintenance as continuous IV infusion: 20-80mcg/kg/minute. Max: 2G/d. ¶C. *L3. S.E: Ventricular arrhythmias, blood dyscrasia, lupus-like syndrome.</td>
    </tr>
    <tr>
      <td>propafenone</td>
      <td>Profex, Rythmex, Rytmonorm</td>
      <td>C</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>propafenone (Profex, Rythmex, Rytmonorm)-[Tab 150, 300mg] PO Start 150mg 3x/d. Increase every 3-4d to 225mg 3x/d, max 300mg 3x/d. ¶C. *L2. S.E: Arrhythmia, ataxia, heart failure, , dyspnea, bronchoconstriction, hepatotoxicity, blurred vision, allergic reactions, impotence.</td>
    </tr>
    <tr>
      <td>quinidine sulfate</td>
      <td>Quinidine Sulfate</td>
      <td>C</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>quinidine sulfate (Quinidine Sulfate)-[Tab 200mg] PO 100-600mg 4-6x/d. Avoid in G6PD. ¶C. *L2. S.E: Hypotension, arrhythmias, cardiac arrest, syncope, hepatotoxicity, blurred vision, diplopia, leukopenia, thrombocytopenia, hypersensitivity reactions, acute psychosis.</td>
    </tr>
    <tr>
      <td>sotalol</td>
      <td>NaN</td>
      <td>B</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>sotalol (29 ג') (Sotacor, Sotalol GM) -[Tab 80, 160mg] β1β2 Blocker PO Start 80mg 2x/d. Increase to 240-320mg/d. ¶B. *L3. S.E: Bradycardia, Torsade de Pointes, hypotension, HF, stroke, dyspnea, sexual dysfunction, depression.</td>
    </tr>
    <tr>
      <td>vernaklant hydrochloride</td>
      <td>Brinavess</td>
      <td>N</td>
      <td>Arrhythmias / Cardiac Arrest</td>
      <td>CARDIOVASCULAR</td>
      <td>vernaklant hydrochloride (Brinavess)-[Soln 20mg/ml] IV Recommended diluents are 0.9% sodium chloride for Inj, lactated ringers for Inj, or 5% glucose for Inj. ≤ 100 kg: 25ml with 20mg/ml is added to 100ml of diluent. The initial infusion is administered as a 3mg/kg dose over 10min, during this period, the patient should be carefully monitored. If conversion to sinus rhythm did not occur with the initial infusion or within the 15min observation period, administer a 2mg/kg second infusion over 10min. Do not administer as an intravenous push or bolus. ¶Not established. S.E: Hypotension, bradycardia, ECG changes, CHF.</td>
    </tr>
    <tr>
      <td>clonidine</td>
      <td>Normopresan</td>
      <td>C</td>
      <td>Antiadrenergics</td>
      <td>CARDIOVASCULAR</td>
      <td>clonidine (Normopresan)-[Tab 0.15mg] PO Start 0.075-0.15mg 2x/d for 2-4wk, increase if necessary. Max 0.9mg/d. ¶C. *L3. S.E: Hypotension, rebound hypertension, arrhythmias, impotence, psoriasis exacerbations, sedation, nasopharyngitis, tremor, xerostomia.</td>
    </tr>
    <tr>
      <td>doxazosin</td>
      <td>Cadex</td>
      <td>C</td>
      <td>Antiadrenergics</td>
      <td>CARDIOVASCULAR</td>
      <td>doxazosin (Cadex)-[Tab 1, 2, 4mg] α1 PO HTN: start 1mg 1x/d. Maintenance 1-16mg 1x/d. Benign Prostatic Hypertrophy: start 1mg 1x/d. Maintenance 1-8mg 1x/d. ¶C. *L4. S.E: Arrhythmias, peripheral edema, blurred vision, insomnia, dyspnea, impotence, depression.</td>
    </tr>
    <tr>
      <td>methyldopa</td>
      <td>Aldomin</td>
      <td>B</td>
      <td>Antiadrenergics</td>
      <td>CARDIOVASCULAR</td>
      <td>methyldopa (Aldomin)-[Tab 250, 500mg] PO Start 250mg 2-3x/d. Maintenance 0.5-2G divided in 2-3x/d. Max 3G/d. ¶B. *L2. S.E: Hepatotoxicity, hemolytic anemia, hypotension, depression, impotence.</td>
    </tr>
    <tr>
      <td>prazosin</td>
      <td>Hypotens</td>
      <td>C</td>
      <td>Antiadrenergics</td>
      <td>CARDIOVASCULAR</td>
      <td>prazosin (Hypotens)-[Tab 0.5, 1, 2, 5mg] α1 PO Start 1mg 2-3x/d at bedtime. Maintenance: 6-15mg/d in divided doses. ¶C. *L4. S.E: Postural hypotension, syncope, hallucinations, urinary incontinence, serum sickness-like reaction.</td>
    </tr>
    <tr>
      <td>terazosin</td>
      <td>Hytrin</td>
      <td>C</td>
      <td>Antiadrenergics</td>
      <td>CARDIOVASCULAR</td>
      <td>terazosin (Hytrin)-[Tab 1, 2, 5, 10mg] (Terazosin Teva)-[Tab 1, 2, 5mg] α1 PO Start 1mg/d at bedtime. Maintenance 1-5mg/d. Max: 20mg/d. ¶C. *L4. S.E: Syncope, postural hypotension, blurred vision, anaphylaxis, lichenoid drug eruption, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>bosentan</td>
      <td>Tracleer</td>
      <td>X</td>
      <td>Other Antihypertensives</td>
      <td>CARDIOVASCULAR</td>
      <td>bosentan (Tracleer)-[FC Tab 62.5, 125mg] PO Pulmonary hypertension: start 62.5mg 2x/d for 4wk. Maintenance 125mg 2x/d. ¶X. *L4. S.E: Hepatotoxicity, anemia, peripheral edema, hypotension.</td>
    </tr>
    <tr>
      <td>epoprostenol</td>
      <td>Flolan</td>
      <td>B</td>
      <td>Other Antihypertensives</td>
      <td>CARDIOVASCULAR</td>
      <td>epoprostenol (Flolan)-[Amp 500, 1500µg] IV Pulmonary hypertension: given by continuous IV pump. ¶B. *L3. S.E: Hypotension, arrhythmias, chest pain, flushing, fever, sepsis, flu-like symptoms, termor, anxiety, pulmonary edema, hedache, thrombocytopenia, hypoxia.</td>
    </tr>
    <tr>
      <td>minoxidil</td>
      <td>Minoxidil</td>
      <td>C</td>
      <td>Other Antihypertensives</td>
      <td>CARDIOVASCULAR</td>
      <td>minoxidil (Minoxidil)-[Tab 5mg] PO Start 5mg/d. Maintenance 10-40mg/d in 1-2 divided doses. Max 100mg/d. ¶C. *L3. S.E: Pericardial effusion, hypotension, sinus tachycardia, edema, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>nitroprusside sodium</td>
      <td>Nipruss</td>
      <td>C</td>
      <td>Other Antihypertensives</td>
      <td>CARDIOVASCULAR</td>
      <td>nitroprusside sodium (Nipruss)-[Amp 60mg] IV Emergency: 0.3µg/kg/min. Then titrate upward to max 10µg/kg/min. ¶C. *L4. S.E: Cyanide toxicity, hypotension, MI, methemoglobinemia, thrombocytopenia, acute phlebitis in the injection site.</td>
    </tr>
    <tr>
      <td>phenoxybenzamine</td>
      <td>Dibenyline</td>
      <td>C</td>
      <td>Other Antihypertensives</td>
      <td>CARDIOVASCULAR</td>
      <td>phenoxybenzamine (Dibenyline)-[Cap 10mg] PO Pheochromocytoma: Start 10mg 2x/d. Usual 20-40mg 2-3x/d. ¶C. S.E: Postural hypotension, tachycardia, inhibition of ejaculation.</td>
    </tr>
    <tr>
      <td>phentolamine</td>
      <td>Regitine</td>
      <td>C</td>
      <td>Other Antihypertensives</td>
      <td>CARDIOVASCULAR</td>
      <td>phentolamine (Regitine)-[Amp 10mg] α Blocker IV IM 0.05-0.1mg/kg/dose repeat as needed every 2-4hrs. Max: 5mg/dose. ¶C. S.E: Hypotension, postural hypotension, arrhythmias, MI, cerebrovascular spasm.</td>
    </tr>
    <tr>
      <td>adrenaline</td>
      <td>Adrenaline</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>adrenaline (Adrenaline)-[Amp 1mg/ml] IM IV SC Asthma/anaphylaxis: SC 0.2-1mg q5-15min (1:1,000), or IM/SC 0.1-0.25mg over 5-15min (1:10,000), or IV 0.1-0.25mg 1-4mcg/min over 5min. Cardiac arrest: IV 0.5-1mg q3-5min. Endotracheal tube 2-2.5mg q3-5min. Intracardiac 0.1-0.5mg to left ventricle. ¶C. S.E: Respiratory difficulties, arrhythmias, tachycardia, hypertension.</td>
    </tr>
    <tr>
      <td>amrinone</td>
      <td>Inocor</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>amrinone (Inocor)-[Amp 5mg/ml] IV Loading dose 0.75mg/kg over 2-3min. Mix solution at 1mg/ml. Maintenance dose 5-10mcg/kg/min. Max 10mg/kg/d. ¶C. S.E: Arrythmias, thrombocytopenia, hypotension.</td>
    </tr>
    <tr>
      <td>dobutamine</td>
      <td>Butamine</td>
      <td>B</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>dobutamine (Butamine)-[Amp 12.5mg/ml] β1(β2α) IV Dilute 20ml in at least 50ml of diluent (Not to exceed 5mg/ml) 2.5-15mcg/kg/min (Not to exceed 40mcg/kg/min). ¶B. *L2. S.E: Hypertension, hypotension, arrhythmia, bronchospasm, hypoglycemia, hypokalemia.</td>
    </tr>
    <tr>
      <td>dobutamine+ascorbic acid</td>
      <td>Dobuject</td>
      <td>B</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>dobutamine+ascorbic acid (Dobuject)-[Amp 50mg/ml, 50mg+1mg] β1(β2α) IV as for dobutamine. ¶B. *L5. S.E: VT, hypertension, hypotension, thrombocytopenia, hypokalemia.</td>
    </tr>
    <tr>
      <td>dopamine</td>
      <td>Docard</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>dopamine (Docard)-[Amp 40mg/ml] IV Dilute solution to 0.8-1.6mg/ml. Initial rate: 2-5mcg/kg/min. Increase by 5-10mcg/kg/min as needed. Max: 20-50mcg/kg/min. ¶C. *L2. S.E: Hyportension, cerebral hemorrhage, arrhythmias.</td>
    </tr>
    <tr>
      <td>ephedrine</td>
      <td>Ephedrine</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>ephedrine (Ephedrine)-[Tab 20, 50mg; Amp 50mg/ml] β1(α1) IV IM SC Hypotension: 25-50mg slow. Asthma: 0.25-0.5ml PO Orthostatic hypotension: 25mg 3x/d. ¶C. *L4. S.E: Hypertension, intracranial hemorrhage.</td>
    </tr>
    <tr>
      <td>midodrine</td>
      <td>Gutron</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>midodrine (Gutron)-[Tab 2.5mg] PO Orthostatic hypotension: start 2.5mg 3x/d. Usual 10mg 3x/d while awake. ¶C. *L3. S.E: Hypertension.</td>
    </tr>
    <tr>
      <td>milrinone</td>
      <td>Primacor</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>milrinone (Primacor)-[Amp 1mg/ml] IV Load 50mcg/kg over 10min. Then 0.375-0.75mcg/kg/min. ¶C. *L4. S.E: Arrhythmias, hypotension, sudden death.</td>
    </tr>
    <tr>
      <td>nesiritide</td>
      <td>Noratak</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>nesiritide (Noratak)-[Amp 1.5mg] IV Congestive heart failure: bolus 2mcg/kg/min, then 0.01mcg/kg/hr. ¶C. *L3. S.E: Hypotension, worsening of renal function.</td>
    </tr>
    <tr>
      <td>norepinephrine</td>
      <td>Levophed</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>norepinephrine (Levophed)-[Amp 1mg/ml] α1β1 IV 4mg in 1000ml 5% Dextrose. Initial dose: 8-12mcg/min. Adjust as needed to maintain BP. Usual 2-4mcg/min. ¶C. S.E: Ischemic injury, bradycardia, hypertension, arrhythmias.</td>
    </tr>
    <tr>
      <td>isosorbide mononitrate</td>
      <td>Monocord, Mononit</td>
      <td>B</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>isosorbide mononitrate (Monocord, Mononit)-[Tab 20, 40mg] (Monocord 50 SR)-[SR Tab/Cap 50mg] (Monolong)-[SR Cap 40, 60mg] PO 20mg 2-3x/d. May increase to 120mg/d. Sustained release: 50-120mg/d. ¶B. *L3. S.E: Angina pectoris, arrhythmias, hypotension, edema, syncope.</td>
    </tr>
    <tr>
      <td>glyceryl trinitrate</td>
      <td>Deponit NT 5</td>
      <td>C</td>
      <td>Pressor / Inotropes</td>
      <td>CARDIOVASCULAR</td>
      <td>glyceryl trinitrate (Deponit NT 5)-[Patch 18.7mg] (Deponit NT 10)-[Patch 37.4mg] (Nitroderm TTS 5)-[Patch 25mg] (Nitroderm TTS 10)-[Patch 50mg] (Nitrolingual Spray)-[Spray 0.4mg] Prophylaxis Angina Pectoris: 1 Patch/d. Max 2 Patches/d. 1-2 sprays under tongue. Max 3 sprays in 15min. ¶C. S.E: Hypotension, reflex tachycardia, exfoliative dermatitis, bradyarrhythmia, syncope.</td>
    </tr>
    <tr>
      <td>streptokinase</td>
      <td>Streptase</td>
      <td>C</td>
      <td>Thrombolytics</td>
      <td>CARDIOVASCULAR</td>
      <td>streptokinase (Streptase)-[Amp 750K, 1500K IU] IV Acute MI: 1500K U over 60min. Maint: 100K U/hr. ¶C. *L2. S.E: Arrhythmias, cholesterol embolus syndrome, major bleeding, anaphylactoid reaction, polyneuropathy, pulmonary edema, hypotension.</td>
    </tr>
    <tr>
      <td>tissue plasminogen activator</td>
      <td>Actilyse</td>
      <td>C</td>
      <td>Thrombolytics</td>
      <td>CARDIOVASCULAR</td>
      <td>tissue plasminogen activator (Actilyse)-[Amp 20, 50mg] IV Acute MI: 15mg bolus then 50mg over 30min, then 35mg over next hr. Or 60mg bolus, then 60mg 1st hr then 20mg 2nd hr then 20mg 3rd hr. If patient ≤67kg 15mg bolus then 0.75mg/kg (max 50mg) over 30min then 0.5mg/kg (max 35mg) over next hr. Or 1.25mg/kg in 3hr regimen as above. Use with concurrent heparin. CVA: 0.9mg/kg 10% of dose bolus over 1min then up to 90mg over 1hr. PE: 100mg over 2hr then restart heparin when PTT ≤twice normal. ¶C. *L2. S.E: Intracranial hemorrhage, gastrointestinal hemorrhage, recurrent ischemia, hypotension, HF, shock, arrhythmia.</td>
    </tr>
    <tr>
      <td>urokinase</td>
      <td>Urokinase Medac</td>
      <td>B</td>
      <td>Thrombolytics</td>
      <td>CARDIOVASCULAR</td>
      <td>urokinase (Urokinase Medac)-[Amp 10K, 50K, 100K, 250K, 500K, 1,000K IU/ml] IV and intracoronary use. 10, 50, 100 dissolved in 2ml of water for injections. 250 dissolved in 5ml water. 500, 1,000 dissolved in 10ml. Used to restore patency. ¶B. S.E: Bleeding, anaphylaxis.</td>
    </tr>
    <tr>
      <td>acetazolamide</td>
      <td>Uramox</td>
      <td>C</td>
      <td>Diuretics-1 -</td>
      <td>CARDIOVASCULAR</td>
      <td>acetazolamide (Uramox)-[Tab 250mg] PO 250-375mg/d. Usual 5mg/kg. Altitude sickness: 0.5-1G in 2-3 divided or SR Tab 500mg 1-2x/d beginning 1-2d before ascent and continue for 2d. ¶C. *L2. S.E: Hepatic necrosis, agranulocytosis, aplastic anemia, metabolic acidosis, hypokalemia, renal insufficiency, anaphylaxis, blood dyscrasias.</td>
    </tr>
    <tr>
      <td>chlorthalidone</td>
      <td>Aquadon</td>
      <td>B</td>
      <td>Diuretics-1 -</td>
      <td>CARDIOVASCULAR</td>
      <td>chlorthalidone (Aquadon)-[Tab 100mg] PO Hypertension: 12.5-25mg single dose. Max 100mg/d. Edema: 50-100mg/d or 100mg alternate days. Max 200mg/d. ¶B. *L4. S.E: Arrhythmia, Stevens-Johnson syndrome, hepatotoxicity, systemic lupus erythematosus.</td>
    </tr>
    <tr>
      <td>furosemide</td>
      <td>Fusid, Furosemide-Fresenius, Furovenir</td>
      <td>C</td>
      <td>Diuretics-1 -</td>
      <td>CARDIOVASCULAR</td>
      <td>furosemide (Fusid, Furosemide-Fresenius, Furovenir)-[Tab 40mg; Amp 20mg/2ml, 250mg/25ml] PO Start 20-80mg. Increase by 20-40mg every 6-8hr until desired response. Max 600mg/d. IV IM start 20-40mg. If needed increase by 20-40mg injected slowly (over 1-2min). Peds: Start 2mg/kg, increase by 1-2mg/kg. ¶C. *L3. S.E: Hypotension, erythema multiforme, Stevens-Johnson syndrome, eosinophilia, hyperuricemia.</td>
    </tr>
    <tr>
      <td>hydrochlorothiazide</td>
      <td>Disothiazide</td>
      <td>B</td>
      <td>Diuretics-1 -</td>
      <td>CARDIOVASCULAR</td>
      <td>hydrochlorothiazide (Disothiazide)-[Tab 25mg] PO Hypertension: 25-50mg/d. Maint: 12.5-100mg/d. Edema: 25-100mg/d. Peds: 2-12yrs 37.5-100mg/d. &lt;2yrs max 37.5mg/d. ¶B. *L3. S.E: Hyperkalemia, metabolic, or respiratory acidosis.</td>
    </tr>
    <tr>
      <td>indapamide</td>
      <td>Pamid</td>
      <td>B</td>
      <td>Diuretics-1 -</td>
      <td>CARDIOVASCULAR</td>
      <td>indapamide (Pamid)-[Tab 2.5mg] PO Hypertension: start 1.25mg/d AM. Increase after 4wks if no response to 2.5mg/d then max 5mg/d. Edema: 2.5-5mg AM. ¶B. *L3. S.E: Hypokalemia, hyponatremia.</td>
    </tr>
    <tr>
      <td>metolazone</td>
      <td>Zaroxolyn</td>
      <td>B</td>
      <td>Diuretics-1 -</td>
      <td>CARDIOVASCULAR</td>
      <td>metolazone (Zaroxolyn)-[Tab 5mg] PO Hypertension: 2.5-5mg 1x/d. Congestive heart failure: 5-20mg 1x/d. Max 80mg/d. ¶B. S.E: Hypokalemia, hyponatremia.</td>
    </tr>
    <tr>
      <td>amiloride+hydrochlorothiazide</td>
      <td>Kaluril</td>
      <td>B</td>
      <td>Diuretics – Potassium Sparing</td>
      <td>CARDIOVASCULAR</td>
      <td>amiloride+hydrochlorothiazide (Kaluril)-[Tab 5mg+50mg] PO Hypertension: 1Tab single or divided dose. Max 2 Tab/d. Edema: 1-2 Tab/d. ¶B. L3. S.E: Hyperkalemia.</td>
    </tr>
    <tr>
      <td>spironolactone</td>
      <td>Aldactone</td>
      <td>C</td>
      <td>Diuretics – Potassium Sparing</td>
      <td>CARDIOVASCULAR</td>
      <td>spironolactone (Aldactone)-[Tab 25mg] (Spironolactone TEVA)-[Tab 25,100mg] PO Diuretic: 50-100mg/d single or divided doses. Congestive heart failure: 25-200mg/d single or divided doses. Primary aldosteronism: 400mg/d Hypokalemia: 25-100mg/d. ¶C. *L2. S.E: Hyperkalemia, gynecomastia.</td>
    </tr>
    <tr>
      <td>abciximab</td>
      <td>ReoPro</td>
      <td>C</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>abciximab (ReoPro)-[Amp 2mg/ml] IV Aggregation inhibitor, percutaneous coronary intervention: 0.25mg/kg bolus then 0.125mcg/kg/min. Max 10mcg/min for 12hr. ¶C. S.E: Bleeding risk, allergic reactions.</td>
    </tr>
    <tr>
      <td>anagrelide hydrochloride</td>
      <td>Anagrid 0.5, Anagrelide Orpha</td>
      <td>C</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>anagrelide hydrochloride (Anagrid 0.5, Anagrelide Orpha)-[Cap 0.5 mg] PO Essential thrombocythemia: Start 0.5mg 4x/d or 1mg 2x/d. Adjust to lowest effective dose. ¶C. *L4. S.E: Cardiovascular toxicity, bleeding risk, pulmonary toxicity.</td>
    </tr>
    <tr>
      <td>acetylsalicylic acid</td>
      <td>Aspirin 81</td>
      <td>C</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>acetylsalicylic acid (Aspirin 81)-[Tab 81mg] (Cartia, Godamed, Tevapirin, Cardiopirin)-[Tab 100mg] (Micropirin)-[Tab 75, 100mg] (Acetosal)-[Tab 300mg] (Gramse Pirin)-[Tab 324mg] (Aspirin 500)-[Tab 500mg] PO Inhibit platelet aggregation: 1Tab/d. ¶C. *L3. S.E: GI bleeding, Reye's syndrome renal failure, thrombocytopenia, respiratory alkalosis and metabolic acidosis, anaphylaxis, hepatotoxicity, hyperkalemia, hypotension, intracranial hemorrhage, pulmonary edema.</td>
    </tr>
    <tr>
      <td>clopidogrel</td>
      <td>Plavix 300</td>
      <td>B</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>clopidogrel (Plavix 300)-[Tab 300mg] (Plavix 75, Clopid 75, Clood, Clopidexcel 75, Clopidogrel Teva)-[Tab 75mg] PO 75mg 1x/d. ¶B. *L3. S.E: Bleeding risk, thrombotic thrombocytopenic purpura. Pharmacogenomic risk: 14-30% slow metabolizers in Israel.</td>
    </tr>
    <tr>
      <td>dipyridamole</td>
      <td>Cardoxin</td>
      <td>B</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>dipyridamole (Cardoxin)-[Tab 75mg; Amp 10mg/2ml] PO 75-100mg 4x/d. IV 0.57mg/kg total infused over 4 minutes. ¶B. *L3. S.E: Angina pectoris.</td>
    </tr>
    <tr>
      <td>eptifibatide</td>
      <td>Integrilin</td>
      <td>B</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>eptifibatide (Integrilin)-[Soln 0.75, 2mg/ml] (Eptifibatide Teva)-[Soln 2mg/ml) IV Acute coronary syndrome: load 180mcg/kg, then 2mcg/kg/min for 3d. Percutaneous coronary intervention: load 180mcg/kg IV bolus before procedure and a second bolus of 180µg/kg then 2mcg/kg/min for 18-24hr after. ¶B. *L3. S.E: Bleeding risk, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>prasugrel as hydrochloride</td>
      <td>Effient</td>
      <td>B</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>prasugrel as hydrochloride (Effient)-[Tab 5, 10mg] PO Start 60mg/d, Continue 10mg/d, consider 5mg 1x/d for patients &lt;60kg. ¶B. *L4. S.E: CABG-related bleeding, thrombotic thrombocytopenic purpura, bleeding, angioedema.</td>
    </tr>
    <tr>
      <td>ticagrelor</td>
      <td>Brilinta</td>
      <td>C</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>ticagrelor (Brilinta)-[Tab 60, 90mg] PO Start 180mg/d following an ACS event. Continue with 90mg 2x/d first year after an ACS event. After one year, administer 60mg 2x/d. ¶C. *L4. S.E: Bleeding, dyspnea, hepatotoxicity, bradyarrhythmias.</td>
    </tr>
    <tr>
      <td>ticlopidine hydrochloride</td>
      <td>Ticlidil</td>
      <td>B</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>ticlopidine hydrochloride (Ticlidil)-[Tab 250mg] PO Stroke: 250mg 2x/d with food. Coronary Artery Stenting: 250mg 2x/d with food together with antiplatelet doses of aspirin for up to 30 days following successful stent implantation. ¶B. *L4. S.E: Neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura, aplastic anemia.</td>
    </tr>
    <tr>
      <td>tirofiban</td>
      <td>Aggrastat</td>
      <td>B</td>
      <td>Antiplatelet Drugs</td>
      <td>CARDIOVASCULAR</td>
      <td>tirofiban (Aggrastat)-[Amp 0.25mg/ml] IV start 25mcg/kg within 5 minutes then 0.15mcg/kg/min. ¶B. S.E: Bleeding risk, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>acipimox</td>
      <td>Olbetam</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>acipimox (Olbetam)-[Cap 250mg] PO 500-750mg/d in divided dose with meals. ¶X. S.E: None.</td>
    </tr>
    <tr>
      <td>atorvastatin calcium trihydrate</td>
      <td>Lipitor</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>atorvastatin calcium trihydrate (Lipitor)-[FC Tab 10, 20, 40, 80mg] PO Start 10mg 1x/d. Max 80mg/d. ¶X. S.E: Hepatotoxicity, CNS toxicity.</td>
    </tr>
    <tr>
      <td>atorvastatin</td>
      <td>Atorva Dex</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>atorvastatin (Atorva Dex)-[Tab 10, 20, 40mg] (Atorva Teva)-[Tab 10, 40, 80mg] (Atorvastatin Teva)-[Tab 10, 20 40, 80mg] (Lipitor)-[FC Tab 10, 20, 40, 80mg] (Litorva)-[Tab 10, 20, 40, 80mg] (Torid)-[Tab 10, 20, 40, 80mg] PO Hyperlipidemia: 10-20mg 1x/d. Max 80mg. ¶X. *L3. S.E: Rhabdomyolysis, hepatotoxicity, CNS toxicity.</td>
    </tr>
    <tr>
      <td>bezafibrate</td>
      <td>Bezafibrate 400</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>bezafibrate (Bezafibrate 400)-[SR Tab 400mg] (Norlip)-[Tab 200mg] PO Dyslipidemia: 400mg 1x/d Peds: 10-20mg/kg/day Max 400mg/d ¶X. S.E: Leukopenia, thrombocytopenia, hepatotoxicity, cholelithiasis, rhabdomyolysis, hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>cholestyramine</td>
      <td>NaN</td>
      <td>C</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>cholestyramine (29 ג') (Chol-less)-[Sachet Pwdr 4G] PO Start 4G 1-2x/d before meals. Increase to 4G 3-4x/d. Max 24 G/d. ¶C. *L1. S.E: Anorexia, bleeding risk.</td>
    </tr>
    <tr>
      <td>ciprofibrate</td>
      <td>Lipanor</td>
      <td>N</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>ciprofibrate (Lipanor)-[Cap 100mg] PO 100mg/d. ¶Not established. S.E: Rhabdomyolysis. Use cautiously in renal insufficiency or impaired hepatic function.</td>
    </tr>
    <tr>
      <td>colestipol</td>
      <td>Colestid</td>
      <td>B</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>colestipol (Colestid)-[Pwdr 5G] PO start 5G 1-2x/d. Increase up to 30G/d in divided dose. ¶B. *L3. S.E: Tachycardia, anorexia.</td>
    </tr>
    <tr>
      <td>ezetimibe</td>
      <td>Ezetrol</td>
      <td>C</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>ezetimibe (Ezetrol)-[Tab 10mg] PO 1x/d. ¶C. S.E: Hepatotoxicity.</td>
    </tr>
    <tr>
      <td>ezetimibe+simvastatin</td>
      <td>Inegy</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>ezetimibe+simvastatin (Inegy)-[Tab 10+10, 10+20, 10+40, 10+80mg] PO Start 10+10-10+20mg 1x/d. 10+80mg is for chronic intake only. Do not take with grapefruit. ¶X. *L3. S.E: Rhabdomyolysis, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>fluvastatin</td>
      <td>Lescol</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>fluvastatin (Lescol)-[Cap 20, 40mg] PO start 20-40mg 1x/d. Max 40mg 2x/d. ¶X. *L3. S.E: Rhabdomyolysis, hepatotoxicity, CNS toxicity.</td>
    </tr>
    <tr>
      <td>pravastatin</td>
      <td>Pravalip, Pravastatin-Teva</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>pravastatin (Pravalip, Pravastatin-Teva)-[Tab 10, 20, 40mg] (Stavenir)-[Tab 40mg] PO Start 40mg 1x/d Max 80mg/d. ¶X. *L3. S.E: Rhabdomyolysis, hepatotoxicity, dermatomyositis.</td>
    </tr>
    <tr>
      <td>rosuvastatin</td>
      <td>Creator, Rosuvastatin-Teva, Stator</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>rosuvastatin (Creator, Rosuvastatin-Teva, Stator)-[FC Tab 5, 10, 20, 40mg] PO 5-40mg 1x/d (use 40mg dose only for patients not reaching LDL-C goal with 20mg). ¶X. *L3. S.E: Liver enzyme abnormalities, myopathy, rhabdomyolysis, headache, abdominal pain, asthenia, nausea.</td>
    </tr>
    <tr>
      <td>simvastatin</td>
      <td>Simovil</td>
      <td>X</td>
      <td>Anti-Hyperlipidemic Agents</td>
      <td>CARDIOVASCULAR</td>
      <td>simvastatin (Simovil) [10, 20, 40mg] (Simvacor, Simvastatin-Teva, Simvaxon)-[Tab 10, 20, 40, 80mg] PO Start 20-40mg 1x/d at night. Max 40-80mg/d. ¶X. *L3. S.E: Rhabdomyolysis, hepatotoxicity, dermatomyositis.</td>
    </tr>
    <tr>
      <td>albumin</td>
      <td>Human Albumin 20% Behring</td>
      <td>C</td>
      <td>Volume Expanders</td>
      <td>CARDIOVASCULAR</td>
      <td>albumin (Human Albumin 20% Behring)-[Infusion 200mg/ml] (Zenalb)– [Soln 20%, 4.5%] IV Hypovolemia: 25G, if no response repeat after 15-30min. Hypoalbuminemia: 50-75G. ¶C. *L1. S.E: Anaphylaxis, HF, syncope, pulmonary edema.</td>
    </tr>
    <tr>
      <td>albumin+plasma protein fraction</td>
      <td>Albunorm 5%, 20%</td>
      <td>N</td>
      <td>Volume Expanders</td>
      <td>CARDIOVASCULAR</td>
      <td>albumin+plasma protein fraction (Albunorm 5%, 20%)-[Soln 50G/1000ml+96%, 200G/1000ml+96%] IV Hypovolemia: 25G, if no response repeat after 15-30min. Hypoalbuminemia: 50-75G.¶Not established. S.E: Anaphylactic shock, arrhythmias.</td>
    </tr>
    <tr>
      <td>starch etherified+sodium chloride</td>
      <td>Haes-Sterile</td>
      <td>C</td>
      <td>Volume Expanders</td>
      <td>CARDIOVASCULAR</td>
      <td>starch etherified+sodium chloride  (Haes-Sterile)-[Soln 60G/L+9G/L, 100G/L+9G/L] IV Dose depends on blood loss. Start 10-20ml slowly, under observation. ¶C. S.E: Anaphylaxis, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema.</td>
    </tr>
    <tr>
      <td>plasma protein fraction</td>
      <td>Albiomin</td>
      <td>C</td>
      <td>Volume Expanders</td>
      <td>CARDIOVASCULAR</td>
      <td>plasma protein fraction (Albiomin) [Soln 20%- 200g/l] IV min dose: 250-500mL at a slow rate. ¶C. S.E: Hypotension.</td>
    </tr>
    <tr>
      <td>aminophylline</td>
      <td>Aminophylline</td>
      <td>C</td>
      <td>Asthma Medications</td>
      <td>PULMONOLOGY</td>
      <td>aminophylline (Aminophylline)-[Soln 250 mg/10ml] IV Adults: 0.51mg/kg/hr. Peds: 0.89mg/kg/hr. ¶C. S.E: Ventricular arrhythmia, seizure.</td>
    </tr>
    <tr>
      <td>ephedrine</td>
      <td>Pertussol Syrup, Tocare Syrup, Tussophedrine NF</td>
      <td>C</td>
      <td>Asthma Medications</td>
      <td>PULMONOLOGY</td>
      <td>ephedrine (Pertussol Syrup, Tocare Syrup, Tussophedrine NF)-[Tab 50mg] α1β1β2 PO Asthma: 25-50mg every 3-4h as needed. ¶C. *L4. S.E: Atrial fibrillation, ventricular premature beats, myocardial ischemia.</td>
    </tr>
    <tr>
      <td>montelukast</td>
      <td>Montair</td>
      <td>B</td>
      <td>Asthma Medications</td>
      <td>PULMONOLOGY</td>
      <td>montelukast (Montair)-[Chew Tab 4, 5mg] (Singulair)-[Tab 10mg] (Montelukast Trima, Montelukast Inovamed, Montelukast Teva, Singulair Chewable Singulair Granules for Kiddies)-[Chew Tab 4, 5mg; Tab 4, 5, 10mg] PO Asthma: 10mg/d. Exercise induced bronchospasm: 10mg 2 hours before exercise. ¶B. *L3. S.E: Allergic granulomatosis angiitis, hepatitis.</td>
    </tr>
    <tr>
      <td>salbutamol</td>
      <td>Salbutamol Sterinebs Teva</td>
      <td>C</td>
      <td>Asthma Medications</td>
      <td>PULMONOLOGY</td>
      <td>salbutamol (Salbutamol Sterinebs Teva)-[Neb Soln 2.5mg/2,5ml, 5mg/2.5ml] (Salbutamol Teva, Salbutrim, Ventolin Inhaler CFC Free)-[Inh Aerosol 100mcg/dose] (Ventolin Diskus)-[Inh Pwdr 200mcg/dose] (Ventolin Injection)-[Soln 0.5mg/ml] (Ventolin Respiration Solution)-[Neb Soln 5mg/ml] (Ventolin Syrup)-[Syrp 2mg/5ml] (Ventolin Tablets)-[Tab 2mg] PO 2-4mg 3-4x/d. Max 8mg-4x/d. Inh 180mcg 4-6x/d. Max 12 inhalations/d. Neb 2.5mg 2-3x/d PRN. ¶C. *L1. S.E: Paradoxical bronchospasm, hypersensitivity reactions, tremors.</td>
    </tr>
    <tr>
      <td>terbutaline</td>
      <td>Bricalin Turbuhaler</td>
      <td>C</td>
      <td>Asthma Medications</td>
      <td>PULMONOLOGY</td>
      <td>terbutaline (Bricalin Turbuhaler)-[Inh Pwdr 0.5mg/dose] (Terbulin Respiratory solution)-[Neb Soln 150mg/15ml] (Terbulin Syrup)-[Syrp 30mg/100ml] PO 2.5-5mg 2-4x/d. Max 7.5mg/d. Peds: 12-15yrs only: 2.5mg 3x/d. Max 7.5mg. ¶C. *L2. S.E: Arrhythmias, cerebral hemorrhage, hypertension, seizures.</td>
    </tr>
    <tr>
      <td>theophylline</td>
      <td>Theotard, Theotrim</td>
      <td>C</td>
      <td>Asthma Medications</td>
      <td>PULMONOLOGY</td>
      <td>theophylline (Theotard, Theotrim)-[SR Cap 100, 200, 300mg] PO starting dose 150mg every 12h, after 3 days 200mg every 12h. Max 600mg/d if tolerated. Peds&lt;45kg: 12-14mg/kg/day to max 300mg/d divided every 12h. Therapeutic range 5-20mcg/ml. ¶C. *L3. S.E: Seizure, arrhythmias, tremor.</td>
    </tr>
    <tr>
      <td>beclomethasone</td>
      <td>QVAR Inhaler</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>beclomethasone (QVAR Inhaler)-[Inh 50, 100mcg/dose] Inhale 1-2 nasal inhalations in each nostril. Peds 6-12yrs: 1 nasal inhalation in each nostril 2x/d. Max daily dose: 2 sprays in each nostril. ¶C. *L2. S.E: Immunosuppression, cataracts, hyperglycemia, osteoporosis, growth retardation in children, muscle atrophy.</td>
    </tr>
    <tr>
      <td>budesonide</td>
      <td>Budicort Respules, Budesonide Sterinebs</td>
      <td>B</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>budesonide (Budicort Respules, Budesonide Sterinebs)-[Neb Susp 1mg/2ml, 0.5mg/2ml] (Budicort Turbuhaler)-[Inh 100, 200mcg/dose] (Miflonide)-[Inh Pwdr 200, 400mcg/dose] Neb 0.25mg 2X/d. Max 1mg/d. Inh 360mcg 2x/d. Max 1440mcg/d. ¶B. *L1. S.E: Immunosuppression, anaphylaxis, angioedema, cataracts, hyperglycemia, osteoporosis, growth retardation in children, muscle atrophy, Churg-Strauss syndrome.</td>
    </tr>
    <tr>
      <td>budesonide+formoterol</td>
      <td>Duoresp Spiromax</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>budesonide+formoterol (Duoresp Spiromax)-[Inh 160+4.5, 320+9 mcg/dose] (Symbicort Turbuhaler)-[Inh 80+4.5, 160+4.5, 320+9 mcg/dose] Inh Asthma and COPD: 80-160mcg 2x/d. Max 320+9mcg 2x/d. ¶C. *L3. S.E: Asthma-related death, localized infections, osteoporosis, growth retardation in children, cataract.</td>
    </tr>
    <tr>
      <td>cromoglycate sodium</td>
      <td>Vicrom 5</td>
      <td>B</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>cromoglycate sodium (Vicrom 5)-[Inh 5 mg/dose] (Cromo-comod Nasal Spray)-[20mg/ml] Inh 2Puffs 2-8x/d. Maint: 1Puff 4x/d. Spin Cap: in spinhaler 20mg 4X/d. Max 8 Cap/d. ¶B. S.E: Bronchospasm, anaphylactic reaction.</td>
    </tr>
    <tr>
      <td>fluticasone propionate</td>
      <td>Flixotide Inhaler</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>fluticasone propionate (Flixotide Inhaler)-[Inh 50, 125, 250, 500µg/dose] (Avamys)-[Spray 27.5µg/dose] (Flixotide Nebules)-[Soln 0.5, 2mg/2ml] (Flixotide CFC Free, Flixotide Diskus)-[50,100,125, 250, 500µg/dose] Inhale 100-1000µg 2x/d. Peds: &gt;4yrs: 50-100µg 2X/d. Nebulized Soln: 0.5-2mg 2x/d. ¶C. *L3. S.E: Immunosuppression, cataracts, hyperglycemia, osteoporosis, growth retardation in children, muscle atrophy.</td>
    </tr>
    <tr>
      <td>fluticasone propionate+formoterol fumarate dehydrate</td>
      <td>Flutiform</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>fluticasone propionate+formoterol fumarate dehydrate (Flutiform)-[Inh 50+5, 125+5, 250+10mg/dose] Inh 2x/d (AM and PM), 250+10 is only for &gt;18. ¶C. *L3. S.E: Candidiasis of the mouth and throat, hyperglycemia, allergic reactions, peripheral edema.</td>
    </tr>
    <tr>
      <td>formoterol</td>
      <td>Foradil</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>formoterol (Foradil)-[Pwdr 12µg/dose. Inhale Cap (Pwdr) 12µg/cap] (Oxis Turbuhaler)-[Inh 9µg/dose] ß2 Inh 1-2Puffs or 1Cap 2x/d. Max 2X/d. ¶C. *L3. S.E: Palpitations, tremor, sleep disturbances.</td>
    </tr>
    <tr>
      <td>ipratropium bromide</td>
      <td>Aerovent</td>
      <td>B</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>ipratropium bromide (Aerovent)-[Soln 0.25 mg/ml (20drops)] (Atrovent)-[Inh 0.25mg] Inh 1-2puffs 3-4x/d. Peds: 6-12yrs: 1-2puffs 3x/d. 3-6yrs: 1puff 3x/d. Nebulized Soln: 0.1-0.5mg (8-40drops) up to 4x/d. Peds: 3-14yrs: 0.1-0.5mg up to 3x/d. ¶B. *L2. S.E: Paralytic ileus, anaphylaxis, palpitations.</td>
    </tr>
    <tr>
      <td>nedocromil sodium</td>
      <td>Tilade Mint</td>
      <td>B</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>nedocromil sodium (Tilade Mint)-[Inh 2mg/dose] Inh 2Puffs 4x/d. Peds &gt;6yr: 2 Puffs 2x/d. ¶B. S.E: Hepatitis.</td>
    </tr>
    <tr>
      <td>salbutamol</td>
      <td>Ventolin Diskus</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>salbutamol (Ventolin Diskus)-[Inh Pwdr 200µg] (Ventolin Inhaler CFC Free, Salbutamol, Salbutrim)-[Inh 100 µg/dose] (Ventolin Respiratory Soln)-[Soln 5mg/ml] ß2 Inh 100-200µg every 3-4hrs as required. Max: 800µg/d. Inhale Caps: 100-200µg 4x/d. Max: 800µg/d. Nebulized Soln: 2.5-5mg dilutes 4x/d. ¶C. *L1. S.E: Tremor, URTI, palpitations, muscle cramps.</td>
    </tr>
    <tr>
      <td>salmeterol</td>
      <td>Serevent Diskus, Servent Inhaler CFC Free</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>salmeterol (Serevent Diskus, Servent Inhaler CFC Free) -[Inh 25, 50µg/dose] ß2 Inh 25-50µg 2x/d. ¶C. *L2. S.E: Tremor, palpitations.</td>
    </tr>
    <tr>
      <td>salmeterol+fluticasone</td>
      <td>Seretide Diskus</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>salmeterol+fluticasone (Seretide Diskus)-[Inh 50+100, 50+250, 50+500µg/dose] ß2+steroid Inh 1Puff 2x/d. Max 50+500 2X/d. Peds: 4-11yrs 1Puff 2x/d 50+100. ¶C. *L3. S.E: Candidiasis of the mouth and throat, hypokalemia, sinusitis, pneumonia, bronchitis.</td>
    </tr>
    <tr>
      <td>terbutaline</td>
      <td>Bricalin, Bricalin Turbuhaler</td>
      <td>C</td>
      <td>Inhaled steroids</td>
      <td>PULMONOLOGY</td>
      <td>terbutaline (Bricalin, Bricalin Turbuhaler)-[Inh 0.5mg/dose. Soln 10mg/ml] (Terbulin)-[Soln 150mg/15ml] ß2 Inh 2 Puffs q4-6h as required. Nebulized Soln: 0.5-1ml (11-22 drops) 2-4x/d. Peds: &gt;8yrs: 0.5ml (11 drops) 2-4x/d. ¶C. *L2. S.E: Tremor, palpitations, hypokalemia, hypertention, tachycardia.</td>
    </tr>
    <tr>
      <td>acetylcysteine</td>
      <td>Reolin Effervescent</td>
      <td>B</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>acetylcysteine (Reolin Effervescent)-[Effervesc Tab 200mg] (Siran 200)-[Pwdr 100, 200mg; Effervesc/Dispers Tab 200mg] PO Mucolytic: 1 Effervesc or Dispers Tab in glass water \ 3x/d. Pwdr 200mg 2-3x/d. 3-5ml of 20% solution nebulized 3-4x/d. Peds: up to 2yrs 100mg 2x/d. ¶B. S.E: Allergic reactions, tachycardia, hypotension.</td>
    </tr>
    <tr>
      <td>alprostadil</td>
      <td>Alprostapint, Prostin VR</td>
      <td>X</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>alprostadil (Alprostapint, Prostin VR)-[Amp 0.5mg/ml, Amp 10, 20mcg/vial] IA IV 0.05-0.1µg/kg/min to maintain patent ductus arteriosus in neonates. ¶X. S.E: Arrhythmias, hypotension, edema, sepsis, hypokalemia, DIC, seizure, apnea in newborn.</td>
    </tr>
    <tr>
      <td>bromhexine</td>
      <td>Movex</td>
      <td>A</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>bromhexine (Movex)-[Tab 8mg, Soln 2mg/ml] (Mucoless, Solvex, Solvex Elixir)-[Tab 8mg; Soln 2mg/ml, 4mg/5ml] PO 8-16mg 3x/d. Peds: 6-14yrs 8mg 3x/d. Inh 4mg 2x/d. Peds: 4-16yrs 1mg 2x/d. 2-6yrs 1mg (10drops) 2x/d. 1-2yrs: 0.5mg (5drops) 2x/d. ¶A. S.E: Allergic reactions, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>carbocysteine</td>
      <td>Mical</td>
      <td>C</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>carbocysteine (Mical)-[Tab 375mg] (Mucolit)-[Cap 375mg; Syrp 250 mg/4ml; Loz 375mg] (Muco-Treat)-[Syrp 250mg/5ml] (Tiptipot Mucolit)-[Drops 75mg/ml] PO 750mg 2x/d. 1500-2250mg/d in 3-4 divided dose. Peds: 6-12yrs 300-750mg/d divided in 3 doses or ½-1Fruit Loz 3X/d or 50drops 4x/d. 2-5yrs 200-500mg/d 2-4 divided doses or ½Fruit Loz 4x/d or 12-25drops 4x/d. ¶C. S.E: Severe allergic reactions, arrhythmia, hypoglycemia.</td>
    </tr>
    <tr>
      <td>cromoglycate sodium</td>
      <td>Lomudal Nasal Solution</td>
      <td>B</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>cromoglycate sodium (Lomudal Nasal Solution)-[Nasal Spray 2%] 1 Spray each nostril 3-4x/d. Max: 6x/d. ¶B. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>dornase alfa</td>
      <td>Pulmozyme</td>
      <td>B</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>dornase alfa (Pulmozyme)-[Neb Soln 2.5mg/2.5ml] Inh 2.5mg 1-2x/d. ¶B. S.E: None.</td>
    </tr>
    <tr>
      <td>diphenhydramine+ ammonium</td>
      <td>Broncho D</td>
      <td>B</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>diphenhydramine+ ammonium (Broncho D)-[Syrp 10+136mg/5ml] PO 15ml q4h. Peds: 6-14yrs: 5-10ml q4h. ¶B. *L3. S.E: Spasms, dyspnea, tachycardia.</td>
    </tr>
    <tr>
      <td>diphenhydramine+pseudoephedrine</td>
      <td>Broncho-kid</td>
      <td>B</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>diphenhydramine+pseudoephedrine (Broncho-kid)-[Syrp 10+20mg/5ml] (Broncholate)-[Syrp 0.2%+0.4%w/v] PO 15ml 3x/d. Peds: &gt;6yr: 5ml 1-3X/d. ¶B+C. *L3. S.E: Palpitations.</td>
    </tr>
    <tr>
      <td>ketotifen</td>
      <td>Profiten</td>
      <td>C</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>ketotifen (Profiten)-[Tab 1mg; Syrp 1mg/5ml] PO Allergy: 1mg 2x/d, 1Tab 2x/d. Peds: 0.5-3yrs 0.5mg 2x/d, ½ Tab 2xd. ¶C. *L3. S.E: Syncope, hematemesis.</td>
    </tr>
    <tr>
      <td>poractant alfa</td>
      <td>Curosurf</td>
      <td>N</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>poractant alfa (Curosurf)-[Susp 80mg] Intratracheal lung surfactant initial dose: 2.5ml/kg birth weight, Max 2 repeated doses of 1.25ml/kg in 24hr. Max total dose: 5ml/kg. ¶Not indicated. S.E: Acute changes in oxygenation and lung compliance.</td>
    </tr>
    <tr>
      <td>calfactant</td>
      <td>Infasurf</td>
      <td>N</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>calfactant (Infasurf)-[Susp 35mg/ml] Intrathecal lung surfactant 3ml/kg birth weight, q12h for up to 3 doses. ¶Not established. S.E: Cyanosis, bradycardia, airway obstruction.</td>
    </tr>
    <tr>
      <td>treprostinil</td>
      <td>Remodulin</td>
      <td>B</td>
      <td>Other Pulmonary Medications</td>
      <td>PULMONOLOGY</td>
      <td>treprostinil (Remodulin)-[Amp 2.5, 5, 10mg/ml] (Tyvaso)-[Amp 1.74mg/2.9ml] SC IV Pulmonary hypertension: Start 1.25mg/kg/min. Increase as necessary. Inh 3 breaths 4x/d. ¶B. S.E: May increase risk of bleeding, particularly in patients receiving anticoagulants.</td>
    </tr>
    <tr>
      <td>famotidine</td>
      <td>Famo, Gastro</td>
      <td>B</td>
      <td>Antiulcer – H2 Antagonists</td>
      <td>GASTROENTEROLOGY</td>
      <td>famotidine (Famo, Gastro)-[FC Tab 10, 20, 40mg] (Famotidine Teva)-[Tab 20, 40mg] PO 40mg PM or 20mg 2x/d for 4-8wks. Zollinger-Ellison Syndrome: 20mg 4x/d. Gastroesophageal Reflux disease (GERD): 20-40mg 2x/d for 12wks. ¶B. *L1. S.E: Necrotizing enterocolitis in fetus or newborn, pancreatitis.</td>
    </tr>
    <tr>
      <td>ranitidine</td>
      <td>Zaridex</td>
      <td>B</td>
      <td>Antiulcer – H2 Antagonists</td>
      <td>GASTROENTEROLOGY</td>
      <td>ranitidine (Zaridex)-[Tab/Cap 150, 300mg] (Zantac)-[Syrp 150 mg/10ml, Amp 25mg] PO 150mg 2X/d or 300mg PM. Maintenance: 150mg at bedtime. IV 50mg slow 3-4x/d. ¶B. *L2. S.E: Necrotizing enterocolitis in fetus or newborn, pancreatitis.</td>
    </tr>
    <tr>
      <td>lansoprazole</td>
      <td>Lanton, Lansoprazole Teva</td>
      <td>B</td>
      <td>Antiulcer – Proton Pump Inhibitors</td>
      <td>GASTROENTEROLOGY</td>
      <td>lansoprazole (Lanton, Lansoprazole Teva)-[Cap 15, 30mg] PO Gastroesophageal reflux disease: Active 30mg/d 4wks. Maintenance 15mg/d. Gastric ulcer: 30mg/d 8wks. H.Pylori eradication: 30mg 2x/d used with clarithromycin (250mg 2x/d)-amoxycillin (1G 2x/d). ¶B. *L3. S.E: Peripheral edema, depression, hepatitis.</td>
    </tr>
    <tr>
      <td>omeprazole</td>
      <td>Losec</td>
      <td>C</td>
      <td>Antiulcer – Proton Pump Inhibitors</td>
      <td>GASTROENTEROLOGY</td>
      <td>omeprazole (Losec)-[Cap 10, 20mg] (Omepra, Omepradex)-[Cap 10, 20, 40mg] (Omeprix, Omepradex-z)-[Caps 20mg] PO Gastroesophageal reflux disease/Esophagitis: 10mg 1x/d. Hypersecretory condition: 20-120mg/d in 2-3 doses, before meal swallow whole with only water. Gastric ulcer: 40mg 1x/d. Used with clarithromycin-amoxycillin-metronidazole (2 of 3) for H.Pylori. ¶C. *L2. S.E: Peripheral edema, dermatitis, hepatitis.</td>
    </tr>
    <tr>
      <td>pantoprazole</td>
      <td>Controloc</td>
      <td>B</td>
      <td>Antiulcer – Proton Pump Inhibitors</td>
      <td>GASTROENTEROLOGY</td>
      <td>pantoprazole (Controloc)-[Tab 20, 40mg; Pwdr 40 mg/VIAL] (Pantoprazole TEVA)-[Tab 40 mg] (Pantoavenir, Ulceron)-[Pwdr40mg/ VIAL] PO IV GERD: 40mg/d for up to 8wks. Hypersecretory conditions: 40mg 2x/d before meal swallow whole with only water. ¶B. *L1. S.E: Sleep disorders, hepatitis, bone fractures.</td>
    </tr>
    <tr>
      <td>dicyclomine</td>
      <td>Notensyl</td>
      <td>B</td>
      <td>Antiulcer - Other</td>
      <td>GASTROENTEROLOGY</td>
      <td>dicyclomine (Notensyl)-[Tab 10mg; Syrp 10mg/5ml] PO Dosage must be adjusted to individual patient needs. ¶B. *L4. S.E: Blurred vision, dysuria.</td>
    </tr>
    <tr>
      <td>esomeprazole</td>
      <td>Nexium</td>
      <td>B</td>
      <td>Antiulcer - Other</td>
      <td>GASTROENTEROLOGY</td>
      <td>esomeprazole (Nexium)-[Tab 20, 40mg] PO GERD Esophagitis: 20mg/d. Duodenal ulcer: Used for 10d with clarithromycin-amoxycillin. ¶B. *L2. S.E: Peripheral edema, insomnia, vertigo, hepatitis, dermatitis, bone fructures.</td>
    </tr>
    <tr>
      <td>misoprostol</td>
      <td>Cytotec</td>
      <td>X</td>
      <td>Antiulcer - Other</td>
      <td>GASTROENTEROLOGY</td>
      <td>misoprostol (Cytotec)-[Tab 200µg] PO Prevention of NSAID ulcer: 200µg 4x/d. ¶X. *L3. S.E: Hypertension HF, edema, gastrointestinal adverse events, renal toxicity, anaphylaxis, anemia.</td>
    </tr>
    <tr>
      <td>sucralfate</td>
      <td>Ulsanic</td>
      <td>B</td>
      <td>Antiulcer - Other</td>
      <td>GASTROENTEROLOGY</td>
      <td>sucralfate (Ulsanic)-[Tab 1G] Active duodenal ulcer: PO 1G 4x/d ½hr before meal and bedtime. ¶B. *L2. S.E: Hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>activated charcoal</td>
      <td>Norit</td>
      <td>s</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>activated charcoal (Norit)-[Tab 125mg] PO 4Tab after meal. ¶safe. S.E: Allergic reactions, perforation of the GI tract and subsequent charcoal peritoneum, electrolyte abnormalities, shock, bronchiolitis obliterans, empyema.</td>
    </tr>
    <tr>
      <td>activated charcoal+ senna+ other</td>
      <td>Novicarbon</td>
      <td>N</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>activated charcoal+ senna+ other (Novicarbon)-[Tab 180mg+105mg+other] PO 1-2Tab during/after meal with fluids. ¶Not established. S.E: Tachycardia.</td>
    </tr>
    <tr>
      <td>aluminum hydroxide+magnesium hydroxide</td>
      <td>Maalox Forte</td>
      <td>s</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>aluminum hydroxide+magnesium hydroxide (Maalox Forte)-[Susp 460mg+400mg] (Maalox Suspension)-[Susp 225+200mg/5ml] PO 1-2 bags as symptoms occur. Max: 12bags/d or 8Tabs/d. ¶safe. S.E: Allergic reactions, electrolyte abnormalities.</td>
    </tr>
    <tr>
      <td>aluminum hydroxide+magnesium hydroxide+simethicone</td>
      <td>Maalox Plus</td>
      <td>s</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>aluminum hydroxide+magnesium hydroxide+simethicone (Maalox Plus)-[Susp 225+200+25mg/5ml; Chewable Tab 200+200+25mg]. PO 5-10ml 4x/d 20min-1hr after meal and bedtime. 1-2Tab chewed 4x/d. ¶safe. S.E: Allergic reactions, electrolyte abnormalities.</td>
    </tr>
    <tr>
      <td>calcium carbonate</td>
      <td>Calcimore</td>
      <td>N</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>calcium carbonate (Calcimore)-[Chew Tab 600mg] (Tums)-[Chew Tab 500, 750, 1000mg] (N-Zarevet)-[Tab 500mg] PO Antacid: 1-2Tab after meal. Supplement: 1-5Tab/d. ¶Not established. Excessive use should be avoided. S.E: Anorexia.</td>
    </tr>
    <tr>
      <td>calcium carbonate+magnesium carbonate</td>
      <td>Fresco</td>
      <td>s</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>calcium carbonate+magnesium carbonate (Fresco)-[Tab 500+12mg] (Rennie Ice, Rennie Orange, Rennie Peppermint)-[Tab 680+80mg] PO 1-2Tab after meal or when necessary. Max: 15 Tab/d. ¶safe. S.E: Allergic reactions, renal failure, rebound hyperacidity, gallstones.</td>
    </tr>
    <tr>
      <td>magnesium carbonate+other</td>
      <td>Rekiv</td>
      <td>N</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>magnesium carbonate+other (Rekiv)-[Tab 0.4G+other] PO 3-6 Tab/d up to 3mnths. ¶Not established. S.E: Diarrhea.</td>
    </tr>
    <tr>
      <td>magnesium hydroxide</td>
      <td>Milk of Magnesia</td>
      <td>s</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>magnesium hydroxide (Milk of Magnesia)-[susp 400mg/5ml] PO &lt;12y 30-60ml 1x/d. 6-11y 15-30ml 1x/d. ¶safe. S.E: Hypermagnesemia, hypotension.</td>
    </tr>
    <tr>
      <td>pepsin+sodium glycerophosphate+nicotinic acid</td>
      <td>Babyzim</td>
      <td>N</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>pepsin+sodium glycerophosphate+nicotinic acid (Babyzim)-[Drops 30+40+10mg/5ml] PO Peds: Dyspepsia: &lt;1yr: 5 drops before+after each meal up to 50drops/d. 1-2y: 20-40drops after every meal. 2-5y: 40-60 drops after every meal. 5-14y: 2.5-5ml after every meal. ¶Notesthablished. S.E: Dyspnea, allergic reactions.</td>
    </tr>
    <tr>
      <td>simethicone</td>
      <td>dimethicone</td>
      <td>C</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>simethicone (dimethicone) (Tiptipot Simicol)-[Drops 40mg/0.6ml] (Gazim X, Simicol)-[Tablets 125 mg] PO: Adults &amp; &gt;12y, 1-2Tab after meals or before sleep. Tab not for &lt;12y. PO Antiflatulent: 0.3-0.6ml before meal. ¶C. *L3. Systemic absorption would be required in order for simethicone to cross the placenta and reach the fetus. S.E: None.</td>
    </tr>
    <tr>
      <td>simethicone+activated charcoal</td>
      <td>Carbosylane</td>
      <td>C</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>simethicone+activated charcoal (Carbosylane)-[Cap 45+140mg] PO Blue&amp;Red Tabs 3x/d before meal. ¶C. S.E: Melena.</td>
    </tr>
    <tr>
      <td>simethicone+aluminum hydroxide+other</td>
      <td>Maalox Plus</td>
      <td>C</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>simethicone+aluminum hydroxide+other (Maalox Plus)-[Tab 25+200mg+other; Susp 25+225mg+other/5ml] PO 1-2Tab 3-4x/d after meal and bedtime. Susp 5-10ml 4x/d after meal and bedtime. Peds: Susp 6-12yr 5ml 3-4x/d after meal and bedtime. ¶C. *L3. S.E: Constipation, diarrhea.</td>
    </tr>
    <tr>
      <td>sodium bicarbonate+simethicone+citric acid</td>
      <td>E-Z-Gas II</td>
      <td>C</td>
      <td>Antacids / Antiflatulent</td>
      <td>GASTROENTEROLOGY</td>
      <td>sodium bicarbonate+simethicone+citric acid (E-Z-Gas II)-[Effervescent granules 55.14+1+38.21%w/w; Tab 10gr+650mg. IV 8.4%] PO Place half of the contents of 1 packet on the tongue and wash down with water, repeat with the remaining contents of the packet. ¶C. S.E: Allergic reactions, dyspnea.</td>
    </tr>
    <tr>
      <td>dimenhydrinate</td>
      <td>Dramamine</td>
      <td>B</td>
      <td>Antiemetic-1</td>
      <td>GASTROENTEROLOGY</td>
      <td>dimenhydrinate (Dramamine)-[Tab 50mg] (Travamin)-[Tab 100mg] PO 50-100mg q4-6h as needed. Motion sickness: ½hr before journey. Peds: 25-50mg 3x/d. &lt;6y not recommended. ¶B. *L2. S.E: Allergic reactions, tinnitus, hypotension, hyperactivity.</td>
    </tr>
    <tr>
      <td>dronabinol</td>
      <td>Ronabin</td>
      <td>C</td>
      <td>Antiemetic-1</td>
      <td>GASTROENTEROLOGY</td>
      <td>dronabinol (Ronabin)-[Cap 2.5, 5, 10mg] PO 5mg 6-8x/d. Increase appetite: 2.5-20mg/d. ¶C. *L3. S.E: Paranoid reaction, euphoria, hypotension, conjunctivitis.</td>
    </tr>
    <tr>
      <td>granisetron</td>
      <td>Granisetron-Teva</td>
      <td>B</td>
      <td>Antiemetic-1</td>
      <td>GASTROENTEROLOGY</td>
      <td>granisetron (Granisetron-Teva)-[Amp 3mg/3ml] (Kytril)-[Amp 3mg, Tab 1mg] (Setron)-[Tab 1mg, Amp 3mg/3ml] IV Nausea with chemotherapy: 10-40µg/kg or up to 3mg over 5min (in 20-50ml) 30min prior to chemo. Max 3 doses. Postop: 1mg given before anesthesia. PO 1mg 2x/d on day of chemo. Peds: 20µg/kg 2x/d. ¶B. *L3. S.E: Mutagenicity, carcinogenicity.</td>
    </tr>
    <tr>
      <td>haloperidol</td>
      <td>Haldol</td>
      <td>C</td>
      <td>Antiemetic-1</td>
      <td>GASTROENTEROLOGY</td>
      <td>haloperidol (Haldol)-[Tab 5mg; Amp 5mg; Drops 2mg/ml; Depot 100mg/ml] (Haloper)-[Tab 0.5, 5, 10mg] (Pericate)-[Amp (Depot) 100mg/ml] IM IV PO 5mg 1-2x/d. Peds: 3-12y 0.5mg/d. Moderate symptoms: PO 0.5-2mg q1h. Severe symptoms: PO 3-5mg q2-3h. ¶C. *L3. S.E: Arrhythmias, neuroleptic malignant syndrome, extrapyramidal parkinsonian symptoms, seizures, VTE, tardive dyskinesia, acute akathisia, acute dystonia, restless leg syndrome.</td>
    </tr>
    <tr>
      <td>metoclopramide</td>
      <td>Pramin</td>
      <td>B</td>
      <td>Antiemetic-1</td>
      <td>GASTROENTEROLOGY</td>
      <td>metoclopramide (Pramin)-[Tab 10mg; Supp 5mg; Amp 10mg/2ml] PO IV IM 10mg 1-3x/d or 0.5mg/kg/d. Peds: 5mg 2-4x/d. Supp 2-3x/d or 0.5mg/kg in divided dose. ¶B. *L2. S.E: Tardive dyskinesia, nervous system disorders, cardiac disorders, renal and hepatic disorders.</td>
    </tr>
    <tr>
      <td>ondansetron</td>
      <td>Zofran</td>
      <td>B</td>
      <td>Antiemetic-1</td>
      <td>GASTROENTEROLOGY</td>
      <td>ondansetron (Zofran)-[Tab 4, 8mg; Amp 2mg/ml] (Ondansetron Invomed)- [Amp 2mg/ml; Tab 4, 8mg]. Chemo nausea: IV 0.15-6mg/kg over 15min, 30min prior to chemo. Repeat 4 &amp; 8hr after. PO 8mg 3x/d Peds: ≥12yrs 8mg 3x/d. 4-11yrs 4mg 3x/d. Postop: IV 4mg over 2-5min or PO 16mg 1hr before anesthesia. ¶B. *L2. S.E: Arrhythmias, bronchospasm.</td>
    </tr>
    <tr>
      <td>atropine</td>
      <td>Atropine Sulphate</td>
      <td>C</td>
      <td>Antidiarrheals</td>
      <td>GASTROENTEROLOGY</td>
      <td>atropine (Atropine Sulphate)-[Tab 0.5mg; Amp 1mg/ml, 20mg/10ml; Inj 0.5, 1, 2mg] (Spasmalgin)-[Tab 0.4mg] PO Antispasmatic: 0.3-1.2mg 4-6x/d PRN. Peds: 0.01mg/kg up to 0.3mg q1-2h. SC IM IV 0.4-0.6mg q4-6h. ¶C. *L3. S.E: Arrhythmias, coma, respiratory depression, glaucoma.</td>
    </tr>
    <tr>
      <td>bismuth subsalicylate</td>
      <td>Kalbeten</td>
      <td>D</td>
      <td>Antidiarrheals</td>
      <td>GASTROENTEROLOGY</td>
      <td>bismuth subsalicylate (Kalbeten)-[Tab/Chew Tab 262, 524mg; Susp 262mg/15ml, 262.5mg/7.5ml] (Pink Bismuth)-[Tab/Chew 262mg; Susp 262.5mg/15ml] (Peptolite)-[Tab/Chew 262mg; Susp 262.5mg/15ml] (Bitni X)-[Tab 262mg; Susp 262mg/15ml, 262mg/7.5ml] PO 2Tab q½-1h up to 15Tab/d. Max 7 doses. ¶D. *L3. S.E: Reye’s syndrome.</td>
    </tr>
    <tr>
      <td>kaolin+pectin</td>
      <td>Kaopectin, Kapectin Forte</td>
      <td>s</td>
      <td>Antidiarrheals</td>
      <td>GASTROENTEROLOGY</td>
      <td>kaolin+pectin (Kaopectin, Kapectin Forte)-[Susp 20g+0.5g/100ml] PO 15-30ml after each loose stool. Double amount also used. Peds: 5-15ml. ¶safe. *L1. S.E: None.</td>
    </tr>
    <tr>
      <td>loperamide</td>
      <td>Imodium</td>
      <td>C</td>
      <td>Antidiarrheals</td>
      <td>GASTROENTEROLOGY</td>
      <td>loperamide (Imodium)-[Cap 2mg] (Loperid, Loperium, Stopit)-[Cap 2mg] (Rekamide)-[Tab 2mg] PO Start 4mg, followed by 2mg after each loose bowel movement. Max: 16mg/d. Peds: Start 2mg, then 1mg after each bowel movement. Max: 4mg/d. ¶C. *L2. S.E: Stevens-Johnson syndrome, toxic epidermal necrolysis, paralytic ileus, megacolon.</td>
    </tr>
    <tr>
      <td>bisacodyl</td>
      <td>Laxadin, Atzirut X</td>
      <td>s</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>bisacodyl (Laxadin, Atzirut X)-[EC Tab 5mg] PO 1-3Tab at bedtime. Peds: 1-2Tab. ¶safe. *L2. S.E: None.</td>
    </tr>
    <tr>
      <td>bisacodyl+hydroxyanisole</td>
      <td>Contalax</td>
      <td>s</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>bisacodyl+hydroxyanisole (Contalax)-[Supp 0.566%] Rectal 1 Supp. Peds: ½Supp. ¶safe. S.E: Tachycardia, confusion, electrolyte loss.</td>
    </tr>
    <tr>
      <td>glycerine</td>
      <td>Glycerine Supp</td>
      <td>N</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>glycerine (Glycerine Supp)-[Supp 1.104 ,3.2g] Rectal: 1 suppository 1x/d as needed. ¶Not established. S.E: Rectal irritation, tenesmus.</td>
    </tr>
    <tr>
      <td>ispaghula psyllium</td>
      <td>Agiocur</td>
      <td>s</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>ispaghula psyllium (Agiocur)-[husks 2.2G/100G, seeds 65G/100G], (Agiolax)-[husks 2.2G/100G, seeds 52G/100G] Bowel regulation, softener: Constipation PO 2.5-30G/d . Peds: ½dose. ¶safe. S.E: Hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>macrogols+mineral salts</td>
      <td>Meroken</td>
      <td>C</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>macrogols+mineral salts (Meroken)-[Pwdr 315g+other] PO Bowel cleaning: Dissolve and drink 240ml every 10min total 3L. ¶C. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>polyethylene glycol 3350</td>
      <td>Normalax</td>
      <td>C</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>polyethylene glycol 3350 (Normalax)-[Pwdr 100%w/w] (Peglax, Regulax)-[Pwdr 99.973%w/w]  PO Laxative: 17G in 200ml of clear liquid 1x/d. ¶C. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>psyllium mucilloid</td>
      <td>Konsyl Easy Mix</td>
      <td>N</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>psyllium mucilloid (Konsyl Easy Mix)-[Pwdr 4.3G] (Konsyl Orange)-[Pwdr 3.5G] PO 1 teaspoon 1-3x/d in a glass of cold water. ¶Not established. *L1. S.E: Dyspnea, dysphagia.</td>
    </tr>
    <tr>
      <td>sennosides senna</td>
      <td>Bekunis</td>
      <td>C</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>sennosides senna (Bekunis)-[Tab 150-220mg] PO 2 Tabs 1x/d- 4 Tabs 2x/d. Peds: 1Tab 1x/d- 2Tabs 2x/d. ¶C. *L3. S.E: Diarrhea, vomiting.</td>
    </tr>
    <tr>
      <td>senna+ other natural</td>
      <td>Eucarbon</td>
      <td>C</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>senna+ other natural (Eucarbon)-[Tab 105mg+other] (Midro-Tea)-[Tea Bag/Granules] PO 2-4Tabs 1-2x/d. Tea: bedtime or morning. PO 1-3 teasp chewed or swallowed with boiling water. ¶C. *L3. S.E: Diarrhea, vomiting, electrolyte abnormalities, constipation.</td>
    </tr>
    <tr>
      <td>sodium phosphate</td>
      <td>Fleet Enema 133</td>
      <td>C</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>sodium phosphate (Fleet Enema 133)-[Enema 60mg/ml] (Fleet Enema 250)-[Enema 160mg/ml] Enema as required. ¶C. *L3. S.E: Mucosal bleeding, electrolyte abnormalities, allergic reactions, nephrolithiasis, arrhythmias, ischemic colitis, renal failure , seizure.</td>
    </tr>
    <tr>
      <td>sodium lauryl sulphoacetate</td>
      <td>Microlet</td>
      <td>A</td>
      <td>Laxatives</td>
      <td>GASTROENTEROLOGY</td>
      <td>sodium lauryl sulphoacetate (Microlet)-[Enema 0.9%W/V] Enema 1tube as required. ¶A. S.E: Irritation of the anak canal, muscle cramps.</td>
    </tr>
    <tr>
      <td>bismuth+benzocaine+zinc+other</td>
      <td>Hemo</td>
      <td>C</td>
      <td>Hemorrhoidals /anal fissure treatment</td>
      <td>GASTROENTEROLOGY</td>
      <td>bismuth+benzocaine+zinc+other (Hemo)-[Supp 180+15+120mg+other] (Rectozorin)-[Supp 100+100+100mg+other] Local: apply as required. ¶C. *L3. S.E: Hypertenstion, allergic reactions.</td>
    </tr>
    <tr>
      <td>glyceryl trinitrate</td>
      <td>Rectogesic</td>
      <td>C</td>
      <td>Hemorrhoidals /anal fissure treatment</td>
      <td>GASTROENTEROLOGY</td>
      <td>glyceryl trinitrate (Rectogesic)-[Oint 0.4%]. Chronic anal fissure: Apply 2.5cm ointment intra-anally every 12h until pain abates, max 8wks. ¶C. S.E: Headaches, hypotension, reflex tachycardia, exfoliative dermatitis, bradyarrhythmia, syncope.</td>
    </tr>
    <tr>
      <td>hydrocortisone+benzocaine+zinc+allantoin+other</td>
      <td>Proctozorin-N</td>
      <td>C</td>
      <td>Hemorrhoidals /anal fissure treatment</td>
      <td>GASTROENTEROLOGY</td>
      <td>hydrocortisone+benzocaine+zinc+allantoin+other (Proctozorin-N)-[Oint 0.5%+5%+10%+2%+other] Apply 2-3x/d. ¶C. *L3. S.E: Allergic reactions, secondary infection, skin atrophy.</td>
    </tr>
    <tr>
      <td>hydrocortisone+pramoxine</td>
      <td>Epifoam</td>
      <td>C</td>
      <td>Hemorrhoidals /anal fissure treatment</td>
      <td>GASTROENTEROLOGY</td>
      <td>hydrocortisone+pramoxine (Epifoam)-[Spray 0.9%+0.9%] Perianal inflammation: Spray 3-4x/d. ¶C. *L3. S.E: Skin atrophy.</td>
    </tr>
    <tr>
      <td>hydrocortisone+lidocaine</td>
      <td>Perinal Spray</td>
      <td>C</td>
      <td>Hemorrhoidals /anal fissure treatment</td>
      <td>GASTROENTEROLOGY</td>
      <td>hydrocortisone+lidocaine (Perinal Spray)-[Spray 0.2%+1%] Perianal pain: Spray 2-3x/d. Supp Oint as required. ¶C. *L2. S.E: Erythema.</td>
    </tr>
    <tr>
      <td>lidocaine+tribenoside</td>
      <td>Procto-Glyvenol</td>
      <td>C</td>
      <td>Hemorrhoidals /anal fissure treatment</td>
      <td>GASTROENTEROLOGY</td>
      <td>lidocaine+tribenoside  (Procto-Glyvenol)-[Supp/Cream 40mg+400mg] Topical Supp: 2x/d then reduce. Cream: as needed. ¶C. S.E: None.</td>
    </tr>
    <tr>
      <td>orlistat</td>
      <td>Xenical</td>
      <td>X</td>
      <td>Weight-loss-1</td>
      <td>GASTROENTEROLOGY</td>
      <td>orlistat (Xenical)-[Cap 120mg] PO 120mg 3x/d with meals. ¶X. *L3. S.E: Upper and lower respiratory infections, rectal pain, fecal incontinence, UTI, hypoglycemia, anxiety.</td>
    </tr>
    <tr>
      <td>dextrose anhydrous+sodium citrate anhydrous+sodium chloride+potassium chloride</td>
      <td>Hydran 60</td>
      <td>A</td>
      <td>Oral rehydration</td>
      <td>GASTROENTEROLOGY</td>
      <td>dextrose anhydrous+sodium citrate anhydrous+sodium chloride+potassium chloride (Hydran 60)-[Pwdr 30+2.581+2+1.491g] (Minerali)-[Soln 75mmol+75mEq+65mEq+20mEq/l] PO Dissolve in 1L water and drink 100ml/kg/d. ¶A. S.E: Eyelid edema, emesis.</td>
    </tr>
    <tr>
      <td>glucose+Na+K+Cl+citrate -</td>
      <td>Orset</td>
      <td>A</td>
      <td>Oral rehydration</td>
      <td>GASTROENTEROLOGY</td>
      <td>glucose+Na+K+Cl+citrate -(Orset)- [Effervesc Tab 120ml] PO Dissolve 1-2Tab in 120ml water and drink after each diarrhea. ¶A. S.E: None.</td>
    </tr>
    <tr>
      <td>mesalazine</td>
      <td>Asacol</td>
      <td>C</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>mesalazine (Asacol)-[Tab 400, 800mg] (Pentasa SR)-[SR Granules 1, 2G; SR Tabs 500mg; Enema 1G/100ml; Supp 1G] (Rafassal, Rafassal Retention Enema)-[Caps 500mg, 1G; Supp 0.5, 1G; Enema 1, 4G; Granules 1, 1.5, 3G] PO PR IBD: 800mg 3x/d. Max 2.5G/d. Enema: 60ml 1x/d. ¶C. *L3. S.E: Eructation, abdominal pain, constipation.</td>
    </tr>
    <tr>
      <td>budesonide</td>
      <td>Budeson</td>
      <td>C</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>budesonide (Budeson)-[Cap 3mg] IBD: PO Active disease: 9mg 1x/d for 8wk. Maint: 6mg 1x/d up to 3 months. ¶C. *L3. S.E: Immunosuppression, cataract, hyperglycemia, depression, euphoria, osteoporosis, growth retardation in children, muscle atrophy.</td>
    </tr>
    <tr>
      <td>domperidone</td>
      <td>Motilium</td>
      <td>B</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>domperidone (Motilium)-[Tab 10mg] PO 10-20mg 3-4x/d. ¶B. *L1. S.E: Palpitations, allergic reactions.</td>
    </tr>
    <tr>
      <td>mebeverine</td>
      <td>Colotal</td>
      <td>B</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>mebeverine (Colotal)-[Tab 135mg] PO 135mg 3x/d before meals. ¶B. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>menthol+other</td>
      <td>Rowachol</td>
      <td>s</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>menthol+other (Rowachol)-[Cap 32mg+other] PO 1-2Cap 3x/d. ¶safe. *L3. S.E: Mouth ulcers.</td>
    </tr>
    <tr>
      <td>menthol+other</td>
      <td>Rectozorin</td>
      <td>C</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>menthol+other (Rectozorin)-[Oint 0.25%+other Supp 5mg] topical. Apply 2-3 times/d. ¶C. *L3. S.E: None.</td>
    </tr>
    <tr>
      <td>octreotide</td>
      <td>Sandostatin</td>
      <td>B</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>octreotide (Sandostatin)-[Soln 0.05, 0.1, 0.2, 0.5mg/ml] (Sandostatin LAR)-[Amp 10, 20, 30mg] SC IV Variceal bleeding: 25-50µg followed by infusion 25µg/hr. AIDS diarrhea: SC 100-500µg 3x/d. Relief of tumor symptoms: SC Start 50µg 1-2x/d. ¶B. *L3. S.E: Cholelithiasis, constipation, hyperglycemia, hypothyroidism.</td>
    </tr>
    <tr>
      <td>orlistat</td>
      <td>Xenical</td>
      <td>X</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>orlistat (Xenical)-[Cap 120mg] PO 120mg 3x/d with meals. ¶X. *L3. S.E: Upper and lower respiratory infections, rectal pain, fecal incontinence, UTI, hypoglycemia, anxiety.</td>
    </tr>
    <tr>
      <td>pancreatin</td>
      <td>Creon 10,000, 25,000</td>
      <td>C</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>pancreatin (Creon 10,000, 25,000)-[Cap 150, 300mg] (Creon micro) [Granules 60.12mg] PO 1-3 Cap with each meal. Granules: 5 granules 3x/d. ¶C. S.E: Ileo-cecum and large bowel strictures, allergic reactions.</td>
    </tr>
    <tr>
      <td>pancreatin+ox bile extract</td>
      <td>Encypalmed</td>
      <td>C</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>pancreatin+ox bile extract (Encypalmed)-[Tab 72+35mg] PO 2-4Tab 3x/d before or during meal. Peds: 1-2Tab 3x/d. ¶C. S.E: Ileo-cecum and large bowel strictures, allergic reactions.</td>
    </tr>
    <tr>
      <td>pancreatin+simethicone</td>
      <td>Pankreoflat</td>
      <td>C</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>pancreatin+simethicone (Pankreoflat)-[Coated Tab 170+80mg] PO 1-2 Tab with meals without chewing. Xray prep: 2 Tab 3-4x/d for 2d. ¶C. S.E: Hypersensitivity reactions, abnormal stool.</td>
    </tr>
    <tr>
      <td>papaverine</td>
      <td>Papaverine HCl</td>
      <td>C</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>papaverine (Papaverine HCl)-[Tab 40mg] (Papaverine Hydrochloride) [Soln 40mg/2ml; Tab 80mg] IV/IM 1-4ml doses injected slowly every 3hr. PO 80mg 2-6x/d. ¶C. S.E: Hepatitis, allergic reactions.</td>
    </tr>
    <tr>
      <td>papaverine+atropine+paracetamol+codeine</td>
      <td>Spasmalgin</td>
      <td>C</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>papaverine+atropine+paracetamol+codeine (Spasmalgin)-[Tab 80+0.4+150+10mg] PO Dyspepsia 1-2Tab 3x/d. Peds: 0.5-1Tab 3x/d. ¶C. S.E: Tachycardia, blurred vision, jaundice, hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>peppermint oil</td>
      <td>China Oel</td>
      <td>N</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>peppermint oil (China Oel)-[Oil 100%] (Colpermin)-[Tab 187mg] PO 1Tab 3x/d 30-60min before meal. Max 2 Tab 3x/d. INH PO Oil: 2-3 drops 2-3x/d. Not safe for children. ¶Not established. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>sulfasalazine</td>
      <td>Salazopyrin, Salazopyrin EN</td>
      <td>B</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>sulfasalazine (Salazopyrin, Salazopyrin EN)-[Tab/EN Tab 500mg] PO Start 3-4G/d in divided doses, then 2G/d maintenance. Peds: &gt;6yrs 40-60mg/kg/d in 3-6 divided doses, and 30mg/kg/d in 4 divided doses for maintenance. ¶B/D(if prolonged use near term (kernicterus). *L3. S.E: Serious infections, hypersensitivity reactions, serious skin reactions.</td>
    </tr>
    <tr>
      <td>sulpiride</td>
      <td>Modal</td>
      <td>N</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>sulpiride (Modal)-[Cap 50, 200mg] PO Ulcer adjuvant 50-100mg 3x/d. ¶Not established. *L2. S.E: Galactorrhea, amenorrhea, fatigue, jaundice.</td>
    </tr>
    <tr>
      <td>ursodeoxycholic acid</td>
      <td>Ursolit</td>
      <td>B</td>
      <td>Other GI Agents</td>
      <td>GASTROENTEROLOGY</td>
      <td>ursodeoxycholic acid (Ursolit)-[Cap 300mg; Tab 100mg] (Ursofalk) [Tab 250, 300mg; Susp 250mg/5ml] PO Primary Biliary Cirrhosis: 13-15mg/kg/d in 2-4 divided doses with food. Gallstones: 8-10mg/kg/d in 2-3 divided dose. ¶B. *L3. S.E: Hypersensitivity reactions, diarrhea, leukopenia.</td>
    </tr>
    <tr>
      <td>acenocoumarol</td>
      <td>Sintrom</td>
      <td>X</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>acenocoumarol  (Sintrom)-[Tab 4mg] PO 1st day: 2-4mg. Follow PT/INR. Similar to warfarin. ¶X. S.E: Hemorrhage, skin necrosis.</td>
    </tr>
    <tr>
      <td>apixaban</td>
      <td>Eliquis</td>
      <td>C</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>apixaban (Eliquis)-[FC Tab 2.5, 5mg] PO DVT/PE: start 10mg 2x/d for 7d, continue 5mg 2x/d for 6mnth, then 2.5mg 2x/d (individualized therapy duration). VTE prophylaxis after hip/knee replacement surgery: 2.5mg 2x/d for 35d (hip) or 12d (knee). Prevention of thromboembolism in AF: 5mg 2x/d. ¶C. S.E: Hemorrhage, anemia, hematuria.</td>
    </tr>
    <tr>
      <td>bivalirudin</td>
      <td>Angiomax</td>
      <td>B</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>bivalirudin (Angiomax)-[Amp 250mg] IV bolus 0.75mg/kg, then 1.75mg/kg/hr. Must use with 300mg/d aspirin. ¶B. S.E: Bleeding, hypotension, hypertension, bradycardia, anxiety, hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>dabigatran etexilate</td>
      <td>Pradaxa</td>
      <td>C</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>dabigatran etexilate (Pradaxa)-[Cap 75, 110, 150mg] PO VTE prophylaxis: 150mg 2x/d. VTE prophylaxis after hip/knee replacement surgery: 110mg/d 1-4h after completed surgery, then 220mg/d for 10d. Prevention of thromboembolism in AF: 150mg 2x/d. ¶C. *L3. S.E: Hemorrhage, anemia, hematuria, liver function abnormalities.</td>
    </tr>
    <tr>
      <td>heparin sodium</td>
      <td>Heparin</td>
      <td>C</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>heparin sodium (Heparin)-[IV 5000IU/ML], (Heparin Lock Flush)-[Single or multiple dose vials 10, 100U/ml] IV load 80U/kg then mix solution of 100U/ml, start at 18U/kg/hr. Adjust by PTT. DVT prophylaxis: SC 5000U 2-3x/d. Peds: IV load 50U/kg, then 25U/kg/hr. (Heparin in 0.9% Sodium Chloride)-[Infus 2U/ml] prepared solution 500ml.maintain patency of access lines. ¶C. *L1. S.E: Hemorrhage, heparin-induced thrombocytopenia, anaphylaxis.</td>
    </tr>
    <tr>
      <td>fondaparinux</td>
      <td>Arixtra</td>
      <td>B</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>fondaparinux (Arixtra)-[Soln 2.5mg/0.5ml, 7.5mg/0.6ml] IV SC &lt;50kg 5mg/d, 50-100kg 7.5mg/d, &gt;100kg 10mg/d for at least 5d until INR 2-3 achieved. Prophylaxis: SC 2.5mg 1x/d, initial dose should be given no earlier than 6-8h after surgery and continued for 5-9d. ¶B. *L3. S.E: Hemorrhage, thrombocytopenia, hypokalemia, anemia, hypotension.</td>
    </tr>
    <tr>
      <td>enoxaparin; low molecular weight heparin</td>
      <td>Clexane, Clexane Forte</td>
      <td>B</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>enoxaparin; low molecular weight heparin (Clexane, Clexane Forte )-[Soln 20mg/0.2ml, 150mg/1.0ml] SC IV DVT prophylaxis moderate risk: 20mg/d. Start 12-24hr post-op or 2hr pre-op if abdominal surgery. High risk prophylaxis: 40mg/d. DVT treatment ± PE: 1mg/kg 2x/d or 1.5mg/kg 1x/d. Unstable angina, non-Q MI: 1mg/kg 2x/d with aspirin (100-325 mg/d) at least 2d. ¶B. *L3. S.E: Hemorrhage, thrombocytopenia, liver function abnormalities, anaphylaxis.</td>
    </tr>
    <tr>
      <td>Fragmin</td>
      <td>dalteparin sodium</td>
      <td>B</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>Fragmin (dalteparin sodium)-[Syringe 2,500IU/0.2ml, 2,500, 10,000, 25,000IU/1ml] SC DVT prophylaxis, abdominal surgery: 2,500U 1-2hr pre-op and 1x/d post-op for 5-10d. If malignancy: double dose. Hip replacement 2,500U 2hr pre-op and same night (&gt;6hr) post-op then 5,000U 1x/d for up to 14d. Unstable angina, non-STE MI: 120U/kg up to 10,000 2x/d with Aspirin (low dose). ¶B. S.E: Hemorrhage, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>Fraxiparine</td>
      <td>nadroparin</td>
      <td>B</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>Fraxiparine (nadroparin)-[Syringe 2,850U/0.3ml, 3,800U/0.4ml, 5,700U/0.6ml, 7,600U/0.8ml] SC DVT prophylaxis: 2850U (0.3ml) 1x/d starting 2-12hrs before surgery. DVT treatment: &gt;50kg: 0.1ml/10kg 2x/d (70kg, 0.7ml) for 10d. ¶B. S.E: Hemorrhage, skin necrosis, hyperkalemia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>rivaroxaban</td>
      <td>Xarelto</td>
      <td>B</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>rivaroxaban (Xarelto)-[FC Tab 2.5, 10, 15, 20mg] PO VTE: start 15mg 2x/d for 21d, then 20mg/d. Prevention of thromboembolism in AF: 20mg/d. VTE prophylaxis after hip/knee replacement surgery: 10mg/d starting 6-10h after surgery for 35d (hip) or 12d (knee). ¶B. *L4. S.E: Hemorrhage, anemia, hypotension, hematuria, peripheral edema, liver function abnormalities.</td>
    </tr>
    <tr>
      <td>warfarin</td>
      <td>Coumadin</td>
      <td>X</td>
      <td>Anticoagulants</td>
      <td>HEMATOLOGY</td>
      <td>warfarin (Coumadin)-[Tab 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10mg] PO Start 1-5mg 1x/d for 1-2d, then adjust dose by PT/INR. Maintenance dose 2-10mg PO/IV 1x/d. ¶X. *L2. S.E: Cholesterol embolization syndrome, skin necrosis, hemorrhage, liver function abnormalities, hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>deferasirox</td>
      <td>Exjade</td>
      <td>C</td>
      <td>Chelation therapy</td>
      <td>HEMATOLOGY</td>
      <td>deferasirox (Exjade)-[Tab 125, 250, 500mg] PO 20mg/kg 1xd, on an empty stomach at least 30min before food. ¶C. *L3. S.E: GI hemorrhages, hepatotoxicity, renal toxicity, bone m.arrow suppression, Stevens Johnson syndrome, diarrhea, vomiting, abdominal pain.</td>
    </tr>
    <tr>
      <td>alemtuzumab</td>
      <td>Mabcampath</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>alemtuzumab (Mabcampath)-[Amp 10mg/ml] IV CLL: slow infusion 12mg/d for 5d then 12mg/d for 12 months. ¶C. *L4. S.E: Significant immunosuppression, hypersensitivity, anaphylaxis, cytokine release syndrome (fever, shivering, myalgia, headache), anemia, leukopenia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>anti-factor VIII inhibitor</td>
      <td>FEIB</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>anti-factor VIII inhibitor (FEIB) (Feiba)-[Amp 500, 1000IU] IV Begin treatment with 50units/kg. Increase to 100units/kg if hemorrhage does not stop. ¶C. S.E: Anaphylaxis, thrombotic and thromboembolic events.</td>
    </tr>
    <tr>
      <td>aprotinin</td>
      <td>proteinase inhibitor</td>
      <td>B</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>aprotinin (proteinase inhibitor) (Protosol)-[Amp 10,000KIU/ml] IV to reduce hemorrhage during surgery. The 1ml initial (test) dose should be administered IV at least 10min before the loading dose, the loading dose is given slowly over 20-30min, after induction of anesthesia but prior to sternotomy. ¶B. S.E: HF, MI, shock, thrombosis, anaphylaxis, CVA, renal failure.</td>
    </tr>
    <tr>
      <td>darbepoetin alfa</td>
      <td>Aranesp</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>darbepoetin alfa (Aranesp)-[Prefill Syringe 10, 20, 30, 40, 50, 60, 80, 100, 300, 500µg] SC IV 0.45µg/kg usual dose. ¶C. *L3. S.E: Arrhythmia or HF in patients with renal failure, thrombosis, dyspnea, peripheral edema, hypertension, procedural hypotension, seizures, MI, stroke.</td>
    </tr>
    <tr>
      <td>erythropoietin</td>
      <td>Eprex</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>erythropoietin (Eprex)-[Amp 5000, 6000, 8000, 20000, 30000, 40000U; Prefill Syringe 500, 1000, 2000, 3000, 4000, 10000U] (Recormon)-[Prefill Syringe 4000, 5000, 6000, 10000, 30000U] IV SC Anemia: 1dose 3x/wk. Renal failure 50-100U/kg. Chemo: 150U/kg. ¶C. (single-dose vials only). S.E: Arrhythmia or HF in patients with renal failure, thrombosis, dyspnea.</td>
    </tr>
    <tr>
      <td>factor VIIa</td>
      <td>Novoseven</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>factor VIIa (Novoseven)-[Amp 1, 2, 5mg] IV Congenital Hemophilia A or B: 90µg/kg. Max 12x/d. Acquired Hemophilia: 70-90µg/kg 8-12x/d. Congenital Factor VII Deficiency: 90µg/kg 4-6x/d. Glanzmann’s Thrombasthenia: 90µg/kg 6-12X/d. Until hemostasis is achieved. ¶C. S.E: Thrombosis.</td>
    </tr>
    <tr>
      <td>factor VIII</td>
      <td>Haemate P, Koate DVI, Immunate</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>factor VIII (Haemate P, Koate DVI, Immunate)-[Amp 250, 500, 1000 IU] (Optivate, Wilate)-[Amp 500, 1000IU] (Fahndi)-[Amp 25, 50, 100IU] (Antihemophilic Factor Human)-[Amp 220-2000IU] IV reconstitute, individualized dosing. Dosage (IU)=Body weight (kg) x Desired Factor VIII level increase (IU/dl or % normal) x 0.5 (IU/kg per IU/dl). ¶C. *L1. S.E: Hypersensitivity reactions, thrombosis.</td>
    </tr>
    <tr>
      <td>factor IX</td>
      <td>Replenine VF, Octanine</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>factor IX (Replenine VF, Octanine)-[Amp 500, 1000IU] (Benefix)-[PDI 250, 500, 2000IU/vial] IV individualized dosing. Dosage (IU) = Body weight (kg) x Desired Factor IX level increase (% of normal) x 1 (IU/kg). ¶C. S.E: Infection risk from human plasma, thrombosis, hypersensitivity reactions, nephrotic syndrome.</td>
    </tr>
    <tr>
      <td>factor XIII</td>
      <td>Fibrogammin P</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>factor XIII (Fibrogammin P)-[Amp 250, 1250IU] (Novothirteen)-[Amp 2500IU] IV individualized dosing. Routine prophylaxis: Initial IV 40U/kg, rate not to exceed 4ml/min. Maintenance: every 4 weeks are based on maintaining through FXIII activity level at 5-20% (use Berichrom activity assay). ¶C. S.E: Hypersensitivity reactions, immunogenicity, thromboembolism.</td>
    </tr>
    <tr>
      <td>fibrinogen+aprotinin+thrombin</td>
      <td>fibrin adhesive set</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>fibrinogen+aprotinin+thrombin (fibrin adhesive set) (Beriplast P Combi Set)-[Pwdr for soln for inj 90mg/ml+1000KIU/ml+500IU/ml, 270mg/3ml+3000KIU/3ml+1500IU/3ml] Hemostasis: cover surface or fill defect. ¶C. S.E: Anaphylactic shock, hypotension, thromboembolism, tachycardia, bronchospasm.</td>
    </tr>
    <tr>
      <td>fibrinogen+thrombin</td>
      <td>Tachosil</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>fibrinogen+thrombin (Tachosil)-[Sponge 5.5mg/cm2+2IU/cm2] Hemostasis: cover surface or fill defect. ¶C. S.E: Anaphylactic shock, hypotension, thromboembolism, tachycardia, bronchospasm.</td>
    </tr>
    <tr>
      <td>filgrastim</td>
      <td>Neupogen</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>filgrastim (Neupogen)-[Amp 30, 48MU; Prefill Syringe 30MU] (Tevagrastim)-[Prefill Syringe 0.6mg/ml] IV SC 5µg/kg/d. ¶C. *L3. S.E: Bone pain, dyspnea, hypotension, bradycardia, gout, splenic rupture.</td>
    </tr>
    <tr>
      <td>hyaluronidase</td>
      <td>Hyalase</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>hyaluronidase (Hyalase)-[Amp 1500IU] SC IM Local injection used to enhance permeation and absorption. ¶C. S.E: Urticaria, angioedema.</td>
    </tr>
    <tr>
      <td>human thrombin+calcium chloride</td>
      <td>Thrombixil</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>human thrombin+calcium chloride (Thrombixil)-[Soln 5.6-6.2mg+800-1200IU] Topical use only. Add 2ml of water and shake until solution is clear in room temperature and sponge target surface. ¶C. S.E: Dyspnea.</td>
    </tr>
    <tr>
      <td>ibrutinib</td>
      <td>Imbruvica</td>
      <td>D</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>ibrutinib (Imbruvica)-[Cap 140mg] PO For MCL: 560mg 1x/d. For CLL/SLL 420mg 1x/d. ¶D. S.E: Infections, atrial fibrillation, hypertension, tumor lysis syndrome, hemorrhage, neutropenia, thrombocytopenia, anemia.</td>
    </tr>
    <tr>
      <td>iloprost</td>
      <td>Ilomedin</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>iloprost (Ilomedin)-[Amp 0.134mg/ml] (Ventavis)-[Inh 0.01mg/ml] IV 2.5-5.0µg 6-9x/d. ¶C. S.E: Syncope, pulmonary venous hypertension, bronchospasm.</td>
    </tr>
    <tr>
      <td>imatinib</td>
      <td>Glivec, Imatinib-Teva</td>
      <td>D</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>imatinib (Glivec, Imatinib-Teva)-[Cap 100, 400mg] PO For CML: 400-600mg 1x/d. Max 400mg 2x/d. ¶D. *L5. S.E: Edema, anemia, neutropenia, thrombocytopenia, CHF, hepatotoxicity, hemorrhage, cardiogenic shock, hypothyroidism, tumor lysis syndrome.</td>
    </tr>
    <tr>
      <td>isoxsuprine</td>
      <td>Vasolan</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>isoxsuprine (Vasolan)-[Tab 10mg] PO Claudication: 10-20mg 3-4x/d. ¶C. S.E: Hypotension, tachycardia.</td>
    </tr>
    <tr>
      <td>lenalidomide</td>
      <td>Revlimid</td>
      <td>X</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>lenalidomide (Revlimid)-[Cap 2.5, 5, 7.5, 10, 15, 20, 25mg] PO For MDS: 10mg 1x/d. For MCL/MM: 25mg 1x/d on days 1-21 of repeated 28-day cycles. ¶X. S.E: Venous and arterial thromboembolism, neutropenia, thrombocytopenia, second primary malignancies, hepatotoxicity, tumor lysis syndrome.</td>
    </tr>
    <tr>
      <td>moroctocog alfa</td>
      <td>Xyntha</td>
      <td>N</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>moroctocog alfa (Xyntha)-[Pwdr 250, 500, 1000, 2000IU/Vial] IV For congenital factor VIII deficiency: The required dosage is determined using the following formula: Required units=body weight(kg) x desired factor VIII rise (IU/dL) x 0.5 (IU/kg per IU/dL). ¶Not established. S.E: Tachycardia, dizziness, headache, hypotension.</td>
    </tr>
    <tr>
      <td>nimodipine</td>
      <td>Nimotop</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>nimodipine (Nimotop)-[Tab 30mg] Subarachnoid hemorrhage: PO 60 mg 6x/d for 21d. ¶C. *L2. S.E: Hypotension, liver damage.</td>
    </tr>
    <tr>
      <td>pentoxifylline</td>
      <td>Oxopurin, Trental</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>pentoxifylline (Oxopurin, Trental)-[SR Cap 400mg] PO 400mg 2-3x/d with meals. ¶C. S.E: Insomnia, tremor, anaphylaxis.</td>
    </tr>
    <tr>
      <td>pomalidomide</td>
      <td>Imnovid</td>
      <td>X</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>pomalidomide (Imnovid)-[Cap 1, 2, 3, 4mg] PO For MM: 4mg/d on days 1-21 of repeated 28-day cycles until disease progression. ¶X. *L5. S.E: Hematologic toxicity, hepatotoxicity, tumor lysis syndrome, dyspnea, diarrhea, constipation.</td>
    </tr>
    <tr>
      <td>protamine</td>
      <td>Prosulf</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>protamine (Prosulf)-[Amp 50mg/5ml] IV Reversal of heparin: 1mg antagonizes ~100USP heparin. ¶C. S.E: Hypotension, non cardiogenic pulmonary edema, pulmonary hypertension.</td>
    </tr>
    <tr>
      <td>protein clottable+thrombin+calcium chloride</td>
      <td>Evicel Human Surgical Sealant</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>protein clottable+thrombin+calcium chloride (Evicel Human Surgical Sealant)-[Soln 50-90mg+800-1200IU+5.6-6.2mg/1ml] Use in patients undergoing surgery. ¶C. S.E: Bardycardia, hypokalemia, hypotension, graft infection, peripheral edema.</td>
    </tr>
    <tr>
      <td>monoxerutin</td>
      <td>Venoruton</td>
      <td>D</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>monoxerutin (Venoruton)-[Cap 300mg; Tab 500mg; Gel 2%] PO Venous insufficiency: Caps: 600-900mg/d with or after meals. Tab 500mg 2x/d with meals. Gel: apply 2x/d. ¶Do not use in 1st trimester. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>nilotinib</td>
      <td>Tasigna</td>
      <td>D</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>nilotinib (Tasigna)-[Cap 150, 200mg] PO For CML: 300mg 2x/d 12hrs apart on an empty stomach. Max 400mg 2x/d. ¶D. *L4. S.E: Prolong QT interval, sudden deaths, myelosuppression, pancreatitis, hepatotoxicity, electrolyte abnormalities, tumor lysis syndrome, hemorrhage, fluid retention.</td>
    </tr>
    <tr>
      <td>rituximab</td>
      <td>Mabthera</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>rituximab (Mabthera)-[Amp 10, 120mg] IV 75mg/m2 in the first cycle and 500mg/m2 in cycles 2–6. ¶C. *L4. S.E: Hepatitis B virus reactivation, tumor lysis syndrome, infections, arrhythmias, renal toxicity, bowel obstruction and perforation, pancytopenia, angioedema, hyperglycemia.</td>
    </tr>
    <tr>
      <td>ruxolitinib</td>
      <td>Jakavi</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>ruxolitinib (Jakavi)-[Tab 5, 15, 20mg] PO 10mg 2x/d, depending on blood cell count. Max 25mg 2x/d. ¶C. S.E: Hypertriglyceridemia, dizziness, hypertension, weight gain, UTI, constipation, hepatotoxicity, hemorrhage.</td>
    </tr>
    <tr>
      <td>thalidomide</td>
      <td>Thalidomide Celgene</td>
      <td>X</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>thalidomide (Thalidomide Celgene)-[Cap 50mg] PO For MM: 200mg/d. For ENL: 1—300mg/d Max 400mg/d. ¶X. *L5. S.E: Ischemic heart disease, peripheral neuropathy, orthostatic hypotension, neutropenia, thrombocytopenia, bradycardia, Stevens-Johnson syndrome, seizures, tumor lysis syndrome, hypocalcemia, edema, thrombosis.</td>
    </tr>
    <tr>
      <td>tranexamic acid</td>
      <td>Hexakapron</td>
      <td>C</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>tranexamic acid (Hexakapron)-[Tab 500mg; Amp 500mg/5ml] PO 1-1.5G 2x/d. IV 4-5G over 1hr then 1G/hr. ¶C. *L3. S.E: Bradyarrhythmia, hypotension, thrombosis, drug-induced myopathy.</td>
    </tr>
    <tr>
      <td>zoledronic acid</td>
      <td>Zomera</td>
      <td>D</td>
      <td>Other Hematologic Agents</td>
      <td>HEMATOLOGY</td>
      <td>zoledronic acid (Zomera)-[Soln 4mg/5ml] IV For Multiple myeloma and bone metastasis: 4mg over no less than 15 minutes every 3-4 weeks for patients with creatinine clearance of greater than 60mL/min. ¶D. S.E: Nausea, fatigue, anemia, bone pain, constipation, fever, vomiting, dyspnea, osteonecrosis of the jaw, renal toxicity.</td>
    </tr>
    <tr>
      <td>carbamazepine</td>
      <td>Tegretol</td>
      <td>D</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>carbamazepine (Tegretol)-[Tab 200mg; Syrup 2%; SR Tab 200, 400mg] (Teril)-[Tab 200mg; SR Tab 200, 400mg] (Timonil Retard)-[SR Tab 300, 600mg] PO Epilepsy: Start 200mg 2x/d, increase at weekly intervals. Max 800-1200mg/d. Peds: 10-20mg/kg/d. Syrup 6-12y start with 1/2 teaspoon (200mg) 4x/d. Increase at weekly intervals by adding up to 100mg/d in 3/4 divided doses. Adults and peds&gt;12y: 1 teaspoon 4x/d. SR Tab start 200mg 2x/d. Increase by 200mg/d until optimal response. Max 1600mg/d in adults only. Trigeminal neuralgia: 100mg 2x/d. Increase up to 200mg/d every 12h to alleviate pain. Max 1200mg/d. ¶D. *L2. S.E: Blood dyscrasia, edema, hyponatremia, ataxia, Stevens-Johnson syndrome, SIADH, diplopia.</td>
    </tr>
    <tr>
      <td>clonazepam</td>
      <td>Clonex</td>
      <td>D</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>clonazepam (Clonex)-[Tab 0.5, 2mg] (Rivotril)-[Drops 2.5mg/ml] PO Start 1.5mg/day in 3 divided doses. Increase dosage by 0.5-1mg every 3 days until seizures fully controlled. Max 20mg/d. Peds: 0.01-0.03mg/kg/d. Max 0.05mg/kg/d in 2-3 divided doses. ¶D. S.E: Respiratory depression.</td>
    </tr>
    <tr>
      <td>diazepam</td>
      <td>Assival</td>
      <td>D</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>diazepam (Assival)-[Tab 2, 5, 10mg; Soln 10mg/2ml] IV/IM 10mg initially. May repeat at 10-15min. Max: 30mg. PO 2-10mg, 2-4x/d. Peds: &gt;6 months 1-2.5mg, 3-4x/d. Increase gradually. ¶D. *L3. S.E: Respiratory depression.</td>
    </tr>
    <tr>
      <td>gabapentin</td>
      <td>Gabapentin Inovamed- Neurontin</td>
      <td>C</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>gabapentin (Gabapentin Inovamed- Neurontin)-[Cap 300, 400mg] (Gabapentin Teva) [300, 400, 600, 800mg] PO &gt;12yrs: 900-1800mg/d in 3 divided doses. 3-12yrs: 10-15mg/kg/day in 3 divided doses. ¶C. *L2. S.E: Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>lacosamide</td>
      <td>Vimpat</td>
      <td>C</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>lacosamide (Vimpat)-[FC Tab 50, 100, 150, 200mg; Syrp 10mg/ml; Soln 10mg/ml] PO/IV 100mg 2x/d, increase by 50mg 2x/d every 7d. Maintenance: 100-200mg 2x/d. ¶C. *L3. S.E: Ataxia, somnolence, amnesia, cognitive disorders, blurred vision, fatigue, vertigo, depression, chest pain.</td>
    </tr>
    <tr>
      <td>lamotrigine</td>
      <td>Lamictal</td>
      <td>C</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>lamotrigine (Lamictal)-[Tab/Chew Tab 2, 5, 25, 50, 100, 200mg] (Lamogine)-[Tab 25, 50, 100, 200mg] (Lamodex) [Tab/Chew 5, 25, 50, 100, 200mg] PO regimens not containing valproic acid: Start 25-50mg 1x/d 14d, then 50mg 2x/d for 14d. Then increase by 50mg every 1-2 weeks. Maintenance: 225-375mg/d in 2 divided dose. Regimens containing valproic acid: start 25mg every other day for 14d, then 25mg 1x/d for another 14d, then increase by 25-50mg/d every 1-2 weeks. Maintenance: 100-200mg/d in 1-2 divided doses. ¶C. *L3. S.E: Stevens-Johnson syndrome, toxic epidermal necrolysis, bone marrow suppression, hepatic necrosis, amnesia, angioedema.</td>
    </tr>
    <tr>
      <td>levetiracetam</td>
      <td>Keppra</td>
      <td>C</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>levetiracetam (Keppra)-[FC Tab 250, 500, 1000mg; Soln 100mg/ml] (Levetiracetam TEVA)-[Tab 100, 250, 500mg] (Levetrim)-[FC Tab 250, 500, 100mg; Soln 100mg/ml] (Levetiracetam Dexcel)-[Tab 250, 500, 750, 1000mg] PO Tab start 500mg 2x/d, increase in increments of 500mg 2x/d every 2-4wks. Max 1500mg 2x/d. Soln start 250mg 2x/d, after 2wks increase to 500mg 2x/d, then increase in increments of 250mg 2x/d every 2wks. Max 1500mg 2x/d. Peds 4-17yrs (Tab/Soln): 10mg/kg 2x/d, increase in increments of 10mg/kg 2x/d every 2-4wks. Max 30mg/kg 2x/d. PO Soln start 250mg 2x/d, after 2wks increase to 500mg 2x/d, then increase in increments of 250mg 2x/d every 2wks. Max 1500mg 2x/d. ¶C. *L3. S.E: Fatigue, somnolence, amnesia, ataxia, hyperkinesia, depression, aggression, personality disorders, anorexia, weight gain, vertigo, blurred vision, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>methsuximide</td>
      <td>NaN</td>
      <td>C</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>methsuximide (29 ג')  (Celontin)-[Cap 300mg] PO Start 300mg/d. Max 1.2G/d. ¶C. S.E: Stevens-Johnson syndrome, proteinuria, periorbital edema, ataxia, blurred vision, depression.</td>
    </tr>
    <tr>
      <td>oxcarbazepine</td>
      <td>Trileptin, Trexapin</td>
      <td>C</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>oxcarbazepine (Trileptin, Trexapin)-[Tab 300, 600mg] PO Start 300mg 1-2x/d. Max 600-3000mg/d. Peds: 8-10mg/kg/d. Max 600mg/kg/day. ¶C. *L3. S.E: Hyponatremia, anaphylaxis, Steven-Johnson Syndrome, suicidal behavior.</td>
    </tr>
    <tr>
      <td>phenobarbital</td>
      <td>Phenobarbitone</td>
      <td>B</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>phenobarbital (Phenobarbitone)-[Tab 15, 100mg] PO anticonvulsant: 50-100mg 2-3x/d. Peds: 15-50mg 2-3x/d. ¶B. *L3. S.E: Stevens-Johnson syndrome, respiratory depression ,bone marrow suppression, hepatotoxicity, osteopenia.</td>
    </tr>
    <tr>
      <td>phenytoin</td>
      <td>Dilantin</td>
      <td>D</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>phenytoin (Dilantin)-[Susp 125mg/5ml] (Epanutin)-[Cap 100mg] IV Load 10-20mg/kg (usual 1000mg) at rate &lt;50mg/min. PO Load 400mg, then 300mg at 2hr and 4hr. Maintenance: 5mg/kg or 100mg 2-4x/d. Max 600mg/d. Peds: &lt;6yrs: 30mg 2x/d. &gt;6yrs: as adult. ¶D. *L2. S.E: Pancytopenia, blood dyscrasias, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis.</td>
    </tr>
    <tr>
      <td>primidone</td>
      <td>Prysoline</td>
      <td>D</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>primidone (Prysoline)-[Tab 250mg] PO Start 125mg 1x/d at night. Increase over 10d to 250mg 3-4x/d. ¶D. *L3. S.E: Ataxia,granulocytopenia, agranulocytosis, red cell hypoplasia and aplasia.</td>
    </tr>
    <tr>
      <td>sulthiame</td>
      <td>Ospolot</td>
      <td>D</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>sulthiame (Ospolot)-[Tab 200mg] PO Start 100mg 2x/d. Usual 300-800mg/d. Peds: Start 3-5mg/kg/d in divided dose. Usual 10-15mg/kg/d. 3-6yrs: 100-200mg/d. 7-10yrs: 300mg/d. 11-14yrs: 200-600mg/d. ¶D. S.E: Weight loss, hallucinations, myasthetic phenomena, thrombocytopenia, leucopenia, coma.</td>
    </tr>
    <tr>
      <td>topiramate</td>
      <td>Topamax, Topiramate Teva, Topitrim</td>
      <td>D</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>topiramate (Topamax, Topiramate Teva, Topitrim)-[Tab 25, 50, 100, 200, 300, 400mg] PO Start 25-50mg at night. Increase weekly by 25-50mg/d in 2 divided doses. Usual 100-200mg 2x/d. Max 400mg/d. Peds: 2-10yrs 25mg/d, can be increased to 25mg 2x/d. ¶D. *L3. S.E: Visual field defects, memory impairment, hyperthermia, metabolic acidosis, kidney stones, sudden unexplained death in epilepsy, URTI, alopecia, chest pain.</td>
    </tr>
    <tr>
      <td>valproic acid</td>
      <td>Depalept, Depalept Chrono</td>
      <td>D</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>valproic acid (Depalept, Depalept Chrono)-[Tab 200, 500mg; EC Tab/SR Tab 500mg; Soln 200mg/ml; Syrp 200mg/5ml] (Orfiril Inject)-[Amp 300mg/3ml] (Valporal)-[Cap 200mg; Syrp 200mg/5ml] PO IV Epilepsy: 10-15mg/kg/d. Adjust every 5d to max 60mg/kg/d. SR Tabs 20-30mg/kg 1-2x/d. Peds: 25mg/kg/d. Bimodal disorder, migraine prophylaxis: 250mg 2-3x/d. ¶D. *L2. S.E: Hepatotoxicity, pancreatitis, thrombocytopenia, peripheral edema, tachycardia.</td>
    </tr>
    <tr>
      <td>vigabatrin</td>
      <td>Sabrilan</td>
      <td>C</td>
      <td>Anticonvulsants_1</td>
      <td>NEUROLOGY</td>
      <td>vigabatrin (Sabrilan)-[Tab 500mg] PO Start 500mg 2x/d. Increase by 500m to max 3,000mg/d. Peds: 10-16yrs 250mg 2x/d to max 2,000mg/d. Infants: 25mg 2x/d .¶C. *L3. S.E: Retinal atrophy, angioedema.</td>
    </tr>
    <tr>
      <td>amitriptyline</td>
      <td>Elatrol, Elatrolet</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>amitriptyline (Elatrol, Elatrolet)-[Tab 25mg] PO 75mg/d, may increase gradually to 150mg/d. ¶C. *L2. S.E: Arrhythmia, orthostatic hypotension, MI, agranulocytosis, depression, suicidal thoughts.</td>
    </tr>
    <tr>
      <td>buclizine+paracetamol+codeine</td>
      <td>Migraleve</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>buclizine+paracetamol+codeine (Migraleve)-[Tab 6.25+500+8mg] PO 2Tab at onset. May repeat after 3-4hrs. ¶C. S.E: Blurred vision.</td>
    </tr>
    <tr>
      <td>clonidine</td>
      <td>Clonnirit</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>clonidine (Clonnirit)-[Tab 25mcg] (Normopresan)-[Tab 150mcg] PO 25mcg 2x/d. May increase to 100-200mcg 2x/d. ¶C. *L3. S.E: Bradycardia, HF, hepatotoxicity, hemolytic anemia.</td>
    </tr>
    <tr>
      <td>eletriptan</td>
      <td>Relert</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>eletriptan (Relert)-[Tab 20, 40, 80mg] PO 20-40mg. May repeat after 2hrs. If inadequate, next attack 80mg max. ¶C. *L3. S.E: Coronary artery spasm, hypertensive crisis, MI, CVA.</td>
    </tr>
    <tr>
      <td>ergotamine+caffeine</td>
      <td>NaN</td>
      <td>X</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>ergotamine+caffeine (29 ג') (Cafergot)-[Tab 1+100mg] PO 2Tabs at onset, then 1Tab at 30min intervals. Max 6 Tab/attack. Max 10Tab/week. ¶X. *L4. S.E: Fibrotic complications.</td>
    </tr>
    <tr>
      <td>metoprolol</td>
      <td>Neobloc</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>metoprolol (Neobloc)-[Tab 100mg] (Lopressor Divitabs)-[SR Tab 200mg] PO 100-450mg/d for prophylaxis. ¶C. *L3. S.E: AV block, bradyarrhythmia.</td>
    </tr>
    <tr>
      <td>naratriptan</td>
      <td>Naramig</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>naratriptan (Naramig)-[Tab 2.5mg] PO 2.5mg. May repeat after 4hr. Max 5mg/d. ¶C. *L3. S.E: Angina pectoris.</td>
    </tr>
    <tr>
      <td>propranolol</td>
      <td>Deralin, Prolol</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>propranolol (Deralin, Prolol)-[Tab 10, 40mg] (Slow Deralin)-[SR Cap 80, 160mg] Prophylaxis: PO Start 80mg/d, increase to 160-240mg/d. Peds: 2 to 4mg/kg/day. ¶C. *L2. S.E: Hypotension, bradycardia, bronchospasm in patients with bronchial asthma. .</td>
    </tr>
    <tr>
      <td>rizatriptan</td>
      <td>Rizalt</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>rizatriptan (Rizalt)-[Tab/Wafer 5, 10mg] PO 5-10mg at onset. May repeat after 2hr. Max 30mg/d. Reduce dose if on propranolol. ¶C. *L3. S.E: Coronary artery spasm, hypertensive crisis, MI, CVA.</td>
    </tr>
    <tr>
      <td>sumatriptan</td>
      <td>Imitrex</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>sumatriptan (Imitrex)-[Tab 50, 100mg; Prefilled Inject 6mg/0.5ml; Nasal Spray 20mg/spray] (Sumatriptan Teva, Sumatridex)-[Tab 50, 100mg] (Sumavel Dosepro)-[Injection 6mg/0.5ml] PO 50mg. If no response after 2hrs, repeat 50mg. Max 200mg/d. SC 6mg may repeat after 1hr, max 12mg/d. Nasal spray 20mg (1spray), max 40mg/d. ¶C. *L3. S.E: Coronary artery spasm, hypertensive crisis, MI, CVA.</td>
    </tr>
    <tr>
      <td>topiramate</td>
      <td>Topamax, Topitrim, Topiramate Teva</td>
      <td>D</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>topiramate (Topamax, Topitrim, Topiramate Teva) [Tab 25, 50, 100, 200, 300, 400, 500mg] PO Start 25mg/d. Increase weekly by 25mg in divided dose. Max 200mg 2X/d. ¶D. *L3. S.E: Glaucoma, hyperthermia, metabolic acidosis, visual field defects, memory impairment, kidney stones, sudden unexplained death in epilepsy, URTI, alopecia, chest pain.</td>
    </tr>
    <tr>
      <td>zolmitriptan</td>
      <td>Zomig, Zomig Rapimelt</td>
      <td>C</td>
      <td>Migraine Therapy</td>
      <td>NEUROLOGY</td>
      <td>zolmitriptan (Zomig, Zomig Rapimelt)-[Tab 2.5mg] PO 2.5mg at onset. May repeat after 2hr. May increase to 5mg. Max 10mg/d. ¶C. *L3. S.E: Coronary artery spasm, hypertensive crisis, MI, CVA.</td>
    </tr>
    <tr>
      <td>amantadine</td>
      <td>PK-Merz</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>amantadine (PK-Merz)-[Tab 100mg; Infus 0.2G/500ml] PO 100mg 2x/d. IV 200mg 1-3x/d as needed. Max rate 55 drops/min. ¶C. *L3. S.E: Neuroleptic malignant syndrome, suicidal ideation, exacerbation of mental disorder.</td>
    </tr>
    <tr>
      <td>apomorphine hydrochloride</td>
      <td>Apo Go Pen</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>apomorphine hydrochloride (Apo Go Pen)-[Soln 10mg/ml] SC Inj starting at 0.2ml up to Max 0.6ml. ¶C. S.E: Nausea, vomiting, syncope, QT prolongation, orthostatic hypotension, hallucinations, psychotic like behavior, coronary events, dyskinesia, increased risk of melanoma, hepatic impairment, renal impairment.</td>
    </tr>
    <tr>
      <td>biperiden</td>
      <td>Dekinet</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>biperiden (Dekinet)-[Tab 2mg] PO 2mg 3-4X/d. Max 16mg/d. ¶C. S.E: Anticholinergic syndrome.</td>
    </tr>
    <tr>
      <td>bromocriptine</td>
      <td>Parilac</td>
      <td>B</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>bromocriptine (Parilac)-[Tab 2.5mg; Cap 10mg] (Parlodel)-[Tab 2.5mg] PO Start 1.25mg 2x/d with meals. Increase every 14-28d. Usual 10-40mg/d. Max 100mg/d. ¶B. *L5. S.E: CVA, seizure, MI.</td>
    </tr>
    <tr>
      <td>entacapone</td>
      <td>Comtan</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>entacapone (Comtan)-[Tab 200mg] PO 200mg to be taken with levodopa/dopa decarboxylase inhibitor. Max 8x/d. ¶C. S.E: Dyskinesia, dystonia, hallucinations.</td>
    </tr>
    <tr>
      <td>levodopa+benzerazide</td>
      <td>Levopar Plus</td>
      <td>N</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>levodopa+benzerazide (Levopar Plus)-[Cap 100mg+25mg, 200mg+50mg] PO Start 1Cap (125) 2x/d. Increase weekly if necessary. Usual 4-8Cap (125) or 2-4Cap (250) in 2-4 divided dose. ¶Not established. *L4(suppresses lactation). S.E: Cardiac arrhythmias.</td>
    </tr>
    <tr>
      <td>levodopa+carbidopa</td>
      <td>Dopicar</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>levodopa+carbidopa (Dopicar)-[Tab 250+25mg] (Sinemet CR)-[Tab 200+50mg] PO Start ½Tab 3x/d. Increase by 1Tab every 1-2d. Usual 3-6 Tab/d. Max 8 Tab/d. CR Tab Start 1Tab 2x/d unless taking levodopa. ¶C. *L4(suppresses lactation). S.E: Glaucoma, melanoma, MI, dyskinesia.</td>
    </tr>
    <tr>
      <td>levaodopa+carbidopa+entacapone</td>
      <td>Stalevo</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>levaodopa+carbidopa+entacapone (Stalevo)-[FC Tab 50+12.5+200, 75+18.5+200, 100+25+200, 125+31.5+200, 150+37.5+200, 200mg+50mg+200mg] PO For the 50/12.5/200mg, 75/18.75/200mg, 100/25/200mg, 125/31.25/200mg, 150/37.5/200mg dosages: Do not take more than 10Tab/d. For the 200/50/200mg dosage: Do not take more than 7Tab/d. ¶C. S.E: Dyskinesias, nausea, diarrhea, chest pain, arrhythmias, dizziness, vomiting, anemia, UTI.</td>
    </tr>
    <tr>
      <td>pergolide</td>
      <td>Pergolide</td>
      <td>B</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>pergolide (Pergolide)-[Tab 0.25, 1.0mg] PO Start 0.05mg 1x/d. Increase 0.1 to 0.15mg every third day. Max 5mg/d. ¶B. S.E: Arrhythmias, MI, HF.</td>
    </tr>
    <tr>
      <td>procyclidine</td>
      <td>Kemadrin</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>procyclidine (Kemadrin)-[Tab 5mg] PO Start 2.5mg 3x/d. Increase 2.5-5mg at 2-3d. Max 30mg/d. ¶C. S.E: None.</td>
    </tr>
    <tr>
      <td>rasagline as mesylate</td>
      <td>Azilect</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>rasagline as mesylate (Azilect)-[Tab 1mg] PO Start 0.5mg/d and increase to 1mg 1x/d. ¶C. S.E: Hypertension, hypotension, serotonin syndrome, exacerbate dyskinesia, hallucinations, increased risk of melanoma, flu syndrome., arthralgia, depression, dyspepsia, hepatic impairment.ropinorole (Requip)-[Tab 2, 4, 8mg] PO Start 0.25mg 3x/d. Increase slowly to 1mg 3x/d. Max 24mg/d. ¶C. *L4. S.E: Blurred vision, high or low blood pressure, arrhythmias.</td>
    </tr>
    <tr>
      <td>selegiline</td>
      <td>Selgin</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>selegiline (Selgin)-[Tab 5mg] PO Start 5mg in morning. Increase to 5mg 2x/d (morning/noon). ¶C. *L4. S.E: GI hemorrhage, arrhythmias.</td>
    </tr>
    <tr>
      <td>trihexyphenidyl</td>
      <td>Partane, Rodenal</td>
      <td>C</td>
      <td>Parkinsonian-Agents</td>
      <td>NEUROLOGY</td>
      <td>trihexyphenidyl (Partane, Rodenal)-[Tab 2, 5mg] PO Start 1mg/d. Increase to 6-10mg/d in 3 divided doses. Max 12-15mg/d. ¶C. S.E: Glaucoma, psychosis.</td>
    </tr>
    <tr>
      <td>betahistine</td>
      <td>Agiserc, Betistine</td>
      <td>H</td>
      <td>Other_Neurologic_Agents</td>
      <td>NEUROLOGY</td>
      <td>betahistine (Agiserc, Betistine)-[Tab 16mg] PO Meniere’s disease/Vertigo: 8-16mg 3x/d. Max 48mg/d. ¶Hazardous. *L4. S.E: None.</td>
    </tr>
    <tr>
      <td>cinnarizine</td>
      <td>Stunarone</td>
      <td>C</td>
      <td>Other_Neurologic_Agents</td>
      <td>NEUROLOGY</td>
      <td>cinnarizine (Stunarone)-[Tab 25mg] PO Dizziness: 25-27mg 3x/d. Max 225mg/d. Peds: 5-12yrs 12.5mg 3-4x/d. &gt;12yrs: 25mg 3-4x/d. ¶C. *L3. S.E: None.</td>
    </tr>
    <tr>
      <td>glatiramer acetate</td>
      <td>Copaxone</td>
      <td>B</td>
      <td>Other_Neurologic_Agents</td>
      <td>NEUROLOGY</td>
      <td>glatiramer acetate (Copaxone)-[Amp 20, 40mg] SC Multiple sclerosis: 20mg/d or 40mg 3x/wk at least 48h apart. ¶B. *L3. S.E: Chest pain, tachycardia, hypertension, dyspnea, infections, amenorreah, impotence, allergic reactions, diplopia.\t</td>
    </tr>
    <tr>
      <td>interferon beta-1A</td>
      <td>Avonex</td>
      <td>C</td>
      <td>Other_Neurologic_Agents</td>
      <td>NEUROLOGY</td>
      <td>interferon beta-1A (Avonex)-[Amp 30µg/vial] (Avonex Solution for Injection)-[Amp 30µg/0.5ml] (Rebif)-[Amp 22µg/0.5ml] Multiple sclerosis: IM 30µg 1x/wk. SC 22-44µg 3x/wk. ¶C. *L3. S.E: Psychiatric disorders, hepatic injury, anaphylaxis, HF, autoimmune disorders, thrombotic microangiopathy.</td>
    </tr>
    <tr>
      <td>interferon beta-1B</td>
      <td>Betaferon</td>
      <td>C</td>
      <td>Other_Neurologic_Agents</td>
      <td>NEUROLOGY</td>
      <td>interferon beta-1B (Betaferon)-[Amp 0.3mg/vial] SC Multiple sclerosis: 0.25mg (1ml) on alternate days. ¶C. *L3. S.E: Hepatic injury, anaphylaxis, psychiatric disorders, HF, injection site necrosis, thrombotic microangiopathy.</td>
    </tr>
    <tr>
      <td>neostigmine</td>
      <td>Neostigmine Hamlen</td>
      <td>C</td>
      <td>Other_Neurologic_Agents</td>
      <td>NEUROLOGY</td>
      <td>neostigmine (Neostigmine Hamlen)-[Amp 2.5mg/ml] IM SC Myasthenia gravis: 1-2.5mg as required. Total daily dose 5-20mg. ¶C. S.E: Anaphylaxis, convulsions, seizure, dysarthria, arrhythmias, respiratory depression, bronchospasm.</td>
    </tr>
    <tr>
      <td>pyridostigmine</td>
      <td>Mestinon</td>
      <td>C</td>
      <td>Other_Neurologic_Agents</td>
      <td>NEUROLOGY</td>
      <td>pyridostigmine (Mestinon)-[Tab 60mg] (Pyridostigmine)-[Tab 30, 60mg] PO Myasthenia gravis: 60mg 10x/d. ¶C. *L2. S.E: Muscarinic and nicotinic side effects.</td>
    </tr>
    <tr>
      <td>riluzole</td>
      <td>Rilutek</td>
      <td>C</td>
      <td>Other_Neurologic_Agents</td>
      <td>NEUROLOGY</td>
      <td>riluzole (Rilutek)-[Tab 50mg] PO ALS: 50mg 2x/d. ¶C. S.E: Hepatic injury, neutropenia, interstitial lung disease.</td>
    </tr>
    <tr>
      <td>linagliptin</td>
      <td>Trajenta</td>
      <td>B</td>
      <td>Diabetics treatment</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>linagliptin (Trajenta)-[Tab 5mg] PO Recommended: 5mg 1x/d. ¶B. S.E: Pancreatitis, hypoglycemia, angioedema, arthralgia, nasopharyngitis.</td>
    </tr>
    <tr>
      <td>linagliptin+metformin</td>
      <td>Trajenta DUO</td>
      <td>B</td>
      <td>Diabetics treatment</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>linagliptin+metformin (Trajenta DUO)-[Tab 2.5+500, 2.5+850, 2.5mg+1000mg] PO Individualize the starting dose based on the patient's current regimen, given 2x/d with meals. Max 2.5mg/1000mg 2x/d. ¶B. S.E: Lactic acidosis, pancreatitis, hypoglycemia, vitamin B12 deficiency, nasopharyngitis.</td>
    </tr>
    <tr>
      <td>saxagliptin</td>
      <td>Onglyza</td>
      <td>B</td>
      <td>Diabetics treatment</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>saxagliptin (Onglyza)-[Tab 2.5, 5mg] PO Recommended dosage is 2.5-5mg 1x/d taken regardless of meals. Patients with moderate or severe renal impairment 2.5mg 1x/d. ¶B. S.E: Pancreatitis, CHF, angioedema, URTI, UTI, edema.</td>
    </tr>
    <tr>
      <td>saxagliptin+metformin</td>
      <td>Kombiglyze XR</td>
      <td>B</td>
      <td>Diabetics treatment</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>saxagliptin+metformin (Kombiglyze XR)-[Tab 5+500, 2.5+1000, 5mg+1000mg] PO Dosage should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability. Administer 1x/d with the evening meal. Max 2000mg+5mg/d, patients with moderate or severe renal impairment max 2.5mg 1x/d of saxagliptin. ¶B. S.E: Lactic acidosis, pancreatitis, CHF, hypoglycemia, angioedema, arthralgia, UTI, URTI.</td>
    </tr>
    <tr>
      <td>sitaglirtin+metformin</td>
      <td>Januet</td>
      <td>B</td>
      <td>Diabetics treatment</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>sitaglirtin+metformin (Januet)-[Tab 50+500, 50+850, 50mg+1000mg] (Januet XR)-[Tab 50+500, 50+1000, 100mg+1000mg] PO Max 100mg+2000mg/d. ¶B. S.E: Nasopharyngitis, URTI.</td>
    </tr>
    <tr>
      <td>sitaglirtin</td>
      <td>Januvia</td>
      <td>B</td>
      <td>Diabetics treatment</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>sitaglirtin (Januvia)-[Tab 25, 50, 100mg] PO recommended dose 100mg 1x/d. ¶B. S.E: Pancreatitis, Stevens-Johnson syndrome, angioedema, arthralgia, dizziness, headach.</td>
    </tr>
    <tr>
      <td>vildagliptin</td>
      <td>Galvus</td>
      <td>B</td>
      <td>Diabetics treatment</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>vildagliptin (Galvus)-[Tab 50mg] PO 50mg 1-2x/d morning or/and evening. Max 100mg/d. ¶B. S.E: Hepatotoxicity, CHF, pancreatitis, hypoglycemia, dizziness, tremor.</td>
    </tr>
    <tr>
      <td>vildagliptin+metformin</td>
      <td>Eucreas</td>
      <td>B</td>
      <td>Diabetics treatment</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>vildagliptin+metformin (Eucreas)-[Tab 50+500, 50+850, 50mg+1000mg] PO 50mg 1-2x/d morning or/and evening. Max 100mg/d. ¶B. S.E: Hepatotoxicity, CHF, pancreatitis, hypoglycemia, dizziness, tremor.</td>
    </tr>
    <tr>
      <td>chlorpropamide</td>
      <td>Diabitex</td>
      <td>C</td>
      <td>Insulin secretagogues: Sulfonylureas</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>chlorpropamide (Diabitex)-[Tab 250mg] PO start 250mg/d. Max 750mg/d. ¶C. *L3. S.E: Hypoglycemia, cholestatic jaundice, urticaria, agranulocytosis, hemolytic anemia, aplastic anemia, pancytopenia, and eosinophilia.</td>
    </tr>
    <tr>
      <td>glyburide</td>
      <td>Gluben</td>
      <td>C</td>
      <td>Insulin secretagogues: Sulfonylureas</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>glyburide (Gluben)-[Tab 5mg] PO 2.5-5mg/d. ¶C. *L2. S.E: Hypoglycemia,hyponatremia, liver function abnormalities, agranulocytosis, hemolytic anemia, aplastic anemia, pancytopenia, SIADH, blurred vision.</td>
    </tr>
    <tr>
      <td>glipizide</td>
      <td>Gluco-Rite</td>
      <td>C</td>
      <td>Insulin secretagogues: Sulfonylureas</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>glipizide (Gluco-Rite)-[Tab 5mg] PO Start 2.5-5mg/d. Usual 15 mg/d. Max 40mg/d. ¶C. *L3. S.E: Hypoglycemia, blood dyscrasias, hyponatremia.</td>
    </tr>
    <tr>
      <td>glimepiride</td>
      <td>Amaryl, Glimepridie TEVA</td>
      <td>C</td>
      <td>Insulin secretagogues: Sulfonylureas</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>glimepiride (Amaryl, Glimepridie TEVA)-[Tab 1, 2, 3, 4mg] PO Start 1-2mg 1X/d with food. Max 8mg/d. ¶C. *L4. S.E: Hypoglycemia, hypersensitivity reactions, hemolytic anemia.</td>
    </tr>
    <tr>
      <td>tolbutamide</td>
      <td>Orsinon</td>
      <td>C</td>
      <td>Insulin secretagogues: Sulfonylureas</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>tolbutamide (Orsinon)-[Tab 500mg] PO Start 1-2G/d. Max 3G/d. ¶C. *L3. S.E: Hypoglycemia, hyponatremia, blood dyscrasias, allergic reactions.</td>
    </tr>
    <tr>
      <td>metformin</td>
      <td>Metformin TEVA, Glucomin, Glucophage</td>
      <td>B</td>
      <td>Biguanides</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>metformin (Metformin TEVA, Glucomin, Glucophage)-[Tab 850mg] PO Start 1Tab with meals. Maint: 1Tab 2x/d with meals. Max dose: 1Tab 3x/d. ¶B. *L1. S.E: Lactic acidosis, vitamin B12 deficiency, hypoglycemia.</td>
    </tr>
    <tr>
      <td>acarbose</td>
      <td>Acrose</td>
      <td>B</td>
      <td>Alpha-glucosidase inhibitors</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>acarbose (Acrose)-[Tab 50, 100mg] (Prandase)-[Tab 50, 100mg] PO Dosage must be individualized on the basis of both effectiveness and tolerance. Max 100mg/d. ¶B. *L3. S.E: Hypoglycemia, gastrointestinal symptoms, jaundice, edema, hepatitis, thrombocytopenia, pneumatosis intestinalis.</td>
    </tr>
    <tr>
      <td>repaglinide</td>
      <td>Novonorm, Repaglinide Teva</td>
      <td>C</td>
      <td>Insulin secretagogues: Nonsulfonylureas</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>repaglinide (Novonorm, Repaglinide Teva)-[Tab 0.5, 1, 2mg] PO Start 0.5-2mg 3x/d 15-30min before meals. Maint: 0.5-4mg 3-4x/d 15-30min before meals. Max 16mg/d. ¶C. *L4. S.E: Hypoglycemia, URTI, arthralgia, angina, MI.</td>
    </tr>
    <tr>
      <td>canagliflozin</td>
      <td>Invokana</td>
      <td>C</td>
      <td>Sodium-glucose-cotransporter-2-inhibitors</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>canagliflozin (Invokana)-[Tab 100, 300mg] PO 100mg 1x/d taken before the first meal of the day. ¶C. S.E: Hypotension, ketoacidosis, acute kidney injury, hyperkalemia, pyelonephritis, hypoglycemia, bone fracture, increased LDL-C, UTI, female genital mycotic infections.</td>
    </tr>
    <tr>
      <td>dapagliflozin</td>
      <td>Forxiga</td>
      <td>C</td>
      <td>Sodium-glucose-cotransporter-2-inhibitors</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>dapagliflozin (Forxiga)-[Tab 6.150, 12.30mg/dose] PO 5mg 1x/d. ¶C. S.E: Hypotension, ketoacidosis, acute kidney injury, pyelonephritis, hypoglycemia, bladder Cancer, increased LDL-C, female genital mycotic infections, UTI.empagliflozin (Jardiance)-[Tab 10, 25mg] PO 10mg 1x/d in the morning. Max 25mg/d. ¶C. S.E: Hypotension, ketoacidosis, acute kidney injury, pyelonephritis, hypoglycemia, genital mycotic infections, UTI.</td>
    </tr>
    <tr>
      <td>rosiglitazone</td>
      <td>Avandia</td>
      <td>C</td>
      <td>Thiazolidinediones</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>rosiglitazone (Avandia)-[Tab 4, 8mg] (Rosi)-[Tab 2, 4, 8mg] (Rosiglitazone Teva)-[Tab 4, 8mg] PO Start 4mg/d in single or divided doses. Max 8mg/d. Avoid use in patients with evidence of hepatic disease. ¶C. *L3. S.E: CHF, MI, edema, anemia, weight gain, bone fracture, elevated liver enzymes.</td>
    </tr>
    <tr>
      <td>pioglitazone</td>
      <td>Actos</td>
      <td>C</td>
      <td>Thiazolidinediones</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>pioglitazone (Actos)-[Tab 15, 30, 45mg] PO Start 15-30mg/d. Max 45mg 1x/d. ¶C. *L3. S.E: CHF, hepatotoxicity, edema, fractures.</td>
    </tr>
    <tr>
      <td>dulaglutide</td>
      <td>Trulicity</td>
      <td>C</td>
      <td>Receptor agonists GLP-1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>dulaglutide (Trulicity)-[Soln 0.75mg/0.5ml, 1.5mg/0.5ml] SC Start 0.75mg 1x/wk, increase up to 1.5mg/wk. ¶C. S.E: C-cell tumors, MEN-2, hypoglycemia, renal impairment, amylase and lipase increase.</td>
    </tr>
    <tr>
      <td>exenatide</td>
      <td>Bydureon</td>
      <td>C</td>
      <td>Receptor agonists GLP-1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>exenatide (Bydureon)-[Pwdr 2mg] (Byetta)-[Soln 250mcg/ml] SC Start 5mcg 2x/d for 30d, up to 10mcg 2x/d, 60min before meal. ¶C. *L3. S.E: Pancreatitis, hypoglycemia, diarrhea, vomiting, change in INR, renal impairment.</td>
    </tr>
    <tr>
      <td>liraglutide</td>
      <td>Saxenda</td>
      <td>X</td>
      <td>Receptor agonists GLP-1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>liraglutide (Saxenda)-[Soln 6mg/1ml] (Victoza)-[Soln 6mg/ml]SC Start 0.6mg/wk, increase until a dose of 3mg is reached. ¶X. S.E: Thyroid C-celltumors, pancreatitis, cholecystitis, hypoglycemia, renal impairment, angioedema, suicidal behavior, diarrhea, dizziness.</td>
    </tr>
    <tr>
      <td>insulin</td>
      <td>all human/recombinant</td>
      <td>B</td>
      <td>Receptor agonists GLP-1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>insulin (all human/recombinant)-[Vials, Cartridge, Prefilled Pen Injector, Penfill Syringe (Novolet)]. ¶B. *L1. S.E: Hypoglycemia, hypokalemia, allergies.</td>
    </tr>
    <tr>
      <td>alogliptin+pioglitazone</td>
      <td>Incersync</td>
      <td>C</td>
      <td>Others_3</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>alogliptin+pioglitazone (Incersync)-[Tab 12.5+30, 25+30, 25mg+45mg] PO Dose should be individualised on the basis of the patient’s current treatment regimen. Max 25mg+45mg/d. Limit initial dose to 15mg 1x/d in patients with NYHA Class I or II heart failure. ¶C. S.E: Fluid retention, CHF, bladder cancer, fractures, renal impairment, weight gain, peripheral oedema, pancreatitis.</td>
    </tr>
    <tr>
      <td>dapagliflozin+metformin</td>
      <td>Xigduo XR</td>
      <td>C</td>
      <td>Others_3</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>dapagliflozin+metformin (Xigduo XR)-[Tab 6.150+1005.04, 12.30mg+1005.04mg] PO Individualize the starting dose based on the patient’s current treatment 1x/d. Max 10mg/2000mg/d. ¶C. S.E: Lactic acidosis, ketoacidosis, acute kidney injury, pyelonephritis, hypoglycemia, vitamin B12 deficiency, increased LDL-C, female genital mycotic infections.</td>
    </tr>
    <tr>
      <td>empagliflozin+metformin</td>
      <td>Jardiance DUO</td>
      <td>C</td>
      <td>Others_3</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>empagliflozin+metformin (Jardiance DUO)-[Tab 5+850, 12.5+850, 5+1000, 12.5mg+1000mg] PO Max 12.5mg/1000mg 2x/d. ¶C. S.E: Lactic acidosis, acute kidney injury, ketoacidosis, hypotension, vitamin B12 deficiency, UTI.</td>
    </tr>
    <tr>
      <td>glucagon</td>
      <td>Glucagen Hypokit</td>
      <td>B</td>
      <td>Others_3</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>glucagon (Glucagen Hypokit)-[Amp 1mg] Hypoglycemia: IV IM SC 1mg. Onset 8-10min. ¶B. *L3. S.E: Allergic reactions, respiratory distress, hypotension.</td>
    </tr>
    <tr>
      <td>liraglutide+insulin</td>
      <td>Xultophy</td>
      <td>N</td>
      <td>Others_3</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>liraglutide+insulin (Xultophy)-[Soln 3.6mg/ml+100 U/ml] SC Individualize the starting dose based on the patient’s current treatment. Adjustment of dose necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness. ¶Not established. S.E: Hypoglycaemia, hyperglycaemia, eye disorder, pancreatitis, thyroid adverse events, dehydration.</td>
    </tr>
    <tr>
      <td>pioglitazone+metformin</td>
      <td>Compectact</td>
      <td>C</td>
      <td>Others_3</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>pioglitazone+metformin (Compectact)-[Tab 15mg+850mg] PO Adjust dosing based on effectiveness and tolerability. Max 45mg+2550mg/d. ¶C. S.E: CHF, lactic acidosis, low pH, increased anion gap, elevated blood lactate, renal impairment, edema, hypoglycemia, bladder cancer, hepatotoxicity, fractures, vitamin B 12 deficiency, weight gain, diarrhea.</td>
    </tr>
    <tr>
      <td>repaglinide+metformin</td>
      <td>Novogard</td>
      <td>C</td>
      <td>Others_3</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>repaglinide+metformin (Novogard)-[Tab 1+500, 2mg+500mg] PO Start with 1mg/500mg 2x/d 15min prior to meals. Max 10mg/2500mg/d or 4mg/1000mg per meal. ¶C. *L4. S.E: Lactic acidosis, hypoglycemia, vitamin B12 deficiency, gastrointestinal symptoms.</td>
    </tr>
    <tr>
      <td>rosiglitazone+metformin</td>
      <td>Avandamet</td>
      <td>C</td>
      <td>Others_3</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>rosiglitazone+metformin (Avandamet)-[Tab 4+1000mg] PO Start 2+500mg 1-2x/d. Max 8+2000mg/d. ¶C. *L3. S.E: HF, myocardial ischemia, lactic acidosis.</td>
    </tr>
    <tr>
      <td>levothyroxine</td>
      <td>Eltroxin, Euthyrox, Synthroid</td>
      <td>A</td>
      <td>Thyroid Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>levothyroxine (Eltroxin, Euthyrox, Synthroid)-[Tab 50, 100µg] PO Start 1-1.7mcg/kg/day Increase as needed at 2-3wk. Max 300mg/d. ¶A. *L1. S.E: Arrhythmias, HF, cardiac arrest, osteoporosis, impaired fertility.</td>
    </tr>
    <tr>
      <td>methimazole</td>
      <td>Mercaptizol</td>
      <td>D</td>
      <td>Thyroid Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>methimazole (Mercaptizol)-[Tab 20mg] PO Start 5-20mg 3x/d. Max 100mg/d. ¶D. *L2. S.E: Blood dyscrasia, lupus like syndrome, insulin autoimmune syndrome, hepatitis, periarteritis, hypoprothrombinemia.</td>
    </tr>
    <tr>
      <td>propylthiouracil</td>
      <td>Propyl-Thiocil</td>
      <td>D</td>
      <td>Thyroid Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>propylthiouracil (Propyl-Thiocil)-[Tab 50mg] PO Start 100mg 3x/d. Maintenance 100-150mg/d. Peds: start 50mg/d. ¶D. L2. S.E: Severe liver injury and acute liver failure, agranulocytosis, hypothyroidism.</td>
    </tr>
    <tr>
      <td>calcitonin</td>
      <td>Salco (salmon</td>
      <td>C</td>
      <td>Hormones_1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>calcitonin (Salco (salmon))-[Amp 100IU/ml] (Miacalcic (salmon))-[Nasal Spray 200IU/spray] SC IM IV Osteoporosis: 100IU/d or 0.5mg/d or 200IU/d nasal spray alternate nostrils. Paget’s disease: 100IU/d or 0.5mg/d. Hypercalcemia: 4-8IU/kg/d. ¶C. *L3. S.E: Hypocalcemia, hypersensitivity, malignancy.</td>
    </tr>
    <tr>
      <td>desmopressin</td>
      <td>Minirin</td>
      <td>B</td>
      <td>Hormones_1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>desmopressin (Minirin)-[Soln 0.1mg/ml; Spray 0.1ml; Tab 0.1, 0.2mg; Amp 4µg/ml] (Octostim)-[Amp 15µg/ml] (Desmopressin Teva)-[Tab 0.1, 0.2mg] Diabetes insipidus: PO 0.05mg 2x/d. Intranasal: 0.1-0.4ml/d. Enuresis: PO 0.2mg/d. ¶B. *L2. S.E: Seizures, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>growth hormone ,somatropin</td>
      <td>Genotropin</td>
      <td>B</td>
      <td>Hormones_1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>growth hormone ,somatropin (Genotropin)-[Amp 5.3, 12mg] SC Doses vary. Usual 0.16-0.24mg/kg/wk. (Norditropin)-[Amp 5, 10, 15mg] SC Doses vary. Usual 0.024-0.034mg/kg/d 6-7 times a week. (Zomacton)-[Pwdr 4, 10mg] SC 0.17-0.23mg/kg per week. In Turner’s syndrome and Renal insufficiency: 0.3mg/kg per week. ¶B/C. *L3. S.E: Impaired glucose tolerance and diabetes mellitus, ICP, hypopituitarism, hypothyroidism,  pancreatitis.</td>
    </tr>
    <tr>
      <td>lanreotide ,somatostatin</td>
      <td>Somatuline</td>
      <td>C</td>
      <td>Hormones_1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>lanreotide ,somatostatin (Somatuline)-[Amp 30mg] (Somatuline Autogel)-[Amp 60, 90, 120mg]. Acromegaly: SC 90mg every 28d for 3 months. Dose adjustment by GH and IGF-1 levels. Gastroenteropancreatic Neuroendocrine Tumors: SC 120mg every 28d. Dose adjustment. ¶C. S.E: Cholelithiasis and gallbladder sludge, hyperglycemia, hypoglycemia, bradycardia, hypertension.</td>
    </tr>
    <tr>
      <td>tetracosactide</td>
      <td>ACTH</td>
      <td>C</td>
      <td>Hormones_1</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>tetracosactide (ACTH) (Synacthen Depot)-[Amp 1mg/1ml] IM IV Rapid screen for adrenocortical deficiency: 1mg single dose or 1mg/d for 3-4d. Peds: &lt;2yrs 0.125mg, 3-6yrs 0.25-0.5mg/d, maintenance 0.25-0.5mg every 2-8d. 7-15yrs: 0.25-1mg/d, maintenance 0.25-1mg every 2-8d. ¶C. S.E: Arrhythmia, hypertension, anaphylaxis, adrenal hemorrhage.</td>
    </tr>
    <tr>
      <td>cyproterone acetate</td>
      <td>Androcur 10, Androcur 50</td>
      <td>N</td>
      <td>Androgens / Anabolics</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>cyproterone acetate (Androcur 10, Androcur 50)-[Tab 10, 50mg] PO 200-300mg/d divided doses, max 300mg/d. Following orchiectomy, reduce dose to 100-200mg/d. IM: 300mg every 1-2 weeks. Paraphilia/hypersexuality: PO 50-600mg/d. IM 300-600mg every 1-2 weeks. ¶Not established. S.E: Hepatotoxicity, suppression of adrenal function, DVT, osteoporosis, gynecomastia, galctorrhea, sexual dysfunction, infertillity (reversible), depression.</td>
    </tr>
    <tr>
      <td>megestrol</td>
      <td>NaN</td>
      <td>X</td>
      <td>Androgens / Anabolics</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>megestrol ((29 ג' (Megace)-[Tab 160mg] (Megestrol)-[Tab 40mg; Susp 40mg/ml] PO 625mg/d. Anorexia/ Cachexia: 400-800mg/d. ¶X. *L3. S.E: Impotence, hypertension, dyspepsia.</td>
    </tr>
    <tr>
      <td>mesterolone</td>
      <td>Proviron</td>
      <td>X</td>
      <td>Androgens / Anabolics</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>mesterolone (Proviron)-[Tab 25mg] PO Oligospermia, hypogonadism, decreased potency: 50-100mg/d divided doses. ¶X. S.E: Prostatic carcinoma, benign and malignant liver tumors, frequent or persistent erections.</td>
    </tr>
    <tr>
      <td>oxandrolone</td>
      <td>Lonavar</td>
      <td>X</td>
      <td>Androgens / Anabolics</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>oxandrolone (Lonavar)-[Tab 2.5mg] PO 0.1-0.045mg/kg/d. ¶X. S.E: Edema with or without HF, oligospermia, acne, menstrual abnormalities, life-threatening peliosis hepatitis, hepatocellular carcinomas, cholestatic hepatitis, jaundice, alterations in clotting factors II, V, VII and X, prolonged PT, electrolyte retention.</td>
    </tr>
    <tr>
      <td></td>
      <td>Testomax</td>
      <td>X</td>
      <td>Androgens / Anabolics</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>(Testomax)-[Gel 25mg/2.5G, 50mg/5G] Apply 5G 1x/d after shower. Max 10G 1x/d. (Sustanon 250, Nebido)-[Amp 250mg] 1,000mg every 10-14 weeks. (Testoviron Depot)-[Amp 250mg] IM 250mg every 2-3wks. ¶X. S.E: DVT, hepatocellular carcinoma, hypercalcemia, seizures.</td>
    </tr>
    <tr>
      <td>betamethasone</td>
      <td>Celestone Chronodose</td>
      <td>C</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>betamethasone (Celestone Chronodose)-[Amp 6.945mg/ml] (Diprospan)-[Amp 7mg/ml] Inflammation: PO 0.6-7.2mg in 2 divided dose. RA/Osteoarthritis: Intrabursal Intraarticular 0.25-2ml. Fetal lung maturity: IM 12mg 1x/d for 2d. ¶C. *L3. S.E: Adrenal suppression, hypertension, HF, hyperglycemia, impotence, menstrual irregularities, cushingoid appearance, pancreatitis, ulcerative esophagitis, GI perforation and hemorrhage, hypernatremia, hypokalemia, decrease in the secretion of TSH, osteoporosis, tendon rupture, aseptic necrosis of bone, impairment in cell-mediated immunity and increased susceptibility to bacterial, viral, fungal and parasitic infections, glaucoma, psychoses, personality or behavioral changes, pseudotumor cerebri, thrombocytopenia, lymphopenia, thrombotic events, glucocorticoid-withdrawal syndrome.</td>
    </tr>
    <tr>
      <td>cortisone</td>
      <td>Cortisone Acetate</td>
      <td>N</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>cortisone (Cortisone Acetate)-[Tab 25mg] PO 25-300mg/d. ¶Not established. S.E: Hypokalemic alkalosis, MI, PUD, pancreatitis,  osteoporosis, severe depression, vertigo, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, glaucoma, thromboembolism.</td>
    </tr>
    <tr>
      <td>dexamethasone</td>
      <td>Dexacort</td>
      <td>C</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>dexamethasone (Dexacort)-[Amp 20mg/ml] (Dexamethasone)-[Tab 0.5, 2mg] IM IV Start 0.5-9mg/d, max 20mg/d. PO 0.5-9mg/d divided in 2-4doses. Fetal lung maturity: IM 6mg 4x/12h. ¶C. *L3. S.E: Immunosuppression, cataracts, hyperglycemia, hypercortisolism, depression, euphoria, osteoporosis, growth retardation in children, muscle atrophy.</td>
    </tr>
    <tr>
      <td>fludrocortisone</td>
      <td>NaN</td>
      <td>C</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>fludrocortisone (29 ג') (Fludrocortisone)-[Tab 100mcg] (Florinef) -[Tab 0.1mg] PO 0.05-0.2mg/d. ¶C. *L3. S.E: Hypertension, hypokalemia, HF, thrombophlebitis, secondary hypocortisolism, increased ICP.</td>
    </tr>
    <tr>
      <td>hydrocortisone</td>
      <td>Hydrocortisone, Hydrocortisone Panpharma</td>
      <td>C</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>hydrocortisone (Hydrocortisone, Hydrocortisone Panpharma)-[Tab 10, 100mg] (Solu-Cortef)-[Amp 100, 125mg/ml] (Cortifoam)-[Foam 10%W/W] IV IM 100-500mg every 6hrs. PO 15-240mg/d divided dose. Foam 1-2x/d for 2-3wks, and every second day thereafter, administered rectally. ¶C. *L3. S.E: Hypertension, hypokalemia, HF, thrombophlebitis, secondary hypocortisolism, increased ICP.</td>
    </tr>
    <tr>
      <td>methylprednisolone</td>
      <td>Depo-Medrol</td>
      <td>C</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>methylprednisolone (Depo-Medrol)-[Amp 40mg/ml] (Depot-Medrol with Lidocaine)-[Amp 40+10mg/ml] (Medrol)-[Tab 4mg] (Methylprednisolone-Mylan)-[Amp 500, 1000mg] (Solu-Medrol)-[Amp 40, 125, 500, 1000mg] IV IM 10-250mg or 10-40mg/kg (varies). Depot: IM, Joints: dose varies, 4-120mg every 1-2wks. PO dose varies, 4-48mg/d. ¶C. *L2. S.E: Immunosuppression, cataracts, hyperglycemia, hypercortisolism, depression, euphoria, osteoporosis, growth retardation in children, muscle atrophy.</td>
    </tr>
    <tr>
      <td>prednisolone</td>
      <td>Pred-Forte</td>
      <td>C</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>prednisolone (Pred-Forte)-[Susp 1%W/V] (Danalone)-[Syrp 15mg/5ml] PO 5-60mg/d. Suspension 2 drops topically in the eyes 4x/d. ¶C. *L2. S.E: Immunosuppression, cataracts, hyperglycemia, hypercortisolism, depression, euphoria, osteoporosis, growth retardation in children, muscle atrophy.</td>
    </tr>
    <tr>
      <td>prednisone</td>
      <td>Prednisone</td>
      <td>C</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>prednisone (Prednisone)-[Tab 1, 5, 20mg] PO 1-2mg/kg or 5-60mg/d. ¶C/D (manufacturer specific). *L2. S.E: Immunosuppression, cataracts, hyperglycemia, hypercortisolism, depression, euphoria, osteoporosis, growth retardation in children, muscle atrophy.</td>
    </tr>
    <tr>
      <td>triamcinolone</td>
      <td>Sterocort</td>
      <td>C</td>
      <td>Corticosteroids</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>triamcinolone (Sterocort)-[Tab 4mg] IM PO start 60mg/d, usual 2.5-100mg/d. Small Joints: 2.5-5mg. Large joints: 5-15mg. Peds: start 0.11-1.6mg/d in 3-4 divided doses. 6-12yrs: start 40mg/d. ¶C. *L3. S.E: Immunosuppression, cataracts, hyperglycemia, hypercortisolism, depression, euphoria, osteoporosis, growth retardation in children, muscle atrophy.</td>
    </tr>
    <tr>
      <td>allopurinol</td>
      <td>Alloril</td>
      <td>C</td>
      <td>Gout Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>allopurinol (Alloril)-[Tab 100, 300mg] PO 200-300mg 1-2x/d, max 800mg/d. ¶C. *L2. S.E: Agranulocytosis, aplastic anemia, renal failure, hepatic necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis.</td>
    </tr>
    <tr>
      <td>colchicine</td>
      <td>Colchicine</td>
      <td>C</td>
      <td>Gout Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>colchicine (Colchicine)-[Tab 0.5mg] PO Acute gout: Start 1.2mg/d, then 0.6mg q1h until relief, until max 8mg/d. Prophylaxis: 0.6mg 1-2x/d. FMF: 1.2 to 2.4mg daily in 1 to 2 divided doses. Titration: Increase or decrease dose in 0.3mg/d increments based on efficacy or adverse effects. ¶C. *L4. S.E: Myelosuppression, neuromyopathy.</td>
    </tr>
    <tr>
      <td>sulfinpyrazone</td>
      <td>Anturan</td>
      <td>C</td>
      <td>Gout Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>sulfinpyrazone (Anturan) 29ג-[Tab 100, 200mg] PO 200-400mg/d in divided doses. Maint: 200-800mg/d. ¶C. S.E: Leukopenia, thrombocytopenia, bronchoconstriction in patients with asthma.</td>
    </tr>
    <tr>
      <td>alendronate</td>
      <td>Maxibone</td>
      <td>C</td>
      <td>Biphosphonates</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>alendronate (Maxibone)-[Tab 70mg] (Fosalan)-[Tab 70mg] PO Osteoporosis postmenopausal prevention: 5mg/d or 35mg 1x/wk. Treatment: 10mg/d or 70mg 1x/wk. Glucocorticoid induced: 5mg/d. Paget’s disease: 40mg/d for 6 months. Taken ½hr before breakfast. ¶C. *L3. S.E: Esophagitis, jaw osteonecrosis.</td>
    </tr>
    <tr>
      <td>pamidronate</td>
      <td>Aredia, Pamidronate</td>
      <td>D</td>
      <td>Biphosphonates</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>pamidronate (Aredia, Pamidronate)-[Amp 30, 90mg] IV Hypercalcemia: 60-90mg over 24hr. Wait 1wk before considering another dose. ¶D. *L2.  S.E. Anorexia, syncope, dyspnea, HF, hypertension, leucopenia, hypokalemia.</td>
    </tr>
    <tr>
      <td>risedronate/risedronic risedronate</td>
      <td>Actonel Once A Month</td>
      <td>C</td>
      <td>Biphosphonates</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>risedronate/risedronic risedronate (Actonel Once A Month)-[Tab 150mg] (Ribone)-[Tab 35, 150mg] (Risedronate Teva)-[Tab 35,75mg] PO Osteoporosis: 35mg/wk or 75mg on 2 consecutive days for a total of 150mg/mnth or 150mg/mnth. ¶C. *L3. S.E: Bone fracture, blurred vision, hypertension, arrhythmia, syncope, upper GI inflamtion, GERD, PUD, UTI, hemorrhoids, hiatus hernia, osteoarthritis, tendonitis, osteonecrosis of the jaw, bronchitis, anemia, colitis, hepatobiliary disorders, hypocalcemia, hypercholesterolemia, cataract, corneal lesions, iritis, uveitis, benign and malignant neoplasms, psychiatric disorders, nephrolithiasis in men with osteoporosis.</td>
    </tr>
    <tr>
      <td>agalsidase, modified beta-galactosidase</td>
      <td>Fabrazyme</td>
      <td>B</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>agalsidase, modified beta-galactosidase (Fabrazyme)-[Amp 5, 35mg/ml] IV Fabry disease: 1mg/kg every 2 wks. (modified alfa–galactosidase) (Replagal)-[Amp 1mg/ml] Fabry disease: 0.2mg/kg every 2 wks. ¶B. S.E: Tachycardia, ventricular wall thickening, hypoacusis.</td>
    </tr>
    <tr>
      <td>alglucerase ,modified ß-glucocerebrosidase</td>
      <td>Ceredase</td>
      <td>C</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>alglucerase ,modified ß-glucocerebrosidase (Ceredase)-[Amp 80IU/ml] IV Gaucher disease: Individualized dosage by patient response. Diluted infusion over 1-2h. Initial dosage may be 2.5units/kg 3x/wk up to 60units/kg 1x/wk or as infrequently as every 4wks. ¶C.S.E: Fever.</td>
    </tr>
    <tr>
      <td>betaine</td>
      <td>Cystadane</td>
      <td>C</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>betaine (Cystadane)-[Pwdr 1G/G] PO Homocystinuria: 3g 2x/d. Max 20G/d. Peds &lt;3yrs start 100mg/kg/d and then increase weekly by 50mg/kg. ¶C. S.E: Nausea, GI distress.</td>
    </tr>
    <tr>
      <td>levocarnitine</td>
      <td>Carnitine</td>
      <td>B</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>levocarnitine (Carnitine)-[Soln 30%] PO Start 1G/d, then 1-3G/d q8-12h. Peds: 50-100mg/kg/d q8-12h, max 3G/d. ¶B. *L3. S.E: Seizures, hypertension, tachycardia.</td>
    </tr>
    <tr>
      <td>imiglucerase, analogue ß-glucocerebrosidase</td>
      <td>Cerezyme</td>
      <td>N</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>imiglucerase, analogue ß-glucocerebrosidase (Cerezyme)-[Amp 200, 400IU] IV Gaucher disease: Individualized dosage by patient response. Diluted infusion over 1-2h. ¶Not established. S.E: Angioedema, dyspnea, cyanosis, hypotension, fever, tachycardia.</td>
    </tr>
    <tr>
      <td>miglustat</td>
      <td>Zavesca</td>
      <td>C</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>miglustat (Zavesca)-[Cap 100mg] PO Gaucher disease: Start 100mg 3x/d. ¶C. S.E: Peripheral neuropathy, tremor, diarrhea, weight loss, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>raloxifene</td>
      <td>Evista</td>
      <td>X</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>raloxifene (Evista)-[FC Tab 60mg] (Raloxifene Teva)-[Tab 60mg] PO 60mg 1x/d. ¶X. *L3. S.E: Retinal vascular occlusion, VT.</td>
    </tr>
    <tr>
      <td>sevelamer</td>
      <td>Renagel</td>
      <td>C</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>sevelamer (Renagel)-[FC Tab 800mg] (Renvela)-[Pwdr 2.4G; FC Tab 800mg] PO 800-1600mg 3x/d. ¶C. *L3. S.E: Thrombosis.</td>
    </tr>
    <tr>
      <td>sodium phosphate+potassium acid phosphate</td>
      <td>Calciless</td>
      <td>C</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>sodium phosphate+potassium acid phosphate (Calciless)-[Tab 285mg+602mg] PO Hypercalcemia or calcium oxalate stones: 1-2 Tab 4x/d. ¶C. S.E: Confusion, tachycardia.</td>
    </tr>
    <tr>
      <td>sodium polystyrene sulfonate</td>
      <td>Kayexalate</td>
      <td>C</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>sodium polystyrene sulfonate (Kayexalate)-[Pwdr 100%] Hyperkalemia: PO 15G 1-4x/d, Rectal 30-50G 4x/d. ¶C. S.E: Hypokalemia, hypocalcemia, hypomagnesemia and significant sodium retention.</td>
    </tr>
    <tr>
      <td>tamoxifen</td>
      <td>Tamoxifen Teva</td>
      <td>D</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>tamoxifen (Tamoxifen Teva)-[Tab 20mg] PO Breast cancer: 20mg 1-2x/d. ¶D. *L5. S.E: Malignant neoplasm of endometrium, stroke, cataract, pulmonary embolism, stevens-johnson syndrome, thromboembolic events.</td>
    </tr>
    <tr>
      <td>zoledronate/zoledronic acid</td>
      <td>Zomera, Zoleronic Teva, Zoleronic Dexcel, Zoleronic Acid TaroZoleronic Acid Hospira, Zoleronic Acid Actavis</td>
      <td>D</td>
      <td>Other Endocrine &amp; Metabolic Agents</td>
      <td>ENDOCRINE / METABOLIC</td>
      <td>zoledronate/zoledronic acid  (Zomera, Zoleronic Teva, Zoleronic Dexcel, Zoleronic Acid TaroZoleronic Acid Hospira, Zoleronic Acid Actavis)-[Soln 4mg] (Tevadronic)-[Soln 0.05m] (Aclasta)-[Soln 5mg] IV Hypercalcemia: 5mg slow IV. ¶D. S.E: Pyrexia, myalgia, arthralgia.</td>
    </tr>
    <tr>
      <td>aspirin</td>
      <td>acetylsalicylic acid</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>aspirin (acetylsalicylic acid) (Acetosal)-[Tab 300mg] (Aspirin Cardio, Cardiopirin, Cartia, Tevapirin)-[EC Tab 100mg] (Godamed)-[Tab 100mg] (Gamse Pirin)-[EC Tab 325mg] (Micropirin)-[EC Tab 75,100mg] (Aspirin 500)-[Tab 500mg] PO Fever: 325-650mg q4h, max 4G/d. Rheumatic diseases: 3G/d in divided doses. MI: 160-162.5mg 1x/d. Ischemic Stroke: 50-325mg 1x/d. Angina Pectoris: 75-325mg 1x/d. ¶C; D(in 3rd trimester). *L3. S.E: GI ulcer and bleeding, acute renal insufficiency, thrombocytopenia, hepatitis, angioedema, asthma, Reye's syndrome,  bronchospasm.</td>
    </tr>
    <tr>
      <td>aspirin+ascorbic acid</td>
      <td>Aspirin C</td>
      <td>D</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>aspirin+ascorbic acid (Aspirin C)-[Effervesc Tab 400+240mg] PO 1-2Tab up to 4x/d. Max 8Tabs/d. Peds: 1Tab up to 4x/d. ¶D. *L3. S.E: GI bleeding, acute renal insufficiency, thrombocytopenia, hepatitis, angioedema, asthma, Reye's syndrome, GI ulcer, bleeding, bronchospasm.</td>
    </tr>
    <tr>
      <td>aspirin+caffeine+paracetamol</td>
      <td>Acamol Focus, Excedrin, Exidol, Paramol Target</td>
      <td>D</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>aspirin+caffeine+paracetamol (Acamol Focus, Excedrin, Exidol, Paramol Target)-[Cap 250mg+65mg+250mg] PO 1Tab q4-6h as needed. ¶D. S.E: GI bleeding, acute renal insufficiency, thrombocytopenia, hepatitis, angioedema, asthma, Reye's syndrome, GI ulcer, bleeding, bronchospasm, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>aspirin+dipyridamole</td>
      <td>Aggenox</td>
      <td>D</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>aspirin+dipyridamole (Aggenox)-[CR Cap 25mg+200mg] PO 1 Cap 2x/d. ¶D. *L3. S.E: Bleeding, renal failure, hepatic failure.</td>
    </tr>
    <tr>
      <td>celecoxib</td>
      <td>Celcox, Celebra</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>celecoxib (Celcox, Celebra)-[Cap 100, 200mg] PO Osteoarthritis: 200mg 1x/d or 100mg 2x/d. RA: 100-200mg 2x/d. Ankylosing Spondylitis: 200mg 1x/d or 100mg 2x/d, if no effect 400mg 1x/d. ¶C; D(in 3rd trimester). *L2. S.E: MI, GI bleeding, GI ulceration and perforation, renal papillary necrosis, exacerbation of asthma.</td>
    </tr>
    <tr>
      <td>diclofenac</td>
      <td>Abitren 50, 100</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>diclofenac (Abitren 50, 100)-[Susp 50mg; SR Tab 100mg] (Abitren Ampoules)-[Amp 78.75mg/3ml] (Betaren)-[SR Tab 100mg] (Cataflam)-[Tab 50mg] (Swiss Relief Dual Release)-[Cap 75mg] (Diclofenac Sodium,Diclovit, Voltaren Emulgel)-[Gel 1%] (Dicloftil)-[Soln 0.1%]ocular (Dicloplast)-[Plaster 140mg] (Dicloren Gel, N-Ke'ev, Physicare Gel)-[Gel 1%; Soln 4%] (Sunactic)-[Gel 3%] (Volraten Acti-Go)-[FC Tab/ Gel/ Cap 12.5mg] (Voltaren Emulgel, Voltaren Emulgel Forte)-[Gel 1%, 23.2mg/g] (Voltaren Ophtha Eye Drops)-[1mg/ml] PO 100-150mg/d in divided doses. Gel Apply thin layer to affected skin 2x/d. Plaster 2x/d. IM 75mg. IV 75mg slow infusion. Eye drops 1-2drops in affected eye 4x/d post-op for 2wks. ¶C; D (in 3rd trimester). *L2. S.E: GI hemorrhage, GI ulceration and perforation, nephrotoxicity, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>diclofenac+misoprostol</td>
      <td>Arthrotec 50, 75</td>
      <td>X</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>diclofenac+misoprostol (Arthrotec 50, 75)-[Tab 50mg+200µg, 75mg+200µg] PO Osteoarthritis: 100-150mg+400-600µg/d. Rheumatoid Arthritis: 100-200mg+400-800µg. ¶X. *L3. S.E: Cardiovascular thrombotic events, MI, stroke, GI bleeding, GI ulceration and perforation.</td>
    </tr>
    <tr>
      <td>etodolac</td>
      <td>Etopan</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>etodolac (Etopan)-[Cap 200, 300mg; Tab 400, 600mg] (Etopan XL)-[ER Tab 400, 500, 600mg] (Etodolac ER Teva)-[Tab 400, 600mg] PO Analgesia: 200-400mg q6-8h. Max 1000mg/d. Osteoarthritis and Rheumatoid Arthritis: 300mg 2-3x/d or 400-500mg 2x/d. Max 1000mg/d. ¶C; D (in 3rd trimester). *L3. S.E: GI hemorrhage, GI ulceration and perforation, nephrotoxicity, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>etoricoxib</td>
      <td>Arcoxia</td>
      <td>N</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>etoricoxib (Arcoxia)-[Tab 30,60,90,120mg] Adolescents &gt;16 years and Adults:  PO- Osteoarthritis: 30-60 mg once daily. Rheumatoid arthritis: 90 mg once daily. Acute gouty arthritis: 120 mg once daily. Ankylosing spondylitis: 90 mg once daily. Postoperative dental surgery pain: 90 mg once daily. ¶Not been established.  S.E Atrial fibrillation, anaphylaxis, HF, palpitations, nephrotoxicity, hepatotoxicity , stomach pain, GI bleeding, cardiovascular events, .</td>
    </tr>
    <tr>
      <td>ibuprofen</td>
      <td>Adex, Advil, Ibuprofen</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>ibuprofen (Adex, Advil, Ibuprofen)-[Cap 200mg] (Adex Liqui-Gels)-[Liq Cap 200, 400mg] (Advil Liqui-Gel, Ibuprofen Liquid-Gels)-[Liq Cap 200mg] (Adex Forte, Ibuprofen Forte)-[Cap 400mg] (Artofen)-[Tab 200, 400mg] (Ibufen)-[Cap 400, 600mg] (Nurofen, Nurofen Forte)-[Liq Cap 200, 400mg; Tab 200, 400mg] (Nurofen Quick)-[Tab 256, 512mg] (Children’s Advil, Iboo for Children )-[Susp 100mg/5ml] (Nurofen for Children)-[Susp 100mg/5ml; Suppositories 60, 125mg] (Tiptip Ibutaf)-[Drops 400mg/5ml] (Ibuleve, Nurofen Gel)-[Gel 5%] PO 200-400mg q4-6h. Rheumatic and arthritic disorders: 300-800mg q4-6 h. Peds: 0.5-12yrs 5-10mg/kg q6-8h. ¶C; D(at &gt;30 weeks gestation). *L1. S.E: GI hemorrhage, GI ulceration and perforation, nephrotoxicity, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>indomethacin</td>
      <td>Indovis</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>indomethacin (Indovis)-[Cap 25mg] PO 25mg 3x/d OR 50mg 2x/d. ¶C. *L3. S.E: GI hemorrhage, GI ulceration and perforation, nephrotoxicity, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>ketoprofen</td>
      <td>Fastum Gel</td>
      <td>B</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>ketoprofen (Fastum Gel)-[Gel 2.5%] (Ketospray)-[Spray 10%] Topical 31.5mg q6-8h. Max 126/mg/d. ¶B; D (in late pregnancy if PO). *L2. S.E: GI hemorrhage, GI ulceration and perforation, nephrotoxicity, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>ketorolac</td>
      <td>Acuvail</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>ketorolac (Acuvail)-[Soln 0.45%] Ocular 1drop 4x/d. ¶C. *L2. S.E: Itching, redness, tearing of the eye, blurred vision or other change in vision.</td>
    </tr>
    <tr>
      <td>nabumetone</td>
      <td>Nabuco</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>nabumetone (Nabuco)-[Tab 500mg] PO 1G 1-2x/d. ¶C; D (if used near term). *L3. S.E: GI hemorrhage, GI ulceration and perforation, nephrotoxicity, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>naproxen</td>
      <td>Narocin, Point, Naproxen Sodium, Naxyn Quick</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>naproxen (Narocin, Point, Naproxen Sodium, Naxyn Quick)-[Tab 275mg] (Naxyn 250, 500)-[Tab 250, 500mg] PO 250-550mg 2x/d. 1G Tab 1x/d. Max 1.25g/d. Pediatric: 2.5-10mg/kg/d. ¶C; D if used near term. *L3. S.E: GI hemorrhage, GI ulceration and perforation, nephrotoxicity, Stevens-Johnson syndrome, pseudoporphyria.</td>
    </tr>
    <tr>
      <td>naproxen+esomeprazole as magnesium trihydrate</td>
      <td>Vimovo</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>naproxen+esomeprazole as magnesium trihydrate (Vimovo)-[MR Tab 500mg+20mg] PO 1Tab 1x/d. ¶C; D if used near term. *L3. S.E: Cardiovascular thrombotic events, myocardial infarction, stroke, GI bleeding, GI ulceration and perforation.</td>
    </tr>
    <tr>
      <td>nimesulide</td>
      <td>Mesulid</td>
      <td>X</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>nimesulide (Mesulid)-[Cap 100mg] PO 100mg 2x/d after meals. ¶X. S.E: GI hemorrhage, GI ulceration and perforation, fluid retention, nephrotoxicity, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>piroxicam</td>
      <td>Brexin</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>piroxicam (Brexin)-[Pwdr Tab 20mg] PO 20mg 1x/d or in divided doses. ¶C/D(during 3rd trimester). *L2. S.E: GI hemorrhage, GI ulceration and perforation, nephrotoxicity, Stevens-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>tofacitinib</td>
      <td>Xeljanz</td>
      <td>C</td>
      <td>Nonsteroidal Anti-Inflammatory Drugs :NSAID</td>
      <td>ANALGESICS</td>
      <td>tofacitinib (Xeljanz)-[Tab 5mg] PO 5mg 2x/d. ¶C. S.E: GI perforations, URTI, headache, diarrhea, nasopharyngitis, lymphomas and other malignancies.</td>
    </tr>
    <tr>
      <td>buprenorphine</td>
      <td>Butrans</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>buprenorphine (Butrans)-[ Patches 5, 10, 20mg] (Subutex)-[Tab 2, 8mg] Transdermal 1-2 patches every 7d. Sublingual 8mg on day 1, then 16mg on day 2 over 3-4 days. Tabs 24mg/d. Switch to buprenorphine+naloxone combination. ¶C. L2. S.E: Hypotension, palpitations, tinnitus, respiratory depression, upper respiratory infection, arrhythmia, hypertension, cyanosis, dyspnea.</td>
    </tr>
    <tr>
      <td>buprenorphine+naloxone</td>
      <td>Suboxone</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>buprenorphine+naloxone (Suboxone)-[Tab 2.16+0.61mg, 8.64+2.44mg] Sublingual 16+4mg/d. ¶C. *L3. S.E: Peripheral edema, heat stroke, vertigo.</td>
    </tr>
    <tr>
      <td>codeine</td>
      <td>Codical, Rekod</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>codeine (Codical, Rekod)-[Tab 20mg] PO initial dose based on patients prior experience. Maintenance 15-60mg q4h as needed. Max 360mg/d.¶C. *L3. S.E: Respiratory depression, bronchospasm, arrhythmia, syncope, urinary retention, constipation.</td>
    </tr>
    <tr>
      <td>codeine+ibuprofen</td>
      <td>Nurofen Plus</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>codeine+ibuprofen (Nurofen Plus)-[Tab 10+200mg] PO 1-2 Tabs q4-6h. ¶C. *L3. S.E: Severe headache, GI bleeding, peptic ulceration, aplastic anemia.</td>
    </tr>
    <tr>
      <td>fentanyl</td>
      <td>Abstral</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>fentanyl (Abstral)-[SL Tab 100, 200, 300, 400 , 600, 800mcg] (Actiq)-[Compressed Tab 200, 400, 600, 800, 1200, 1600mcg] (Breakyl)-[Buccal film 200, 400, 600, 800 1200mcg] (Penta)-[Patches 12.5, 25, 50, 75, 100mcg; Soln 0.05mg/ml] (Fentadol)-[Patches 2.1, 4.2, 8.4, 12.6, 16.8mg] (Fentanyl Ianssen, Fentanyl Panpharma)-[Soln 0.05mg/ml] Sublingual Buccal Transdermal IV Epidural IM 2-50μg/kg. Patch 1 every 3d. ¶C. *L2. S.E: Respiratory depression, hypotension, confusion and abuse potential.</td>
    </tr>
    <tr>
      <td>hydromorphone</td>
      <td>Palladone, Palladone Inject, Palladone SR</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>hydromorphone (Palladone, Palladone Inject, Palladone SR)-[Cap 1.3, 2.6mg; SR Cap 4, 8, 24mg; Amp 10mg/ml] PO 2-4mg q4-6h when necessary. IM/SC 1-2mg q2-3h when necessary. IV 0.2-1mg q2-3h when necessary. SR Cap 1Cap q12h. ¶C. *L3. S.E: Agitation, convulsions, hyperventilation.</td>
    </tr>
    <tr>
      <td>methadone</td>
      <td>Adolan</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>methadone (Adolan)-[Soln 40mg/100ml] (Methadone)-[Soln 50mg/ml] PO Severe pain: 5-10mg q8-10h. Detox: 20-30mg 1x/d, may be titrated to 40mg/d in divided doses. ¶C. *L3. S.E: Respiratory depression, hypotension, confusion, abuse potential, cardiac arrest, shock, respiratory arrest, depression.</td>
    </tr>
    <tr>
      <td>morphine</td>
      <td>M.I.R.</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>morphine (M.I.R.)-[Tab 15, 30mg] (MCR)-[CR Tab 10, 30, 100mg] (Morphine)-[Soln 1, 20mg/ml] (Morphine HCL)-[Soln 10, 20mg/ml] (Oramorph)-[Soln 20mg/ml] PO 15-30mg q4h or 1 CR Tab 1x/d. IM/SC 5-20mg q4h. IV 5-15mg q4h. Bioavailability~30%. ¶C. *L3. S.E: Arrhythmia, hypertension, hypotension, palpitations, syncope, anemia, thrombocytopenia, gastroenteritis, abnormal liver function, edema, coma, delirium, tremor, vasodilation, impotence.</td>
    </tr>
    <tr>
      <td>oxycodone</td>
      <td>Oxycod Syrup</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>oxycodone (Oxycod Syrup)-[Syrp 10mg/5ml] (Oxycod Forte Syrup)-[Syrp 10mg/ml] (Oxycontin 5, 10, 20, 40, 80)-[CR Tab 5, 10, 20, 40, 80mg] PO 5-15mg 4-6x/d when necessary. ¶C. *L3. S.E: Respiratory depression, hypotension.</td>
    </tr>
    <tr>
      <td>oxycodone+naloxone</td>
      <td>Targin</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>oxycodone+naloxone (Targin)–[ER Tab 2.5+5, 5+10, 10+20, 20+40mg] PO up to 80mg oxycodone 40mg/naloxone 80mg/d. ¶C. S.E: Respiratory depression, CNS depression, hypotension, diarrhea.</td>
    </tr>
    <tr>
      <td>pethidine</td>
      <td>Dolestin</td>
      <td>B</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>pethidine (Dolestin)-[Amp 50mg/ml] IM IV SC 50-100mg q3-4h PRN. ¶B. S.E: Hypersensitivity, severe respiratory insufficiency.</td>
    </tr>
    <tr>
      <td>tramadol</td>
      <td>Tramadex OD</td>
      <td>C</td>
      <td>Narcotics {Agonists/Antagonists}</td>
      <td>ANALGESICS</td>
      <td>tramadol (Tramadex OD)-[Tab 100, 200, 300mg] (Tramal)-[Cap 50mg; Inj 100mg/2ml; Suppository100mg] (Tramadex)-[Drops 100mg/ml; Tab 50, 100mg] (Tramaraz)-[Drops 100mg/ml] (Tramal Retard 100)-[SR Tab 100mg] (Trama Injection, Tramadol Rotexmedica)-[Inj 100mg/2ml] PO Tab 50-100mg 4-6x/d when necessary, max 400mg/d. Drops: 20-40 drops 3-4x/d, max 160drops/d (elderly 120 drops). Cap/SR Tab: 100mg/d, max 300mg/d. ¶C. *L3. S.E: Seizure, suicide, serotonin syndrome, anaphylactoid reactions, respiratory depression, withdrawal symptoms.</td>
    </tr>
    <tr>
      <td>codeine+paracetamol</td>
      <td>Codabrol,Cod-Acamol</td>
      <td>C</td>
      <td>Other Analgesics {+combinations}</td>
      <td>ANALGESICS</td>
      <td>codeine+paracetamol (Codabrol,Cod-Acamol)-[Tab 15+325mg] PO codeine 15-60mg 1-6x/d, paracetamol 300-1000mg 1-6x/d when necessary Max codeine 360mg/d, paracetamol 4000mg/d. Peds: 0.5mg/kg 1-6x/d when necessary. ¶C. S.E: Hepatotoxicity, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, death related to ultra-rapid metabolism.</td>
    </tr>
    <tr>
      <td>codeine+paracetamol+caffeine</td>
      <td>Rokacet, Rokacet Pls</td>
      <td>C</td>
      <td>Other Analgesics {+combinations}</td>
      <td>ANALGESICS</td>
      <td>codeine+paracetamol+caffeine (Rokacet, Rokacet Pls)-[Tab 10mg+500mg+30mg, 15mg+500mg+50mg] PO 1Tab 6x/d as needed. Max 5Tab/d. ¶C. S.E: Respiratory depression, hypotension, hepatotoxicity, thrombocytopenic purpura, pancytopenia, tachycardia, urticaria.</td>
    </tr>
    <tr>
      <td>dipyrone</td>
      <td>Optalgin</td>
      <td>A</td>
      <td>Other Analgesics {+combinations}</td>
      <td>ANALGESICS</td>
      <td>dipyrone (Optalgin)-[Tab/Cap 500mg; Drops 500mg/ml; Amp 1G/2ml] (V-Dalgin)-[Drops 500mg/ml; Syrp 1.25g/5ml] PO 0.5-1g 1-4x/d, max 4G/d. IM, IV 1-2.5G 1-4x/d, max 5G/d. Susp 0.3G 1-4x/d. Drops 25-50 1-4x/d, max 200drops/d. Peds: 3-12mnths 2-6 drops 1-4x/d, 1-3yrs 4-12drops 1-4x/d, 4-6yrs 6-19drops 1-4x/d, 7-9yrs 10-25drops 1-4x/d, 10-12yrs 12-37drops 1-4x/d, 13-14yrs: 19-44drops 1-4xd. ¶A during first trimester; C during second trimester; D during last trimester. S.E: Hypotension, anaphylactic shock, arrhythmias, renal injury, Steven Johnson syndrome, pancytopenia, agranulocitosis.</td>
    </tr>
    <tr>
      <td>oxycodone+paracetamol</td>
      <td>Percocet-5</td>
      <td>C</td>
      <td>Other Analgesics {+combinations}</td>
      <td>ANALGESICS</td>
      <td>oxycodone+paracetamol (Percocet-5)-[Tab 5+325mg] PO 1Tab 4x/d when necessary. Max 12Tab/d. ¶C. S.E: Hepatotoxicity, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis.</td>
    </tr>
    <tr>
      <td>oxycodone+aspirin</td>
      <td>Percodan</td>
      <td>C</td>
      <td>Other Analgesics {+combinations}</td>
      <td>ANALGESICS</td>
      <td>oxycodone+aspirin (Percodan)-[Tab 5+325mg] PO 1Tab 4x/d when necessary. Peds: 0.25-0.5Tab 4x/d. ¶C;D(in third trimester). *L3. S.E: Respiratory depression, severe hypotension, coagulation abnormalities, gross GI bleeding, PUD.</td>
    </tr>
    <tr>
      <td>paracetamol/acetaminophen</td>
      <td>Abrol, Acamol, Dexamol, Maccabimol, Panadol, Sensamol</td>
      <td>B</td>
      <td>Other Analgesics {+combinations}</td>
      <td>ANALGESICS</td>
      <td>paracetamol/acetaminophen (Abrol, Acamol, Dexamol, Maccabimol, Panadol, Sensamol)-[Tab/Cap 500mg] (Sensamol Junior)-[160mg/5ml] (Abrolet)-[Susp 150, 250mg; Syrp 125mg/5ml] (Acamoli)-[Susp 80, 150, 250mg; Syrp 125, 250mg/5ml] (Apotel)-[Syrp 150mg/ml] (Avcamol)-[Granules 250, 500mg/stick pack] (Dexamol Kid, Paramol Kat)-[Chew Tab 250mg] (Maccabimol kid)-[Susp 150, 250mg] (Paramol)-[Cap 500mg] (Tiptipot Novimol)-[Drops 100mg/ml] (Supramol)-[Susp 150, 500mg] (Paracetamol B.Braun, Paracetamol Fresenius, Paracetamol Taro, Perfalgan)-[Soln 10mg/ml] PO 325-650mg 4-6x/d or 1000mg 6-8x/d, max 4G/d. IV 1000mg 4x/d or 650mg 6x/d. Peds: PO 10-15mg/kg/dose 4-6x/d. Neonates: 10-15mg/kg 3-4x/d, max 90mg/kg/d. PO Drops: &lt;1yr 20-40drops, 1-6yr 40-80drops all up to 4x/d. PR Suppositories 325-650mg q4-6h. Peds: PR Suppositories 3-12mnths 80mg q6h, 1-3yrs 80mg q4h, 3-6yrs 120mg q4-6h, 6-12yrs 325mg q4-6h. ¶B(PO and rectally); C(IV). S.E: Hepatotoxicity, cholestasis, acute pancreatitis, acute renal failure, intrinsic renal disease, anaphylaxis, thrombocytopenia, methemoglobinemia, acetaminophen-induced eosinophilic pneumonia, hypotension, hypokalemia, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis.</td>
    </tr>
    <tr>
      <td>paracetamol+caffeine</td>
      <td>Dexamol Plus, Paramol Plus</td>
      <td>B</td>
      <td>Other Analgesics {+combinations}</td>
      <td>ANALGESICS</td>
      <td>paracetamol+caffeine (Dexamol Plus, Paramol Plus)-[Cap 500mg+50mg] PO 2Cap 4x/d. ¶B. S.E: Caffeinism, fibrocystic breast disease, hepatotoxicity, cholestasis, acute pancreatitis, intrinsic renal disease, anaphylaxis, thrombocytopenia, methemoglobinemia, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, eosinophilic pneumonia, hypotension.</td>
    </tr>
    <tr>
      <td>paracetamol+tramadol hydrochlorid</td>
      <td>Zaldiar</td>
      <td>C</td>
      <td>Other Analgesics {+combinations}</td>
      <td>ANALGESICS</td>
      <td>paracetamol+tramadol hydrochlorid (Zaldiar)-[FC Tab 325mg+37.5mg] PO Start 1-2Tab, the shortest time between doses must be at list 6hr. Max: 8Tab/d(2,600mg+300mg). ¶C. *L2. S.E: Skin redness, dizziness, vomiting, diarrhea, sweating, swelling of the tongue, neck and face.</td>
    </tr>
    <tr>
      <td>auranofin</td>
      <td>Ridaura</td>
      <td>C</td>
      <td>Anti-Rheumatic/Anti-Arthritic-Agents</td>
      <td>ANALGESICS</td>
      <td>auranofin (Ridaura)-[Tab 3mg] PO 3mg 2x/d or 6mg 1x/d. ¶C. S.E: Pancytopenia, eosinophilia, proteinuria, hematuria.</td>
    </tr>
    <tr>
      <td>diacerein</td>
      <td>Diatrim</td>
      <td>X</td>
      <td>Anti-Rheumatic/Anti-Arthritic-Agents</td>
      <td>ANALGESICS</td>
      <td>diacerein (Diatrim) -[Cap 50mg] PO Osteoarthritis: 50mg 2x/d. ¶X. S.E: Melanosis coli, hepatic disorders.</td>
    </tr>
    <tr>
      <td>etanercept</td>
      <td>Enbrel</td>
      <td>B</td>
      <td>Anti-Rheumatic/Anti-Arthritic-Agents</td>
      <td>ANALGESICS</td>
      <td>etanercept (Enbrel)-[Amp 25, 50mg/ml] Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis: 50mg/wk. Plaque Psoriatic Patients: starting dose: 50mg 2x/wk for 3 months, maintenance dose: 50mg/wk. JIA ≥ 63kg: 50mg/wk, &lt; 63kg 0.8mg/kg/wk. ¶B. *L2. S.E: Bacterial and viral infections, invasive fungal infections, reactivation of latent tuberculosis, lymphoma and other malignancies, lupus-like syndrome, autoimmune hepatitis.</td>
    </tr>
    <tr>
      <td>hydroxychloroquine</td>
      <td>Plaquenil</td>
      <td>X</td>
      <td>Anti-Rheumatic/Anti-Arthritic-Agents</td>
      <td>ANALGESICS</td>
      <td>hydroxychloroquine (Plaquenil)-[Tab 200mg] PO Systemic Lupus Erythematosus: Start 400mg 1-2x/d. Maintenance 200-400mg/d. RA: Start 400-600mg 1x/d. Maintenance: 200-400mg/d. ¶X only in treatment of Malaria. *L2. S.E: Retinopathy, macular degeneration, psychosis, suicidal behavior, cardiomyopathy, bone marrow suppression, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, fulminant hepatic failure, allergic reactions, hypoglycemia.</td>
    </tr>
    <tr>
      <td>leflunomide</td>
      <td>Arava</td>
      <td>X</td>
      <td>Anti-Rheumatic/Anti-Arthritic-Agents</td>
      <td>ANALGESICS</td>
      <td>leflunomide (Arava)-[Tab 10, 20, 100mg] PO RA: 100mg 1x/d for 3d, then 10-20mg/d. ¶X. *L4. S.E: Hepatotoxicity, immunosuppression, bone marrow supression, Stevens-Johnson syndrome, toxic epidermal necrolysis, eosinophilia, malignancy, peripheral neuropathy, interstitial lung disease.methotrexate (Abitrexate)-[Amp 25mg/ml; soln 1000mg/10ml] (Methotrexate Ebewe)-[Tab 2.5mg; Amp 10, 20, 100 mg/ml] (Methotrexate Lederle) -[Tab 2.5mg] (Metoject)-[Amp 50mg/ml] RA: PO Start 7.5 mg/wk single dose or 2.5mg q12h for 3 doses as course once weekly. Max 20mg/wk. Psoriasis: PO IV IM 10-25mg/wk or PO 2.5mg q12h for 3 doses as course once weekly. Max 30mg/wk. Consider folate supplementation. ¶X. *L3. S.E: GI ulceration and bleeding, , pancreatitis, , aplastic anemia, pancytopenia, ,  agranulocytosis, eosinophilia, bone marrow suppression, tumor lysis syndrome, hypogammaglobulinemia, pericarditis, pericardial effusion, hypotension, thromboembolic events, hemiparesis, paresis, convulsions, encephalopathy, hepatotoxicity, , fatal opportunistic infections, conjunctivitis, pulmonary toxicity, toxic epidermal necrolysis, Stevens-Johnson syndrome, skin necrosis, ,  renal failure, infertility, vasculitis, diabetes, osteoporosis, sudden death, lymphoma, soft tissue necrosis, , anaphylactoid reactions.</td>
    </tr>
    <tr>
      <td>sulfasalazine</td>
      <td>Salazopyrin</td>
      <td>B</td>
      <td>Anti-Rheumatic/Anti-Arthritic-Agents</td>
      <td>ANALGESICS</td>
      <td>sulfasalazine (Salazopyrin)-[Tab/EN Tab 500mg] PO Adults: initial: 3-4g/d divided within 8hr, maintenance: 2g/d. Peds: initial 40-60mg/kg/d divided into 3-6 doses, maintenance: 30mg/kg/d in 4 divided doses. ¶B. *L3. S.E: Fatal sepsis and pneumonia, agranulocytosis, neutropenia, myelosuppression.\t</td>
    </tr>
    <tr>
      <td>tocilizumab</td>
      <td>Actemra</td>
      <td>C</td>
      <td>Anti-Rheumatic/Anti-Arthritic-Agents</td>
      <td>ANALGESICS</td>
      <td>tocilizumab (Actemra)-[Soln For SC 162mg/0.9ml; Soln for IV 20mg/ml] SC &lt;100kg: 162mg every other week. &gt;100kg: 162mg every week. IV: 4mg/kg every 4 weeks followed by an increase to 8mg/kg every 4 weeks based on clinical response. ¶C. *L3. S.E: GI perforation, serious infection develops, URTI, nasopharyngitis, headache, hypertension, increased ALT.</td>
    </tr>
    <tr>
      <td>baclofen</td>
      <td>Baclosal, Lioresal</td>
      <td>C</td>
      <td>Muscle_Relaxants</td>
      <td>ANALGESICS</td>
      <td>baclofen (Baclosal, Lioresal)-[Tab 10, 25mg] PO Start 5mg 3x/d. Increase every 3d to 20mg/d. Max 40-80mg/d. ¶C. *L2. S.E: Coma, seizure, death after abrupt withdrawal.</td>
    </tr>
    <tr>
      <td>botulinum toxin, type A</td>
      <td>Botox, Botulinum Antitoxin A, B</td>
      <td>C</td>
      <td>Muscle_Relaxants</td>
      <td>ANALGESICS</td>
      <td>botulinum toxin, type A (Botox, Botulinum Antitoxin A, B)-[Amp 100IU] (Dysport)-[Amp 500IU] IM Cervical Dystonia: 500IU. Glabellar lines: 50IU in 5 equal aliquots of 10IU each. Max 1000IU. ¶C. *L3. S.E: Arrhythmia, syncope, hepatotoxicity, anaphylaxis.</td>
    </tr>
    <tr>
      <td>dantrolene</td>
      <td>Dantrium</td>
      <td>C</td>
      <td>Muscle_Relaxants</td>
      <td>ANALGESICS</td>
      <td>dantrolene (Dantrium)-[Amp 20mg] IV Malignant Hyperthermia: 1mg/kg, continue until symptoms subside or max 10mg/kg. ¶C. *L4. S.E: Hepatotoxicity.</td>
    </tr>
    <tr>
      <td>orphenadrine</td>
      <td>Flexin</td>
      <td>C</td>
      <td>Muscle_Relaxants</td>
      <td>ANALGESICS</td>
      <td>orphenadrine (Flexin)-[Amp 30mg/ml]IM IV 60mg 1-2x/d. ¶C. *L3. S.E: Lightheadedness, dizziness, syncope.Contraindication to perform hazardous activities.</td>
    </tr>
    <tr>
      <td>orphenadrine+paracetamol</td>
      <td>Muscol</td>
      <td>C</td>
      <td>Muscle_Relaxants</td>
      <td>ANALGESICS</td>
      <td>orphenadrine+paracetamol (Muscol)-[Tab 30mg+500mg] PO 1-2Tab 3-4x/d. ¶C. S.E: Reye’s Syndrome in patienets with influenza.Contraindication to perform hazardous activities.</td>
    </tr>
    <tr>
      <td>benzydamine</td>
      <td>Easy Gel</td>
      <td>S</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>benzydamine (Easy Gel)-[Gel 5%](Tantum Verde)-[Oral Rinse 0.15%] Mucositis, pharyngitis: Gel: Apply 3-6x/d. Oral Rinse: rinse 3-4x/d for at least 30sec followed by expulsion from the mouth. ¶Should not be used in pregnancy or lactation unless considered essential. S.E: Localized numbness, drowsiness, headache, pharyngitis, burning of skin.</td>
    </tr>
    <tr>
      <td>capsaicin</td>
      <td>Zostrix, Zostrix-HP</td>
      <td>B</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>capsaicin (Zostrix, Zostrix-HP)-[Cream 0.025%, 0.075%] Arthritis: Apply 3-4x/d. ¶B. *L3. S.E: None.</td>
    </tr>
    <tr>
      <td>diclofenac</td>
      <td>Dicloplast</td>
      <td>B</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>diclofenac (Dicloplast)-[Patches 140mg] (Dicloren Gel, N-KE’EV, Physicare Gel, Sunactic 3%, Volatren Emulgel)-[Gel 1%] (Swiss Relief)- [spray gel 4%] Plaster: place 2x/d. Gel: spread 4x/d. ¶B; D in 3rd trimester. *L2. S.E: Cardiovascular, GI manifestations.</td>
    </tr>
    <tr>
      <td>ethanolamine oleate</td>
      <td>Ethanolamine Oleate</td>
      <td>C</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>ethanolamine oleate (Ethanolamine Oleate)-[Amp 0.91%+4.23%] IV Varicose veins: inject 1.5-5ml per varix. Max 20ml. ¶C. S.E: Pleural infusion/infiltration, esophageal reactions, bacteremia.</td>
    </tr>
    <tr>
      <td>ibuprofen</td>
      <td>Ibuleve</td>
      <td>C</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>ibuprofen (Ibuleve)-[Gel 5%] Apply 3x/d. ¶C. *L1. S.E: Local skin reactions, hepatitis when used for prolonged period.</td>
    </tr>
    <tr>
      <td>lidocaine</td>
      <td>After Burn Spray</td>
      <td>B</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>lidocaine (After Burn Spray)-[Spray 0.5%] (Esracain)-[Gel 2%. Cream 5%] (Xylocaine)-[Spray 10%] Apply 3-4x/d or more. Soln: amount according to procedure and age. ¶B. C in 3rd tri. *L2. S.E: None.</td>
    </tr>
    <tr>
      <td>lidocaine+prilocaine</td>
      <td>Emla 5%</td>
      <td>B</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>lidocaine+prilocaine (Emla 5%)-[Cream/Patch 2.5%+2.5%] Apply 2.5g cream or 1patch 1hr before procedure. Cover cream with occlusive dressing. ¶B. S.E: None</td>
    </tr>
    <tr>
      <td>methyl salicylate+menthol</td>
      <td>Ben Gay Cream</td>
      <td>C</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>methyl salicylate+menthol (Ben Gay Cream)-[Cream 15%+10%] (Ben-Gay Ultra Strength Cream)-[Cream 30%+10%+4%camphor] (Radian B Muscle Rub)-[1.43% camphor, 0.005% capsicum oleoresin, 2.54%+0.42%] (Radian B Spray)-[Spray 0.6%+1.4%+1.2% aspirin+0.6% camphor] Apply several times per day as required. ¶C. *L3. S.E: None.</td>
    </tr>
    <tr>
      <td>piroxicam</td>
      <td>Exipan, Feldene gel</td>
      <td>C</td>
      <td>Topical_Analgesics</td>
      <td>ANALGESICS</td>
      <td>piroxicam (Exipan, Feldene gel)-[Gel 0.5%] Apply 2-4x/d. ¶C(1st trimester) D (3rd trimester). *L2. S.E: Wheezing, dyspnea , fever, Steven Johnson syndrome, toxic epidermal necrolysis, edema in face, lips or eyelids, pruritus.</td>
    </tr>
    <tr>
      <td>phenazone+tetracaine</td>
      <td>Otidin Drops,  Anaesthetic Ear Drops</td>
      <td>C</td>
      <td>Ear Drop Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>phenazone+tetracaine (Otidin Drops,  Anaesthetic Ear Drops)-[Soln 5%+0.5%] Fill auditory canal 3-4x/d until pain subsides. ¶C. S.E: Cardiac arrest and hypotension from excessive systemic absorption, CNS depression or excitation, respiratory arrest, drug-induced keratoconjunctivitis.</td>
    </tr>
    <tr>
      <td>betamethasone</td>
      <td>Betnesol Eye, Ear, Nose Drops</td>
      <td>C</td>
      <td>Ear Drop Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>betamethasone (Betnesol Eye, Ear, Nose Drops)-[Soln 0.1%] Apply 1-2 drops into eye q1-2h. ¶C. *L2. S.E: Topical irritation, burning, ophthalmic conjunctivitis, contact dermatitis, immune suppression (prolonged use).</td>
    </tr>
    <tr>
      <td>neomycin+benzocaine+phenylephrine+sodium propionate</td>
      <td>Otomycin</td>
      <td>D</td>
      <td>Ear Drop Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>neomycin+benzocaine+phenylephrine+sodium propionate (Otomycin)-[Soln 3%+0.35%+0.25%+5%] Fill canal until external ear is full. Keep ear steady for 5min. 3-4x/d. ¶D. S.E: Rash, local inflammation.</td>
    </tr>
    <tr>
      <td>neomycin+dexamethasone</td>
      <td>Dethamycin</td>
      <td>C</td>
      <td>Ear Drop Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>neomycin+dexamethasone (Dethamycin)-[Soln 0.5%+0.1%] Apply 2-3Drops 3-4x/d. ¶C. *L3. S.E: Irritation, pain.</td>
    </tr>
    <tr>
      <td>neomycin+hydrocortisone</td>
      <td>Hycomycin Eye, Ear, Nose Ointment</td>
      <td>D</td>
      <td>Ear Drop Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>neomycin+hydrocortisone (Hycomycin Eye, Ear, Nose Ointment)-[Oint 0.5%+2.5%] Apply 1cm 1-3x/d. ¶D. *L3. S.E: Rash, local inflammation, edema of face, lips, tongue, difficulty breathing, wheezing.</td>
    </tr>
    <tr>
      <td>polymyxin B+neomycin+dexamethasone</td>
      <td>Desoren, Dex-Otic</td>
      <td>C</td>
      <td>Ear Drop Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>polymyxin B+neomycin+dexamethasone (Desoren, Dex-Otic)-[Soln 10,000IU+5 mg+1mg/ml] Apply 2-3Drops 3-4x/d. Peds: 1-2Drops 3-4x/d. ¶C. *L3. S.E: Hypersensitivity reactions, secondary infection, glaucoma, high intraocular pressure, wound healing impairment.</td>
    </tr>
    <tr>
      <td>saline+other</td>
      <td>Balanced Irrigating Salt Solution</td>
      <td>A</td>
      <td>Ear Drop Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>saline+other (Balanced Irrigating Salt Solution)-[Soln] as needed. ¶A. S.E: None.</td>
    </tr>
    <tr>
      <td>urea hydrogen peroxide</td>
      <td>Exterol Ear Drops</td>
      <td>N</td>
      <td>Ear Drop Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>urea hydrogen peroxide (Exterol Ear Drops)-[Soln 5%] Apply up to 5 drops 3-4x/d for 3-4d. ¶Not established. S.E: Bubbling sensation in ear, dizziness, loss of hearing, irritation or pain in ear.</td>
    </tr>
    <tr>
      <td>azelastine</td>
      <td>Rhinolast</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>azelastine (Rhinolast)-[Spray 0.1%] 1-2 Sprays each nostril 2x/d. ¶C. *L3. S.E: Somnolence.</td>
    </tr>
    <tr>
      <td>beclomethasone</td>
      <td>Rhinocort</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>beclomethasone (Rhinocort)-[Spray 50µg] adults and children &gt;6 yrs: 1-2 nasal inhalations each nostril 2x/d. ¶C. *L2. S.E: Dizziness, nausea, nasal congestion, large mucous discharge, headache, stomach ache, hypersensitivity reaction, local irritation, ocular pain, nosebleeds.</td>
    </tr>
    <tr>
      <td>betamethasone</td>
      <td>Betnesol Eye, Ear, Nose Drops</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>betamethasone (Betnesol Eye, Ear, Nose Drops)-[Drops 0.1%] 2-3Drops each nostril 2-4x/d. Peds: ½dose. ¶C. *L2. S.E: Immune suppression (prolonged use).</td>
    </tr>
    <tr>
      <td>budesonide micronized</td>
      <td>Nasocort Aqua</td>
      <td>B</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>budesonide micronized (Nasocort Aqua)-[Spray 32, 64µg/dose] 1 Spray each nostril 1x/d. Max 4 Sprays each nostril once or divided dose. ¶B. *L1. S.E: None</td>
    </tr>
    <tr>
      <td>cromoglycate sodium</td>
      <td>Lomudal Nasal Solution</td>
      <td>B</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>cromoglycate sodium (Lomudal Nasal Solution)-[Nasal Spray 2%] 1 Spray each nostril 3-4x/d. Max 6x/d. ¶B. S.E: None.</td>
    </tr>
    <tr>
      <td>dexamethasone+neomycin</td>
      <td>Dethamycin, Dexamycin</td>
      <td>D</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>dexamethasone+neomycin (Dethamycin, Dexamycin)-[Soln 0.1%+0.5%] Apply 1-2Drops 3-4x/d. ¶D. *L3. S.E: Irritation,  pain and burning in the nose.</td>
    </tr>
    <tr>
      <td>fluticasone</td>
      <td>Allegro, Flixonase</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>fluticasone (Allegro, Flixonase)-[Spray 0.05%] (Flixonase Nasule drops)-[Susp 400µg] 2 Sprays each nostril 1x/d. Peds: 1 Spray. Susp: Use 1-2x/d. ¶C. *L3. S.E: Headaches, nasal septal perforation, nose bleeding, dyspnea, hypersensitivity reactions, blurred vision, glaucoma, cataract, increased intraocular pressure, hypertension, thinning and pigmentation of the skin,  weight gain.</td>
    </tr>
    <tr>
      <td>neomycin+hydrocortisone</td>
      <td>Hycomycin Eye, Ear, Nose Ointment</td>
      <td>D</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>neomycin+hydrocortisone (Hycomycin Eye, Ear, Nose Ointment)-[Oint 0.5%+2.5%] Apply 1cm 1-3x/d. ¶D. *L3. S.E: Rash, local inflammation, edema of face, lips, tongue, difficulty breathing, wheezing.</td>
    </tr>
    <tr>
      <td>mometasone</td>
      <td>Nasonex</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>mometasone (Nasonex)-[Nasal Spray 50 µg/spray] 2 Sprays/d each nostril. ¶C. *L3.  S.E: Headache, epistaxis, nasal ulceration, hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>mupirocin</td>
      <td>Bactroban Nasal</td>
      <td>B</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>mupirocin (Bactroban Nasal)-[Oint 2%] Apply 3x/d for 5d. ¶B. *L1. S.E: Local pain.</td>
    </tr>
    <tr>
      <td>naphazoline</td>
      <td>Alnase</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>naphazoline (Alnase)-[Nasal spray/ Drops 0.05%] 1-2 sprays in each nostril every 6hr. ¶C. *L3. S.E: Local stinging.</td>
    </tr>
    <tr>
      <td>phenylephrine+dimethindene</td>
      <td>Vibrocil Microdoser</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>phenylephrine+dimethindene (Vibrocil Microdoser)-[Spray/Drops 0.25G+0.025G] 1-2 Sprays each nostril 3-4x/d. 3-4Drops 3-4x/d. Peds: 1-2 Drops 3-4x/d. ¶C. S.E: Nasal burning.</td>
    </tr>
    <tr>
      <td>phenylephrine+naphazoline+mepyramine</td>
      <td>Alnase</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>phenylephrine+naphazoline+mepyramine (Alnase)-[ Spray/ Drops Spray 0.25%+0.05%+0.5%] 2 Drops each nostril 4-8x/d or 2 Sprays several times, max 3-5days. ¶C. S.E: Nasal burning.</td>
    </tr>
    <tr>
      <td>triamcinolone</td>
      <td>Steronase</td>
      <td>C</td>
      <td>Nasal Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>triamcinolone (Steronase)-[Spray 55µg] 2 Sprays each nostril 1x/d. Peds: 1 Spray. ¶C. *L3. S.E: Impaired wound healing, glaucoma.</td>
    </tr>
    <tr>
      <td>benzocaine+chlorbutol+eugenol</td>
      <td>Dentin</td>
      <td>N</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>benzocaine+chlorbutol+eugenol (Dentin)-[Soln 8%+2%+9%] Tooth pain: Apply on cotton applicator as required. ¶Not established. S.E: Hypersensitivity, contact dermatitis, localized burning, methemoglobinemia.</td>
    </tr>
    <tr>
      <td>chlorhexidine</td>
      <td>Corsodyl</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>chlorhexidine (Corsodyl)-[Soln 0.2%; Gel 1%] (Tarodent)-[Soln 0.2%] (Periochip)-[Chip 2.5mg] Soln: Rinse with 10ml for 30 sec 2x/d. Gel: Brush teeth 1-2x/d. Chip: Insert into pocket. ¶C. *L4. S.E: Dysgeusia, increased tartar formation, mouth discoloration and irritation, hypersensitivity, erythema.</td>
    </tr>
    <tr>
      <td>choline salicylate+cetalkonium</td>
      <td>Baby Gum, Teejel Gel</td>
      <td>N</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>choline salicylate+cetalkonium (Baby Gum, Teejel Gel)-[Gel 8.7%+0.01%] Teething, etc. Apply to gums q4h, no more than 6 times. ¶Not established. S.E: None.</td>
    </tr>
    <tr>
      <td>clotrimazole</td>
      <td>Oralten</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>clotrimazole (Oralten)-[Lozenge 10mg] Oral candida: Suck 1Loz 5x/d. ¶C. *L1. S.E: Pruritus, hypersensitivity, abnormal LFTs, hepatic impairment.</td>
    </tr>
    <tr>
      <td>dichlorobenzyl alcohol+amylmetacresol</td>
      <td>Strepsils</td>
      <td>N</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>dichlorobenzyl alcohol+amylmetacresol (Strepsils)-[Loz 1.2mg+0.6mg] (Strepsils Plus)-[Loz 1.2mg+0.6mg+10mg lidocaine] Sore throat: Suck every 2-3hrs, no more the 8 loz per day. ¶Not established. S.E: Hypersensitivity.</td>
    </tr>
    <tr>
      <td>lidocaine+cetrimonium+tyrothricin</td>
      <td>Lemocin</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>lidocaine+cetrimonium+tyrothricin (Lemocin)-[Lozenge 1+2+4mg] 1Loz q1-3h, and no more than 12Loz per day. ¶C. S.E: Local irritation, edematous mouth and throat.</td>
    </tr>
    <tr>
      <td>miconazole</td>
      <td>Daktarin Oral Gel</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>miconazole (Daktarin Oral Gel)-[Gel 2%] &gt;1yr: 2.5ml 4x/d. &lt;1yr: 1.25ml 4x/d. ¶C. *L2. S.E: Hypersensitivity, face edema, Steven-Johnson syndrome, toxic epidermal necrolysis.</td>
    </tr>
    <tr>
      <td>nystatin</td>
      <td>Nystatin Ready Mix</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>nystatin (Nystatin Ready Mix)-[Ready Mix 100,000 U/ml] PO 4-6ml 4x/d (swish/swallow) Peds: Premature baby 1ml 4xd, bigger babies 2ml 4xd. ¶C. *L1. S.E: Hypersensitivity.</td>
    </tr>
    <tr>
      <td>pilocarpine</td>
      <td>Salagen</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>pilocarpine (Salagen)-[Tab 5mg] PO Xerostomia, Sjogren’s: 5mg 3x/d (up to 15-30 mg per day). ¶C. *L3. S.E: Weakness, confusion, anxiety, eye pain, chest pain, respiratory problems, abdominal pain.</td>
    </tr>
    <tr>
      <td>triamcinolone</td>
      <td>Oracort</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>triamcinolone (Oracort)-[Paste 0.1%] Aphthous ulcers, other conditions: Apply 2-3x/d after meals. ¶C. *L3. S.E: Skin hypersensitivity, irritation around mouth.</td>
    </tr>
    <tr>
      <td>triamcinolone+lidocaine</td>
      <td>Oracort E</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>triamcinolone+lidocaine (Oracort E)-[Paste 0.1%+3%] Apply 2-3x/d.  ¶C. S.E: Skin hypersensitivity, irritation around mouth.</td>
    </tr>
    <tr>
      <td>triamcinolone+ demeclocycline</td>
      <td>Ledermix Paste</td>
      <td>C</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>triamcinolone+ demeclocycline (Ledermix Paste)-[Paste 10mg+30mg] Apply 2-3x/d.  ¶C. *L3. Hypersensitivity, bronchospasm, irritation around mouth.</td>
    </tr>
    <tr>
      <td>tyrothricin+benzocaine</td>
      <td>Kalgaron, Kalgaron Spray</td>
      <td>D</td>
      <td>Oral Preparations</td>
      <td>EAR NOSE THROAT</td>
      <td>tyrothricin+benzocaine (Kalgaron, Kalgaron Spray)-[Loz 1+2mg, 2+3.5mg; Spray 0.75+1.5mg/dose] (Rafathricin with Benzocaine)-[Lozenge 1+2mg] Suck 1Loz q1-3h. Spray: 1x q3h. ¶D. S.E: Local irritation, swelling of the mouth/throat.</td>
    </tr>
    <tr>
      <td>chlorpheniramine Maleate</td>
      <td>Ahiston</td>
      <td>C</td>
      <td>Antihistamines - 1st generation</td>
      <td>EAR NOSE THROAT</td>
      <td>chlorpheniramine Maleate (Ahiston)-[Tab 2mg] PO 2-4mg 3-4x/d. Peds: 6-12yr: 1-2mg 3-4x/d. ¶C. *L3. S.E: Arrhythmias, hemolytic anemia, hepatitis, urinary retention.</td>
    </tr>
    <tr>
      <td>dimenhydrinate</td>
      <td>Travamin</td>
      <td>B</td>
      <td>Antihistamines - 1st generation</td>
      <td>EAR NOSE THROAT</td>
      <td>dimenhydrinate (Travamin)-[Tab 100mg] PO 50-100mg q4-6h, max 400mg/d. Peds: 25-50mg q4-6h, max 150mg per day. ¶B. *L2. S.E: Tachycardia, thickening of bronchial secretions.</td>
    </tr>
    <tr>
      <td>diphenhydramine+paracetamol</td>
      <td>Dexamol PM</td>
      <td>C</td>
      <td>Antihistamines - 1st generation</td>
      <td>EAR NOSE THROAT</td>
      <td>diphenhydramine+paracetamol (Dexamol PM)-[Cap 25mg+500mg] PO 2 Caps at night. ¶C. S.E: Diarrhea, hypersensitivity, rash, abdominal pain.</td>
    </tr>
    <tr>
      <td>promethazine</td>
      <td>Promethazine</td>
      <td>C</td>
      <td>Antihistamines - 1st generation</td>
      <td>EAR NOSE THROAT</td>
      <td>promethazine (Promethazine)-[Syr 5 mg/5ml] (Prothiazine)-[Tab 25mg; Amp 50mg/2ml; Syrp 5mg/5ml] PO IV IM Allergy: 25mg 1-2x/d. Nausea: 25mg  4-6x/d. Peds: Allergy 2-5yrs 5-15ml 1-3x/d, 6-12yrs 10-25ml 1-2x/d, max 25ml/d. Nausea: 2-5yrs 5ml 4-6x/d, max 20ml/d, 6-12yrs 10ml 1-2x/d, max 20ml/d. ¶C. *L2. S.E: Arrhythmia, hyper-hypotension, nonspecific QT changes, orthostatic hypotension, catatonic states, confusion, delirium, seizure, dermatitis, leukopenia, thrombocytopenia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>cetirizine</td>
      <td>Histazine</td>
      <td>B</td>
      <td>Antihistamines – 2nd generation</td>
      <td>EAR NOSE THROAT</td>
      <td>cetirizine (Histazine)-[Tab 10mg; Syrp 0.1%] (Zyllergy)-[Cap 10mg] PO Allergies: &gt;6yrs: 5-10mg or 10ml 1x/d or 5ml 2x/d. 2-6yrs: 5ml 1x/d or 2.5ml 2x/d. ¶B. *L2. S.E: Drowsiness, insomnia, abdominal pain, xerostomia, anaphylaxis, angioedema, ataxia, chest pain, convulsions, hepatic insufficiency.</td>
    </tr>
    <tr>
      <td>desloratadine</td>
      <td>Aerius</td>
      <td>C</td>
      <td>Antihistamines – 2nd generation</td>
      <td>EAR NOSE THROAT</td>
      <td>desloratadine (Aerius)-[Tab 5mg; Syrp 0.5mg/ml] PO 1Tab 1x/d. Peds: 6-11yrs: 5ml 1x/d. 2-5yrs: 2.5ml 1x/d. ¶C. *L2. S.E: Headache, irritability, diarrhea, URTI, drowsiness, insomnia, UTI, hypersensitivity, hepatitis.</td>
    </tr>
    <tr>
      <td>dimethindene</td>
      <td>Fenistil</td>
      <td>B</td>
      <td>Antihistamines – 2nd generation</td>
      <td>EAR NOSE THROAT</td>
      <td>dimethindene (Fenistil)-[Drops 1mg/ml] Drops: 20-40 drops 3x/d. Peds: 1mcg/kg. 1-12months: 3-10 drops 3x/d. 1-3yrs 10-15 drops 3x/d. 3-12yrs 15-20 drops 3x/d. ¶B. S.E: Drowsiness, dry mouth and throat, hypersensitivity.</td>
    </tr>
    <tr>
      <td>diphenhydramine+ammonium chloride</td>
      <td>Broncho D</td>
      <td>B</td>
      <td>Antihistamines – 2nd generation</td>
      <td>EAR NOSE THROAT</td>
      <td>diphenhydramine+ammonium chloride (Broncho D)-[Syr 10mg+136 mg/5ml] PO 15ml 6x/d. ¶B. S.E: Spasm, hypotension.</td>
    </tr>
    <tr>
      <td>fexofenadine</td>
      <td>Telfast 120, 180</td>
      <td>C</td>
      <td>Antihistamines – 2nd generation</td>
      <td>EAR NOSE THROAT</td>
      <td>fexofenadine (Telfast 120, 180)-[FC Tab 120, 180mg] PO 120mg or 180mg 1x/d . ¶C. *L2. S.E: Headache, dizziness, myalgia, dysmenorrhea, URTI, hypersensitivity, insomnia, dyspnea.</td>
    </tr>
    <tr>
      <td>loratadine</td>
      <td>Lorastine</td>
      <td>B</td>
      <td>Antihistamines – 2nd generation</td>
      <td>EAR NOSE THROAT</td>
      <td>loratadine (Lorastine)-[Tab 10mg; Syrp 1 mg/ml] (Loratadine, Loratadine-Teva)-[Tab 10mg] (Loratrim)-[Syrp 0.1 g/ml] PO 10mg or 10ml 1x/d. Peds: &gt;30kg: 10mg. ≤30kg: 5mg. ¶B. *L1. S.E: Stomatitis, hyperkinesia, dysphonia.</td>
    </tr>
    <tr>
      <td>mizolastine</td>
      <td>Mizollen</td>
      <td>C</td>
      <td>Antihistamines – 2nd generation</td>
      <td>EAR NOSE THROAT</td>
      <td>mizolastine (Mizollen)-[Tab 10mg] PO 10mg/d. ¶C. S.E: Hearing loss, HF, hepatotoxicity, neuropathy.</td>
    </tr>
    <tr>
      <td>pseudoephedrine</td>
      <td>Sinufed, Sinufed Kid Day Syrup</td>
      <td>C</td>
      <td>Decongestants_1</td>
      <td>EAR NOSE THROAT</td>
      <td>pseudoephedrine (Sinufed, Sinufed Kid Day Syrup)-[Tab 60mg; Syrp 30mg/5ml] (Tiptipot Afalpi)-[Drops 15 mg/ml] PO 1Tab 4x/d. Peds: 6-12yrs 5ml 4x/d, max 20ml/d. &gt;12 yrs 10ml 4x/d, max 40ml/d. ¶C. *L3. S.E: Arrhythmia, cardiovascular collapse with hypotension, hypertension,  hallucinations, agranulocytosis, hemolytic anemia, thrombocytopenia, tremor.</td>
    </tr>
    <tr>
      <td>pseudoephedrine+ibuprofen</td>
      <td>Nurofen Cold &amp; Flu, Advil Cold &amp; Sinus</td>
      <td>C</td>
      <td>Decongestants+NSAID</td>
      <td>EAR NOSE THROAT</td>
      <td>pseudoephedrine+ibuprofen (Nurofen Cold &amp; Flu, Advil Cold &amp; Sinus)-[Tab 30+200mg] PO 1Tab 4-6x/d, up to max 6Tab/d. ¶C; D in last trimester. *L3. S.E: Severe allergic reactions, hallucinations, seizures, ulcers, GI hemorrhage with or without perforation, pancreatitis, nephrotoxicity, hypertension, tachycardia, aseptic meningitis, ibuprofen-induced hepatitis, SIADH, hypoglycemia, metabolic acidosis.</td>
    </tr>
    <tr>
      <td>pseudoephedrine+paracetamol</td>
      <td>Acamol Tsinun Classic Day, Dexamol Sinus Day Care, Paramol AF Day Care</td>
      <td>C</td>
      <td>Decongestants+NSAID</td>
      <td>EAR NOSE THROAT</td>
      <td>pseudoephedrine+paracetamol (Acamol Tsinun Classic Day, Dexamol Sinus Day Care, Paramol AF Day Care)-[Cap 25+500mg] (Acamol Tsinun Liquigel Day)-[Cap 30+250mg] PO 2Cap up to 4-6x/d. ¶C. S.E: Severe allergic reactions, arrhythmia, hallucinations, seizures, yellowing of skin or eyes, hypertension, insomnia, hepatotoxicity, acute biliary pain, cholestasis, nephrotoxicity, thrombocytopenia, metabolic acidosis.</td>
    </tr>
    <tr>
      <td>codeine</td>
      <td>Codical, Rekod</td>
      <td>C</td>
      <td>Cough_Suppressants1</td>
      <td>EAR NOSE THROAT</td>
      <td>codeine (Codical, Rekod)-[Tab 20mg] PO 20-40mg 6x/d as needed. Max 120mg/d. ¶C. *L3. S.E: Bronchospasm, laryngospasm, respiratory depression, respiratory arrest, palpitations, syncope, cardiac arrest, seizures, withdrawal reactions, paralytic ileus, toxic megacolon, pancreatitis, hallucinations, insomnia, hyperglycemia.</td>
    </tr>
    <tr>
      <td>dextromethorphan</td>
      <td>Tarodex</td>
      <td>C</td>
      <td>Cough_Suppressants1</td>
      <td>EAR NOSE THROAT</td>
      <td>dextromethorphan (Tarodex)-[Syrp 7.5, 15mg/5ml] PO 5ml 6x/d or 10ml 4x/d. Peds: 6-12yrs 10ml 3-4x/d, max 40ml/d. 2-6yrs 5ml 3-4x/d, max 20ml/d. ¶C. *L1. S.E: Opioid like respiratory depression, hypersensitivity.</td>
    </tr>
    <tr>
      <td>guaiacolsulfonate</td>
      <td>Guaiacol</td>
      <td>C</td>
      <td>Cough_Suppressants1</td>
      <td>EAR NOSE THROAT</td>
      <td>guaiacolsulfonate (Guaiacol)-[Syrp 375mg/5ml] PO 2ml 4-5x/d. ¶C. S.E: Severe allergic reactions.</td>
    </tr>
    <tr>
      <td>guaiacolsulfonate+codeine</td>
      <td>Cod-Guaiacol</td>
      <td>C</td>
      <td>Cough_Suppressants1</td>
      <td>EAR NOSE THROAT</td>
      <td>guaiacolsulfonate+codeine (Cod-Guaiacol)-[Syrp 375+5mg/5ml] PO 15ml 4x/d. ¶C. S.E: Hypotension, diplopia, hallucinations, biliary tract obstruction, hyperglycemia, pancreatitis, splenomegaly, palpitations, impotence, hypothermia.</td>
    </tr>
    <tr>
      <td>guaiacosulfonate+codeine+ephedrine</td>
      <td>Pertussol, Tocare</td>
      <td>C</td>
      <td>Cough_Suppressants1</td>
      <td>EAR NOSE THROAT</td>
      <td>guaiacosulfonate+codeine+ephedrine (Pertussol, Tocare)-[Syrp 120+2+6 mg/5ml] PO 10ml 3x/d and 10ml before bed. Peds 6-12: 5ml 3x/d. ¶C. S.E: Tachycardia, fever.</td>
    </tr>
    <tr>
      <td>guaifenesin</td>
      <td>Resyl, Vitussin</td>
      <td>C</td>
      <td>Cough_Suppressants1</td>
      <td>EAR NOSE THROAT</td>
      <td>guaifenesin (Resyl, Vitussin)-[Syrp 100mg/5ml] PO 10-20ml 3-4x/d. Peds: 6-12yrs: 5-10ml 3-4x/d. 2-6yrs: 2.5-5ml 3-4x/d. ¶C. *L2. S.E: Hypersensitivity.</td>
    </tr>
    <tr>
      <td>guaifenesin+dextromethorphan</td>
      <td>Kuffex DM, Tussin DM</td>
      <td>C</td>
      <td>Cough_Suppressants1</td>
      <td>EAR NOSE THROAT</td>
      <td>guaifenesin+dextromethorphan (Kuffex DM, Tussin DM)-[Syrp 100+10mg/5ml] PO 10-20ml 3-4x/d. Peds: 6-12yrs: 5-10ml 3-4x/d. 2-6yrs: 2.5-5ml 3-4x/d. ¶C. *L1. S.E: Hypersensitivity, opioid like respiratory depression, hallucinations.</td>
    </tr>
    <tr>
      <td>oxolamine</td>
      <td>Symphocal Honey and Lemon Flavor, Symphocal Raspberry Flavor</td>
      <td>N</td>
      <td>Cough_Suppressants1</td>
      <td>EAR NOSE THROAT</td>
      <td>oxolamine (Symphocal Honey and Lemon Flavor, Symphocal Raspberry Flavor)-[Syrp 1g/100ml, 10mg/ml] PO 15-30ml up to 6x/d. Peds: 6-12yrs: 10ml up to 6x/d. ¶Not established. S.E: Heartburn.</td>
    </tr>
    <tr>
      <td>chlorpheniramine</td>
      <td>Ahiston</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>chlorpheniramine (Ahiston)-[Tabs 2mg] PO 1-2Tab 3-4x/d after meals. Peds: 6-12yrs: 0.5-1Tab 3-4x/d. ¶C. *L3. S.E: hepatic disorders, arrhythmia.</td>
    </tr>
    <tr>
      <td>chlorpheniramine+phenylephrine+caffeine+paracetamol</td>
      <td>Coldex</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>chlorpheniramine+phenylephrine+caffeine+paracetamol (Coldex)-[Cap/Tab 2+10+30+300mg] PO 1Cap/Tab q4h with meals. Peds: 1Cap/Tab 3x/d. ¶C. S.E: Hepatotoxicity, duodenal ulcers, sedation, extrapyramidal reactions, insomnia, paresthesias, neuritis, convulsions, hallucinations, diplopia, vertigo,, hypotension, arrhythmias, pancytopeniahemolytic anemia, thrombocytopenia, leukopenia, agranulocytosis, fever, nephrotoxicity.</td>
    </tr>
    <tr>
      <td>dexchlorpheniramine+pseudoephedrine</td>
      <td>Histadex</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>dexchlorpheniramine+pseudoephedrine (Histadex)-[Syrp 1mg+25, mg/5ml] (Nussidex)-[Tab 1mg+25mg; Syrp 1+25mg/5ml] PO 1-2Tab 2x/d or 5-10ml of syrup 2x/d. Peds: 1Tab/d or 5ml/d of syrup. ¶C. *L3. S.E: Severe allergic reactions, blurred vision, seizures, palpitations, fever, hallucinations, hemolytic anemia, hypoplastic anemia, pancytopenia, agranulocytosis, neuritis, hypotension.</td>
    </tr>
    <tr>
      <td>chlorpheniramine+pseudoephedrine+paracetamol</td>
      <td>Acamol Tsinun Classic Night, Dexamol Sinus Night Care, Paramol AF Night Care</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>chlorpheniramine+pseudoephedrine+paracetamol (Acamol Tsinun Classic Night, Dexamol Sinus Night Care, Paramol AF Night Care)-[Cap 2+25+500mg] (Acamol Tsinun Liquigel Night)-[Cap 2+30+250mg] (Acamoli Cold Syrup)-[Syrp 1+15+160mg/5ml] PO 1-2Cap at night. Syrup 10ml 3-4x/d. Peds: ½-1Cap at night. Syrup: 5-10ml 3-4x/d. ¶C. S.E: Severe allergic reactions, hallucinations, hepatotoxicity, anemia, pancreatitis.</td>
    </tr>
    <tr>
      <td>diphenhydramine+pseudoephedrine</td>
      <td>Broncho-Kid, Broncholate</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>diphenhydramine+pseudoephedrine (Broncho-Kid, Broncholate)-[Syrp 10+20mg/5ml] PO 15ml 3x/d. Peds: 5ml 1-3x/d. ¶C. *L3. S.E: Severe allergic reactions, blurred vision, diplopia, palpitations, fever, hallucinations, seizures, hypotension, hypertension, arrhythmias, pancytopenia hemolytic anemia, agranulocytosis.</td>
    </tr>
    <tr>
      <td>diphenhydramine+pseudoephedrine+paracetamol</td>
      <td>Broncholate Plus</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>diphenhydramine+pseudoephedrine+paracetamol (Broncholate Plus)-[Tab 30+20+400mg] PO 1-2Tab 2x/d. ¶C. S.E: Severe allergic reactions, fast or irregular heartbeat, hallucinations, seizures, hepatotoxicity.</td>
    </tr>
    <tr>
      <td>loratadine+pseudoephedrine</td>
      <td>Clarinase Repetabs</td>
      <td>B</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>loratadine+pseudoephedrine (Clarinase Repetabs)-[Tab 5+120mg] PO 1Tab 2x/d. ¶B. *L3. S.E: Severe allergic reactions, seizures, syncopal episodes, palpitations arrhythmias including torsades de pointes, cardiac arrest.</td>
    </tr>
    <tr>
      <td>promethazine+guaiacolsulfonate+ipecacuanha</td>
      <td>Promethazine Expectorant</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>promethazine+guaiacolsulfonate+ipecacuanha (Promethazine Expectorant)-[Syrp 100+1000+200mg/100ml] PO 5-10ml 3-4x/d. ¶C. S.E: Hypotension, fever, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>promethazine+guaifenesin+ipecacuanha</td>
      <td>Prothiazine Expectorant</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>promethazine+guaifenesin+ipecacuanha (Prothiazine Expectorant)-[Syr 5+45+10mg/5ml] PO 10-15ml 2-3x/d. Peds: 5-10yrs: 5ml 2-3x/d. 2-5yrs: 2.5-5ml/d. ¶C. S.E: Blurred vision, fever, thrombocytopenia, hallucinations.</td>
    </tr>
    <tr>
      <td>triprolidine+pseudoephedrine</td>
      <td>Histamine Care</td>
      <td>C</td>
      <td>Antihistamine+Decongestants1</td>
      <td>EAR NOSE THROAT</td>
      <td>triprolidine+pseudoephedrine (Histamine Care)-[Syrp 1.25+30mg/5ml] (Histafed)-[Tab 2.5+60mg; Syr 1.25+30mg/5ml] PO 1Tab, max 4x/d or 10ml q4-6h, max 4x/d. Peds: 6-12yrs: 5ml 3-4x/d. ¶C. *L3. S.E: Blurred vision, dyspnea, fever, arrhythmias.</td>
    </tr>
    <tr>
      <td>chlorpheniramine+dextromethorphan+guaifenesin</td>
      <td>Alcinal New Syrup</td>
      <td>C</td>
      <td>Antihistamine+Cough Suppressants2</td>
      <td>EAR NOSE THROAT</td>
      <td>chlorpheniramine+dextromethorphan+guaifenesin (Alcinal New Syrup)-[Syrp 1+7.88+105mg/5ml] PO 10-20ml 3-4x/d. Peds: 6-12yrs: 5-10ml 3-4x/d. ¶C. S.E: Blurred vision, hypersensitivity, arrhythmias, hypotension, anemia, liver damage, chest pain, depression, fever.</td>
    </tr>
    <tr>
      <td>oxomemazine+guaiacosulfonate</td>
      <td>Oxacatin</td>
      <td>C</td>
      <td>Antihistamine+Cough Suppressants2</td>
      <td>EAR NOSE THROAT</td>
      <td>oxomemazine+guaiacosulfonate (Oxacatin)-[Syrp 1.65+33mg/5ml] PO 5-10ml 2-3x/d. Peds: 1-4yrs 10-20ml/d. ¶C. *L3. S.E: Vision disturbance, photosensitivity.</td>
    </tr>
    <tr>
      <td>phenyltoloxamine+codeine</td>
      <td>Codivis</td>
      <td>C</td>
      <td>Antihistamine+Cough Suppressants2</td>
      <td>EAR NOSE THROAT</td>
      <td>phenyltoloxamine+codeine (Codivis)-[Cap 10+30mg; Syr 3.3+10 mg/4.5ml] PO 1Cap 2x/d. 13.5ml 2x/d. ¶C. *L3. S.E: Increased ICP drug dependence, blurred vision, diplopia, glaucoma, seizures, depression, euphoria, hallucinations, nightmares, vertigo, cholestasis, palpitations, hyperglycemia, pancreatitis, hypothermia, fever, splenomegaly, lymphadenopathy, arrhythmias, impotence, hypotension, dyspnea.</td>
    </tr>
    <tr>
      <td>pseudoephedrine+dextromethorphan+guaifenesin+paracetamol</td>
      <td>Dexamol Cold Day Care, Paramol AF, Shiul Day Care</td>
      <td>C</td>
      <td>Decongestant+Cough Suppressants3</td>
      <td>EAR NOSE THROAT</td>
      <td>pseudoephedrine+dextromethorphan+guaifenesin+paracetamol (Dexamol Cold Day Care, Paramol AF, Shiul Day Care)-[Cap 25+10+200+325mg] PO 1-2Cap up to 4x/d. ¶C. S.E: Severe allergic reactions, hallucinations, seizures, liver damage, pancreatitis, nephrotoxicity, palpitations, hypertension, agranulocytosis, neutropenia, pancytopenia, nightmares.</td>
    </tr>
    <tr>
      <td>chlorpeniramine+dextromethorphan+ pseudoephedrine+ paracetamol</td>
      <td>Acamol Tsinun &amp; Shapaat Night</td>
      <td>C</td>
      <td>Antihistamine+Decongestant+Cough_Suppressants4</td>
      <td>EAR NOSE THROAT</td>
      <td>chlorpeniramine+dextromethorphan+ pseudoephedrine+ paracetamol (Acamol Tsinun &amp; Shapaat Night)-[Cap 2+15+30+500mg] (Dexamol Cold Night Care, Paramol AF and Shiul Night)-[Cap 2+10+25+500mg] PO 1-2 Cap at night. ¶C. S.E: Severe allergic reactions, arrhytmia, hallucinations, seizures, liver damage, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, pancytopenia, agranulocytosis, hypertension, hypotension, depression, nightmares.</td>
    </tr>
    <tr>
      <td>diphenhydramine+pseudoephedrine+codeine</td>
      <td>Broncholate Forte</td>
      <td>C</td>
      <td>Antihistamine+Decongestant+Cough_Suppressants4</td>
      <td>EAR NOSE THROAT</td>
      <td>diphenhydramine+pseudoephedrine+codeine (Broncholate Forte)-[Syrp 10+20+5mg/ml] PO 5-10ml 3-4x/d. ¶C. S.E: Dyspnea, seizures, allergic reactions,arrhythmia, hypertension, hypotension, hypothermia,  hallucinations, vertigo, blurred vision, diplopia, glaucoma, nightmares.</td>
    </tr>
    <tr>
      <td>triprolidine+pseudoephedrine+codeine</td>
      <td>Histafed Compound Linctus</td>
      <td>C</td>
      <td>Antihistamine+Decongestant+Cough_Suppressants4</td>
      <td>EAR NOSE THROAT</td>
      <td>triprolidine+pseudoephedrine+codeine (Histafed Compound Linctus)-[Syrp 1.25+30+5mg/5ml] PO 10ml, max 4x/d. Peds: 6-12yrs 5ml, max 4x/d. ¶C. S.E: Severe allergic reactions, blurred vision, fever, hallucinations, arrhythmia, seizures.</td>
    </tr>
    <tr>
      <td>triprolidine+pseudoephedrine+guaifenesin</td>
      <td>Histafed Expectorant, Cold Care</td>
      <td>C</td>
      <td>Antihistamine+Decongestant+Cough_Suppressants4</td>
      <td>EAR NOSE THROAT</td>
      <td>triprolidine+pseudoephedrine+guaifenesin (Histafed Expectorant, Cold Care)-[Syrp 1.25+30+100mg/5ml] PO 10ml, max 4x/d. Peds: 6-12yrs 5ml, max 4x/d. ¶C. S.E: Insomnia, arrhythmia, fever, hallucinations.</td>
    </tr>
    <tr>
      <td>chloramphenicol</td>
      <td>Chlorphenicol Skin Ointment, Synthomycine</td>
      <td>C</td>
      <td>Antibacterial/Antibiotic</td>
      <td>DERMATOLOGY</td>
      <td>chloramphenicol (Chlorphenicol Skin Ointment, Synthomycine)-[Oint 3%] Topical Apply 3-4x/d. ¶C(PO) ; Not established (topical). *L4. S.E: Allergic reactions, fever, thrombocytopenia, anemia, neutropenia, agranulocytosis.</td>
    </tr>
    <tr>
      <td>fusidic acid</td>
      <td>Fucidin, Staphiderm</td>
      <td>C</td>
      <td>Antibacterial/Antibiotic</td>
      <td>DERMATOLOGY</td>
      <td>fusidic acid (Fucidin, Staphiderm)-[Cream 2%] Dermal Apply 3-4x/d for max 2wks. ¶C(Oral use). S.E: Allergic reactions, dyspnea.</td>
    </tr>
    <tr>
      <td>gentamicin</td>
      <td>Gentatrim</td>
      <td>C</td>
      <td>Antibacterial/Antibiotic</td>
      <td>DERMATOLOGY</td>
      <td>gentamicin (Gentatrim)-[Cream/Oint 0.1%] Topical  Apply 3-4x/d. ¶C(topical); D(PO). *L2. S.E: Photosensitization, erythema, pruritis.</td>
    </tr>
    <tr>
      <td>metronidazole</td>
      <td>Noritate</td>
      <td>B</td>
      <td>Antibacterial/Antibiotic</td>
      <td>DERMATOLOGY</td>
      <td>metronidazole (Noritate)-[Cream 1%] (Rozex Gel, ZIdoval Gel)-[Gel 0.75%]    Bacterial Vaginosis: Apply 1-2x/d for 5d. Acne Rosacea: Apply 1x/d. ¶B. *L2. S.E: Symptomatic candida cervicitis/vaginitis, UTI, hypertension, contact dermatitis, basal cell carcinoma, allergic reactions.</td>
    </tr>
    <tr>
      <td>mupirocin</td>
      <td>Bactoderm, Bactroban Dermal, Bactroban Nasal, Mupirocine-Teva</td>
      <td>B</td>
      <td>Antibacterial/Antibiotic</td>
      <td>DERMATOLOGY</td>
      <td>mupirocin (Bactoderm, Bactroban Dermal, Bactroban Nasal, Mupirocine-Teva)-[Oint 2%] Topical Apply 2-3x/d up to 10d. Nasal Oint: Apply 2xd for 3-10d. ¶B. *L1. S.E: Tachycardia, fever (pseudomonas colitis), allergic reactions.</td>
    </tr>
    <tr>
      <td>paromomycin+methylbenzethonium</td>
      <td>Leshcutan</td>
      <td>D</td>
      <td>Antibacterial/Antibiotic</td>
      <td>DERMATOLOGY</td>
      <td>paromomycin+methylbenzethonium (Leshcutan)-[Oint 15%+12%] Topical Cutaneous Leishmaniasis: Apply 2x/d for 10-20d. ¶D(PO); Not established (topical). S.E: Local pain, swelling of the lips and mouth.</td>
    </tr>
    <tr>
      <td>tetracycline</td>
      <td>Recycline</td>
      <td>B</td>
      <td>Antibacterial/Antibiotic</td>
      <td>DERMATOLOGY</td>
      <td>tetracycline (Recycline)-[Oint 3%] Topical Apply 1-3x/d. ¶B. S.E: Dermatitis.</td>
    </tr>
    <tr>
      <td>bifonazole</td>
      <td>Agispor, Bifonazole</td>
      <td>B</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>bifonazole (Agispor, Bifonazole)-[Cream/Gel/Susp 1%] (Agispor Shampoo)-[Shampoo 1%] Topical Skin mycoses: Apply ½cm or 3 drops 1x/d. Seborrhoeic dermatitis of the scalp: Shampoo scalp and wash with 2 applications of the shampoo each time. Leave shampoo on the scalp for 5min before rinsing. Repeat 3x/wks for 4wks. ¶B. S.E: Allergic reactions, dizziness, nausea, swelling.</td>
    </tr>
    <tr>
      <td>bifonazole+urea</td>
      <td>Agispor Onychoset</td>
      <td>B</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>bifonazole+urea (Agispor Onychoset)-[Oint 1%+40%] Topical Nails: Apply 1x/d thin layer sufficient to cover the entire nail surface. ¶B. S.E: Dermatitis, pruritus.</td>
    </tr>
    <tr>
      <td>butenafine Hydrovhloride</td>
      <td>Mentax</td>
      <td>C</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>butenafine Hydrovhloride (Mentax)-[ Dermal Cream 1%] Topical Tinea corporis, Tinea cruris, Tinea versicolor: 1x/d for 2wks. Tinea pedis 2x/d for 1wk or 1x/d for 4wks. ¶C. *L3. S.E: Irritation, blisters, local inflammation.</td>
    </tr>
    <tr>
      <td>ciclopirox</td>
      <td>Bactrafen Nail Laquer</td>
      <td>B</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>ciclopirox (Bactrafen Nail Laquer)-[Lacquer 8%] (Cicloderm)-[Cream/Soln 1%] (Ciclopoli)-[Nail Laquer 8%] (Funginail)-[Funginail 8%] (Myconail)-[Lacquer 8%] (Mycoster)-[8% Nail Laquer].Topical Apply to affected area 1-2x/d until better. ¶B. *L3. S.E: Local inflammation, peeling of the skin around the nails.</td>
    </tr>
    <tr>
      <td>clotrimazole</td>
      <td>Agisten Aloevera</td>
      <td>B</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>clotrimazole (Agisten Aloevera)-[Cream 1%) (Agisten Cream)-[Cream 1%] (Agisten Paste)-[Paste 1%] (Agisten Solution)-[Solution 1%] (CanestenCream)-[Cream 1%] (Clotrimaderm, Clotrimazole)-[Cream 1%] Topical Dermatophytosis, cutaneous candidiasis (Cream 1%) Apply 2x/d for 4wks. Dermatologic infection (Cream or Sol.): Apply 2x/d for 7d. ¶B. *L1. S.E: Syncope, hypotension, dyspnea.</td>
    </tr>
    <tr>
      <td>econazole</td>
      <td>Gyno Pevaryl</td>
      <td>C</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>econazole (Gyno Pevaryl)-[Ovules 1500mg] 1x/d before bed time for 3d. ¶C. *L3. S.E: Itching, stinging,erythema.</td>
    </tr>
    <tr>
      <td>isoconazole nitrate</td>
      <td>Isogen Cream</td>
      <td>B</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>isoconazole nitrate  (Isogen Cream)-[Cream 1%] (Tevaderm)-[Cream 1%] Topical Apply 1x/d until better. ¶B. S.E: Irritation.</td>
    </tr>
    <tr>
      <td>ketoconazole</td>
      <td>Ketozol Shampoo</td>
      <td>C</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>ketoconazole (Ketozol Shampoo)-[Shampoo 2%) (Nizoral Cream)-[Cream 2%] Topical Cutaneous candidiasis/Tinea corporis/Tinea cruris/Tinea pedis/Tinea versicolor:1x/d for 2wks. Seborrheic dermatitis: Topical 2x/d for 4wks. Dandruff Shampoo: Apply 5-10ml to wet scalp, leave for 5min, and rinse. Repeat once every 1-2wks. ¶C. *L2. S.E: Peeling of the skin, blisters, local abscesses.</td>
    </tr>
    <tr>
      <td>menthol+others</td>
      <td>Tiger Balm Red &amp; White</td>
      <td>N</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>menthol+others (Tiger Balm Red &amp; White) -[Cream Cajuput oil 7%, Camphor 11%, Clove oil 5%, Dementholised mint oil 6%, Menthol 10%] Topical Apply as required. ¶Not established. S.E: Contact dermatitis.</td>
    </tr>
    <tr>
      <td>miconazole Nitrate</td>
      <td>Daktacort Cream</td>
      <td>C</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>miconazole Nitrate (Daktacort Cream)-[Cream 2%] (Daktarin Cream)-[Cream 2%] (Daktarin Oral Gel)-[Gel 2%] (Fungiderm)-[Cream 2%] (Gyno Daktarin 3 Soft Capsulse)-[Vaginal Caps 400mg] (Gyno Daktarin 7)-[ Cream 2%] (Pitrion)-[Cream 2%] Topical Cream: Apply 2x/d for 7d. Peds: Oral gel: 6-24months 1.25ml 4x/d after meals, &gt;2yrs 2.5ml 4x/d after meals. Vaginal Cream: 1x/d before bed time for 7d. ¶C. *L2. S.E: Topical use: Irritation of the skin. Systemic use: Suffocation, hepatitis.</td>
    </tr>
    <tr>
      <td>nystatin</td>
      <td>Dermacombin Cream</td>
      <td>C</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>nystatin (Dermacombin Cream)-[Cream 100000IU/G] (Dermacombin Oint)-[Oint [130000IU/G] (Nystatin Ready Mix)-[Susp 102000IU/ML] Topical Susp: age&lt;1month: 1ml 4x/d, 1month&lt;age&lt; 5yrs: 2ml 4x/d, age&gt;5yrs: 4-6ml 4x/d Oint: Apply 2x/d. ¶C. *L1. S.E: Allergic reactions, rash, eczema, and pain on application.</td>
    </tr>
    <tr>
      <td>terbinafine hydrochloride</td>
      <td>Dermasil, Lamisil Cream</td>
      <td>B</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>terbinafine hydrochloride (Dermasil, Lamisil Cream)-[Cream 1%] (Lamisil Dermagel)-[Gel 1%] (Lamisil Once)-[Sol 1%] (Lamisil Spray)-[Sol 1%] (Lamisil Tablet)-[Tab 250mg] (Patir)-[Cream1%] (Terbinafine Teva 250mg)-[Tab 250mg] Topical Tinea pedis/Tinea Capitis/Cutaneous candidiasis: Cream: apply 1-2x/d 1-2wks. Gel: 1x/d 1-2wks. Soln: 1-2x/d 1-2wks. PO Onychomycosis: 250mg 1x/d for 6wks. Toenail: 250mg 1x/d for 12wks. Peds: Tinea capitis &lt;25kg: 125mg 1x/d, 25-35kg: 187.5mg 1x/d &gt;35kg: 250mg 1x/d for 6wks. Onychomycosis: 10-20kg: 62.5mg 1x/d  20-40kg: 125mg 1x/d &gt;40kg: 250mg 1x/d for 6wks. ¶B. *L2. S.E: Systemic use: Headache, diarrhea, dyspepsia, visual disturbance. Local use: Rash, pruritus, urticaria.</td>
    </tr>
    <tr>
      <td>tolnaflate+salicylic acid+benzoate</td>
      <td>Phytoderm Compositum</td>
      <td>C</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>tolnaflate+salicylic acid+benzoate (Phytoderm Compositum)-[Oint: 1%+3%+6%] Topical athletes foot: Apply 2-3x/d. ¶C. S.E: Irritation, rash, local inflammation.</td>
    </tr>
    <tr>
      <td>undecylenate</td>
      <td>±Zn</td>
      <td>C</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>undecylenate(±Zn) (Undecyl)-[Pwdr Oint 2%+20%] Dermal Apply several x/d. ¶C(PO); Not established (topical). S.E: Local irritation or rash, inflammation of the skin, lips, throat or tongue.</td>
    </tr>
    <tr>
      <td>undecylenate</td>
      <td>±Zn</td>
      <td>C</td>
      <td>Antifungal-2</td>
      <td>DERMATOLOGY</td>
      <td>undecylenate (±Zn)+aluminum chlorohydrate (Fungimon)-[Pwdr 3%+ 18% +3%] Athletes foot: Apply 2x/d. ¶C(PO); Not established (topical). S.E: Irritation, rash.</td>
    </tr>
    <tr>
      <td>aciclovir</td>
      <td>Zovirax, Aciclovir SP, Xerclear</td>
      <td>B</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>aciclovir (Zovirax, Aciclovir SP, Xerclear)-[Cream 5%] (V-Ral)-[Oint 5%] (Acyclo-V, Zovirax)-[Tab 200, 400mg] (Acyclovenir)-[Pwdr 250mg] (Zovirax Tablets Dispersible)-[Dispersible Tab 800mg] Cream: Apply 5x/d every 4hr up to 10d. Oint: 1cm 5x/d until better. IV Herpes simplex infection: 5mg/kg infused at a constant rate over 1h, q8h for 7d. VZV infection: 10mg/kg infused at a constant rate over 1h, q8h for 7d. PO Acute treatment: 800mg 5x/d for 7-10d. Genital herpes: 200mg 5x/d for 10d. Peds Chickenpox: 20mg/kg 4x/d for 5d. Adults Chickenpox: 800mg 4x/d for 5d. ¶B. *L2. S.E: Anaphylaxis, hypotension, DIC, hemolysis, vasculitis, leukopenia, hyperbilirubinemia, jaundice, coma, seizures, psychosis, encephalopathy, alopecia, renal failure.</td>
    </tr>
    <tr>
      <td>extract from camellia sinensis</td>
      <td>Veregen</td>
      <td>N</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>extract from camellia sinensis (Veregen)-[Oint 10%] Topical external genital and perianal warts: Up to 250mg 3x/d. ¶Not established. S.E: Erythema, pruritus, ulcer.</td>
    </tr>
    <tr>
      <td>fluorouracil+salicylic acid</td>
      <td>Verrumal Solution</td>
      <td>X</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>fluorouracil+salicylic acid (Verrumal Solution)-[Soln 0.5G+10G/100G] Topical Warts: Apply 2-3x/d. ¶X. *L5. Do not use in patients with DPD enzyme deficiency syndrome. S.E: Eosinophilia, leukocytosis, erythema, hyperpigmentation, stomatitis, thrombocytopenia, neutropenia, neurotoxicity.</td>
    </tr>
    <tr>
      <td>imiquimod</td>
      <td>Aldara, Aquimod Cream, Perrimod</td>
      <td>C</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>imiquimod (Aldara, Aquimod Cream, Perrimod)-[Cream 5%] Topical Perianal Warts/Condyloma Acuminata: Apply a thin layer 3x/wk prior to bedtime until total clearance. Actinic Keratosis: Apply a thin layer 2x/wk for 16wks limited to areas ≤25cm2. Superficial basal cell carcinoma: 1x/d 5d/wk for 6wks. ¶C. *L3. S.E: Blisters on the skin, body aches or pain, dyspnea.</td>
    </tr>
    <tr>
      <td>penciclovir</td>
      <td>Fenlips, Fenlips Color</td>
      <td>B</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>penciclovir (Fenlips, Fenlips Color)-[Cream 1%] Topical Herpes Labialis: Apply q2h during walking hours for 4d. Use only for children over 12yrs. ¶B. *L3. S.E: Headache, pruritus.</td>
    </tr>
    <tr>
      <td>podophyllotoxin</td>
      <td>Condylox</td>
      <td>C</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>podophyllotoxin (Condylox)-[Soln 0.5%]Topical External genital and perianal warts: Apply 1-2x/d for 3 consecutive days of the week, up to 4wks. ¶C. *L3. S.E: Skin ulcers, itching.</td>
    </tr>
    <tr>
      <td>salicylic acid</td>
      <td>Carnation Callous Caps, Carnation Corn Caps</td>
      <td>C</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid (Carnation Callous Caps, Carnation Corn Caps)-[Patches 40%] Topical Apply 1-3x/d. Before applying product, soak area in warm water for 5min; dry area thoroughly, then apply medication. Repeat procedure every 48h as needed for up to 14d. ¶C. *L3. S.E: Irritation, dyspnea.</td>
    </tr>
    <tr>
      <td>salicylic acid+benzocaine</td>
      <td>Noxacorn</td>
      <td>C</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid+benzocaine (Noxacorn)-[Soln 10%+2%] Topical Apply 1-2 drops x/d for 2wks. ¶C. S.E: Irritation, dyspnea.</td>
    </tr>
    <tr>
      <td>salicylic acid+lactate+camphor+pyroxylin</td>
      <td>Salatac Gel</td>
      <td>C</td>
      <td>Antiviral</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid+lactate+camphor+pyroxylin (Salatac Gel)-[Gel 12%+4%+2%+7%] Topical Apply 1-2 Drops 1x/d before bed time up to 12wks. ¶C. S.E: Irritation.</td>
    </tr>
    <tr>
      <td>betamethasone</td>
      <td>Betacorten, Betnovate</td>
      <td>C</td>
      <td>Topical Steroids</td>
      <td>DERMATOLOGY</td>
      <td>betamethasone (Betacorten, Betnovate)-[Cream Oint 0.1%] (Betacorten Diluted)-[Cream 0.025%] (Betacorten Scalp Application, Betnovate Scalp Application)-[Soln 0.1%] (Bettamousse)-[Cream 0.12%] (Diprolene)-[Cream Oint 0.05%] (Diprosone)-[Cream Oint Lotion 0.05%] (Betacap)-[Soln 0.12%w/w] Topical Apply 1-2x/d. ¶C(second and third trimesters); D(first trimester). *L3. S.E: Folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.</td>
    </tr>
    <tr>
      <td>betamethasone+salicylic acid</td>
      <td>Diprosalic</td>
      <td>C</td>
      <td>Topical Steroids</td>
      <td>DERMATOLOGY</td>
      <td>betamethasone+salicylic acid (Diprosalic)-[Oint Soln 0.05%+3%/2%] Topical  Apply 2x/d up to 2wks. ¶C. S.E: Irritation, dryness, folliculitis, dermatitis.</td>
    </tr>
    <tr>
      <td>clobetasol propionate</td>
      <td>Dermovate</td>
      <td>C</td>
      <td>Topical Steroids</td>
      <td>DERMATOLOGY</td>
      <td>clobetasol propionate (Dermovate)-[Cream Oint Soln Applicat 0.05%] (Clobetasol PropionateTrima Cream,)-[Cream Soln 0.05%] Topical Apply 1-2x/d up to 5d for facial skin and no Clobetasol Propionate Trima Scalp more the 2wks. ¶C. *L5. S.E: Hypercorticism, suppression of hypothalamic-pituitary-adrenal (HPA) axis, kaposi sarcoma.</td>
    </tr>
    <tr>
      <td>diflucortolone valerate</td>
      <td>Neriderm Cream, Neriderm Ointment, Tevaderm</td>
      <td>C</td>
      <td>Topical Steroids</td>
      <td>DERMATOLOGY</td>
      <td>diflucortolone valerate (Neriderm Cream, Neriderm Ointment, Tevaderm)-[Cream Oint 0.1%, 0.3%] Topical Apply 2x/d. ¶C. S.E: Hypertension, hypothalamic-pituitary-adrenal axis suppression, Immunosuppression, osteoporosis, glaucoma, failure to thrive, kaposi sarcoma.</td>
    </tr>
    <tr>
      <td>flumetasone+salicylic acid</td>
      <td>Topisalen</td>
      <td>C</td>
      <td>Topical Steroids</td>
      <td>DERMATOLOGY</td>
      <td>flumetasone+salicylic acid (Topisalen)-[Oint 0.02%+3%] Topical Apply 1-2x/d. ¶C. S.E: Rash, local infection , dizziness, hearing loss.</td>
    </tr>
    <tr>
      <td>hydrocortisone</td>
      <td>Cortizone</td>
      <td>C</td>
      <td>Topical Steroids</td>
      <td>DERMATOLOGY</td>
      <td>hydrocortisone (Cortizone)-[Cream Oint 0.5, 1%] (Lanacort)-[Cream 1%] (Efficort)-[Cream 0.127%] Topical apply 3-4x/d. ¶C.*L2. SE: None.</td>
    </tr>
    <tr>
      <td>mometasone</td>
      <td>Elocom</td>
      <td>C</td>
      <td>Topical Steroids</td>
      <td>DERMATOLOGY</td>
      <td>mometasone (Elocom)-[Cream Oint Lotion 0.1%] Apply 1x/d. ¶C. *L3. SE: Skin infection, folliculitis, moniliasis, paresthesia, skin atrophy, cataract.</td>
    </tr>
    <tr>
      <td>flucocinonide+bifonazole</td>
      <td>Comagis</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>flucocinonide+bifonazole (Comagis)-[Cream 1%+0.05%] Topical Apply 1x/d for 2-4wks. ¶C. S.E: ICP, acne, dermatitis, folliculitis, Cushing’s syndrome, growth retardation, kaposi sarcoma, glycosuria.</td>
    </tr>
    <tr>
      <td>chloramphenicol+prednisolone</td>
      <td>Threolone</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>chloramphenicol+prednisolone (Threolone)-[Oint 3%+0.5%] Topical Apply 2-4x/d. ¶C. S.E: Bone marrow hypoplasia.</td>
    </tr>
    <tr>
      <td>ciclopiroxolamine+gentamycin+clobetasone</td>
      <td>Cicloderm-C</td>
      <td>B</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>ciclopiroxolamine+gentamycin+clobetasone (Cicloderm-C)-[Cream 1%+0.1%+0.05%] Topical Apply 2x/d. ¶B. S.E: Redness, local feeling of warmth and tingling, dry skin and itching.</td>
    </tr>
    <tr>
      <td>clotrimazole+gentamycin+betamethasone</td>
      <td>Triderm</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>clotrimazole+gentamycin+betamethasone (Triderm)-[Cream 10mg+1mg+0.5mg/g] Apply 2x/d. ¶C. S.E: Erythema, blistering, peeling, edema, pruritis, urticarial.</td>
    </tr>
    <tr>
      <td>clotrimazole+hydrocortisone acetate</td>
      <td>Hydroagisten</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>clotrimazole+hydrocortisone acetate (Hydroagisten)-[Cream1%+1%] Topical Apply to affected area 2x/d. ¶C. S.E: Erythema, blistering, peeling, edema, pruritis, urticarial.</td>
    </tr>
    <tr>
      <td>clotrimazole+ neomycin+dexamethasone</td>
      <td>Polycutan, Tevacutan</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>clotrimazole+ neomycin+dexamethasone (Polycutan, Tevacutan)-[Cream 1%+0.645%+0.044%] Topical Apply 2-3x/d. ¶C. S.E: Erythema, blistering, peeling, edema, pruritis, urticarial.</td>
    </tr>
    <tr>
      <td>fusidic acid+betamethasone</td>
      <td>Fucicort</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>fusidic acid+betamethasone (Fucicort)-[Cream 2%+0.1%] Apply 2-3x/d. ¶C. S.E: Pain, ,anaphylaxis, superinfection, conjunctivitis.</td>
    </tr>
    <tr>
      <td>fusidate+hydrocortisone</td>
      <td>Fucidin H</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>fusidate+hydrocortisone (Fucidin H)-[Cream 20+10mg/g] Topical Apply up to 4x/d. ¶C. S.E: Glaucoma, excessive sweating, local inflammation, eczema worsening.</td>
    </tr>
    <tr>
      <td>gentamicin+betamethasone</td>
      <td>Betacorten-G</td>
      <td>D</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>gentamicin+betamethasone (Betacorten-G)-[Cream Oint 0.1%+0.1%] (Diprogenta)-[Cream Oint 1+0.5mg/g] Topical Apply 1-2x/d. ¶D. SE: Burning, itching, dry skin, hypopigmentation, hypersensitivity.</td>
    </tr>
    <tr>
      <td>gentamicin+prednisolone</td>
      <td>Aflumycin</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>gentamicin+prednisolone (Aflumycin)-[Cream 0.16%+0.5%] Topical Apply to conjunctival sac 1-3x/d. ¶C. S.E: Infection, ocular irritation, glaucoma, ocular herpes simplex.</td>
    </tr>
    <tr>
      <td>ichthammol+hamamelis+zinc+titanium+benzoin siam</td>
      <td>Inotyol</td>
      <td>N</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>ichthammol+hamamelis+zinc+titanium+benzoin siam (Inotyol)-[Oint 1.474+0.984+14.763+5.905+0.1G/100G] Topical Apply 1x/d. ¶Not established. SE: Rash, local irritation.</td>
    </tr>
    <tr>
      <td>isoconazole+diflucortolone</td>
      <td>Tevaderm</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>isoconazole+diflucortolone (Tevaderm)-[Cream 1%+0.1%] Topical Apply 1-2x/d for 2-4wks. ¶C. S.E: Hypertension, localized burning, steroid withdrawal syndrome, contact dermatitis, urticaria, cushingoid appearance, glycosuria, weight gain, hypersensitivity, cataract, glaucoma, failure to thrive.</td>
    </tr>
    <tr>
      <td>miconazole+hydrocortisone</td>
      <td>Daktacort</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>miconazole+hydrocortisone (Daktacort)-[Cream 20+10mg/g] Topical Apply 2-3x/d. ¶C. *L2. S.E: Allergic contact dermatitis, burning, hypopigmentation, adrenal suppression, immunosuppression, Kaposi sarcoma.</td>
    </tr>
    <tr>
      <td>methylprednisolone+neomycin+other</td>
      <td>Neo-medrol Acne Lotion</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>methylprednisolone+neomycin+other (Neo-medrol Acne Lotion)-[Aluminum chlorohydroxide 200mg/ml, methylprednisolone 2.5mg/ml, neomycin 2.5mg/ml, sulfur 50mg/ml] Topical Apply 1x/d. ¶C. *L2. S.E: Localized atrophy, secondary infection, allergic contact dermatitis, hypersensitivity reactions, acneiform eruptions.</td>
    </tr>
    <tr>
      <td>neomycin+hydrocortisone</td>
      <td>Hycomycin</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>neomycin+hydrocortisone (Hycomycin)-[Oint 0.5%+2.5%] Topical Apply 3-4x/d. ¶C. S.E: Affective disorders, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.</td>
    </tr>
    <tr>
      <td>nystatin+neomycin+gramicidin+triamcinolone</td>
      <td>Dermacombin, Kenacomb</td>
      <td>C</td>
      <td>Anti-Infective+Steroid Combinations</td>
      <td>DERMATOLOGY</td>
      <td>nystatin+neomycin+gramicidin+triamcinolone (Dermacombin, Kenacomb)-[Cream Oint 100KU+2.5mg+0.25mg+1mg/g] Topical Apply 2-4x/d. ¶C. *L1. S.E: Itching, irritation, dryness.</td>
    </tr>
    <tr>
      <td>chlorhexidine</td>
      <td>Bactoscrub, Septadine Tarhitz, Septal Scrub</td>
      <td>B</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>chlorhexidine (Bactoscrub, Septadine Tarhitz, Septal Scrub)-[Soln 4%] Surgical scrub (Septalone hospital concentrate)-[Soln 5%] Dilution of 10% in 70% alcohol and 1% glycerine in water: Surgical scrub. 0.5% in 70% alcohol: Disinfect medical equipment, preop skin. 0.05% in water: storage sterile medical equipment, wash wounds and burns. ¶B. *L4. S.E: Topical: Allergic sensitization, hypersensitivity reaction, rough skin, xeroderma.</td>
    </tr>
    <tr>
      <td>chlorhexidine+isopropanol</td>
      <td>Alcohol Chlorhexidine-Teva, Alcosept, Alcoxidine, Septadine, Septol, V-Tabur</td>
      <td>A</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>chlorhexidine+isopropanol (Alcohol Chlorhexidine-Teva, Alcosept, Alcoxidine, Septadine, Septol, V-Tabur)-[Soln 0.5%+70%]Topical Clean area with solution. ¶A. S.E: Allergic sensitization, hypersensitivity reaction, rough skin, xeroderma.</td>
    </tr>
    <tr>
      <td>chlorhexidine+benzoxonium</td>
      <td>Merfen Spray First Aid</td>
      <td>S</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>chlorhexidine+benzoxonium (Merfen Spray First Aid) [Spray 5+1mg/ml] Spray 1-2x/d. ¶Safe for external use only. S.E: Urticaria, anaphylaxis.</td>
    </tr>
    <tr>
      <td>chlorhexidine+benzoxonium+Vit.A</td>
      <td>Vita Merfen</td>
      <td>S</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>chlorhexidine+benzoxonium+Vit.A (Vita Merfen)-[Oint 0.5%+0.1%+0/2%] Topical Apply thin layer. ¶Safe for external use only. S.E: Rush.</td>
    </tr>
    <tr>
      <td>chlorhexidine+cetrimide.</td>
      <td>NaN</td>
      <td>N</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>chlorhexidine+cetrimide. () [] ¶Not established. S.E: Irritation, rash.</td>
    </tr>
    <tr>
      <td>hydrogen peroxide</td>
      <td>Hydrogen Peroxide, Hydrogen Peroxide Floris</td>
      <td>N</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>hydrogen peroxide (Hydrogen Peroxide, Hydrogen Peroxide Floris)-[Soln 3%] Clean the affected area 1-3x/d. ¶Not established. SE: irritation of buccal mucous membrane or “hairy tongue”, fatal metabolic acidosis, seizures, renal failure and CNS depression.</td>
    </tr>
    <tr>
      <td>povidone-Iodine</td>
      <td>Iodiflor, Iodo-vit Iodispray</td>
      <td>D</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>povidone-Iodine (Iodiflor, Iodo-vit Iodispray)-[Soln 10%; Soap 7.5%; Ointment 10%; Spray 10%] (Polysept)-[Soln 10%; Oint 10%] (Iodine Tincture Floris)-[Tincture 2.5% with 2.5% Potassium iodide] (Polydine)-[Soln Oint 10%; Cleanser 7.5%; Tincture 10%; Soap(Pessary) 5%] (Yodon)-[Soln 10%+citrate+hydog. phos.] Topical Apply as required. ¶D. *L4. Large amounts of iodine during pregnancy can cause fetal goiter or hyperthyroidism. Transient hypothyroidism in the newborn has also been reported following topical or vaginal use prior to delivery. S.E: Burnings</td>
    </tr>
    <tr>
      <td>salicylic acid+benzoic acid</td>
      <td>Spirit Whitfield</td>
      <td>C</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid+benzoic acid (Spirit Whitfield)-[Liq 3%+6%] Apply 1-3x/d. ¶C. S.E: Skin irritation.</td>
    </tr>
    <tr>
      <td>salicylic acid</td>
      <td>Spirit Salicyl 2%</td>
      <td>C</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid (Spirit Salicyl 2%)-[Topical 2%] Apply several x/d. ¶C. *L3. S.E: Skin irritation.</td>
    </tr>
    <tr>
      <td>sulphadiazine silver</td>
      <td>Silverol</td>
      <td>B</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>sulphadiazine silver (Silverol)-[Cream 1%] Burns: Apply 2x/d. ¶B(first and second trimesters); X(third trimester). *L3. SE: Transient leukopenia, skin necrosis, erythema multiforme, interstitial nephritis.</td>
    </tr>
    <tr>
      <td>triclosan</td>
      <td>Dermax</td>
      <td>N</td>
      <td>Antiseptics</td>
      <td>DERMATOLOGY</td>
      <td>triclosan (Dermax)-[Solution 1%]  Mix in hands with water, apply and rinse. ¶Not established. *L3. S.E: Irritation, local inflammation.</td>
    </tr>
    <tr>
      <td>finasteride</td>
      <td>Propecia, Proavenir, Finasteride Teva</td>
      <td>X</td>
      <td>Alopecia</td>
      <td>DERMATOLOGY</td>
      <td>finasteride (Propecia, Proavenir, Finasteride Teva)-[Tab 1mg] PO 1mg 1x/d. ¶X. SE: Neoplasm of male breast (rare and under investigation).</td>
    </tr>
    <tr>
      <td>minoxidil</td>
      <td>Hairgaine, Hairgaine Foam, Noxidil, Regaine, Regaine Foam</td>
      <td>C</td>
      <td>Alopecia</td>
      <td>DERMATOLOGY</td>
      <td>minoxidil (Hairgaine, Hairgaine Foam, Noxidil, Regaine, Regaine Foam) [Soln foam 5%] (Minoxi 2, 5)-[Spray Soln 2, 5%] Topical Soln: Apply 1ml 2x/d to the scalp. Spray: Apply 2x/d. ¶C. *L3. S.E: Angina, pericardial effusion, reflex tachycardia, Stevens-Johnson syndrome, leukopenia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>benzyl benzoate</td>
      <td>Scabiex</td>
      <td>B</td>
      <td>Anti-scabies / Anti-lice</td>
      <td>DERMATOLOGY</td>
      <td>benzyl benzoate (Scabiex)-[Lotion 25%] Topical Scabies: Apply and massage 2x/d, then 3-4x/wk ¶B. SE: None.</td>
    </tr>
    <tr>
      <td>crotamiton</td>
      <td>Eurax</td>
      <td>C</td>
      <td>Anti-scabies / Anti-lice</td>
      <td>DERMATOLOGY</td>
      <td>crotamiton (Eurax)-[Cream Lotion 10%] Topical Scabies: Apply and Massage once and again after 24h, a cleaning bath should be taken 48h after the last application. Pruritus: Apply several x/d. ¶C. SE: Dermatitis, pruritus, rash, allergic sensitivity.</td>
    </tr>
    <tr>
      <td>crotamiton+sulfur</td>
      <td>Duo-Scabil</td>
      <td>C</td>
      <td>Anti-scabies / Anti-lice</td>
      <td>DERMATOLOGY</td>
      <td>crotamiton+sulfur (Duo-Scabil)-[Cream 10%+8%] Scabies: Apply several x/d. ¶C. S.E: Dermatitis, pruritus, rash, allergic sensitivity.</td>
    </tr>
    <tr>
      <td>malathion</td>
      <td>Prioderm CRM</td>
      <td>B</td>
      <td>Anti-scabies / Anti-lice</td>
      <td>DERMATOLOGY</td>
      <td>malathion (Prioderm CRM)-[Shampoo 40G] Topical Lice: Apply once for max 10min. Repeat after 7-9d. ¶B. *L3. S.E: Skin and scalp irritation, second degree burns.</td>
    </tr>
    <tr>
      <td>malathion+permethrin+piperonyl butoxide</td>
      <td>Para Plus</td>
      <td>C</td>
      <td>Anti-scabies / Anti-lice</td>
      <td>DERMATOLOGY</td>
      <td>malathion+permethrin+piperonyl butoxide (Para Plus)-[Spray 0.25%+0.50%+2%] Topical Lice: Apply for 10min max. Repeat after 1wk. ¶C. S.E: Pruritis.</td>
    </tr>
    <tr>
      <td>permethrin</td>
      <td>Lyclear Dermal, Mite-X</td>
      <td>B</td>
      <td>Anti-scabies / Anti-lice</td>
      <td>DERMATOLOGY</td>
      <td>permethrin (Lyclear Dermal, Mite-X)-[Cream 5%] (New-Nok)-[Lotion 1%] (Nok, Zehu-Ze)-[Cream Shampoo 1%] (Sof-Sof)-[Lotion 0.2%] Topical Scabies: Apply 5% to whole body should be removed by washing after 8-14h . Adult: 1 tube. Peds: ⅛-½ tube. Lice: apply creamfor 10min 1x. ¶B. *L2. S.E: Pruritus, seizure.</td>
    </tr>
    <tr>
      <td>adapalene</td>
      <td>Adaferin</td>
      <td>C</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>adapalene (Adaferin)-[Gel Cream 0.1%] Topical Apply 1x/d at night. ¶C. *L3. S.E: Erythema.</td>
    </tr>
    <tr>
      <td>azelaic acid</td>
      <td>Skinoderm</td>
      <td>B</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>azelaic acid (Skinoderm)-[Cream 20%] Topical apply 1x/d for 1wk, from second week apply 2x/d. ¶B. *L3. S.E: Photosensitivity.</td>
    </tr>
    <tr>
      <td>benzoyl peroxide</td>
      <td>Benzac AC Gel</td>
      <td>C</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>benzoyl peroxide (Benzac AC Gel)-[Gel 2.5, 5, 10%] Topical Start  1x/d. Up to 2-3x/d. Mask: 1x/d. ¶C. *L2. S.E: Dyspnea, syncope, swelling of the face.</td>
    </tr>
    <tr>
      <td>benzoyl peroxide+clindamycin</td>
      <td>Duac</td>
      <td>C</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>benzoyl peroxide+clindamycin (Duac)-[Gel 5/1w/w%] Topical Apply 1x/d at evening. ¶C. *L2. S.E: Hypersensitivity, colitis.</td>
    </tr>
    <tr>
      <td>clindamycin</td>
      <td>Zindaclin</td>
      <td>B</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>clindamycin (Zindaclin)-[Gel 1%] Topical Apply 1x/d. ¶B. *L2. S.E: Severe colitis.</td>
    </tr>
    <tr>
      <td>erythromycin</td>
      <td>Acnetrim</td>
      <td>B</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>erythromycin (Acnetrim)-[Soln 2%] (Aknemycin)-[Cream 1%] Topical Apply 2x/d. ¶B. *L3. S.E: Severe stomach pain, yellow eyes, syncope.</td>
    </tr>
    <tr>
      <td>erythromycin+benzoyl peroxide</td>
      <td>Benzamycin Topical Gel</td>
      <td>C</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>erythromycin+benzoyl peroxide (Benzamycin Topical Gel)-[Gel 0.8G/87.125mg/G] Topical Apply 1-2x/d. ¶C. S.E: Inflammation of the face, eyes and nose.</td>
    </tr>
    <tr>
      <td>erythromycin+tretinoin</td>
      <td>Aknemycin Plus</td>
      <td>D</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>erythromycin+tretinoin (Aknemycin Plus)-[Soln 4%+0.025%] Topical Apply 1-2x/d after shower. ¶D. S.E: Blurred vision at night.</td>
    </tr>
    <tr>
      <td>isotretinoin</td>
      <td>Curatane, RoAccutane</td>
      <td>X</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>isotretinoin (Curatane, RoAccutane)-[Cap 5, 10, 20, 40mg] PO 0.5-1mg/kg/d in 2 divided dose for 15-20wks. Usual 1mg/kg. ¶X. *L5. S.E: Severe abdominal pain, pancreatitis, impaired hearing, hepatitis, hyperostosis, corneal opacities, hypersensitivity.</td>
    </tr>
    <tr>
      <td>neomycin+methylprednisolone+sulfur+chlorhydroxide</td>
      <td>Neo-Medrol</td>
      <td>N</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>neomycin+methylprednisolone+sulfur+chlorhydroxide (Neo-Medrol)-[Lotion 0.25%+0.25%+5%+20%] Topical Apply 1-2x/d. ¶Not established. S.E: Skin atrophy, secondary infection, folliculitis, hypertrichosis, allergic contact dermatitis, ototoxicity, nephrotoxicity.</td>
    </tr>
    <tr>
      <td>salicylic acid</td>
      <td>Spirit Salicyl</td>
      <td>C</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid (Spirit Salicyl)-[Spirit 2%] Topical Apply 1-3x/d. ¶C. *L3. S.E: Syncope, face swelling, hearing loss.</td>
    </tr>
    <tr>
      <td>tretinoin</td>
      <td>Ret-Avit</td>
      <td>C</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>tretinoin (Ret-Avit)-[Cream Gel 0.025, 0.05%] Topical Apply 1-2x/d. ¶C. *L3. S.E: Hypopigmentation.</td>
    </tr>
    <tr>
      <td>triclosan</td>
      <td>Dermax</td>
      <td>N</td>
      <td>Acne Preparations</td>
      <td>DERMATOLOGY</td>
      <td>triclosan (Dermax)-[Liq Soap 1%] Topical Use as required. ¶Not established *L3. S.E: None.</td>
    </tr>
    <tr>
      <td>acitretin</td>
      <td>Neotigason</td>
      <td>X</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>acitretin (Neotigason)-[Cap 10, 25mg] PO 25-50mg 1x/d for 2-4wks, max 75mg/d. Maint: 25-50mg/d for 6-8wks. Max 6months. Avoid pregnancy for 3years. ¶X. *L5. S.E: Hepatotoxicity, hypertriglyceridemia, pancreatitis, ICP.</td>
    </tr>
    <tr>
      <td>calcipotriol</td>
      <td>Daivonex</td>
      <td>C</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>calcipotriol (Daivonex)-[Oint Cream 50µg/g; Soln 50µg/ml] Topical Apply 2x/d, max 100G/wk. Soln: apply a few drops to scalp 1-2x/d. ¶C. *L3. S.E: Worsening of psoriasis, pigmentation.</td>
    </tr>
    <tr>
      <td>calcipotriol+betamethasone</td>
      <td>Daivobet Ointment, Xamiol Gel</td>
      <td>C</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>calcipotriol+betamethasone (Daivobet Ointment, Xamiol Gel)-[Oint 50µg+0.5mg/G] Topical Apply 1x/d for up to 4wk, max 14g/d. ¶C. S.E: Fever, loss of voice.</td>
    </tr>
    <tr>
      <td>cetrimide</td>
      <td>Cetrimide Shampoo</td>
      <td>N</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>cetrimide (Cetrimide Shampoo)-[Shampoo 10%] Topical Use as required. ¶Not established. S.E: Skin irritation.</td>
    </tr>
    <tr>
      <td>coal tar</td>
      <td>Alphosyl “2 in 1” Shampoo with Conditioner</td>
      <td>C</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>coal tar (Alphosyl “2 in 1” Shampoo with Conditioner)-[Shampoo 5%] (T/Gel Shampoo)-[Shampoo 2%] Topical: Apply on hair and scalp for several minutes, 2x/wk. ¶C. *L2. S.E: None.</td>
    </tr>
    <tr>
      <td>coal tar+salicylic acid+coconut oil</td>
      <td>Capasal Therapeutic Shampoo</td>
      <td>N</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>coal tar+salicylic acid+coconut oil (Capasal Therapeutic Shampoo)-[Shampoo 1%+0.5%+1%] Use 1-2x/d as required. ¶Not established. S.E: Severe irritation.</td>
    </tr>
    <tr>
      <td>dithranol</td>
      <td>Dithrocream</td>
      <td>C</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>dithranol (Dithrocream)-[Cream 0.1, 0.25, 0.5, 1, 2%] Topical Apply thin layer 1x/d. Start 0.1%. ¶C. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>selenium sulfide</td>
      <td>Sebosel</td>
      <td>C</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>selenium sulfide (Sebosel)-[Soln 2.5%] Topical Dandruff, seborrheic dermatitis: Shampoo 5-10ml 2x/wk for 2wks. Tinea versicolor: Shampoo 1x/d for 7d. ¶C. *L3. S.E: Skin irritation.</td>
    </tr>
    <tr>
      <td>tacalcitol</td>
      <td>Curatoderm</td>
      <td>N</td>
      <td>Psoriasis / Seborrhea / Scaling</td>
      <td>DERMATOLOGY</td>
      <td>tacalcitol (Curatoderm)-[Oint 4.17µg/G] Topical: Apply 1x/d at night. ¶Not established. S.E: Hypercalcaemia.</td>
    </tr>
    <tr>
      <td>becaplermin</td>
      <td>Regranex Gel</td>
      <td>C</td>
      <td>Leg Ulcer/Wound Treatments {see antiseptics}</td>
      <td>DERMATOLOGY</td>
      <td>becaplermin (Regranex Gel)-[Gel 0.01%] Topical Diabetic ulcers: Apply 1x/d. ¶C. S.E: Carcinogenesis, mutagenesis, impairment of fertility.</td>
    </tr>
    <tr>
      <td>benzocaine</td>
      <td>Hurricaine</td>
      <td>C</td>
      <td>Topical Anesthetics</td>
      <td>DERMATOLOGY</td>
      <td>benzocaine (Hurricaine)-[Gel 20%] (Kanka)-[Soln 20%] Topical Apply as required. Max 4x/d. ¶C. *L2. S.E: Hypersensitivity.</td>
    </tr>
    <tr>
      <td>benzocaine+thymol+other</td>
      <td>Pronestin</td>
      <td>B</td>
      <td>Topical Anesthetics</td>
      <td>DERMATOLOGY</td>
      <td>benzocaine+thymol+other (Pronestin)-[Liq 3%] Topical Apply up to 4x/d. ¶B. S.E: Blurred vision, difficulty in urination, dyspnea, swelling.</td>
    </tr>
    <tr>
      <td>lidocaine</td>
      <td>Esracain</td>
      <td>B</td>
      <td>Topical Anesthetics</td>
      <td>DERMATOLOGY</td>
      <td>lidocaine (Esracain)-[Jelly 2%; Oint 5%] (Xylocaine)-[Jelly 2%; Spray 10%] Topical Apply 3-4x/d or more. ¶B. *L2. S.E: Carcinogenesis, mutagenesis, impairment of fertility, unconsciousness, respiratory depression, bradycardia, hypotension.</td>
    </tr>
    <tr>
      <td>lidocaine+hydrocortisone</td>
      <td>Perinal Spray</td>
      <td>C</td>
      <td>Topical Anesthetics</td>
      <td>DERMATOLOGY</td>
      <td>lidocaine+hydrocortisone (Perinal Spray)-[Spray 1%+0.2%] Topical Spray 2-3x/d. ¶C. S.E: Glucose intolerance, hyperglycemia, subcutaneous hemorrhage, bleeding.</td>
    </tr>
    <tr>
      <td>lidocaine+prilocaine</td>
      <td>Emla 5%</td>
      <td>B</td>
      <td>Topical Anesthetics</td>
      <td>DERMATOLOGY</td>
      <td>lidocaine+prilocaine (Emla 5%)-[Cream 2.5%+2.5%] Topical Apply 2.5G cream or 1 patch 1h before procedure. Cover with occlusive dressing. ¶B. S.E: Cardiac and respiratory arrest, arrhythmias, decreased myocardial contractility, methemoglobinemia, seizure, asystole, anaphylaxis, status asthmaticus.</td>
    </tr>
    <tr>
      <td>chlorhexidine+lidocaine</td>
      <td>Cathejell</td>
      <td>B</td>
      <td>Topical Anesthetics</td>
      <td>DERMATOLOGY</td>
      <td>chlorhexidine+lidocaine (Cathejell)-[Gel 0.05/2%w/w] Topical Apply into urethra no more than 1 syringe. ¶B. S.E: Local irritation, allergic reactions.</td>
    </tr>
    <tr>
      <td>aluminum chlorhydrate</td>
      <td>Anhydrol Forte</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>aluminum chlorhydrate (Anhydrol Forte)-[Soln 20%] Topical Hyperhidrosis: Apply 1x/d at bedtime. Granulation tissue growth: Allow packing saturated in Lumicain to remain in nail groove for 48h. ¶C. S.E: Hypersensitivity.</td>
    </tr>
    <tr>
      <td>benzalkonium+paraffin+isopropyl myristate</td>
      <td>Emulsiderm</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>benzalkonium+paraffin+isopropyl myristate (Emulsiderm)-[Emulsion 0.5%+25%+25%w/w] Use in bath, add 30ml for every 15-20cm of water in bath or apply to the skin. Peds: add 15ml. For dry skin conditions. ¶C. S.E: None.</td>
    </tr>
    <tr>
      <td>benzocaine</td>
      <td>Hurricaine, Kanka</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>benzocaine (Hurricaine, Kanka)-[Gel 20%] Topical Apply 3-4x/d. ¶C. *L2. S.E: Angioedema, methemoglobinemia.</td>
    </tr>
    <tr>
      <td>calamine+zinc oxide</td>
      <td>Calamine Lotion Floris</td>
      <td>N</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>calamine+zinc oxide (Calamine Lotion Floris)-[Lotion 15%+5%] Topical Apply as required. ¶Not established. S.E: Rash.</td>
    </tr>
    <tr>
      <td>comfrey root</td>
      <td>Traumaplant</td>
      <td>X</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>comfrey root (Traumaplant)-[Cream 10g] Topical Apply as required. Do not use for more than 3wks. ¶X. *L5. S.E: Swelling of the face, liver problems.</td>
    </tr>
    <tr>
      <td>dexpanthenol</td>
      <td>vitamin B5</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>dexpanthenol (vitamin B5) (Bepanthen)-[Oint Lotion 5%] Topical Apply 1-3x/d. ¶C. S.E: Severe allergic reactions.</td>
    </tr>
    <tr>
      <td>dexpanthenol+chlorhexidine</td>
      <td>Bepanthen Plus</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>dexpanthenol+chlorhexidine (Bepanthen Plus)-[Cream 5%+0.5%] Topical Apply 1-4x/d. ¶C. S.E: Anaphylaxis, allergic dermatitis, eczema, dyspnea.</td>
    </tr>
    <tr>
      <td>dimethindene</td>
      <td>Fenistil Gel</td>
      <td>B</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>dimethindene (Fenistil Gel)-[Gel/Roll On Lotion 0.1%] Topical Apply 2-4x/d. ¶B. S.E: Tachycardia, blurred vision.</td>
    </tr>
    <tr>
      <td>fluorouracil</td>
      <td>Efudix</td>
      <td>X</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>fluorouracil (Efudix)-[Oint 5%] Topical Sun spots: Apply 1-2x/d for 2-4wks. Healing may not be apparent for 1-2months. ¶X. *L4. S.E: Coronary atherosclerosis, thrombophlebitis, gastrointestinal ulcer, myelosuppression, cerebellar syndrome, visual changes, stenosis of lacrimal system.</td>
    </tr>
    <tr>
      <td>hydroquinone</td>
      <td>Esomed</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>hydroquinone (Esomed)-[Gel 2%]Topical Skin spots: Apply 2x/d. ¶C. *L3. S.E: Dermatitis.</td>
    </tr>
    <tr>
      <td>ichthyol</td>
      <td>Ichthammol ointment</td>
      <td>N</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>ichthyol (Ichthammol ointment)-[Oint 10%] Topical Apply 2-3x/d, Max continued use 4wks. ¶Not established. *L3. S.E: Skin irritation.</td>
    </tr>
    <tr>
      <td>isothipendyl</td>
      <td>Thio-Gel</td>
      <td>N</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>isothipendyl (Thio-Gel)-[Gel 0.75%] Topical Apply 2-3x/d. ¶Not established. S.E: Photosensitivity, allergic reactions.</td>
    </tr>
    <tr>
      <td>lactate+urea</td>
      <td>U-Lactin</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>lactate+urea (U-Lactin)-[Cream 5%+10%] Topical Apply 2x/d. ¶C. S.E. Swelling of the mouth.</td>
    </tr>
    <tr>
      <td>pimecrolimus</td>
      <td>Elidel Cream</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>pimecrolimus (Elidel Cream)-[Cream 1%] Topical Apply 2x/d. ¶C. *L2. S.E: Rare cases of malignancy (skin and lymphoma).</td>
    </tr>
    <tr>
      <td>polidocanol+soy oil</td>
      <td>Balneum Plus</td>
      <td>B</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>polidocanol+soy oil (Balneum Plus)-[Soln 15+82.95G/100G] Dermal 30-45ml for full bath. ¶B. *L3. S.E: Reddening, itching and burning.</td>
    </tr>
    <tr>
      <td>pramocaine+hydrocortisone</td>
      <td>Epifoam</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>pramocaine+hydrocortisone (Epifoam)-[Spray foam 0.9%+0.9%] (Proctofoam H.C)-[Foam 1%] Topical PR Apply rectally 3-4x/d. ¶C. S.E: Acne-like rash, skin atrophy, secondary infection, perioral dermatitis, allergic contact dermatitis.</td>
    </tr>
    <tr>
      <td>salicylic acid</td>
      <td>Salikaren</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid (Salikaren)-[Oint 3%] (Carnation Callous Caps, Carnation Corn Caps)-[Patches 40%) (Spirit Salicyl)-[Spirit 2G/100ml, 2%] Topical Apply 2-3x/d. Patches: change patch every 2-3d, Max duration of treatment 2wks. ¶C. *L3. S.E: Cracking, irritation, local inflammation.</td>
    </tr>
    <tr>
      <td>salicylic acid+coal tar+coconout oil</td>
      <td>Capasal Therapeutic Shampoo</td>
      <td>A</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid+coal tar+coconout oil (Capasal Therapeutic Shampoo)-[Shampoo 0.5%+1%+1%] Topical use as shampoo. ¶A. S.E: Irritation.</td>
    </tr>
    <tr>
      <td>salicylic acid+betamethasone</td>
      <td>Diprosalic Lotion</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid+betamethasone (Diprosalic Lotion) [Lotion 20+0.5mg/g; Oint 30+0.5mg/g]. Topical Dermal Apply 2x\d. ¶C. S.E: Irritation, local infection.</td>
    </tr>
    <tr>
      <td>salicylic acid+benzocaine</td>
      <td>Noxacorn</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid+benzocaine (Noxacorn)-[Liq 10.5%+2.1%] (Spirit Whitfiels Floris)-[Spirit 3%+6%] Topical Repeat treatment q10d as needed. ¶C. S.E: Irritation.</td>
    </tr>
    <tr>
      <td>salicylic acid+benzoic acid+tolnaftate</td>
      <td>Phyoderm Compositum</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid+benzoic acid+tolnaftate (Phyoderm Compositum)-[Oint 30+60+10mg/g] Dermal Apply to the affected areas 2-3x/d. ¶C. S.E:  irritation.</td>
    </tr>
    <tr>
      <td>salicylic acid+benzoic acid+lidocaine</td>
      <td>Pitrisol Solution</td>
      <td>N</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicylic acid+benzoic acid+lidocaine (Pitrisol Solution)-[Soln 3%+6%+1%] Topical Apply to affected area 2-3x/d. ¶Not established. S.E: None.</td>
    </tr>
    <tr>
      <td>salicyilc acid+others</td>
      <td>Salatac Gel</td>
      <td>B</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicyilc acid+others (Salatac Gel)-[Gel 12%] Topical 1-2 drops 1x/d. ¶B. S.E: Irritation, local pain.</td>
    </tr>
    <tr>
      <td>salicyilc acid+fumetasone pivalate</td>
      <td>Topisalen</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicyilc acid+fumetasone pivalate (Topisalen)-[Oint 3%+0.02%]. Topical Apply to the affected areas 2-4x/d. ¶C. S.E: Rash, local inflammation or infection.</td>
    </tr>
    <tr>
      <td>salicyilc acid+fluorouracil</td>
      <td>Verrumal solution</td>
      <td>X</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>salicyilc acid+fluorouracil (Verrumal solution)-[Soln 10+0.5G/100G] Topical Apply to the affected areas 2-3x/d. ¶X. S.E: Erosive skin reactions, intense burning sensation.</td>
    </tr>
    <tr>
      <td>tacrolimus</td>
      <td>Protopic</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>tacrolimus (Protopic)-[Oint 0.03%, 0.1%] Dermatitis: Apply topically 2x/d. ¶C. *L3. S.E: Rare cases of malignancy.</td>
    </tr>
    <tr>
      <td>trolamine/ triethanolamine</td>
      <td>Biafine</td>
      <td>C</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>trolamine/ triethanolamine (Biafine)-[Cream 0.67%] Apply up to 4x/d. ¶C. *L3. S.E: Irritation.</td>
    </tr>
    <tr>
      <td>zinc oxide+other</td>
      <td>Inotyol, Rectozorin</td>
      <td>N</td>
      <td>Anti-Pruritics &amp; Other Dermatologic Agents</td>
      <td>DERMATOLOGY</td>
      <td>zinc oxide+other (Inotyol, Rectozorin)-[Oint 14.763G/100G] (Calmin Lotion Floris)-[Lotion 5%] (Hemo Suppositories)-[Supp 120mg] Topical Rectal Lotion: Apply as required. Suppositories: every morning and evening, and after every bowel movement. ¶Not established. S.E: Rash, nausea, pain, irritation.</td>
    </tr>
    <tr>
      <td>Harmonet, Meliane, Emily, Flame</td>
      <td>gestodene 0.075mg+ethinyl estradiol 20µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Harmonet, Meliane, Emily, Flame (gestodene 0.075mg+ethinyl estradiol 20µg)-[21Tab] ¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Floret, Shelly</td>
      <td>gestodene 0.075mg+ethinyl estradiol 30µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Floret, Shelly (gestodene 0.075mg+ethinyl estradiol 30µg) [21 Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Feminet, Mercilon</td>
      <td>desogestrel 0.15mg+ethinyl estradiol 20µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Feminet, Mercilon (desogestrel 0.15mg+ethinyl estradiol 20µg)-[21 Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Minesse</td>
      <td>gestodene 0.060mg+ethinyl estradiol 15µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Minesse (gestodene 0.060mg+ethinyl estradiol 15µg)-[28 FC Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Gynera, Minulet</td>
      <td>gestodene 0.075mg+ethinyl estradiol 30µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Gynera, Minulet (gestodene 0.075mg+ethinyl estradiol 30µg)-[21 Tab], ¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Cerazette</td>
      <td>desogestrel 0.075mg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Cerazette (desogestrel 0.075mg)-[28 FC Tab], ¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Microdiol</td>
      <td>desogestrel 0.15mg+ethinyl estradiol 30µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Microdiol (desogestrel 0.15mg+ethinyl estradiol 30µg)-[21 Tab], ¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Microgynon</td>
      <td>levonorgestrel 0.15mg+ ethinyl estradiol 30µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Microgynon (levonorgestrel 0.15mg+ ethinyl estradiol 30µg)-[21 Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Nordette</td>
      <td>levonorgestrel 0.15mg+ ethinyl estradiol 30µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Nordette (levonorgestrel 0.15mg+ ethinyl estradiol 30µg)-[28 Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Seasonique, Seasonique L</td>
      <td>levonorgestrel 0.15mg+ethinyl estradiol 0.01mg+ethinyl estradiol 0.03/0.02mg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Seasonique, Seasonique L (levonorgestrel 0.15mg+ethinyl estradiol 0.01mg+ethinyl estradiol 0.03/0.02mg)-[91 Tab]¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Ortho-Cyclen</td>
      <td>norgestimate 0.25mg+ethinyl estradiol 35µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Ortho-Cyclen (norgestimate 0.25mg+ethinyl estradiol 35µg)-[21 Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Yasmin</td>
      <td>drospirenone 3.0mg+ethinyl estradiol 20µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Yasmin (drospirenone 3.0mg+ethinyl estradiol 20µg)-[21 FC Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Yaz</td>
      <td>drospirenone 3.0mg+ ethinyl estradiol 30µg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Yaz (drospirenone 3.0mg+ ethinyl estradiol 30µg)-[21 FC Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Yasmin plus</td>
      <td>drospirenone 3.0mg+ethinyl estradiol 30µg+levomefolate 0.451mg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Yasmin plus (drospirenone 3.0mg+ethinyl estradiol 30µg+levomefolate 0.451mg)[28 FC Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Yaz Plus</td>
      <td>drospirenone 3.0mg+ethinyl estradiol 20µg+levomefolate 0.451mg</td>
      <td>X</td>
      <td>Oral Contraceptive Agents</td>
      <td>OB-GYN</td>
      <td>Yaz Plus (drospirenone 3.0mg+ethinyl estradiol 20µg+levomefolate 0.451mg) [28 FC Tab].¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>Depo-Provera, Sayana</td>
      <td>medroxyprogesterone acetate Suspension 150mg/ml 104mg/0.65ml</td>
      <td>X</td>
      <td>Progesterone only contraceptives</td>
      <td>OB-GYN</td>
      <td>Depo-Provera, Sayana (medroxyprogesterone acetate Suspension 150mg/ml 104mg/0.65ml) IM SC PO 150mg every 12wk. ¶X. S.E: Vaginitis, osteoporosis, amenorrhea, leucorrhea, acne, depression, decreased libido.</td>
    </tr>
    <tr>
      <td>Femulen</td>
      <td>NaN</td>
      <td>X</td>
      <td>Progesterone only contraceptives</td>
      <td>OB-GYN</td>
      <td>Femulen (29 ג') (ethynodiol diacetate 0.5mg)-[28Tab] PO 1x/d. ¶X. S.E: None.</td>
    </tr>
    <tr>
      <td>Microlut</td>
      <td>levonorgestrel 0.03mg</td>
      <td>X</td>
      <td>Progesterone only contraceptives</td>
      <td>OB-GYN</td>
      <td>Microlut (levonorgestrel 0.03mg)-[28 Tab] PO 1x/d. ¶X. S.E: Allergic reactions, migraine, vaginal bleeding, amenorrhea, arterial and venous thrombosis, stroke, benign/malignant liver tumors, diabetes mellitus, depression.</td>
    </tr>
    <tr>
      <td>Afterday, Norlevo, Postinor</td>
      <td>levonorgestrel 1.5mg</td>
      <td>X</td>
      <td>Progesterone only contraceptives</td>
      <td>OB-GYN</td>
      <td>Afterday, Norlevo, Postinor (levonorgestrel 1.5mg)-PO 1.5mg as soon as possible, preferably within 12h and no later than 72h after unprotected intercourse. ¶X. S.E: Vaginal bleeding, anaphylaxis, arterial and VT.</td>
    </tr>
    <tr>
      <td>Norlevo</td>
      <td>levonorgestrel 0.75mg</td>
      <td>X</td>
      <td>Progesterone only contraceptives</td>
      <td>OB-GYN</td>
      <td>Norlevo (levonorgestrel 0.75mg) Emergency contraception: 1st Tab within 72h of unprotected intercourse, 2nd Tab 12h later. ¶X. S.E:Vaginal bleeding, anaphylaxis, arterial and venous thrombosis.</td>
    </tr>
    <tr>
      <td>Multiload 250</td>
      <td>NaN</td>
      <td>X</td>
      <td>Copper IUD</td>
      <td>OB-GYN</td>
      <td>Multiload 250() [3yrs: standard, short, mini]. ¶X.S.E: Abnormal vaginal hemorrhage, cervical perforation, dysmenorrhea, dyspareunia, ectopic pregnancy, embedment of intrauterine system in the myometrium, leukorrhea, pelvic pain, spontaneous migration of the IUD, uterine perforation.</td>
    </tr>
    <tr>
      <td>Multiload 375</td>
      <td>NaN</td>
      <td>X</td>
      <td>Copper IUD</td>
      <td>OB-GYN</td>
      <td>Multiload 375 ()[5yrs]. ¶X.S.E: Abnormal vaginal hemorrhage, cervical perforation, dysmenorrhea, dyspareunia, ectopic pregnancy, embedment of intrauterine system in the myometrium, leukorrhea, pelvic pain, spontaneous migration of the IUD, uterine perforation.</td>
    </tr>
    <tr>
      <td>Nova-T</td>
      <td>[5yrs]</td>
      <td>X</td>
      <td>Copper IUD</td>
      <td>OB-GYN</td>
      <td>Nova-T ([5yrs]). ¶X.S.E: Abnormal vaginal hemorrhage, cervical perforation, dysmenorrhea, dyspareunia, ectopic pregnancy, embedment of intrauterine system in the myometrium, leukorrhea, pelvic pain, spontaneous migration of the IUD, uterine perforation.</td>
    </tr>
    <tr>
      <td>Mirena</td>
      <td>levonorgestrel 52mg, 20µg/d IUD</td>
      <td>X</td>
      <td>Progestative IUD</td>
      <td>OB-GYN</td>
      <td>Mirena (levonorgestrel 52mg, 20µg/d IUD)-[5yrs]. S.E: Ectopic pregnancy, intrauterine pregnancy, GAS sepsis, PID, bleeding, perforation, ovarian cyst.¶X. *L3.</td>
    </tr>
    <tr>
      <td>Janess</td>
      <td>levonorgestrel 13.5mg IUD</td>
      <td>X</td>
      <td>Progestative IUD</td>
      <td>OB-GYN</td>
      <td>Janess (levonorgestrel 13.5mg IUD)-[3yrs]. S.E: Ectopic pregnancy, intrauterine pregnancy, GAS sepsis, PID, bleeding, perforation, ovarian cyst.¶X. *L3.</td>
    </tr>
    <tr>
      <td>cabergoline</td>
      <td>Dostinex</td>
      <td>B</td>
      <td>Infertility / Ovulation Induction / GnRH Agonists</td>
      <td>OB-GYN</td>
      <td>cabergoline (Dostinex)-[Tab 0.5mg] (Cabotrim)-[Tab 0.5, 2mg] PO Hyperprolactinemia: 0.25-1mg 2x/wk. ¶B. *L4. S.E: Arrhythmias, MI, HF.</td>
    </tr>
    <tr>
      <td>human chorionic gonadotropin</td>
      <td>HCG</td>
      <td>X</td>
      <td>Infertility / Ovulation Induction / GnRH Agonists</td>
      <td>OB-GYN</td>
      <td>human chorionic gonadotropin (HCG) (Pregnyl)-[Amp 5000U] IM Ovulation induction: 5,000-10,000U 1x/d. Cryptorchidism: 4000U 3x/wk for 3wk. Hypogonadism (male): 500-1,000U 3x/wk for 3wk, then 2x/wk for 2wk OR 4000U 3x/wk for 6-9mnth, then 2000U 3x/wk for 3mnth. ¶X. S.E: Headache, irritability,  depression, fatigue, edema, precocious puberty, gynecomastia.</td>
    </tr>
    <tr>
      <td>clomiphene citrate</td>
      <td>Ikaclomin</td>
      <td>X</td>
      <td>Infertility / Ovulation Induction / GnRH Agonists</td>
      <td>OB-GYN</td>
      <td>clomiphene citrate (Ikaclomin)-[Tab 50mg] PO Ovulation induction: Start 50mg 1x/d for 5d. Increase dose in patients who do not ovulate. ¶X. *L4. S.E: Arrhythmia, migraine headache, paresthesia, seizure, stroke, syncope.</td>
    </tr>
    <tr>
      <td>estradiol+norgestrel</td>
      <td>Progyluton</td>
      <td>X</td>
      <td>Infertility / Ovulation Induction / GnRH Agonists</td>
      <td>OB-GYN</td>
      <td>estradiol+norgestrel (Progyluton)-[Tab 11d X 2mg, 10d X 2mg+0.5mg] PO 1X/d from 5th day of cycle for 21d. Pause 7d. ¶X. *L3. S.E: Arterial and venous thrombosis, pulmonary embolism, cerebral thrombosis, gallbladder disease, hypertension, hepatic neoplasm.</td>
    </tr>
    <tr>
      <td>follitropin FSH</td>
      <td>Gonal-F</td>
      <td>X</td>
      <td>Infertility / Ovulation Induction / GnRH Agonists</td>
      <td>OB-GYN</td>
      <td>follitropin FSH (Gonal-F)- [Soln 600IU/ml Pwdr 5.5mcg] (Puregon)- [Soln 833IU/ml] IM SC Variable dose. ¶X. *L3. S.E: Embolism and thrombosis, acute respiratory distress syndrome, ovary hyperstimulation syndrome.</td>
    </tr>
    <tr>
      <td>follitropin FSH+lutropin LH</td>
      <td>Pergoveris</td>
      <td>X</td>
      <td>Infertility / Ovulation Induction / GnRH Agonists</td>
      <td>OB-GYN</td>
      <td>follitropin FSH+lutropin LH (Pergoveris) [Pwdr 150IU+75IU] SC .¶X. S.E: Thromboembolism, ovarian cysts.</td>
    </tr>
    <tr>
      <td>ganirelix</td>
      <td>Orgalutran</td>
      <td>X</td>
      <td>Infertility / Ovulation Induction / GnRH Agonists</td>
      <td>OB-GYN</td>
      <td>ganirelix (Orgalutran)-[Amp 0.25mg] LHRH antagonist SC 0.25mg 1x/d. ¶X. *L3. S.E: Ectopic pregnancy, thrombotic disorder.</td>
    </tr>
    <tr>
      <td>letrozole</td>
      <td>Femara, Lebrest, Letrozole-Dexcel, Letrozole-Farmoz, Letrozole-Teva</td>
      <td>X</td>
      <td>Infertility / Ovulation Induction / GnRH Agonists</td>
      <td>OB-GYN</td>
      <td>letrozole (Femara, Lebrest, Letrozole-Dexcel, Letrozole-Farmoz, Letrozole-Teva)-[Tab 2.5mg] PO 2.5mg/d, patients with cirrhosis or severe hepatic impairment: 2.5mg every other day. ¶X.*L4. S.E: Fatigue, dizziness, edema, bone pain, hypercholesterolemia.</td>
    </tr>
    <tr>
      <td>buserelin</td>
      <td>Suprefact</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>buserelin (Suprefact)-[Rods for implant 9.9mg] Prostate cancer: initial dose: 500mcg q8h for 7d. Maintenance: 200mcg 1x/d. Endometriosis: 400mcg 3x/d for 6-9mnth. ¶X. S.E: Thromboembolism, edema, depression, thrombocytopenia, QT interval prolongation.</td>
    </tr>
    <tr>
      <td>cetrorelix</td>
      <td>Cetrotide</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>cetrorelix (Cetrotide)-[Amp 0.25mg] SC 0.25mg 1x/d. ¶X. S.E: Anaphylaxis.</td>
    </tr>
    <tr>
      <td>goserelin</td>
      <td>Zoladex, Zoladex LA</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>goserelin (Zoladex, Zoladex LA)-[Implant 3.6, 10.8mg] SC 3.6mg 1x/mnth or 10.8 mg 3x/mnth. Variable duration by indication. ¶X. *L3. S.E: DVT.</td>
    </tr>
    <tr>
      <td>leuprorelin</td>
      <td>Lucrin</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>leuprorelin (Lucrin)-[Amp 3.75, 11.25mg] SC IM 3.75mg 1x/mnth or 11.25mg every 3mnth. ¶X. S.E: DVT.</td>
    </tr>
    <tr>
      <td>nafarelin</td>
      <td>Synarel Nasal</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>nafarelin (Synarel Nasal)-[Nasal Spray 200µg/spray] 400µg 4x/d or 600µg 3x/d. ¶X. S.E: DVT.</td>
    </tr>
    <tr>
      <td>triptorelin</td>
      <td>Decapeptyl</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>triptorelin (Decapeptyl)-[Amp 0.1mg, CR 3.75mg] (Decapeptyl depot)-[Amp 11.25, 22.5, 3.75mg] (Diphereline)-[Amp 0.1, 3.75mg] IM 3.75mg every 4wk OR 11.25mg every 12wk OR 22.5mg every 24wk ¶X. *L3. S.E: Transient increase in serum testosterone, metastatic vertebral lesions, urinary tract obstruction, QT interval prolongation, cardiovascular disease.</td>
    </tr>
    <tr>
      <td>menotropin HMG</td>
      <td>HMG+FSH+LH</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>menotropin HMG (HMG+FSH+LH) (Menogon)-[Amp 75+75IU] (Menopur)-[Amp 75,600,1200 IU] SC IM. Initial dose 225IU 1x/d add up to 150IU at least every 2d. ¶X. *L3. S.E: Embolism and thrombosis, acute respiratory distress syndrome, ovary hyperstimulation syndrome.</td>
    </tr>
    <tr>
      <td>lutropin LH  alfa</td>
      <td>Luveris 75</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>lutropin LH  alfa (Luveris 75)-[Amp 75IU] SC 2 injections every treatment cycle. ¶X. *L3. S.E: Vaginal bleeding, stomach or pelvic discomfort.</td>
    </tr>
    <tr>
      <td>follitropin FSH+ lutropin LH</td>
      <td>Pergoveris</td>
      <td>X</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>follitropin FSH+ lutropin LH (Pergoveris) [Pwdr 150+ 75IU] SC. ¶X. S.E: Thromboembolism, ovarian cysts.</td>
    </tr>
    <tr>
      <td>quinagolide</td>
      <td>Norprolac</td>
      <td>B</td>
      <td>GnRH-agonists</td>
      <td>OB-GYN</td>
      <td>quinagolide (Norprolac)-[Tab 25, 50, 75, 150µg] PO 25µg/d for 3d, then 50µg/d for 3d, then 75µg/d. ¶B. S.E: Behavioral change, binge eating, psychosis.</td>
    </tr>
    <tr>
      <td>atosiban</td>
      <td>Atosiban</td>
      <td>C</td>
      <td>Tocolytics</td>
      <td>OB-GYN</td>
      <td>atosiban (Atosiban)-[Soln 7.5mg/ml] IV Bolus: 6.75mg. High dose: 300µg/min 3h. Low dose: 100µg/min for up to 4-5h. Max 48h &lt; 330mg. ¶C. S.E: Hot flashes, tachycardia, hypotension, insomnia, fever.</td>
    </tr>
    <tr>
      <td>magnesium sulfate</td>
      <td>Magnesium Sulfate</td>
      <td>D</td>
      <td>Tocolytics</td>
      <td>OB-GYN</td>
      <td>magnesium sulfate (Magnesium Sulfate)-[Amp 50%] Eclampsia: 10-14G over 2-4min. Solution 10G in 500ml (20mg/ml), 2G/hr=100ml/hr. Monitor respirations and reflexes. ¶D. *L1. S.E: Hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression proceeding to respiratory paralysis, Hypocalcemia.</td>
    </tr>
    <tr>
      <td>dinoprostone</td>
      <td>Prostin E2</td>
      <td>C</td>
      <td>Labor Induction / Cervical Ripening / Uterotonics</td>
      <td>OB-GYN</td>
      <td>dinoprostone (Prostin E2)-[Vag Tab 3, 10mg Vag Gel 1, 2mg/3G] (Propess)-[SR Vag Pessary 10mg] Vaginal Cervical ripening: Tab 10mg posterior fornix for 12h. Vag Gel 1mg. May be given another 1-2mg after 6. ¶C. *L3. SE: Postpartum DIC, anaphylaxis.</td>
    </tr>
    <tr>
      <td>oxytocin</td>
      <td>Oxytocin Injection</td>
      <td>X</td>
      <td>Labor Induction / Cervical Ripening / Uterotonics</td>
      <td>OB-GYN</td>
      <td>oxytocin (Oxytocin Injection)-[Amp 10U] IM IV Induction of Labor: Start 0.5-1mU/min at 30-60min intervals the dose should be gradually increased in increments of 1-2mU/min until the desired contraction pattern has been established. Then, the dose may be reduced by similar increments. ¶X. *L2. SE: None.</td>
    </tr>
    <tr>
      <td>methylergometrine/methylergonovine</td>
      <td>Methergin</td>
      <td>C</td>
      <td>Labor Induction / Cervical Ripening / Uterotonics</td>
      <td>OB-GYN</td>
      <td>methylergometrine/methylergonovine (Methergin)-[Tab 0.125mg] PO Postpartum Hemorrhage: 1-2 Tabs 3-4x/d for 2-7d. ¶C. *L2(acute use); *L4(chronic use). S.E: Hypertension, hypotension, seizures, MI, arterial spasm, arrhythmias, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diaphoresis, foul taste.</td>
    </tr>
    <tr>
      <td>mifepristone</td>
      <td>Mifegyne</td>
      <td>X</td>
      <td>Abortion</td>
      <td>OB-GYN</td>
      <td>mifepristone (Mifegyne)-[Tab 200mg] PO Early pregnancy termination: 600mg 1x followed 36-48h later by PO 400µg misoprostol. ¶X. *L3. S.E: Hypertension, vaginal bleeding, endometrial hypertrophy, hypokalemia, peripheral edema, dyspnea.</td>
    </tr>
    <tr>
      <td>dinoprost trometamol</td>
      <td>Prostin F2 Alpha</td>
      <td>X</td>
      <td>Abortion</td>
      <td>OB-GYN</td>
      <td>dinoprost trometamol (Prostin F2 Alpha)-[Amp 5mg/ml] Intra-amniotic 40mg for abortion. ¶X. *L3. S.E: Vaginal bleeding, uterine infections, DIC, cervix perforation, dyspnea, tachycardia, hypovolemic shock, syncope.</td>
    </tr>
    <tr>
      <td>Estrogenus</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Estrogenus ()[Tab 0.3, 0.45, 0.625, 1.25, 0.9, 1.25mg] Menopausal symptoms: 0.45 mg-1.25mg 1x/d. Breast CA: 10mg, 3x/d for at least 3 mnth ¶X.</td>
    </tr>
    <tr>
      <td>tibolone</td>
      <td>Livial</td>
      <td>N</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>tibolone (Livial)-[Tab 2.5mg] PO Menopausal symptoms 1Tab 1x/d. ¶Not established. S.E: DVT, thromboembolism, endometrial carcinoma, breast cancer, CVA, hepatitis, prolonged vaginal bleeding.</td>
    </tr>
    <tr>
      <td>Estrofem [Tab 1, 2mg] PO 1Tab 1x/d.</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Estrofem [Tab 1, 2mg] PO 1Tab 1x/d. () ¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>Evorel 50 [Patch 3.2mg] Patch 2x/wk</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Evorel 50 [Patch 3.2mg] Patch 2x/wk ().¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>Progynova [Tab 2mg]</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Progynova [Tab 2mg] () PO 1x/d for 21 d. ¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>estriol</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>estriol () ¶X. *L3. S.E: Fluid retention, postmenopausal spotting, cervical discharge.</td>
    </tr>
    <tr>
      <td>Premaril MP 28 [Tab 0.625+2.5mg]</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Premaril MP 28 [Tab 0.625+2.5mg] () PO usually 1-2x/d.¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>Activelle [Tab 1+0.5mg] PO 28 Tabs.</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Activelle [Tab 1+0.5mg] PO 28 Tabs. () 1x/d. ¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>Evorel Conti</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Evorel Conti () [Transdermal Equivalent 3.2+11.2mg] Patch 2x/wk. ¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>Evorel Sequi</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Evorel Sequi () [Transdermal Equivalent 3.2mg, 3.2mg+11.2mg] Patch 2x/wk (E 2wk, then E+P 2wk ).¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>Eviana</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Eviana () [Tab 0.5+0.1mg] PO 1x/d. ¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>Novofem</td>
      <td>NaN</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Novofem () [Tab 16 x 1mg then 12 x 1+1mg] PO 16d E then 12d E+P.¶X. SE: Stroke, coronary heart disease, VTE, endometrial cancer, breast cancer, ovarian cancer.</td>
    </tr>
    <tr>
      <td>dydrogesterone</td>
      <td>Duphaston</td>
      <td>D</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>dydrogesterone (Duphaston)-[Tab 10mg] PO 2x/d. ¶D.</td>
    </tr>
    <tr>
      <td>medroxyprogesterone acetate</td>
      <td>Provera</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>medroxyprogesterone acetate (Provera)-[Tab 5mg] PO 5-10mg/d for 12-14 consecutive d/mnth. Only for women receiving 0.625mg conjugated estrogens. ¶X. *L4. SE: Stroke, coronary heart disease, VTE, breast cancer, endometrial cancer, ovarian cancer, probable dementia.</td>
    </tr>
    <tr>
      <td>Crinone</td>
      <td>NaN</td>
      <td>B</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Crinone () [Gel 8%/90mg] Vag 1x/d after ovulation or arbitarly on the 18th-21st d of cycle. ¶B. *L3. S.E: UTI, intermenstrual bleeding.</td>
    </tr>
    <tr>
      <td>Endometrin [Tab 100mg]</td>
      <td>NaN</td>
      <td>B</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Endometrin [Tab 100mg] () Vag 1Tab 2-3x/d starting at oocyte retrieval and continuing for 12wk. ¶B. *L3. S.E: UTI, ovary hyperstimulation syndrome, vaginal bleeding.</td>
    </tr>
    <tr>
      <td>Utrogestan -[Soft Caps 100, 200mg]</td>
      <td>NaN</td>
      <td>B</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>Utrogestan -[Soft Caps 100, 200mg] () Hormone Replacement Therapy: PO Vag 200mg 12-14 d/mnth or 300mg 10d/mnth divided in 2 intakes. Premenopause: PO 300mg/d divided in 2 intakes 10-20d. Luteal Insufficiency: PO Vag 200-300mg/d divided in 2 intakes for 10d per cycle (17th-26th inclusive). ¶B. *L3. S.E: Amenorrhea, intercurrent bleeding, cholestatic jaundice, acne, VT.</td>
    </tr>
    <tr>
      <td>norethisterone</td>
      <td>Primolut-Nor</td>
      <td>X</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>norethisterone (Primolut-Nor)-[Tab 5mg] PO Endometriosis: 1Tab 3x/d for 6 mnth. Amenorrhea, abnormal bleeding: 1Tab 3x/d for 10d. Premenstrual Tension: 1Tab/d for 10d starting 16d after last period. Period Delay: 1Tab 3x/d start 3d before period should start. ¶X. S.E: Exacerbation of epilepsy, migraines, peripheral edema, severe visual or hearing disturbance, thrombophlebitis, VT, dyspnea, jaundice, hepatitis, itching of the whole body, hypertension.</td>
    </tr>
    <tr>
      <td>progesterone BP</td>
      <td>Gestone</td>
      <td>B</td>
      <td>Menopausal Agents / Hormones</td>
      <td>OB-GYN</td>
      <td>progesterone BP (Gestone)-[Amp 50, 100mg/ml] IM Dysfunctional bleeding: 5-10mg/d for 5-10d until 2d before expected menses. ¶B. *L3. S.E: Amenorrhea, cholestatic jaundice, mental depression.</td>
    </tr>
    <tr>
      <td>raloxifene</td>
      <td>Evista, Raloxifene Teva</td>
      <td>X</td>
      <td>Selective Estrogen Receptor Modulators</td>
      <td>OB-GYN</td>
      <td>raloxifene (Evista, Raloxifene Teva)-[Tab 60mg] Osteoporosis: PO 1x/d. ¶X. *L3. S.E: Chest pain, VT, vaginal bleeding, vaginitis, leucorrhea, endometrial disorders, gastroenteritis, pneumonia, weight gain, peripheral edema, migraine, depression.</td>
    </tr>
    <tr>
      <td>tamoxifen</td>
      <td>Tamoxifen Teva</td>
      <td>D</td>
      <td>Selective Estrogen Receptor Modulators</td>
      <td>OB-GYN</td>
      <td>tamoxifen (Tamoxifen Teva)-[Tab 20mg] PO Breast cancer: 10-20mg 2x/d. ¶D. *L5. S.E: Endometrial adenocarcinoma, uterine sarcoma, atrophic endometrium, endometriosis, vaginal bleeding, amenorrhea, hypercalcemia, thrombocytopenia, stroke, edema, phlebitis, VT.</td>
    </tr>
    <tr>
      <td>econazole</td>
      <td>Gyno-Pevaryl</td>
      <td>C</td>
      <td>Other Vaginal Preparations / Lubricants</td>
      <td>OB-GYN</td>
      <td>econazole (Gyno-Pevaryl)-[Vag Ovul 150mg] Candida: Insert at night for 3d. ¶C. *L3. S.E: Contact dermatitis.</td>
    </tr>
    <tr>
      <td>imiquimod</td>
      <td>Aldara, Aquimod, Perrimod</td>
      <td>C</td>
      <td>Other Vaginal Preparations / Lubricants</td>
      <td>OB-GYN</td>
      <td>imiquimod (Aldara, Aquimod, Perrimod)-[Cream 5%] Genital warts: apply 3x/wk for up to 16wks. Leave on 6-10hrs before wash. ¶C. *L3. S.E: Fungal infections, viral infections, anorexia, squamous cell carcinoma, lymphadenopathy, AF, chest pain, eczema,  anxiety.</td>
    </tr>
    <tr>
      <td>isoconazole</td>
      <td>Isogen</td>
      <td>B</td>
      <td>Other Vaginal Preparations / Lubricants</td>
      <td>OB-GYN</td>
      <td>isoconazole (Isogen)-[Cream 1%] Cream: Apply 1x/d. ¶B. S.E: Contact dermatitis.</td>
    </tr>
    <tr>
      <td>metronidazole</td>
      <td>Flagyl</td>
      <td>B</td>
      <td>Other Vaginal Preparations / Lubricants</td>
      <td>OB-GYN</td>
      <td>metronidazole (Flagyl)-[Vag Tab 500mg] (Zidoval)-[Gel 0.75%] Trichomomas vaginitis: 1Tab/d for 10d often combined with oral tabs. Non-specific vaginitis: 1Tab/d for 7d often combined with oral tabs. Bacterial vaginosis: Gel: Insert 1-2x/d for 5d at night. ¶B. *L2. S.E: Symptomatic candida cervicitis/vaginitis, UTI, pancreatitis, proctitis, syncope, ataxia, convulsive seizures, peripheral neuropathy, URTI, sinusitis, bronchitis, leukopenia, leukocytosis, hypertension, basal cell carcinoma.</td>
    </tr>
    <tr>
      <td>miconazole</td>
      <td>Daktarin, Gyno-Daktarin 7</td>
      <td>C</td>
      <td>Other Vaginal Preparations / Lubricants</td>
      <td>OB-GYN</td>
      <td>miconazole (Daktarin, Gyno-Daktarin 7)-[Cream/Vag Cream 2%; Vag Caps 400mg] Candida: Apply cream at night for 7d. Insert vaginal caps 1x/d for 3d. ¶C. *L2. S.E: Allergic reactions, UTI, vaginal bleeding.</td>
    </tr>
    <tr>
      <td>nystatin</td>
      <td>Nystatin</td>
      <td>C</td>
      <td>Other Vaginal Preparations / Lubricants</td>
      <td>OB-GYN</td>
      <td>nystatin (Nystatin)-[Vag Tab 100,000IU] Insert 1x/d before bed time for 2wks. ¶C. *L1. S.E: Hypersensitivity.</td>
    </tr>
    <tr>
      <td>podophyllotoxin</td>
      <td>Condylox</td>
      <td>C</td>
      <td>Other Vaginal Preparations / Lubricants</td>
      <td>OB-GYN</td>
      <td>podophyllotoxin (Condylox)-[Soln 0.5%] Genital warts: Apply 2x/d for 3d of week and repeat up to 4wks. ¶C. *L3. S.E: Bleeding of treated skin, hematuria, dizziness, vomiting, oral ulcers.</td>
    </tr>
    <tr>
      <td>polvidone iodine</td>
      <td>Polydine</td>
      <td>V</td>
      <td>Other Vaginal Preparations / Lubricants</td>
      <td>OB-GYN</td>
      <td>polvidone iodine (Polydine)-[Pess 5%] (Polysept)-[Douche 10%] (Iodiflor)-[Soap] Vaginitis: Dilute 15ml in 1l water for douche 2x/wk. Pessary: 1x/d 7d. Bar soap as needed. ¶Vaginal products should not be used during pregnancy. S.E: Severe allergic reactions.</td>
    </tr>
    <tr>
      <td>alendronate</td>
      <td>Fosalan Once Weekly, Maxibone</td>
      <td>C</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>alendronate (Fosalan Once Weekly, Maxibone)-[Tab 70mg] (Tevanate)-Tab 10mg] PO Osteoporosis postmenopausal prevention1tab/wk. Taken ½hr before breakfast. ¶C. *L3. S.E: Esophageal stricture, esophageal ulcer, esophagitis, convulsions, arrhythmia, osteonecrosis of the jaw, atypical subtrochanteric and diaphyseal femoral fractures, Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, scleritis, episcleritis, hypocalcemia, hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>calcitonin</td>
      <td>Salco (salmon</td>
      <td>C</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>calcitonin (Salco (salmon))-[Amp 100IU/ml] (Miacalcic (salmon))-[Nasal Spray 200IU/spray] SC IM IV Osteoporosis: 100IU/d or 0.5mg/d or 200IU/d nasal spray alternate nostrils. Paget’s disease: 100IU/d or 0.5mg/d. Hypercalcemia: 4-8IU/kg/d. ¶C. *L3. S.E: Hypocalcemia, hypersensitivity, malignancy.</td>
    </tr>
    <tr>
      <td>denosumab</td>
      <td>Prolia</td>
      <td>D</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>denosumab (Prolia)-[Soln 60mg/1ml] (Xgeva)-[Soln 120mg/1.7ml] SC Recommended dose: 120mg every 4wks. ¶D. *L4. S.E: Hypocalcemia, hypercalcemia, osteonecrosis of the jaw, hypophosphatemia, dyspnea.</td>
    </tr>
    <tr>
      <td>ibandronic acid as sodium monohydrate</td>
      <td>Ibandronic acid inovamed</td>
      <td>C</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>ibandronic acid as sodium monohydrate (Ibandronic acid inovamed)-[Tab 50mg] PO 150mg 1x month. Do not eat, drink (except for water),or take other medication for 60min after. ¶C. S.E: Hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, back pain, dyspepsia, pain in extremity, diarrhea.</td>
    </tr>
    <tr>
      <td>pamidronate</td>
      <td>Aredia</td>
      <td>D</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>pamidronate (Aredia)-[Pwdr 30, 90mg] IV Moderate hypercalcemia: 60-90mg given as a single dose. Severe hypercalcemia: 90mg given as a single dose. Intravenous infusion over 2-24h. ¶D. *L2. S.E: Renal toxicity, hypercalcemia, hypokalemia, hypomagnesemia, hypomagnesemia, osteonecrosis of the jaw, musculoskeletal pain, atypical femoral fractures, fever.</td>
    </tr>
    <tr>
      <td>raloxifene</td>
      <td>Evista, Raloxifene Teva</td>
      <td>X</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>raloxifene (Evista, Raloxifene Teva)-[Tab 60mg] PO 60mg 1x/d. ¶X. *L3. S.E: VT, stroke, hypertriglyceridemia, hepatotoxicity, peripheral edema, flu syndrome, hot flashes.</td>
    </tr>
    <tr>
      <td>risedronate</td>
      <td>Actonel Once A Month</td>
      <td>C</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>risedronate (Actonel Once A Month)-[Tab 150mg] (Ribone)-[Tab 35, 150mg] (Risedronate Teva)-[Tab 35,75mg] PO Osteoporosis: 35mg/wk or 75mg on 2 consecutive days for a total of 150mg/mnth or 150mg/mnth. ¶C. *L3. S.E: Infection, flu syndrome, hypertension, peripheral edema, bone fracture, bronchitis, UTI.</td>
    </tr>
    <tr>
      <td>tibolone</td>
      <td>Livial</td>
      <td>N</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>tibolone (Livial)-[Tab 2.5mg] PO Menopausal symptoms 1Tab 1x/d. ¶Not established. S.E: DVT, thromboembolism, endometrial carcinoma, breast cancer, CVA, hepatitis, prolonged vaginal bleeding.</td>
    </tr>
    <tr>
      <td>zoledronic acid</td>
      <td>Aclasta</td>
      <td>D</td>
      <td>Osteoporosis  treatment</td>
      <td>OB-GYN</td>
      <td>zoledronic acid (Aclasta)-[Soln 5mg/100ml] (Tevadronic)-[Soln 0.5mg/ml] IV Single intravenous infusion of 5mg once a year. ¶D. S.E: Hypocalcemia, renal impairment, osteonecrosis of the jaw, atypical femoral fractures, flu-like illness, vomiting, diarrhea.</td>
    </tr>
    <tr>
      <td>cyproterone acetate</td>
      <td>Androcur</td>
      <td>D</td>
      <td>Other OB/GYN</td>
      <td>OB-GYN</td>
      <td>cyproterone acetate (Androcur)-[Tab 10] PO Androgenization in women: Start 10mg 1x/d for 15d/mnth with estrogen or estrogen with progesteron for 21d/mnth. ¶Do not use in pregnancy. S.E: Depression, obesity, hepatotoxicity, benign and malignant liver tumors, GI hemorrhage, hypersensitivity reactions, hyperglycemia, meningioma, thromboembolic events, anemia, adrenocortical suppression.</td>
    </tr>
    <tr>
      <td>cyproterone acetate+ethinyl estradiol</td>
      <td>Diane 35</td>
      <td>D</td>
      <td>Other OB/GYN</td>
      <td>OB-GYN</td>
      <td>cyproterone acetate+ethinyl estradiol (Diane 35)-[Tab 2mg+35µg] PO 1Tab 21d. ¶Do not use in pregnancy. S.E: MI, DVT, pulmonary embolism, CVA, breast cancer, benign and malignant liver tumors, acute or chronic liver dysfunctions, chloasma.</td>
    </tr>
    <tr>
      <td>danazol</td>
      <td>Danol</td>
      <td>X</td>
      <td>Other OB/GYN</td>
      <td>OB-GYN</td>
      <td>danazol (Danol)-[Caps 200mg] Endometriosis: PO 200-800mg/d for 3-6mnths. Angioedema: PO 200mg 2-3x/d. Fibrocystic Breast Disease: PO 50-200mg 2x/d. ¶X. *L5. S.E: ICP, hepatic disturbance, thrombosis, thromboembolism, benign and malignant liver tumors, amenorrhea, insulin resistance, increase in LDL cholesterol, depression, carpal tunnel syndrome, blurred vision, interstitial pneumonitis.</td>
    </tr>
    <tr>
      <td>Rh D immune globulin</td>
      <td>KamRHO-D, Rhophylac 300</td>
      <td>C</td>
      <td>Hemolytic disease in newborn</td>
      <td>OB-GYN</td>
      <td>Rh D immune globulin (KamRHO-D, Rhophylac 300)-[Amp 300µg/2ml] (Winrho SDF)-[Pwdr for Inj 1500, 5000IU/Vial] Administer to mother to prevent hemolytic disease in newborn: Antepartum prophylaxis: IM IV 300µg within at 28-30wk of gestation. Postpartum prophylaxis: IV 120µg within 72h of delivery. NEVER GIVE TO NEONATE. ¶C. *L2. S.E:, AKI, DIC, fever, hypotension, hemolytic anemia, , hemoglobinemia, tachycardia, cardiac arrest, HF, MI, jaundice, hypersensitivity.</td>
    </tr>
    <tr>
      <td>chenodeoxycholic acid</td>
      <td>Chenofalk</td>
      <td>X</td>
      <td>Nephrolithiasis / Alkalinization</td>
      <td>UROLOGY</td>
      <td>chenodeoxycholic acid (Chenofalk)-[Cap 250mg] PO 13-16mg/kg/d in 2 divided doses AM and PM. ¶X. S.E: Fever, dose-related serum aminotransferase (mainly SGPT) elevations, intrahepatic cholestasis, leukopenia, hypercholesterolemia.</td>
    </tr>
    <tr>
      <td>pinene+camphene+other</td>
      <td>Rowachol</td>
      <td>N</td>
      <td>Nephrolithiasis / Alkalinization</td>
      <td>UROLOGY</td>
      <td>pinene+camphene+other (Rowachol)-[Cap 17+5mg+other] (Rowatinex)-[Cap 31mg+15mg] 1-2Cap 3x/d. Peds: 1Cap 2x/d. ¶Not established. S.E: None.</td>
    </tr>
    <tr>
      <td>potassium citrate+sodium citrate</td>
      <td>Alkasolve</td>
      <td>C</td>
      <td>Nephrolithiasis / Alkalinization</td>
      <td>UROLOGY</td>
      <td>potassium citrate+sodium citrate (Alkasolve)-[Tab 330+300mg] PO Urinary alkalinization: 9-16Tab/d after meal. ¶C. S.E: Nausea.</td>
    </tr>
    <tr>
      <td>sodium citrate+bicarbonate+other</td>
      <td>Urikal</td>
      <td>N</td>
      <td>Nephrolithiasis / Alkalinization</td>
      <td>UROLOGY</td>
      <td>sodium citrate+bicarbonate+other (Urikal)-[Sachet Pwdr 2,457+1,200mg+other] PO Mix in 250ml water. 1Sachet 3x/d for 2d. ¶Not established. S.E: Tachycardia, hypertension.</td>
    </tr>
    <tr>
      <td>sodium phosphate+potassium acid phosphate</td>
      <td>Calciless</td>
      <td>N</td>
      <td>Nephrolithiasis / Alkalinization</td>
      <td>UROLOGY</td>
      <td>sodium phosphate+potassium acid phosphate (Calciless)-[Tab 285+602mg] PO Hypercalcemia or calcium oxalate stones: 3Tab first day, then 2Tab 3x/d. ¶Not established. S.E: Hypotension.</td>
    </tr>
    <tr>
      <td>alfuzosin</td>
      <td>Xatral</td>
      <td>B</td>
      <td>Benign_Prostatic_Hyperplasia</td>
      <td>UROLOGY</td>
      <td>alfuzosin (Xatral)-[Tab 2.5mg; FC Tab 5, 10mg] (Alfu-Kal XL, Alfuzosin ER Teva)-[Tab ER 10mg] PO 2.5mg 3-4x/d. FC Tab 5mg 2x/d after breakfast and after dinner or 10mg 1x/d after dinner. ¶B. *L4. S.E: Syncope, URTI, hypotension or postural hypotension, arrhythmia, impotence, hepatocellular and cholestatic liver injury, toxic epidermal necrolysis, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>doxazosin</td>
      <td>Cadex</td>
      <td>C</td>
      <td>Benign_Prostatic_Hyperplasia</td>
      <td>UROLOGY</td>
      <td>doxazosin (Cadex)-[Tab 1, 2, 4mg] PO Start 1mg 1x/d. Usual 1-8mg/d. Max 8mg/d. ¶C. *L4. S.E: Intraoperative Floppy Iris syndrome, decreases in total and LDL serum cholesterol and serum triglycerides, syncope arrhythmias, MI, CVA, impotence, hematuria, neutropenia, blood dyscrasia, hypersensitivity, hepatitis.</td>
    </tr>
    <tr>
      <td>dutasteride</td>
      <td>Avodart</td>
      <td>X</td>
      <td>Benign_Prostatic_Hyperplasia</td>
      <td>UROLOGY</td>
      <td>dutasteride (Avodart)-[Cap 0.5mg] PO 1Cap 1x/d. Inhibits 5α-reductase. ¶X. S.E: Impotence, decreased libido, ejaculation disorders, gynecomastia, male breast cancer, depression.</td>
    </tr>
    <tr>
      <td>finasteride</td>
      <td>Finasteride Teva, Proavenir, Propecia</td>
      <td>X</td>
      <td>Benign_Prostatic_Hyperplasia</td>
      <td>UROLOGY</td>
      <td>finasteride (Finasteride Teva, Proavenir, Propecia)-[Tab 1mg] (Pro-Cure, Finasteride Inovamed)-[Tab 5mg] PO 5mg 1x/d. ¶X. S.E: Impotence, abnormal ejaculation, gynecomastia, erectile dysfunction, male infertility, poor seminal quality, decreased libido, high-grade prostate cancer, cutaneous leukocytoclastic vasculitis, depression.</td>
    </tr>
    <tr>
      <td>lipidosterolic extract</td>
      <td>Permixon</td>
      <td>N</td>
      <td>Benign_Prostatic_Hyperplasia</td>
      <td>UROLOGY</td>
      <td>lipidosterolic extract (Permixon)-[Cap 160mg] PO 1Cap 2x/d with meals. ¶Not established. S.E: Hepatobiliary disorders, gynecomastia.</td>
    </tr>
    <tr>
      <td>phenoxybenzamine</td>
      <td>Dibenyline</td>
      <td>C</td>
      <td>Benign_Prostatic_Hyperplasia</td>
      <td>UROLOGY</td>
      <td>phenoxybenzamine (Dibenyline)-[Cap 10mg] PO 1-2mg/kg/d split into 2 doses. ¶C. S.E: Postural hypotension, tachycardia, inhibition of ejaculation.</td>
    </tr>
    <tr>
      <td>tamsulosin</td>
      <td>Tamsulosin Inovamed, Omnic Ocas</td>
      <td>B</td>
      <td>Benign_Prostatic_Hyperplasia</td>
      <td>UROLOGY</td>
      <td>tamsulosin (Tamsulosin Inovamed, Omnic Ocas)-[SR Cap 0.4mg]  (Tamsulin, Tamsulosin Teva, Omnic)-[MR Cap 0.4mg] (Promnix)-[Cap 0.4mg] PO 0.4mg/d. Max 0.8mg/d. ¶B. *L3. S.E: Infections, chest pain, insomnia, somnolence, abnormal ejaculation, decreased libido, blurred vision.</td>
    </tr>
    <tr>
      <td>terazosin</td>
      <td>Terazosin Teva</td>
      <td>C</td>
      <td>Benign_Prostatic_Hyperplasia</td>
      <td>UROLOGY</td>
      <td>terazosin (Terazosin Teva)-[Tab 1, 2, 5mg] (Hytrin Starter Pack)-[Tab 1mg] (Hytrin)-[Tab 2, 5, 10mg] PO start 1mg 1x/d at bedtime. Increase gradually. Maintenance 1-5mg/d. Max 20mg/d. ¶C. *L4. S.E: Syncope, atrial fibrillation, orthostatic hypotension, hypotension, Intraoperative Floppy Iris syndrome, blurred vision, decreases in serum triglycerides and VLDL cholesterol,  increases in HDL cholesterol, impotence, hypersensitivity reactions including anaphylaxis, lichenoid drug eruption, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>alprostadil</td>
      <td>Caverject</td>
      <td>C</td>
      <td>Erectile Dysfunction</td>
      <td>UROLOGY</td>
      <td>alprostadil (Caverject)-[Amp 10, 20µg/ml] (Prostin)-[Amp 0.5mg/ml] IM 1-40µg intracavernosal injection at lowest dose for erection, given over 5-10sec ¶C. S.E: Apnea, bradycardia, penile pain.</td>
    </tr>
    <tr>
      <td>sildenafil</td>
      <td>Viagra, Sildenafil Teva, Sildenafil Actavis, Sildex, Tarim, Via-Avenir</td>
      <td>B</td>
      <td>Erectile Dysfunction</td>
      <td>UROLOGY</td>
      <td>sildenafil (Viagra, Sildenafil Teva, Sildenafil Actavis, Sildex, Tarim, Via-Avenir)-[Tab 25, 50, 100mg] (Sil-On 100, Zeus)-[Tab 100mg] PO Start 50mg/d 0.5-4hr prior to intercourse, max 1x/d. Usual 25-100mg/d. Contraindicated with nitrates. ¶B. *L3. S.E: Hypotension, vision loss, hearing loss, priapism, vaso-occlusive crisis, dyspepsia, edema, cardiovascular, CVA, and vascular events.</td>
    </tr>
    <tr>
      <td>tadalafil</td>
      <td>Adcirc</td>
      <td>B</td>
      <td>Erectile Dysfunction</td>
      <td>UROLOGY</td>
      <td>tadalafil (Adcirc)-[FC Tab 20mg](Cialis)-[Tab 2.5, 5, 10, 20mg] (Tadalis Teva)-[Tab 10, 20mg] PO as needed for erectile dysfunction: Start 10mg/d. Usual 5-20mg/d at least 30min prior to intercourse. Once a day use for erectile dysfunction: Start 2.5mg/d. Usual 2.5-5mg/d at the same time, regardless to timing of sexual activity. ¶B. S.E: Prolonged erection, priapism, nasopharyngitis, respiratory tract infection, dyspepsia.</td>
    </tr>
    <tr>
      <td>duloxetine</td>
      <td>Duloxetine DR Teva</td>
      <td>B</td>
      <td>Neurogenic Bladder and other Agents</td>
      <td>UROLOGY</td>
      <td>duloxetine (Duloxetine DR Teva)-[Cap 20, 40mg] PO Start 20mg 2x/d up to 40mg 2x/d. ¶B. *L3. S.E: Insomnia, anxiety, headache, dizziness, tremor, blurred vision, vertigo, hypertension, diarrhea, vomiting, fatigue.</td>
    </tr>
    <tr>
      <td>mesna</td>
      <td>Mexan, Uromitexan</td>
      <td>B</td>
      <td>Neurogenic Bladder and other Agents</td>
      <td>UROLOGY</td>
      <td>mesna (Mexan, Uromitexan)-[Amp 400mg] Uroprotectant to be given with ifosfamide or oxazaphosphorine. IV Bolus: 20% of oxazaphosphorine dose at times 0, 4, and 8hrs. ¶B. S.E: Constipation, anorexia, gingival bleeding, blood dyscrasia, paresthesia, syncope, chest pain, hypotension, palpitations, hypokalemia, AKI, peripheral edema, alopecia, hematuria, dysuria, pneumonia, conjunctivitis, blurred vision, dyspnea.</td>
    </tr>
    <tr>
      <td>oxybutynin</td>
      <td>Lyrinel</td>
      <td>B</td>
      <td>Neurogenic Bladder and other Agents</td>
      <td>UROLOGY</td>
      <td>oxybutynin (Lyrinel)-[Tab 5, 10mg] (Novitropan)-[Tab 5mg] PO Overactive bladder: 5mg 2-3x/d. Max 20mg/d. Peds: 5mg 2x/d. Max 15mg/d. ¶B. S.E: Palpitations, constipation, diarrhea, GERD, somnolence, confusion, UTI, urinary retention, dysuria, blurred vision, cough.</td>
    </tr>
    <tr>
      <td>phenazopyridine</td>
      <td>Sedural</td>
      <td>B</td>
      <td>Neurogenic Bladder and other Agents</td>
      <td>UROLOGY</td>
      <td>phenazopyridine (Sedural)-[Tab 100mg] PO Dysuria: 200mg 3x/d after meals. Turns urine/contact lenses orange. ¶B. *L3. S.E: Dyspnea, hemolytic anemia, methemoglobinemia, peripheral edema, hyperbillirubinemia.</td>
    </tr>
    <tr>
      <td>solifenacin succinat</td>
      <td>Vesicare</td>
      <td>C</td>
      <td>Neurogenic Bladder and other Agents</td>
      <td>UROLOGY</td>
      <td>solifenacin succinat (Vesicare)-[FC Tab 5, 10mg] PO 5mg 1x/d. Max 10mg 1x/d. ¶C. *L4. S.E: Angioedema and anaphylactic reactions, GI disorders, narrow-angle glaucoma, blurred vision, QT prolongation, UTI.</td>
    </tr>
    <tr>
      <td>tolterodine</td>
      <td>Detrusitol</td>
      <td>C</td>
      <td>Neurogenic Bladder and other Agents</td>
      <td>UROLOGY</td>
      <td>tolterodine (Detrusitol)-[Cap SR 2, 4mg] (Tolterodine Teva)-[Cap 2,4mg] PO Overactive Bladder: 1-2mg 2x/d. SR Tab: 2-4mg 1x/d. ¶C. *L3. S.E: Constipation, ulcerated stomatitis, dysuria, infections, weight gain, vertigo.</td>
    </tr>
    <tr>
      <td>trospium</td>
      <td>Spasmex</td>
      <td>C</td>
      <td>Neurogenic Bladder and other Agents</td>
      <td>UROLOGY</td>
      <td>trospium (Spasmex)-[FC Tab 15, 30mg] PO 60mg/d in the morning. ¶C. S.E: Angioedema of the face, CNS effects, constipation.</td>
    </tr>
    <tr>
      <td>acyclovir</td>
      <td>Zovirax</td>
      <td>B</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>acyclovir (Zovirax)-[Oint 3%] Apply 1cm inside the lower conjunctival sac  5x/d. Continue at least 3d after healing is complete. ¶B. *L2. S.E: Conjunctivitis, blepharitis.</td>
    </tr>
    <tr>
      <td>chloramphenicol</td>
      <td>Phenicol</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>chloramphenicol (Phenicol)-[Soln 0.5%] (Synthomycine)-[Oint 5%] Apply 1-2drops 4-6x/d. Oint: Apply 1cm every 3h. Continue at least 48h after healing is complete. ¶C. *L4. S.E: Blurred vision, blood dyscrasia, local inflammation.</td>
    </tr>
    <tr>
      <td>chloramphenicol+polymyxin B</td>
      <td>Phenimixin, Tarocidin</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>chloramphenicol+polymyxin B (Phenimixin, Tarocidin)-[Soln 0.2%+0.25MIU] Apply 1-2 drops in affected eye(s) q3-6h for 7-10d. For external use only .¶C. *L4. S.E: Bone marrow depression, aplastic anemia, abnormal bleeding.</td>
    </tr>
    <tr>
      <td>ciprofloxacin</td>
      <td>Ciloxan</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>ciprofloxacin (Ciloxan)-[Soln 3mg/ml] Bacterial conjunctivitis: Apply 1-2 drops q2h for 2d then 1-2 drops every 4hr for next 5d. Corneal ulcers: Day1: 2drops every 15min for the first 6h, then every 30min for the rest of the day. Day 2: 2drops/h. Day 3: 14: 2drops every 4h. ¶C. *L3. S.E: White crystalline precipitates, corneal deposits, eyelid margin crusting, keratopathy, punctate keratitis, eyelid exfoliation, diplopia, rhinitis.</td>
    </tr>
    <tr>
      <td>fusidic acid</td>
      <td>Fucithalmic Viscous Eye Drops</td>
      <td>N</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>fusidic acid (Fucithalmic Viscous Eye Drops)-[Soln 1%] Apply 1drop 2x/d. For external use only. ¶Not established.S.E: Eye irritation.</td>
    </tr>
    <tr>
      <td>gatifloxacin</td>
      <td>Zymar</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>gatifloxacin (Zymar)-[Ophthalmic Soln 3mg/ml] Ocular 1 drop every 2hrs in the affected eye(s) while awake, up to 8 times on day 1. Instill 1 drop 2-4 times daily in the affected eye(s) while awake on days 2 through 7. ¶C. *L3. S.E: Eye irritation, dysgeusia, and eye pain.</td>
    </tr>
    <tr>
      <td>gentamIcin</td>
      <td>Lacromycin, Opti-Genta</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>gentamIcin (Lacromycin, Opti-Genta)-[Soln 0.3%] Apply 1-2drops 2-4x/d. ¶C. *L2. S.E: Hypersensitivity reactions, nonspecific conjunctivitis, thrombocytopenic purpura, hallucinations, fungal and bacterial corneal ulcers.</td>
    </tr>
    <tr>
      <td>lomefloxacin</td>
      <td>Okacin Eye Drops</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>lomefloxacin (Okacin Eye Drops)-[Soln 0.3%] Apply 5drops in 20min or 1drop/hr for 6-10hrs. Maint: 1drop 2-3x/d 7-9d. ¶C. *L3. S.E: Dyspnea.</td>
    </tr>
    <tr>
      <td>loteprednol etabonate</td>
      <td>Lotemax</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>loteprednol etabonate (Lotemax)-[ Susp 5mg/1ml] Ocular 1 drop instilled into the affected eye(s) 4x/d. ¶C. *L3. S.E: elevated intraocular pressure, secondary ocular infection, headache, rhinitis, pharyngitis.</td>
    </tr>
    <tr>
      <td>loteprednol etabonate+tobramycin</td>
      <td>Zylet</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>loteprednol etabonate+tobramycin (Zylet)-[Susp 5mg/ml+3mg/ml] Apply 1-2 drops into the conjunctival sac of the affected eye every 4-6hrs. ¶C. *L3. S.E: Intraocular pressure, cataracts, secondary ocular infection, burning and stinging upon instillation.</td>
    </tr>
    <tr>
      <td>ofloxacin</td>
      <td>Oflox</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>ofloxacin (Oflox)-[Soln 0.3%l] Bacterial conjunctivitis: Apply 1-2drops every 2-4hrs for 2d then 4x/d for up to 7d. Corneal Ulcers: Apply 1-2drops every 30min while awake and every 4-6h while retiring for 2d, then 1-2drops/h while awake for the next 4d, then 1-2drops 4x/d for another 2d. ¶C. *L2. S.E: Keratitis, chemical conjunctivitis, periorbital edema, blurred vision, dyspnea, anaphylactic reaction/shock, ventricular arrhythmia, torsades de pointes.</td>
    </tr>
    <tr>
      <td>polymyxin B+bacitracin+neomycin</td>
      <td>Bamyxin</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>polymyxin B+bacitracin+neomycin (Bamyxin)-[Oint 5KU+400IU+5mg/g] Apply 1cm every 3-4h for 7-10d. ¶C. *L3. S.E: Anaphylaxis.</td>
    </tr>
    <tr>
      <td>sulfacetamide</td>
      <td>Sulfacid</td>
      <td>C</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>sulfacetamide (Sulfacid)-[Soln 10%] 1-2drops every 2-3hr for 7-10d. ¶C. *L2. S.E: Nonspecific conjunctivitis, bacterial corneal ulcers, fungal corneal ulcers, allergic reactions, systemic lupus erythematosus-like fatal syndrome, secondary infections.</td>
    </tr>
    <tr>
      <td>tobramycin</td>
      <td>Tobrex</td>
      <td>B</td>
      <td>Anti-infection</td>
      <td>OPHTHALMOLOGY</td>
      <td>tobramycin (Tobrex)-[Soln/Oint 0.3%] Apply 1-2drops every 4hr. Oint: Apply 1-1.5cm every 2-3x/d. ¶B. *L3. S.E: Allergic conjunctivitis and blepharitis.</td>
    </tr>
    <tr>
      <td>phenylephrine+naphazoline+mepyramine maleate</td>
      <td>Alnase</td>
      <td>D</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>phenylephrine+naphazoline+mepyramine maleate (Alnase)-[Spray/Soln 0.25%+0.05%+0.5%] Apply 2drops/Sprays every 3-6h for 3-5d max. ¶Do not use in 1st or 3rd trimester. S.E: Tachycardia, dizziness, tremors, sleeping disorders.</td>
    </tr>
    <tr>
      <td>azelastine</td>
      <td>Optilast</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>azelastine (Optilast)-[Soln 0.05%] Apply 1drop 2x/d. ¶C. *L3. S.E: Conjunctivitis, influenza-like symptoms, dyspnea, pharyngitis, rhinitis.</td>
    </tr>
    <tr>
      <td>boric acid</td>
      <td>Boric Acid Eye Drops</td>
      <td>N</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>boric acid (Boric Acid Eye Drops)-[Soln 1.9%] Apply as needed. ¶Not established. S.E: Blurred vision.</td>
    </tr>
    <tr>
      <td>cromoglycate sodium</td>
      <td>Opricrom, Cromoptic, Cromo Comod</td>
      <td>B</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>cromoglycate sodium (Opricrom, Cromoptic, Cromo Comod)-[Soln 2%] Apply 1-2drops 4x/d. ¶B. S.E: Dyspnea, nausea, swelling of face, lips, or eyelids.</td>
    </tr>
    <tr>
      <td>nedocromil sodium+other</td>
      <td>Tilavist</td>
      <td>B</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>nedocromil sodium+other (Tilavist)-[Soln 2%+other] Apply 1-2drops 2x/d. ¶B. *L2. S.E: Conjunctivitis, rhinitis.</td>
    </tr>
    <tr>
      <td>diclofenac</td>
      <td>Voltaren Ophtha Eye Drops</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>diclofenac (Voltaren Ophtha Eye Drops)-[Soln 0.1%] Ocular Drops: Apply 1drop 4x/d. ¶C. *L2. S.E: Corneal erosion, blurred vision, conjunctivitis, iritis, rhinitis, drug-induced hepatotoxicity, corneal infiltrates, perforation, thinning, ulceration.</td>
    </tr>
    <tr>
      <td>dexamethasone</td>
      <td>Maxidex, Sterodex</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>dexamethasone (Maxidex, Sterodex)-[Soln 0.1%] Apply 1-2drops 4-6x/d. ¶C. *L3. S.E: Cataract, elevation of intraocular pressure, conjunctival hemorrhage and edema, conjunctivitis, vitreous floaters,  vitreous detachment, vitreous opacities, retinal aneurysm, corneal erosion, keratitis, anterior chamber inflammation, retinal tear, eyelid ptosis, keratoconjunctivitis sicca, blurred vision, glaucoma with optic nerve damage, secondary ocular infection, hypertension, bronchitis.</td>
    </tr>
    <tr>
      <td>diphenhydramine+naphazoline+boric acid</td>
      <td>Optryl</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>diphenhydramine+naphazoline+boric acid (Optryl)-[Soln 0.1%+0.025%+2.2%] Apply 1drop up to 4x/d. ¶C. S.E: Severe allergic reactions, blurred vision, conjunctivitis, rhinitis.</td>
    </tr>
    <tr>
      <td>emedastine</td>
      <td>Emadine</td>
      <td>B</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>emedastine (Emadine)-[Soln 0.05%] Apply 1drop max 4x/d. ¶B. S.E: Blurred vision, rhinitis, sinusitis, dermatitis.</td>
    </tr>
    <tr>
      <td>fluorometholone</td>
      <td>Flarex, FML</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>fluorometholone (Flarex, FML)-[Soln 0.1%] Apply 1-2drops 2-4x/d. ¶C. S.E: Increased intraocular pressure, corneal calcification and ulcers, visual disturbance, cataract, ulcerative keratitis, ocular infection, punctate keratitis, acute anterior uveitis, perforation of the globe, conjunctivitis, ptosis, systemic hypercorticoidism.</td>
    </tr>
    <tr>
      <td>ketotifen</td>
      <td>Zaditen Eye Drops</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>ketotifen (Zaditen Eye Drops)-[Soln 0.345 mg/ml] Apply 1drop 2-3x/d. ¶C. *L3. S.E: Conjunctival congestion, conjunctivitis, rhinitis, pharyngitis.</td>
    </tr>
    <tr>
      <td>levocabastine</td>
      <td>Livostin Eye Drops</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>levocabastine (Livostin Eye Drops)-[Soln 0.05%] Apply 1drop 2-4x/d. ¶C. *L2. S.E: Visual disturbances, dyspnea, pharyngitis.</td>
    </tr>
    <tr>
      <td>lodoxamide</td>
      <td>Alomide</td>
      <td>B</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>lodoxamide (Alomide)-[Soln 0.1%] Apply 1-2drops 4x/d. ¶B. S.E: Corneal erosion, scales on eyelids, keratitis, blepharitis.</td>
    </tr>
    <tr>
      <td>naphazoline</td>
      <td>Naphasal</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>naphazoline (Naphasal)-[Drops 0.05%] (Naphcon Forte)-[Drops 0.1%] Apply 1drop every 3-4hrs. ¶C. *L3. S.E: Severe allergic reactions, blurred vision, arrhythmia, elevation of intraocular pressure.</td>
    </tr>
    <tr>
      <td>prednisolone</td>
      <td>Pred Forte</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>prednisolone (Pred Forte)-[Drops 1%] Apply 1-2drops 2-4x/d for 1wk. ¶C. *L2. S.E: Elevation of intraocular pressure, glaucoma, optic nerve damage, posterior subcapsular cataract formation, posterior subcapsular cataract formation, perforation of the globe, keratitis, conjunctivitis, corneal ulcers, ptosis, bacterial fungal and viral secondary ocular infections, visual disturbance, anaphylactic symptoms, systemic hypercorticoidism.</td>
    </tr>
    <tr>
      <td>tetrahydrozoline</td>
      <td>Azoline, Stilla Drops, Stilla Singles, View, Visine Original Eye Drops, V-Zoline, Eye Relief</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>tetrahydrozoline (Azoline, Stilla Drops, Stilla Singles, View, Visine Original Eye Drops, V-Zoline, Eye Relief)-[Soln 0.05%] Apply 1-2drops up to 4x/d. ¶C. *L3. S.E: Blurred vision, blepharoconjunctivitis, hypertension, bradycardia, rebound effect.</td>
    </tr>
    <tr>
      <td>tetrahydrozoline+zinc sulfate</td>
      <td>Visine AC</td>
      <td>C</td>
      <td>Anti-inflammatory/Decongestants/Anti-allergy</td>
      <td>OPHTHALMOLOGY</td>
      <td>tetrahydrozoline+zinc sulfate (Visine AC)-[Soln 0.05%+0.25%] Apply 1-2drops up to 4x/d. ¶C. *L3. S.E: Blurred vision, increased intraocular pressure, blepharoconjunctivitis, hypertension, bradycardia.</td>
    </tr>
    <tr>
      <td>betamethasone+neomycin</td>
      <td>Betnovate-N</td>
      <td>D</td>
      <td>Anti-inflammatory + Anti-infectiion</td>
      <td>OPHTHALMOLOGY</td>
      <td>betamethasone+neomycin (Betnovate-N)-[Oint/Cream 0.1%+0.5%] Apply 2-3drops every 2-3hrs. ¶D (PO); Not established (topical). *L3. S.E: Weight gain, hypertension, in psoriatic patiens- pustular psoriasis.</td>
    </tr>
    <tr>
      <td>dexamethasone+chloramphenicol+polymyxin B</td>
      <td>Tarocidin D</td>
      <td>D</td>
      <td>Anti-inflammatory + Anti-infectiion</td>
      <td>OPHTHALMOLOGY</td>
      <td>dexamethasone+chloramphenicol+polymyxin B (Tarocidin D)-[Soln 0.25mg+2mg+2500IU/ml] Apply 1-2drops q4-6h for 5-7d. ¶D. *L4. S.E: Elevated intraocular pressure, unusual bleeding, visual disturbances.</td>
    </tr>
    <tr>
      <td>dexamethasone+neomycin</td>
      <td>Dethamycin, Dexamycin</td>
      <td>C</td>
      <td>Anti-inflammatory + Anti-infectiion</td>
      <td>OPHTHALMOLOGY</td>
      <td>dexamethasone+neomycin (Dethamycin, Dexamycin)-[Soln 0.1%+0.5%] Start 1-2drops/h during the day, and 1-2drops/2h at night. Maintenance 1drop 3-4x/d. ¶C. *L3. S.E: Elevation of intraocular pressure, glaucoma, posterior subcapsular cataract, optic nerve damage, acute anterior uveitis, perforation of the globe, keratitis, conjunctivitis, corneal ulcers, ptosis, secondary bacterial or fungal infection.</td>
    </tr>
    <tr>
      <td>dexamethasone+neomycin+phenylephrine</td>
      <td>Dexefrin</td>
      <td>C</td>
      <td>Anti-inflammatory + Anti-infectiion</td>
      <td>OPHTHALMOLOGY</td>
      <td>dexamethasone+neomycin+phenylephrine (Dexefrin)-[Soln 0.1%+0.5%+0.12%] Apply 2drops 4x/d. ¶C. *L3. S.E: Blurred vision, secondary eye infections, elevated intraocular pressure, glaucoma, optic nerve damage, posterior subcapsular cataract, formation and delayed wound healing, acute anterior uveitis, keratitis, conjunctivitis, corneal ulcers, ptosis.</td>
    </tr>
    <tr>
      <td>dexamethasone+neomycin+polymyxin B</td>
      <td>Maxitrol</td>
      <td>B</td>
      <td>Anti-inflammatory + Anti-infectiion</td>
      <td>OPHTHALMOLOGY</td>
      <td>dexamethasone+neomycin+polymyxin B (Maxitrol)-[Soln/Oint 0.1%+3500IU+6000IU/ml] (Deso Care, Dex-Otic)-[0.1%+0.5%+10000U/ml] Apply 1-2drops 4-6x/d. Oint: Apply 1cm 3-4x/d. ¶B. *L3. S.E: Elevated intraocular pressure, glaucoma, optic nerve damage, posterior subcapsular cataract, formation and delayed wound healing, acute anterior uveitis, perforation of the globe, keratitis, conjunctivitis, corneal ulcers, ptosis.</td>
    </tr>
    <tr>
      <td>sulfacetamide+prednisolone</td>
      <td>Blephamide</td>
      <td>C</td>
      <td>Anti-inflammatory + Anti-infectiion</td>
      <td>OPHTHALMOLOGY</td>
      <td>sulfacetamide+prednisolone (Blephamide)-[Soln 10%+0.2%] Apply 2drops 6x/d. ¶C. *L2. S.E: Acute anterior uveitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, intraocular pressure, glaucoma, optic nerve damage, posterior subcapsular cataract, delayed wound healing, ptosis, secondary infections.</td>
    </tr>
    <tr>
      <td>acetazolamide</td>
      <td>Uramox</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>acetazolamide (Uramox)-[Tab 250mg] PO 250mg 1-4x/d. Usual 5mg/kg/d. ¶C. *L2. S.E: Metabolic acidosis, electorlite abnormalities, choroidal detachment, delirium, renal insufficiency, nephrolithiasis, nephrocalcinosis, toxic epidermal necrolysis, Stevens-Johnson syndrome, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, , pancytopenia, anaphylaxis, impotence, stupor.</td>
    </tr>
    <tr>
      <td>apraclonidine</td>
      <td>Iopidine</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>apraclonidine (Iopidine)-[Soln 0.5%] Apply 1-2drops 3x/d. ¶C. S.E: Rhinitis, dermatitis, ocular irritation, eyelid edema.</td>
    </tr>
    <tr>
      <td>betaxolol</td>
      <td>Betoptic-S</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>betaxolol (Betoptic-S)-[Soln 0.28%] ß Apply 1drops 2x/d. ¶C. *L3. S.E: Bradycardia, chest pain, palpitations, peripheral edema, dyspnea, URTI, lethargy, paresthesia, diarrhea, impotence, antibody development.</td>
    </tr>
    <tr>
      <td>bimatoprost</td>
      <td>Lumigan, Latisse</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>bimatoprost (Lumigan, Latisse)-[Soln 0.3%] Apply 1drop 1x/d at night. ¶C. *L3. S.E: Ocular irritaion, corneal erosion, allergic conjunctivitis, blurred vision, abnormal liver function, hypertension.</td>
    </tr>
    <tr>
      <td>brinzolamide</td>
      <td>Alcon Azopt</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>brinzolamide (Alcon Azopt)-[Soln 1%] Apply 1drop 3x/d. ¶C. S.E: Blepharitis, ocular irritation, blurred vision, allergic reactions, dermatitis, rhinitis.</td>
    </tr>
    <tr>
      <td>brimonidine</td>
      <td>Alphagan, Bromatidine Teva</td>
      <td>B</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>brimonidine (Alphagan, Bromatidine Teva)-[Soln 0.15%] Apply 1drop 3x/d. ¶B. *L3. S.E: Ocular irritation, blurred vision, blepharoconjunctivitis, corneal erosion, blurred vision, cataract, vitreous disorder, URTI, depression, hypercholesterolemia.</td>
    </tr>
    <tr>
      <td>dipivefrine</td>
      <td>Difrin</td>
      <td>B</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>dipivefrine (Difrin)-[Soln 0.1%] Apply 1drop 2x/d. ¶B. *L2. S.E: Tachycardia, arrhythmias, hypertension, follicular conjunctivitis, papillary conjunctivitis, blepharoconjunctivitis, corneal toxicity, blurred vision, bronchospasm.</td>
    </tr>
    <tr>
      <td>dorzolamide</td>
      <td>Trusopt, Dorzolomide Teva</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>dorzolamide (Trusopt, Dorzolomide Teva)-[Soln 2%] Apply 1drop 3x/d. ¶C. *L3. S.E: Conjunctivitis, eyelid inflammation, blurred vision, ocular allergic reactions, fatigue.</td>
    </tr>
    <tr>
      <td>latanoprost</td>
      <td>Glauprost, Xalatan</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>latanoprost (Glauprost, Xalatan)-[Soln 0.005%] (Latano Avenir)-[Soln 0.05%] Apply 1drop 1x/d at night. ¶C. *L3. S.E: Iris pigmentation, ocular irritation, blurred vision, URTI, bronchitis, allergic skin reactions, UTI, abnormal liver function.</td>
    </tr>
    <tr>
      <td>latanoprost+timolol</td>
      <td>Xalacom, Latoxap</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>latanoprost+timolol (Xalacom, Latoxap)-[Soln 0.005%+0.5%] Apply 1drop 1x/d. ¶C. *L3. S.E: Ocular irritation, increased iris pigmentation.</td>
    </tr>
    <tr>
      <td>levobunolol</td>
      <td>Betagan</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>levobunolol (Betagan)-[Soln 0.5%] Apply 1-2drops 1x/d. ¶C. *L3. S.E: Arrhythmia, hypotension, syncope, heart block, cerebral vascular accident, HF, depression, Stevens-Johnson Syndrome, bronchospasm, dyspnea, impotence, masked symptoms of hypoglycemia in insulin-dependent diabetics, diplopia, ptosis.</td>
    </tr>
    <tr>
      <td>methazolamide</td>
      <td>Methazolamide Teva</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>methazolamide (Methazolamide Teva) -[Tab 25, 50mg] PO 50-100mg 2-3x/d. ¶C. S.E: Hearing dysfunction, flaccid paralysis, convulsions, melena, crystalluria, metabolic acidosis, electrolyte imbalance, hepatic insufficiency, sulfonamide reactions, renal calculi.</td>
    </tr>
    <tr>
      <td>pilocarpine</td>
      <td>Pilocarpine</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>pilocarpine (Pilocarpine)-[Soln 2, 3,4%] Open Angle: Apply 1drops up to 4x/d. Narrow Angle: 1drop 3x/30min. ¶C. *L3. S.E: Blurred vision, ciliary spasm, conjunctival vascular congestion, vitreous hemorrhaging, retinal detachment, changes in blood pressure, arrhythmia, bronchial spasm, pulmonary edema.</td>
    </tr>
    <tr>
      <td>timolol</td>
      <td>Tiloptic</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>timolol (Tiloptic)-[Soln 0.5%] (V-Optic)-[Soln 0.25, 0.5%] (Nylol Gel)-[Gel 0.1%] Apply 1drop 2x/d. Gel: 1x/d. ¶C. *L3. S.E: Blurred vision, eyelid erythema, hypertension, peripheral edema, respiratory infection.</td>
    </tr>
    <tr>
      <td>timolol+dorzolamide</td>
      <td>Cosopt, Timodor, Dorzolamide Timolol Teva</td>
      <td>C</td>
      <td>Glaucoma Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>timolol+dorzolamide (Cosopt, Timodor, Dorzolamide Timolol Teva)-[Soln 0.5%+2%] Apply 1drop 2x/d. ¶C. *L3. S.E: Taste pervertion, ocular irritation, blurred vision, superficial punctate keratitis, conjunctival disorders, eyelid disorders, corneal erosion, blepharitis, bronchitis, hypertension, URTI, UTI.</td>
    </tr>
    <tr>
      <td>atropine</td>
      <td>Atrospan</td>
      <td>C</td>
      <td>Mydriatics / Cyclopegics</td>
      <td>OPHTHALMOLOGY</td>
      <td>atropine (Atrospan)-[Soln 1%] Apply 1-2drops 1-4x/d or before procedure. ¶C. *L3. S.E: Ocular irritation, photosensitivity, skin irritation.</td>
    </tr>
    <tr>
      <td>cyclopentolate</td>
      <td>NaN</td>
      <td>C</td>
      <td>Mydriatics / Cyclopegics</td>
      <td>OPHTHALMOLOGY</td>
      <td>cyclopentolate ((29 ג' (Colircusi)-[Soln 1%] Apply 1-2drops 1-2x before procedure. May repeat in 5 to 10min. Cycloplegia 6-24hr, mydriasis 24hr. ¶C. *L3 (after 6h). S.E: CNS disturbances, elevated ICP.</td>
    </tr>
    <tr>
      <td>phenylephrine</td>
      <td>Efrin-10</td>
      <td>C</td>
      <td>Mydriatics / Cyclopegics</td>
      <td>OPHTHALMOLOGY</td>
      <td>phenylephrine (Efrin-10)-[Soln 10%] Apply 1drops 1-3x/d or before procedure. ¶C. *L3. S.E: Arrhythmia, tachycardia.</td>
    </tr>
    <tr>
      <td>tropicamide</td>
      <td>Mydramide</td>
      <td>C</td>
      <td>Mydriatics / Cyclopegics</td>
      <td>OPHTHALMOLOGY</td>
      <td>tropicamide (Mydramide)-[Soln 0.5%] Apply 1-2drops before procedure. ¶C. *L3. S.E: Blurred vision, increased intraocular pressure, psychotic reactions, tachycardia, vasomotor or cardiorespiratory collapse.</td>
    </tr>
    <tr>
      <td>cellulose-derivative containing-</td>
      <td>Genteal Eye-Drops, Genteal Gel, Tears Naturale Free, Tears Natural II, Artelac</td>
      <td>C</td>
      <td>Lubricants – Artificial Tears</td>
      <td>OPHTHALMOLOGY</td>
      <td>cellulose-derivative containing-(Genteal Eye-Drops, Genteal Gel, Tears Naturale Free, Tears Natural II, Artelac). ¶C. S.E: Eye burning, eye pain, visual disturbance, allergic reactions.</td>
    </tr>
    <tr>
      <td>benzalkonium containing-</td>
      <td>Claritone</td>
      <td>C</td>
      <td>Lubricants – Artificial Tears</td>
      <td>OPHTHALMOLOGY</td>
      <td>benzalkonium containing-(Claritone). ¶C. S.E: Eye burning, eye pain, visual disturbance, allergic reactions.</td>
    </tr>
    <tr>
      <td>lacrimol</td>
      <td>polyvinyl alcohol</td>
      <td>C</td>
      <td>Lubricants – Artificial Tears</td>
      <td>OPHTHALMOLOGY</td>
      <td>lacrimol (polyvinyl alcohol) containing.(Hypotears E, Lacrimol, Liquifilm Tears, Refresh, V-Crima). ¶C. S.E: Eye burning, eye pain, visual disturbance, allergic reactions.</td>
    </tr>
    <tr>
      <td>lanolin containing-</td>
      <td>Duratears</td>
      <td>C</td>
      <td>Lubricants – Artificial Tears</td>
      <td>OPHTHALMOLOGY</td>
      <td>lanolin containing-(Duratears). ¶C. S.E: Eye burning, eye pain, visual disturbance, allergic reactions.</td>
    </tr>
    <tr>
      <td>polyacrylic acid containing-</td>
      <td>Viscotears, Liposic</td>
      <td>C</td>
      <td>Lubricants – Artificial Tears</td>
      <td>OPHTHALMOLOGY</td>
      <td>polyacrylic acid containing-(Viscotears, Liposic). ¶C. S.E: Eye burning, eye pain, visual disturbance, allergic reactions.</td>
    </tr>
    <tr>
      <td>saline containing-</td>
      <td>Tipotaf, Saline Eye Drops</td>
      <td>C</td>
      <td>Lubricants – Artificial Tears</td>
      <td>OPHTHALMOLOGY</td>
      <td>saline containing-(Tipotaf, Saline Eye Drops). ¶C. S.E: Eye burning, eye pain, visual disturbance, allergic reactions.</td>
    </tr>
    <tr>
      <td>sodium hyaluronate containing-</td>
      <td>Eyecon</td>
      <td>C</td>
      <td>Lubricants – Artificial Tears</td>
      <td>OPHTHALMOLOGY</td>
      <td>sodium hyaluronate containing-(Eyecon). ¶C. S.E: Eye burning, eye pain, visual disturbance, allergic reactions.</td>
    </tr>
    <tr>
      <td>acetylcholine</td>
      <td>Miochol-E</td>
      <td>N</td>
      <td>Other Ophthalomolgic Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>acetylcholine (Miochol-E)-[Soln 2%] Apply for miosis. ¶Not established. S.E: Corneal edema, corneal clouding, corneal decompensation, bradycardia, hypotension.</td>
    </tr>
    <tr>
      <td>benoxinate</td>
      <td>Localin</td>
      <td>C</td>
      <td>Other Ophthalomolgic Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>benoxinate (Localin)-[Soln 0.4%] Surface anesthesia: Apply 2drops for tonometry. Minor procedures: 2drops 3x at 90sec intervals. ¶C. S.E: Blurred vision.</td>
    </tr>
    <tr>
      <td>fluorescein</td>
      <td>Fluorescein Serb</td>
      <td>C</td>
      <td>Other Ophthalomolgic Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>fluorescein (Fluorescein Serb)-[Amp 10%] IV for retinal angiography. ¶C. S.E: Syncope, dysguesia, urticaria, vomiting.</td>
    </tr>
    <tr>
      <td>indocyanine green</td>
      <td>ICG Pulsion</td>
      <td>C</td>
      <td>Other Ophthalomolgic Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>indocyanine green (ICG Pulsion)-[Amp 25mg] IV for retinal angiography. ¶C. S.E: Anaphylactic reactions.</td>
    </tr>
    <tr>
      <td>indomethacin</td>
      <td>Indocollyre</td>
      <td>B</td>
      <td>Other Ophthalomolgic Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>indomethacin (Indocollyre)-[Soln 0.1%] Prevent miosis: Apply 4drops the day before surgery, and 4drops in the 3h preceding surgery. Inflammation, analgesia: Apply 1drop 4-6x/d. ¶B; D in 3rd trimester. S.E: Blurred vision, dyspnea, corneal injury.</td>
    </tr>
    <tr>
      <td>verteporfin</td>
      <td>Visudyne</td>
      <td>C</td>
      <td>Other Ophthalomolgic Agents</td>
      <td>OPHTHALMOLOGY</td>
      <td>verteporfin (Visudyne)-[Amp 15 mg] IV Macular degeneration: inject then activate with laser light photodynamic therapy. ¶C. S.E: Abnormal vision, administration site edema and inflammation.</td>
    </tr>
    <tr>
      <td>anti-thymocyte globulin</td>
      <td>Lymphoglobuline (equine</td>
      <td>C</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>anti-thymocyte globulin (Lymphoglobuline (equine)-[Amp 100mg/5ml] IV Renal transplant rejection: 10-15mg/kg/d for 14-21doses. Aplastic anemia: 10-20mg/kg for 8-14 doses. (Thymoglobulin (rabbit))-[Amp 25mg/VIAL] IV Transplant rejection: 1.5mg/kg/d for 7-14d. Aplastic anemia: 2.5-3.5mg/kg for 5 consecutive days. ¶C. S.E: Blood dyscrasia, dyspnea, infections, malignant tumors, hypotension, serum sickness.</td>
    </tr>
    <tr>
      <td>azathioprine</td>
      <td>Imuran</td>
      <td>D</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>azathioprine (Imuran)-[FC Tab 25, 50mg] PO RA: Start 1mg/kg (50-100mg) single or 2 divided dose. Maintenance: lowest effective dose, for 12wk. Max 2.5mg/kg/d. Renal transplant: Start 3-5mg/kg/d, at the time of transplant. Maintenance 1-3mg/kg/d. ¶D. *L3. S.E: Blood dyscrasia, pancreatitis, malignant tumors, hepatic dysfunction, alopecia, infections, anorexia.</td>
    </tr>
    <tr>
      <td>basiliximab</td>
      <td>Simulect</td>
      <td>B</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>basiliximab (Simulect)-[Amp 20mg] IV Prevent transplant rejection: Start 20mg 2hr before transplant. Then 20mg 4d after. Often used with cyclosporin and steroids. ¶B. S.E: GI hemorrhage, gum hyperplasia, melena, esophagitis, electrolyte disorders, hyperlipidemia, diabetes, neuropathy, dysuria, impotence, hematuria, renal tubular necrosis, peripheral edema, infections, hypotension, HF, arrhythmias, dyspnea, depression, anxiety, blood dyscrasia, cataract, conjunctivitis.</td>
    </tr>
    <tr>
      <td>busulphan</td>
      <td>Busulfex</td>
      <td>D</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>busulphan (Busulfex)-[Amp 60mg/10ml] IV Bone Marrow Transplantation (BMT) conditioning 0.8mg/kg 4x/d for 4d, then on BMT day -3 add cyclophosphamide. ¶D. *L5. S.E: Pancytopenia, esophagitis, anorexia, hematemesis, GI bleeding, hyperbilirubinemia, hepatic veno-occlusive disease, graft versus host disease, edema, infections, arrhythmia, hypertension, hypotension, dyspnea, rhinitis, insomnia, anxiety, depression, urinary disorders, hyperglycemia, electrolyte disturbances.</td>
    </tr>
    <tr>
      <td>cyclosporine</td>
      <td>Deximune</td>
      <td>C</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>cyclosporine (Deximune)-[Cap 25, 50, 100mg] (Cyclosporin)-[Cap 25, 100mg] (Cyclosporin Oral Solution)-[Soln 100mg/ml] (Sandimmun, Sandimmun Neoral)-[ Cap 25, 50, 100mg; Oral Soln 100mg/ml; Amp 50mg] Organ transplant - rejection prophylaxis IV Dose varies, usual start 2-4mg/kg/d. Slow infusion diluted. PO Cap, Soln: 8-12mg/kg/d divided in 2doses. ¶C. *L3. S.E: Renal failure, tremors, hypertrichosis, acne, elevated liver enzymes, blood dyscrasia, gingival hyperplasia, hypertension, hypersensitivity reactions.</td>
    </tr>
    <tr>
      <td>daclizumab</td>
      <td>anti-Tac</td>
      <td>C</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>daclizumab (anti-Tac) (Zenapax)-[Amp 25 mg/5ml] IV Prevent transplant rejection 1mg/kg. ¶C. S.E: Gastritis, hemorrhoids, edema of the extremities, diabetes mellitus, hypertension, hypotension, renal tubular necrosis, hydronephrosis, hematuria, renal insufficiency, anaphylaxis, dyspnea, pulmonary edema, atelectasis, pharyngitis, hypoxia, pleural effusion, tachycardia, thrombosis, blurred vision, depression.</td>
    </tr>
    <tr>
      <td>muromonab-CD3</td>
      <td>Orthoclone OKT3</td>
      <td>C</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>muromonab-CD3 (Orthoclone OKT3)-[Amp 1mg/ml] IV Graft rejection: 5mg/d for 10-14d. Rejection prophylaxis: 5mg/d. ¶C. S.E: Neoplasia, arrhythmias, tremor, edema, dyspnea, leukopenia, CMV infection, herpes simplex, fungal bacterial protozoal and viral infections.</td>
    </tr>
    <tr>
      <td>mycophenolate</td>
      <td>Cellcept</td>
      <td>D</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>mycophenolate (Cellcept)-[Cap 250mg; Tab 500mg] (Mycophenolate Teva)-[Tab 500mg] Renal transplantation- Rejection prophylaxis: PO 1G 2x/d initiated 72h after transplantation. Peds: 720mg 2x/d. Usually with cyclosporin and steroids. ¶D. *L4. S.E: Lymphoma, malignancy, infections, neutropenia, pure red cell aplasia, GI disorders.</td>
    </tr>
    <tr>
      <td>sirolimus</td>
      <td>Rapamune</td>
      <td>C</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>sirolimus (Rapamune)-[Soln 1mg/ml; Tab 1mg] Organ Transplant- Rejection Prophylaxis PO 6mg followed by 2mg/d. ¶C. *L4. S.E: Angioedema, hypersensitivity reactions, fluid accumulation, hyperlipidemia, increasing serum creatinine, proteinuria, interstitial lung disease, lymphoma, malignancy, decline in renal function, peripheral edema, hypertension, fever, anemia, thrombocytopenia, VT, bone necrosis, infections.</td>
    </tr>
    <tr>
      <td>tacrolimus</td>
      <td>Prograf, Tacrocel</td>
      <td>C</td>
      <td>Immunosuppressants</td>
      <td>IMMUNOLOGY</td>
      <td>tacrolimus (Prograf, Tacrocel)-[Cap 0.5, 1, 5mg; Amp 5mg] (Advagraf)-[Cap PR 0.5, 1, 3, 5mg] Prophylaxis of transplant rejection: PO 0.1-0.2mg/kg/d divided in 2doses. IV 0.01-0.05mg/kg/d. Peds: PO 0.3mg/kg/d divided in 2doses. IV: 0.05mg/kg/d. ¶C. *L3. S.E: Lymphoma, increased risk of bacterial, viral, fungal and protozoal infections, nephrotoxicity, neurotoxicity, hyperkalemia, hypertension, anaphylactic reactions, myocardial hypertrophy, pure red cell aplasia, tremor, peripheral edema, anemia, abnormal renal function, diabetes mellitus, leucopenia, pericardial effusion, hyperlipidemia.</td>
    </tr>
    <tr>
      <td>BCG vaccine</td>
      <td>BCG Vaccine</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>BCG vaccine  (BCG Vaccine)-[Amp] (BCG Vaccine SSI)-[Amp 0.75mg/ml] Intradermal injection: 0.2-0.3ml. ¶C. S.E: Cystitis, anemia, leukopenia, coagulopathy, fever, renal toxicity.</td>
    </tr>
    <tr>
      <td>cytomegalovirus immune globulin</td>
      <td>Megalotect CP</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>cytomegalovirus immune globulin (Megalotect CP)-[Amp] IV 50IU/kg on transplantation day or the day prior. ¶C. S.E: Fever, allergic reactions, hypotension, arthralgia.</td>
    </tr>
    <tr>
      <td>diphtheria toxoid, tetanus toxoid, pertussis</td>
      <td>Adacel, Boostrix, Tripacel, Infanrix</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>diphtheria toxoid, tetanus toxoid, pertussis (Adacel, Boostrix, Tripacel, Infanrix)-[Prefill Syringe 0.5ml] (DT COQ)-[Amp 0.5ml] IM 0.5ml. ¶C. As with other inactivated vaccines, it is not expected that vaccination with Boostrix harms the fetus. However, human data from prospective clinical studies on the use of Boostrix during pregnancy are not available. S.E: Conjunctivitis, fever, URTI, syncope, anaphylactic and anaphylactoid reactions, hypotonic-hyporesponsiveness episodes, convulsions.</td>
    </tr>
    <tr>
      <td>diphtheria toxoid, tetanus toxoid, pertussis, hemophilus influenza</td>
      <td>InfanrixHib, Tetract-Hib, Actacel</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>diphtheria toxoid, tetanus toxoid, pertussis, hemophilus influenza (InfanrixHib, Tetract-Hib, Actacel)-[Amp 0.5ml] IM 0.5ml at 2, 4, 6, 12mnths. ¶C. S.E: Fever, hypokinesia, gastroenteritis, URTI, eczema, conjunctivitis.</td>
    </tr>
    <tr>
      <td>diphtheria toxoid, tetanus toxoid, pertussis, poliovirus</td>
      <td>Tetracoq</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>diphtheria toxoid, tetanus toxoid, pertussis, poliovirus (Tetracoq)-[Amp] (Infarinx IPV Hib, Infarinx IPV, Adacel Polio)-[Prefill Syringe 0.5ml] IM 1dose primary: given 3x, with at least 1mnth intervals and booster 1yr after last injection. ¶C. S.E: URTI, bronchitis, urticaria, dermatitis, anaphylactic and anaphylactoid reactions, fever, apnea.</td>
    </tr>
    <tr>
      <td>diphtheria toxoid, tetanus toxoid, pertussis, poliovirus, hemophilus influenza</td>
      <td>Infanrix Polio-Hib</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>diphtheria toxoid, tetanus toxoid, pertussis, poliovirus, hemophilus influenza (Infanrix Polio-Hib), Pediacel-[Prefill Syringe/Amp] (Pentact-HIB, Poliacel)-[Amp 0.5ml] IM 0.5ml 2dose at 1-2mnth interval. Booster: 1yr later. ¶C. S.E: Fever, anaphylactic reaction, convulsions, apnea.</td>
    </tr>
    <tr>
      <td>hemophilus influenza B vaccine</td>
      <td>Act-HIB</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>hemophilus influenza B vaccine (Act-HIB)-[Amp 0.5ml] IM SC Peds: Before 6mnths: 3 successive doses of 0.5ml administrated 1-2mnths apart, followed by a booster injection 1yr after the third injection. 6-12mnths: 2 doses of 0.5ml administrated one month apart, followed by a booster injection at 18mnths. 1-5yrs: 0.5ml single dose. ¶C. *L3. S.E: Fever, convulsions.</td>
    </tr>
    <tr>
      <td>hepatitis A vaccine</td>
      <td>Avaxim 160U, Avaxim 80U Pediatric,  Havrix 720 Junior, Epaxal, Vaqta 25U-[Amp 0.5ml] (Vaqta 50U, Havrix 1440</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>hepatitis A vaccine (Avaxim 160U, Avaxim 80U Pediatric,  Havrix 720 Junior, Epaxal, Vaqta 25U-[Amp 0.5ml] (Vaqta 50U, Havrix 1440)-[Amp 1ml] Adults: IM 1ml 1dose. Booster 6-12mnths. Peds: IM 0.5ml 1 dose. Booster 6-12mnths ¶C. *L3. S.E: URTI, anaphylaxis, paresthesia, convulsions, Guillain-Barré syndrome, transverse myelitis, neuralgic amyotrophy, vasculitis, angioneurotic edema, erythema multiforme, fever.</td>
    </tr>
    <tr>
      <td>hepatitis A, hepatitis B vaccine</td>
      <td>Twinrix Pediatric, Twinrix Adult</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>hepatitis A, hepatitis B vaccine (Twinrix Pediatric, Twinrix Adult)-[Amp 0.5, 1ml] IM Adults: 1ml 3doses: 0, 1mnth, 6mnth. Peds: 0.5ml same schedule. ¶C. *L3. S.E: Headache, GI symptoms, injection site reactions.</td>
    </tr>
    <tr>
      <td>hepatitis B immune globulin</td>
      <td>Hyperhep B S/D</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>hepatitis B immune globulin (Hyperhep B S/D)-[Amp 15-18%] IM Acute Exposure to blood containing HBsAg: 1dose after exposure and 1dose after 1mnth. Perinatal exposure of infants born to HBsAg-positive mothers: 1dose at birth with hepatitis B vaccine soon after birth. Sexual exposure to an HBsAg-positive person: 1dose within 2wks of last sexual exposure. Household exposure to persons with acute HBV infection: 1dose with hepatitis B vaccine. (Hepagam B)-[Amp 312IU/ml] (Zutectra)-[Soln 500IU] IM Prevention of hepatitis B following liver transplantation: 10,000IU on the day of transplantation, then 2000-10,000IU/d for 7d and as necessary.SC &lt;75kg:500/iu per week. &gt;75kg: 1000IU per week. ¶C. S.E: Angioedema, anaphylactic reactions.</td>
    </tr>
    <tr>
      <td>hepatitis B vaccine</td>
      <td>Bio-Hep B</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>hepatitis B vaccine (Bio-Hep B)-[Amp 50µg/5ml] (Engerix-B, Engerix-B Ped)-[Amp/Syringe 10µg/0.5ml, 20 µg/ml] (Sci-B-Vac)-[Amp 2.5, 5µg/0.5ml, 10µg/ml] IM 3doses of 1ml: 0, 1mnth, 6mnth. Peds: 0-10yrs: 0.5ml of lower dose injection, same times. ¶C. *L2. S.E: Headache, GI symptoms, injection site reactions, fatigue, irritability.</td>
    </tr>
    <tr>
      <td>human immunoglobulin</td>
      <td>Intraglobulin F</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>human immunoglobulin (Intraglobulin F)-[Soln 50mg/ml] IV dosage varies by indication. ¶C. S.E: Hypotension, anaphylactoid reactions, hemolytic anemia, aseptic meningitis syndrome, thromboembolism, acute kidney injury.</td>
    </tr>
    <tr>
      <td>human papillomavirus vaccine types 16+18</td>
      <td>Cervarix</td>
      <td>B</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>human papillomavirus vaccine types 16+18 (Cervarix)-[Susp 20+20 µg/0.5ml] IM 3doses of 0.5ml: 0, 1mnth, 6mnth. ¶B. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>human papillomavirus vaccine types 6+11+16+18</td>
      <td>Gardasil</td>
      <td>B</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>human papillomavirus vaccine types 6+11+16+18 (Gardasil)-[Susp 20+40+40+20 µg/0.5ml] IM 3doses of 0.5ml: 0, 2 mnth, 6mnth. ¶B. S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>influenza vaccine</td>
      <td>Fluvirin,  Focteria, Pandemrix</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>influenza vaccine (Fluvirin,  Focteria, Pandemrix)-[Amp] IM 0.5ml. ¶C. *L1. S.E: Fever, shock, angioedema, febrile convulsions, encephalomyelitis, neuritis, Guillain Barré syndrome, vasculitis.</td>
    </tr>
    <tr>
      <td>japanese encephalitis vaccine</td>
      <td>Japanese Encephalitis Vaccine</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>japanese encephalitis vaccine (Japanese Encephalitis Vaccine)-[Amp] IM 0.5ml/dose on day 0 and 28. Peds: &lt;3yrs: 0.25ml/dose on day 0 and 28. ¶C. *L3. S.E: Headache, fatigue, injection site reactions, fever, GI symptoms, myalgia.</td>
    </tr>
    <tr>
      <td>measles, mumps, rubella</td>
      <td>Priorix</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>measles, mumps, rubella (Priorix)-[Amp 0.5ml] (Priorix Tetra)-[ Pwdr 10^3+10^4.4+10^3CCID+varicella 10^3.3PFU] SC IM 0.5ml. ¶C. Do not give M-M-R II to pregnant females. Pregnancy should be avoided for 3mnths following vaccination. S.E: Fever, febrile seizures, hypersensitivity, diarrhea, vomiting, rash, syncope, thrombocytopenia, ADEM, anaphylaxis, Guillain Barre syndrome, IgA vasculitis.</td>
    </tr>
    <tr>
      <td>measles, mumps, rubella, varicella</td>
      <td>Proquad</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>measles, mumps, rubella, varicella  (Proquad)-[Amp 0.5ml] IM 1st dose at 12-15mnths (or up to 12yrs), 2nd dose at 4-6yrs. Must have 3mnths between doses. ¶Contraindicated. S.E: Fever, febrile seizures, hypersensitivity, diarrhea, vomiting, rash, syncope, thrombocytopenia, ADEM, anaphylaxis, Guillain Barre syndrome, IgA vasculitis.</td>
    </tr>
    <tr>
      <td>neisseria meningitidis vaccine</td>
      <td>Mencevax ACWY, Menomune-A/C/Y/W-135</td>
      <td>B</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>neisseria meningitidis vaccine (Mencevax ACWY, Menomune-A/C/Y/W-135)-[Amp 0.5ml] SC 0.5ml. ¶B. S.E: Apnea, Guillain-Barré syndrome, syncope.</td>
    </tr>
    <tr>
      <td>poliovirus vaccine</td>
      <td>Imovax Polio</td>
      <td>N</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>poliovirus vaccine (Imovax Polio)-[Amp/Prefill Syringe 0.5ml] Inactivated: IM SC 0.5ml. (Polio Sabin)-[Vial] Sabin: PO 2-3drops. ¶Not established. *L2. S.E: Anorexia, irritability, tenderness.</td>
    </tr>
    <tr>
      <td>rabies immune globulin</td>
      <td>Hyperrab</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>rabies immune globulin (Hyperrab)-[Amp 150U/ml] IM 20U/kg. ¶C. S.E: Anaphylaxis, encephalitis, death, meningitis, neuroparalytic events, Guillain Barre syndrome, myelitis, retrobulbar neuritis, multiple sclerosis.</td>
    </tr>
    <tr>
      <td>rabies vaccine</td>
      <td>Rabipur, Verorab</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>rabies vaccine (Rabipur, Verorab)-[Amp 2.5IU/ml=0.5ml=1dose] IM Prophylaxis: 20units/kg in a single dose, administration of RIG is not recommended after the seventh day post vaccine. ¶C. *L3. S.E: Anaphylaxis, encephalitis, death, meningitis, neuroparalytic events, Guillain Barre syndrome, myelitis, retrobulbar neuritis, multiple sclerosis.</td>
    </tr>
    <tr>
      <td>salmonella typhi vaccine</td>
      <td>typhoid</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>salmonella typhi vaccine (typhoid) (Typherix)-[Amp 0.5ml] IM SC 0.5ml single dose. Duration: 3yr. ¶C. S.E. syncope, tenderness.</td>
    </tr>
    <tr>
      <td>streptococcal pneumonia vaccine</td>
      <td>Prevenar 13, Pneumovax 23, Synflorix</td>
      <td>B</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>streptococcal pneumonia vaccine (Prevenar 13, Pneumovax 23, Synflorix)-[Prefill Syringe 0.5ml] IM SC 0.5ml. ¶B. S.E: Altered immunocompetence, apnea.</td>
    </tr>
    <tr>
      <td>tetanus immune globulin</td>
      <td>Hypertet S/D</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>tetanus immune globulin (Hypertet S/D) Prefill Syringe 250U] IM 0.5ml. ¶C. *L2. S.E: Fever, viral infections particularly hepatitis C.</td>
    </tr>
    <tr>
      <td>varicella vaccine</td>
      <td>Varilrix</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>varicella vaccine (Varilrix)-[Amp 0.5ml] SC 0.5ml. Immunocompromised: higher dose. (Varitect)-[Amp 25IU/ml] IV 1ml/kg not later than 96hrs after exposure. ¶Contraindicated. *L2. S.E: Fever, anaphylaxis, rash, encephalitis, Guillain Barre syndrome.</td>
    </tr>
    <tr>
      <td>yellow fever virus vaccine</td>
      <td>Stamaril</td>
      <td>C</td>
      <td>Vaccines / Immunoglobulins</td>
      <td>IMMUNOLOGY</td>
      <td>yellow fever virus vaccine (Stamaril)-[Amp 0.5ml] SC IM 0.5ml. ¶C. *L4. S.E: Anaphylaxis, angioedema, diarrhea, lymphadenopathy.</td>
    </tr>
    <tr>
      <td>belimumab</td>
      <td>Benlysta</td>
      <td>C</td>
      <td>Autoantibody-Positive Systemic Lupus Erythematosus</td>
      <td>IMMUNOLOGY</td>
      <td>belimumab (Benlysta)-[Pwdr 120, 400mg] IV 10mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. ¶C. S.E: Infections, progressive multifocal leukoencephalopathy, depression, nasopharyngitis, bronchitis, insomnia, pain in extremity.</td>
    </tr>
    <tr>
      <td>busulphan</td>
      <td>Busulfex</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>busulphan (Busulfex)-[Amp 60mg] (Myleran)-[Tab 2mg] ¶D. *L5. S.E: Anorexia, hypocalcemia, hypokalemia, insomnia, fever, hypertension, hypotension, neutropenia, myelosuppression, tachycardia, thrombosis, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>carboplatin</td>
      <td>Carboplatin</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>carboplatin (Carboplatin)-[Amp 10 mg/ml] ¶D. *L5. S.E: Leukopenia, neutropenia, ototoxicity, peripheral neuropathies, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>carmustine</td>
      <td>Gliadel Wafer</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>carmustine (Gliadel Wafer)-[Wafer 7.7mg] ¶D. *L5. S.E: Leukopenia, neutropenia, ototoxicity, peripheral neuropathies, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>chlorambucil</td>
      <td>Leukeran</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>chlorambucil (Leukeran)-[FC Tab 2mg] ¶D. *L5. S.E: Anemia, hallucinations, leukopenia, neutropenia, pancytopenia, thrombocytopenia, tremor.</td>
    </tr>
    <tr>
      <td>cisplatin</td>
      <td>Abiplatin</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>cisplatin (Abiplatin)-[Amp 1mg/ml]. ¶D. *L5. S.E: Acute renal failure, electrolyte disturbances, hemolytic uremic syndrome, myelosuppression, ototoxicity.</td>
    </tr>
    <tr>
      <td>cyclophosphamide</td>
      <td>Endoxan</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>cyclophosphamide (Endoxan)-[Amp 500, 1000mg] ¶D. *L5. S.E: Cardiotoxicity, hypersensitivity, hyponatremia, immunosuppression, myelosuppression, pulmonary toxicity, nephrotoxicity, secondary malignancies.</td>
    </tr>
    <tr>
      <td>dacarbazine</td>
      <td>Dacarbazine-Dacin</td>
      <td>C</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>dacarbazine (Dacarbazine-Dacin)-[Amp 200mg] (Dacarbazine-Medac)-[Pwdr 200, 500,1000mg] ¶C. S.E: Anorexia, hepatotoxicity, leukopenia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>Ifosfamide</td>
      <td>NaN</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>Ifosfamide ((29 ג' (Ifosfamide)-[Amp 1, 2G]. ¶D. *L4. S.E: Anemia, anorexia, cardiotoxicity, hepatotoxicity, leucopenia, peripheral neuropathy, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>lomustine</td>
      <td>NaN</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>lomustine ((29 ג'  (Lomustine)-[Tab 40mg] ¶D. S.E: Hepatotoxicity, nephrotoxicity, myelosuppression, pulmonary toxicity.</td>
    </tr>
    <tr>
      <td>melphalan</td>
      <td>Alkeran</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>melphalan (Alkeran)-[Tab 2mg; Amp 50mg]. ¶D. *L5. S.E: Hypersensitivity, myelosuppression.</td>
    </tr>
    <tr>
      <td>streptozotocin</td>
      <td>Zanosar</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>streptozotocin (Zanosar)-[Amp 1.02G]. ¶D. S.E: Hypoglycemia, inflammation, myelosuppression.</td>
    </tr>
    <tr>
      <td>temozolomide</td>
      <td>Temo</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>temozolomide (Temo)-[Cap 5, 20, 100, 140, 180, 250mg] (Temodal)-[Cap 5, 20, 100, 250mg]. ¶D. *L5. S.E: Anorexia, blurred vision, dyspnea, fatigue, insomnia, viral infection.</td>
    </tr>
    <tr>
      <td>thiotepa</td>
      <td>Tepadina</td>
      <td>D</td>
      <td>Alkylating agents</td>
      <td>ONCOLOGY</td>
      <td>thiotepa (Tepadina)-[Amp 15, 100mg] ¶D. S.E: Blurred vision, myelosuppression, prolonged apnea.</td>
    </tr>
    <tr>
      <td>doxorubicin</td>
      <td>Adriblastina</td>
      <td>D</td>
      <td>Antibiotics_2</td>
      <td>ONCOLOGY</td>
      <td>doxorubicin (Adriblastina)-[Amp 10, 50mg] (Caelyx)-[Amp 2mg/ml] (Doxorubicin “Ebewe”, Doxorubicin-Teva)-[Amp 2mg] (Myocet)-[Pwdr 50mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>amifostine</td>
      <td>NaN</td>
      <td>C</td>
      <td>Antibiotics_2</td>
      <td>ONCOLOGY</td>
      <td>amifostine ((29 ג' (Amifostine, Ethyol)-[Amp 500mg]. ¶C.</td>
    </tr>
    <tr>
      <td>bleomycin</td>
      <td>Bleomycin-PFI</td>
      <td>D</td>
      <td>Antibiotics_2</td>
      <td>ONCOLOGY</td>
      <td>bleomycin (Bleomycin-PFI)-[Amp 15mg]. ¶D.*L4.</td>
    </tr>
    <tr>
      <td>daunorubicin</td>
      <td>NaN</td>
      <td>D</td>
      <td>Antibiotics_2</td>
      <td>ONCOLOGY</td>
      <td>daunorubicin ((29 ג' (Daunoxome)-[Amp 20mg] ¶D. *L5.</td>
    </tr>
    <tr>
      <td>epirubicin</td>
      <td>Epirubicin</td>
      <td>D</td>
      <td>Antibiotics_2</td>
      <td>ONCOLOGY</td>
      <td>epirubicin (Epirubicin)-[Amp 2mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>idarubicin</td>
      <td>Zavedos</td>
      <td>D</td>
      <td>Antibiotics_2</td>
      <td>ONCOLOGY</td>
      <td>idarubicin (Zavedos)-[Amp 10mg]. ¶D.</td>
    </tr>
    <tr>
      <td>mitomycin</td>
      <td>Mitomycin C</td>
      <td>D</td>
      <td>Antibiotics_2</td>
      <td>ONCOLOGY</td>
      <td>mitomycin (Mitomycin C)-[Amp 2, 10mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>mitoxantrone</td>
      <td>Mitoxantron-Ebewe</td>
      <td>D</td>
      <td>Antibiotics_2</td>
      <td>ONCOLOGY</td>
      <td>mitoxantrone (Mitoxantron-Ebewe)-[Amp 2mg/ml]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>capecitabine</td>
      <td>Capecitabine-Inovamed</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>capecitabine (Capecitabine-Inovamed)-[Tab 500mg] (Capecitabine-Teva)-[Tab 150, 500mg] (Xeloda)-[Tab 150, 500mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>cladribine</td>
      <td>Litak 10</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>cladribine (Litak 10)-[Amp 2mg/ml] .¶D. *L5.</td>
    </tr>
    <tr>
      <td>cytarabine</td>
      <td>Alexan</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>cytarabine (Alexan)-[Amp 50mg] (Cytosar)-[Amp 0.5, 1G]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>fludarabine</td>
      <td>Fludara</td>
      <td>B</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>fludarabine (Fludara)-[Amp 50mg]. ¶B.</td>
    </tr>
    <tr>
      <td>fluorouracil</td>
      <td>Fluorouracil</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>fluorouracil (Fluorouracil)-[Amp 50mg] (Efudix)-[Cream 5%]. ¶D.*L4.</td>
    </tr>
    <tr>
      <td>fotemustine</td>
      <td>Muphoran</td>
      <td>N</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>fotemustine (Muphoran)-[Amp 208mg]. ¶Not established.</td>
    </tr>
    <tr>
      <td>gemcitabine</td>
      <td>Gemcitabine</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>gemcitabine (Gemcitabine)-[Amp 40mg] (Gemcitabine-Teva)-[Amp 0.2, 1, 2G] (Gemcitabine-Actavis(-[Amp 0.2, 1G] (Gemcitabine-Medac)-[Amp 0.2, 1, 1.5G] (Gemnil ,Gemzar, Meditabine)-[Amp 0.2, 1G]. ¶D. *L4.</td>
    </tr>
    <tr>
      <td>hydroxyurea</td>
      <td>NaN</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>hydroxyurea ((29 ג' (Hydroxycarbamide)-[Cap 500mg]. ¶D. *L2.</td>
    </tr>
    <tr>
      <td>lomustine</td>
      <td>NaN</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>lomustine ((29 ג' (Lomustine)-[Tab 10, 40mg]. ¶D.</td>
    </tr>
    <tr>
      <td>mercaptopurine</td>
      <td>Puri-Nethol</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>mercaptopurine (Puri-Nethol)-[Tab 50mg]. ¶D. *L3.</td>
    </tr>
    <tr>
      <td>methotrexate</td>
      <td>Abitrexate</td>
      <td>X</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>methotrexate (Abitrexate)-[Amp 25, 100mg/ml] (Methotrexat)-[Amp 10, 20, 100mg; Tab 2.5mg] (Methotrexate-Lederle)-[Tab 2.5mg]. ¶X. *L3.</td>
    </tr>
    <tr>
      <td>miltefosine</td>
      <td>Miltex</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>miltefosine (Miltex)-[Soln 0.6G/10ml]. ¶D.</td>
    </tr>
    <tr>
      <td>thioguanine</td>
      <td>Lanvis</td>
      <td>D</td>
      <td>Antimetabolites</td>
      <td>ONCOLOGY</td>
      <td>thioguanine (Lanvis)-[Tab 40mg]. ¶D.</td>
    </tr>
    <tr>
      <td>anastrozole</td>
      <td>Anastrol, Anastrozole-Teva</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>anastrozole (Anastrol, Anastrozole-Teva)-[Tab 1mg] (Arimidex)-[Tab 1mg]. ¶X. *L5.</td>
    </tr>
    <tr>
      <td>bicalutamide</td>
      <td>Bicalutamide-Inovamed,Casodex</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>bicalutamide (Bicalutamide-Inovamed,Casodex)-[Tab 50, 150mg] (Bicalutamide-Teva, Medimide)-[Tab 50mg] (Bicamide)-[Tab 150mg]. ¶X.</td>
    </tr>
    <tr>
      <td>buserelin</td>
      <td>Suprefact Depot</td>
      <td>N</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>buserelin (Suprefact Depot)-[Implant 9.9mg]. ¶Not established.</td>
    </tr>
    <tr>
      <td>cyproterone acetate</td>
      <td>Androcur</td>
      <td>N</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>cyproterone acetate (Androcur)-[Tab 10, 50mg]. ¶Not established.</td>
    </tr>
    <tr>
      <td>estramustine</td>
      <td>Estracyt</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>estramustine (Estracyt)-[Cap 140mg]. ¶X.</td>
    </tr>
    <tr>
      <td>exemestane</td>
      <td>Aromasin</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>exemestane (Aromasin)-[Tab 25mg] (Exemestane-Inovamed, Exemestane-Teva, Exetane)-[Tab 25mg]. ¶X.*L5.</td>
    </tr>
    <tr>
      <td>goserelin</td>
      <td>Zoladex</td>
      <td>D</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>goserelin (Zoladex)-[Implant 3.6, 10.8mg]. ¶D-in patients with advanced breast cancer/X-in patients with endometriosis and endometrial thinning. *L3.</td>
    </tr>
    <tr>
      <td>irinotecan</td>
      <td>Campto</td>
      <td>D</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>irinotecan (Campto)-[Amp 20mg] )Irinomed, Irinotecan)-[Amp 20mg]. ¶D.</td>
    </tr>
    <tr>
      <td>letrozole</td>
      <td>Femara, Lebrest, Letrozole-Dexcel, Letrozole-Farmoz, Letrozole-Teva</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>letrozole (Femara, Lebrest, Letrozole-Dexcel, Letrozole-Farmoz, Letrozole-Teva)-[Tab 2.5mg]. ¶X.*L4.</td>
    </tr>
    <tr>
      <td>leuprorelin</td>
      <td>Lucrin Depot</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>leuprorelin (Lucrin Depot)-[Amp 3.75, 11.25mg]. ¶X.</td>
    </tr>
    <tr>
      <td>medroxyprogesterone acetate</td>
      <td>Depo-Provera</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>medroxyprogesterone acetate (Depo-Provera)-[Amp 150mg/ml] (Provera)-[Tab 5mg] (Sayana)-[Amp 104mg/0.65ml] . ¶X. *L4.</td>
    </tr>
    <tr>
      <td>megestrol</td>
      <td>NaN</td>
      <td>D</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>megestrol ((29 ג' (Megace)-[Tab 160mg] (Megestrol)-[Tab 40mg]. ¶D.*L3.</td>
    </tr>
    <tr>
      <td>octreotide</td>
      <td>Sandostatin</td>
      <td>B</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>octreotide (Sandostatin)-[Amp 0.05, 0.1, 0.2, 0.5mg/ml] (Sandostatin LAR)-[Amp 10, 20, 30mg]. ¶B.*L3.</td>
    </tr>
    <tr>
      <td>tamoxifen</td>
      <td>Tamoxifen-Teva</td>
      <td>D</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>tamoxifen (Tamoxifen-Teva)-[Tab 10, 20mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>testosterone</td>
      <td>Androgel</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>testosterone (Androgel)-[Gel 50mg] (Testomax)-[Gel 25, 50mg] (Testoviron Depot)-[Amp 250mg]. ¶X.</td>
    </tr>
    <tr>
      <td>topotecan</td>
      <td>Hycamtin</td>
      <td>D</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>topotecan (Hycamtin)-[Amp 4mg; Cap 0.25, 1mg] (Potactasol, Topotecan)-[Amp 1, 4mg]. ¶D.</td>
    </tr>
    <tr>
      <td>triptorelin</td>
      <td>Decapeptyl, Diphereline</td>
      <td>X</td>
      <td>Hormones</td>
      <td>ONCOLOGY</td>
      <td>triptorelin (Decapeptyl, Diphereline)-[Amp 0.1, 3.75mg CR] (Diphereline, Decapeptyl-Depot)-[Amp 3.75, 11.25mg]. ¶X.</td>
    </tr>
    <tr>
      <td>adalimumab</td>
      <td>Humira</td>
      <td>N</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>adalimumab (Humira)-[Soln 40mg/0.8ml] SC Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis: 40mg every other week. Crohn's disease and ulcerative colitis: day 1 160mg, day 15 80mg, day 29 begin a maintenance dose of 40mg every other week. ¶Not established. *L3. S.E: Infections, malignancies, pancytopenia, CHF, lupus-like syndrome (stop treatment if syndrome develops).</td>
    </tr>
    <tr>
      <td>aldesleukin</td>
      <td>interleukin-2</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>aldesleukin (interleukin-2) (Proleukin)-[Amp 18M IU]. ¶C. S.E: Coma, somnolence, capillary leak syndrome, impaired neutrophil function, Should be administered under the supervision of an experienced cancer chemotherapy physician in a facility with cardiopulmonary or intensive specialists and intensive care facilities available.</td>
    </tr>
    <tr>
      <td>basiliximab</td>
      <td>Simulect</td>
      <td>B</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>basiliximab (Simulect)-[Powdr 20mg] IV 20mg 2x/d. Peds &gt;35kg: 10mg 2x/d. ¶B. S.E: Edema, fever, viral infection, hyperkalemia, hypokalemia, dyspnea, hyperglycemia, hypercholesterolemia, hypophosphatemia, hyperuricemia, UTI, hypertension, anemia.</td>
    </tr>
    <tr>
      <td>BCG</td>
      <td>Immucyst</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>BCG (Immucyst)-[Amp 27mg] (Onco Tice)-[Amp 200-800M IU CFU]. ¶C. S.E: Fever, flu-like symptoms, aneurysms, UTI, eye complaints.</td>
    </tr>
    <tr>
      <td>bevazcizumab</td>
      <td>Avastin</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>bevazcizumab (Avastin)-[Soln 25mg/ml] IV 10-15mg/kg every 2-3wks. Do not administer as an IV push or bolus. Do not initiate for 28d following major surgery and until surgical wound is fully healed. ¶C. S.E: GI perforation or fistula, hemorrhage, wound healing and surgical complications, VT, hypertension, posterior reversible encephalopathy syndrome, proteinuria, ovarian failure, epistaxis.</td>
    </tr>
    <tr>
      <td>brentuximab vedotin</td>
      <td>Adcetris</td>
      <td>D</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>brentuximab vedotin (Adcetris)-[Pwdr 50mg/vial] IV Intravenous infusion over 30min every 3wks. Recommended dose is 1.8mg/kg, (reduce dose in patients with mild hepatic impairment). ¶D. S.E: Progressive multifocal leukoencephalopathy, peripheral neuropathy, hematologic toxicitiy, tumor lysis syndrome, hepatotoxicity, pulmonary toxicity, GI complications.</td>
    </tr>
    <tr>
      <td>canakinumab</td>
      <td>Ilaris</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>canakinumab (Ilaris)-[Soln 150mg/1ml] SC &lt;40kg: 2mg/kg every 4wks. Max 4mg/kg every 4wks. &gt;40kg: 150mg every 4wks. Max 300mg every 4wks. ¶C. S.E: Diarrhea, influenza, weight increased, nasopharyngitis.</td>
    </tr>
    <tr>
      <td>certolizumab pegol</td>
      <td>Cimzia</td>
      <td>B</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>certolizumab pegol (Cimzia)-[Soln 200mg/ml] SC 200mg 2x/d. ¶B. *L3. S.E: Infections, lymphoma, CHF, hepatitis B virus reactivation, pancytopenia, lupus-like syndrome (stop treatment if syndrome develops).</td>
    </tr>
    <tr>
      <td>cetuximab</td>
      <td>Erbitux</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>cetuximab (Erbitux)-[Soln 5mg/ml] IV Administer 400mg/m2 initial dose as a 120min intravenous infusion followed by 250mg/m2 weekly infused over 60min. ¶C. *L4. S.E: Cardiopulmonary arrest, pulmonary toxicity, dermatologic toxicity, hypomagnesemia, headache, diarrhea, infection.</td>
    </tr>
    <tr>
      <td>eculizumab</td>
      <td>Soliris</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>eculizumab (Soliris)-[Soln 10mg/ml] IV 600mg weekly for the first 4wks, 900mg for the fifth dose 1wk later, then 900mg every 2wks. ¶C. S.E: UTI, nasopharyngitis, anemia, cough, peripheral edema, hypertension.</td>
    </tr>
    <tr>
      <td>golimumab</td>
      <td>Simponi</td>
      <td>B</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>golimumab (Simponi)-[Soln 50mg/0.5ml] SC 50mg 1x/month. Ulcerative colitis: start 200mg, followed by 100mg at Week 2 and then 100mg every 4wks. ¶B. *L3. S.E: Infections, hepatitis B Reactivation, malignancies, CHF, lupus-like syndrome (stop treatment if syndrome develops)</td>
    </tr>
    <tr>
      <td>imatinib</td>
      <td>Glivec, Imatinib-Teva</td>
      <td>D</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>imatinib (Glivec, Imatinib-Teva)-[Cap 100, 400mg] for CML 400-600mg 1x/d. Max 400mg 2x/d. ¶D. *L5. S.E: Edema, anemia, neutropenia, thrombocytopenia, HF, hepatotoxicity, hemorrhage, cardiogenic shock, hypothyroidism, tumor lysis syndrome.</td>
    </tr>
    <tr>
      <td>interferon alpha-2A</td>
      <td>Roferon-A</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>interferon alpha-2A (Roferon-A)-[Prefill Syringe 3, 4.5, 6, 9M IU]. ¶C. S.E: Flu-like symptoms, pancytopenia, hypocalcaemia, anorexia, arrhythmias, alopecia, weight loss.</td>
    </tr>
    <tr>
      <td>interferon alpha-2B</td>
      <td>Intron A</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>interferon alpha-2B (Intron A)-[Amp 10M IU; Pen Inject 18M IU]. ¶C. *L3. S.E: Pharyngitis, viral infections, leukopaenia, thrombocytopaenia, lymphadenopathy, lymphopenia, hypothyroidism, hyperthyroidism, anorexia, hypocalcaemia, hyperuricemia, depression, libido decreased, blurred vision, vertigo, tinnitus, palpitation, tachycardia, hypertension.</td>
    </tr>
    <tr>
      <td>natalizumab</td>
      <td>Tysabri</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>natalizumab (Tysabri)-[Soln 300mg/15ml] IV Multiple sclerosis and Crohn's disease: 300mg intravenous infusion (in 100ml 0.9% sodium chloride) over 1h every 4wks. ¶C. *L3. S.E: UTI, lower respiratory tract infection, depression, influenza-like illnes</td>
    </tr>
    <tr>
      <td>ofatumumab</td>
      <td>Arzerra</td>
      <td>N</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>ofatumumab (Arzerra)-[Soln 100mg/5ml, 1000mg/50ml] IV 300mg on day 1, followed 1wk later by 1,000mg on day 8 (Cycle 1), followed by 1,000mg on day 1 of subsequent 28d cycles for a min of 3 cycles until best response or a max of 12 cycles. ¶Not established. *L3. S.E: Hepatitis B virus reactivation, tumor lysis syndrome, neutropenia, leucopenia, edema.</td>
    </tr>
    <tr>
      <td>panitumumab</td>
      <td>Vectibix</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>panitumumab (Vectibix)-[Soln 20mg/ml] IV Administer 6mg/kg every 14days as an intravenous infusio over 60min(≤1000mg) or 90min(&gt;1000mg). ¶C. S.E: Dermatologic toxicity, diarrhea, anorexia, hypomagnesemia, hypokalemia, increased tumor progression, pulmonary fibrosis, interstitial lung disease, ocular toxicity.</td>
    </tr>
    <tr>
      <td>ranibizumab</td>
      <td>Lucentis</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>ranibizumab (Lucentis)-[Soln 10mg/ml] Ophthalmic Intravitreal Injection 0.5mg given as a single intravitreal injection. The interval between two doses injected into the same eye should not be shorter than one month. ¶C. S.E: Conjunctival hemorrhage, eye pain, vitreous floaters, increases in intraocular pressure, endophthalmitis, retinal detachments, blurred vision, anemia, edema.</td>
    </tr>
    <tr>
      <td>rituximab</td>
      <td>Mabthera</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>rituximab (Mabthera)-[Amp 10, 120mg] IV Initiate infusion 50mg/hr. In the absence of infusion toxicity, increase infusion rate by 50mg/hr increments every 30min. Max 400mg/hr. ¶C. *L4. S.E: Hepatitis B virus reactivation, tumor lysis syndrome, infections, arrhythmias, renal toxicity, bowel obstruction and perforation, pancytopenia, angioedema, hyperglycemia.</td>
    </tr>
    <tr>
      <td>trastuzumab</td>
      <td>Herceptin</td>
      <td>D</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>trastuzumab (Herceptin)-[Amp 440mg; SC 600mg/5ml] (Kadcyla)-[Amp 20mg]. ¶D. *L4. S.E: Significant immunosuppression (including the risk of developing opportunistic bacterial, fungal, and viral infections), hypersensitivity, anaphylactoid reaction related to chimeric antibody, cardiotoxicity, nephrotic syndrome, interstitial pneumonia.</td>
    </tr>
    <tr>
      <td>alemtuzumab</td>
      <td>Mabcampath</td>
      <td>C</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>alemtuzumab (Mabcampath)-[Amp 10mg/ml] IV CLL: slow infusion 12mg/d for 5d then 12mg/d for 12 months. ¶C. *L4. S.E: Significant immunosuppression, hypersensitivity, anaphylaxis, cytokine release syndrome (fever, shivering, myalgia, headache), anemia, leukopenia, thrombocytopenia.</td>
    </tr>
    <tr>
      <td>infliximab</td>
      <td>Remicade, Remsima</td>
      <td>B</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>infliximab (Remicade, Remsima)-[Pwdr 100mg] IV IBD, Ankylosing Spondylitis, Psoriasis: 5mg/kg at 0, 2, 6wks, maint 5mg/kg every 8 wk. RA: 3mg/kg at 0, 2, 6wks maintenance every 8wk. ¶B. *L2. S.E: Myelosuppression, CHF, optic neuritis, reactivation of tuberculosis, increased risk of infection, demyelinating disease of CNS.</td>
    </tr>
    <tr>
      <td>ustekinumab</td>
      <td>Stelara</td>
      <td>B</td>
      <td>Immunomodulators</td>
      <td>ONCOLOGY</td>
      <td>ustekinumab (Stelara)-[Soln 45mg/0.5ml] SC Start 45mg 1x/d, followed by a 45mg 4wks later and then every 12wks. &gt;100kg: start 90mg 1x/d, followed by a 90mg 4wks later and then every 12wks. ¶B. S.E: Nasopharyngitis, infections, dizziness, depression, malignancies.</td>
    </tr>
    <tr>
      <td>docetaxel )Docetaxel)-[Amp 40mg]</td>
      <td>Docetaxel-Ebewe, Docetaxel-Hospira</td>
      <td>D</td>
      <td>Mitotic inhibitors</td>
      <td>ONCOLOGY</td>
      <td>docetaxel )Docetaxel)-[Amp 40mg] (Docetaxel-Ebewe, Docetaxel-Hospira)-[Amp 10mg] (Docetaxel-Teva,Taxotere)-[Amp 20mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>etoposide</td>
      <td>VP-16</td>
      <td>D</td>
      <td>Mitotic inhibitors</td>
      <td>ONCOLOGY</td>
      <td>etoposide (VP-16) (Etoposid, Etoposid-Ebewe)-[Amp 20mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>paclitaxel</td>
      <td>Ebetaxel, Pacliavenir, Paclitaxel-Teva</td>
      <td>D</td>
      <td>Mitotic inhibitors</td>
      <td>ONCOLOGY</td>
      <td>paclitaxel (Ebetaxel, Pacliavenir, Paclitaxel-Teva)-[Amp 6mg/ml]. ¶D.*L5.</td>
    </tr>
    <tr>
      <td>teniposide</td>
      <td>NaN</td>
      <td>D</td>
      <td>Mitotic inhibitors</td>
      <td>ONCOLOGY</td>
      <td>teniposide ((29 ג' (VM-26) (Vumon) -[Amp 50mg/5ml]. ¶D. *L4.</td>
    </tr>
    <tr>
      <td>vinblastine</td>
      <td>Blastovin</td>
      <td>D</td>
      <td>Mitotic inhibitors</td>
      <td>ONCOLOGY</td>
      <td>vinblastine (Blastovin)-[Amp 1mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>vincristine</td>
      <td>Vincristine</td>
      <td>D</td>
      <td>Mitotic inhibitors</td>
      <td>ONCOLOGY</td>
      <td>vincristine (Vincristine)-[Amp 1mg/ml]. ¶D.*L5.</td>
    </tr>
    <tr>
      <td>vinorelbine</td>
      <td>Navelbine</td>
      <td>D</td>
      <td>Mitotic inhibitors</td>
      <td>ONCOLOGY</td>
      <td>vinorelbine (Navelbine)-[Amp 10, 20, 30mg/ml] (Vinorelbin-Ebewe,Vinorelbin-Actavis, Vinorelbin-Trima)-[Amp 10mg]. ¶D. *L5.</td>
    </tr>
    <tr>
      <td>amifostine</td>
      <td>NaN</td>
      <td>C</td>
      <td>Others_2</td>
      <td>ONCOLOGY</td>
      <td>amifostine ((29 ג' (Amifostine, Ethyol)-[Amp 500mg] ¶C. S.E: Hypocalcemia, vomiting, Stevens-Johnson syndrome, hypotension.</td>
    </tr>
    <tr>
      <td>asparaginase</td>
      <td>Kidrolase</td>
      <td>C</td>
      <td>Others_2</td>
      <td>ONCOLOGY</td>
      <td>asparaginase (Kidrolase)-[Amp 10K IU] ¶C. *L3. S.E: Pancreatitis, hypersensitivity reaction, glucose intolerance, thrombosis and hemorrhage, hyperglycemia, vomiting, nausea, thrombosis, hyperbilirubinemia, fever, diarrhea.</td>
    </tr>
    <tr>
      <td>dexrazoxane</td>
      <td>Cardioxane</td>
      <td>D</td>
      <td>Others_2</td>
      <td>ONCOLOGY</td>
      <td>dexrazoxane (Cardioxane)-[Amp 500mg] ¶D. S.E: Myelosuppression, cardiac toxicity, CHF, secondary malignancies, alopecia, vomiting, anorexia, fever, infection, sepsis, diarrhea, neurotoxicity.</td>
    </tr>
    <tr>
      <td>disodium clodronate</td>
      <td>Bonefos</td>
      <td>N</td>
      <td>Others_2</td>
      <td>ONCOLOGY</td>
      <td>disodium clodronate (Bonefos)-[Tab 800mg] ¶Not established. S.E: Osteonecrosis, bone and muscle pain, swelling and irritation of the uvea.</td>
    </tr>
    <tr>
      <td>levamisole</td>
      <td>NaN</td>
      <td>C</td>
      <td>Others_2</td>
      <td>ONCOLOGY</td>
      <td>levamisole ((29 ג' (Ergamisol)-[Tab 50mg] ¶C. S.E: Fever, diarrhea, metallic taste, nausea, alopecia, flu-like symptoms, infection.</td>
    </tr>
    <tr>
      <td>streptozocin</td>
      <td>NaN</td>
      <td>D</td>
      <td>Others_2</td>
      <td>ONCOLOGY</td>
      <td>streptozocin ((29 ג' (Zanosar)-[Amp 1G] ¶D. S.E: Vomiting, hematological toxicity.</td>
    </tr>
    <tr>
      <td>tretinoin</td>
      <td>Ret-Avit</td>
      <td>C</td>
      <td>Others_2</td>
      <td>ONCOLOGY</td>
      <td>tretinoin (Ret-Avit)-[Cream 0.025, 0.05%; Gel 0.025, 0.05%) (Vesanoid)-[Cap 10mg]. ¶C. *L4(orally)/L3(topically). S.E: Temporary hyper- or hypopigmentation.</td>
    </tr>
    <tr>
      <td>alprazolam</td>
      <td>Alpralid, Xanagis</td>
      <td>D</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>alprazolam (Alpralid, Xanagis)-[Tab 0.25, 0.5, 1mg] (Xanax XR)-[ER Tab 0.5, 1, 2mg] PO 0.25-0.5mg 2-3x/d, usual 4mg/d. ER Tab: 0.5-4.5mg/d in 1-2 divided dose. Usual 5-6mg/d. Max 10mg/d. ¶D. *L3. S.E: Respiratory depression, apnea, desaturation in pediatric patients, agitation.</td>
    </tr>
    <tr>
      <td>brotizolam</td>
      <td>Bondormin, Brotizolam-Teva</td>
      <td>X</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>brotizolam (Bondormin, Brotizolam-Teva)-[Tab 0.25mg] PO Insomnia: 0.25mg at night. Elderly: ½Tab or 2Tab. The tablet should not be taken on a full stomach. ¶X. S.E: Hepatic dysfunction, anemia, thrombocytopenia, eosinophilia.</td>
    </tr>
    <tr>
      <td>clobazam</td>
      <td>Frisium</td>
      <td>C</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>clobazam (Frisium)-[Tab 10mg] PO Anxiety: start: 10mg/d, day 7: 20mg. Max 30mg/d. ¶C. *L3. S.E: Constipation, pyrexia, fatigue, pneumonia, decreased appetite, somnolence, dysarthria, insomnia.</td>
    </tr>
    <tr>
      <td>clorazepate</td>
      <td>Tranxal</td>
      <td>D</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>clorazepate (Tranxal)-[Cap 5, 15mg] PO 7.5-15mg 3x/d. ¶D. *L3. S.E: Respiratory depression, apnea, desaturation in pediatric patients, agitation.</td>
    </tr>
    <tr>
      <td>diazepam</td>
      <td>Assival</td>
      <td>D</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>diazepam (Assival)-[Tab 2, 5, 10mg; Amp 10mg/2ml] PO 2-10mg 2-4x/d. Peds: 1-2.5mg 3-4x/d. IV IM 2-20mg and may be repeated in 1-4hrs. PR see anticonvulsants. ¶D. *L3/L4(chronic use). S.E: Respiratory depression, apnea, desaturation in pediatric patients, agitation.</td>
    </tr>
    <tr>
      <td>flunitrazepam</td>
      <td>Hypnodorm</td>
      <td>U</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>flunitrazepam (Hypnodorm)-[Tab 2mg] PO Insomnia: 0.05-2mg at night. ¶Use during pregnancy is not recommended. *L3/L4 (chronic use). S.E: Amnesia, delirium, fatigue, hepatic dysfunction syncope, vertigo.</td>
    </tr>
    <tr>
      <td>lorazepam</td>
      <td>Lorivan</td>
      <td>D</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>lorazepam (Lorivan)-[Tab 1mg] PO Sleep: 2-4mg at night. Anxiety: 1mg 2-3x/d. Max 10mg/d. Premedication: 2-3mg nite before operation, 2-4mg 1-2hrs before operation. ¶D. *L3. S.E: Respiratory depression, apnea, desaturation in pediatric patients, agitation.</td>
    </tr>
    <tr>
      <td>nitrazepam</td>
      <td>Numbon</td>
      <td>C</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>nitrazepam (Numbon)-[Tab 5mg] PO Insomnia: 2.5-10mg at nite. ¶C.</td>
    </tr>
    <tr>
      <td>oxazepam</td>
      <td>Vaben</td>
      <td>D</td>
      <td>Anxiolytics / Hypnotics - Benzodiazepines</td>
      <td>PSYCHIATRY</td>
      <td>oxazepam (Vaben)-[Tab 10mg] PO 10-45mg/d divided. ¶D. *L3. S.E: Edema, hepatic dysfunction, leucopenia, minor diffuse skin rashes, tremor.</td>
    </tr>
    <tr>
      <td>phenobarbital</td>
      <td>Phenobarbitone</td>
      <td>D</td>
      <td>Anxiolytics / Hypnotics – Barbituates</td>
      <td>PSYCHIATRY</td>
      <td>phenobarbital (Phenobarbitone)-[Tab 15, 100mg] PO Sedative: 30-120mg/d in 2-3 divided dose. Max 400mg/d. Bedtime hypnotic: 100-200mg. ¶D. S.E: *L3. Anemia, vertigo, respiratory depression, fever, hepatitis, hyperactivity, Steven-Johnson syndrome.</td>
    </tr>
    <tr>
      <td>biperiden</td>
      <td>Dekinet</td>
      <td>C</td>
      <td>Anxiolytics/Hypnotics – Anticholinergic/Antihistaminergic</td>
      <td>PSYCHIATRY</td>
      <td>biperiden (Dekinet)-[Tab 2mg] PO Dosage should be individualized. Begin with 1/2Tab 2x/d, and gradually increase to 1Tab 3-4x/d. Then decrease continuously to the lowest dosage regimen which adequately controls the symptoms. ¶C. S.E: Hypotension, drowsiness, urinary retention, vision blurred, constipation.</td>
    </tr>
    <tr>
      <td>doxylamine</td>
      <td>Sleep-Aid, Tonight</td>
      <td>A</td>
      <td>Anxiolytics/Hypnotics – Anticholinergic/Antihistaminergic</td>
      <td>PSYCHIATRY</td>
      <td>doxylamine (Sleep-Aid, Tonight)-[Tab 25mg] PO Sleep: 25mg 30min before bedtime. Antiemetic in pregnancy: ½Tab + Vit. B6 3-4x/d. ¶A. *L3. S.E: Decrease in urine volume, face swelling.</td>
    </tr>
    <tr>
      <td>hydroxyzine</td>
      <td>Otarex</td>
      <td>C</td>
      <td>Anxiolytics/Hypnotics – Anticholinergic/Antihistaminergic</td>
      <td>PSYCHIATRY</td>
      <td>hydroxyzine (Otarex)-[Tab 25mg] PO 25mg 3-4x/d or 0.5-1mg/kg single or divided dose as needed. Max 100mg. Peds&gt;6yrs: 50-100mg/d divided. Peds&lt;6yrs: 50mg/d divided. ¶C. *L1. S.E: Drowsiness, tremor, depression, diarrhea, hypotension, edema, angioedema, photosensitivity, blurred vision.</td>
    </tr>
    <tr>
      <td>buspirone</td>
      <td>Sorbon</td>
      <td>B</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>buspirone (Sorbon)-[Tab 10mg] PO Anxiety: Start 5mg 2-3x/d. Increase every 2-3d. Maint: 15-30mg in divided dose. Max 60mg/d. ¶B. *L3. S.E: MI, CVA.</td>
    </tr>
    <tr>
      <td>levomepromazine, methotrimeprazine</td>
      <td>Nozinan, Ronexine</td>
      <td>N</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>levomepromazine, methotrimeprazine (Nozinan, Ronexine)-[Tab 25, 100mg] PO Start 25-200mg/d. Max 400mg/d. Pain: 50mg 2-5x/d. ¶Not established. S.E: Blurred vision, confusion, tremors, jaundice, dizziness.</td>
    </tr>
    <tr>
      <td>mianserin</td>
      <td>Bonserin</td>
      <td>B</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>mianserin (Bonserin)-[Tab 30mg] PO initial dosage 30mg/d. Effective dosage usually between 30-90mg/d. Max 200mg/d. ¶B. S.E: Blurred vision, dizziness, edema, psychiatric disorders, sexual dysfunction, bone marrow depression, hyponatremia</td>
    </tr>
    <tr>
      <td>nortriptyline</td>
      <td>Nortylin</td>
      <td>N</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>nortriptyline (Nortylin)-[Tab 25mg] PO 25mg 3x/d. Elderly patients: 30-50mg/d. Max 150mg/d. Not recommended for children. ¶Not established. *L2. S.E: MI, arrhythmias, exacerbation of psychosis, seizures, bone marrow depression, thrombocytopenia, blurred vision, tremors, extrapyramidal symptoms, increased or decreased libido, impotence, testicular swelling, jaundice.</td>
    </tr>
    <tr>
      <td>passiflora+valerian+thiamine+pyridoxine</td>
      <td>Calmanervin</td>
      <td>N</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>passiflora+valerian+thiamine+pyridoxine (Calmanervin)-[Tab 250mg+60mg+10mg+10mg] PO Sedative:1Tab 3-4X/d. Hypnotic: 2Tab at nite. ¶Not established. S.E: Nausea, hepatic toxicity(prolonged use).</td>
    </tr>
    <tr>
      <td>passiflora+valerian+crataegus herba+cartaegus fructus+lupuli strobulus</td>
      <td>Nerven-Dragees</td>
      <td>N</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>passiflora+valerian+crataegus herba+cartaegus fructus+lupuli strobulus (Nerven-Dragees)-[Tab 60mg+90mg+90mg+21mg+42mg] PO 1-2Tab 3x/d. Sleep: 2Tab at nite. ¶Not established. S.E: Drowsiness.</td>
    </tr>
    <tr>
      <td>perphenazine</td>
      <td>Perphenan</td>
      <td>C</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>perphenazine (Perphenan)-[Tab 4, 8mg] PO Tranquilizer: 4-8mg 3x/d. Usual 8-40mg/d. Antiemetic: 8-16mg/d 2-3x/d in divided dose. Max 65mg/d. ¶C. *L3. S.E: Parkinsonian symptoms, neuroleptic malignant syndrome, tardive dyskinesia, acute dystonia, ECG changes, pancytopenia.</td>
    </tr>
    <tr>
      <td>pericyazine</td>
      <td>Neuleptil</td>
      <td>N</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>pericyazine (Neuleptil)-[Cap 10mg; Drops 4% 1drop=1mg] PO 30-100mg/d in 2-3 divided doses. Max 200mg/d. Peds&gt;3yrs: 0.1-0.5mg/kg/d. ¶Not established. S.E: Anxiety, breast tissue enlargement in men, diabetes, dizziness, hyperglycemia, impotence, prolonged QT interval, vision problems.</td>
    </tr>
    <tr>
      <td>triclofos</td>
      <td>Triclonam</td>
      <td>C</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>triclofos (Triclonam)-[Syrup 500mg/5ml] PO Sleep: 10-20ml at night. &lt;1yr:2.5-1mg/d. 1-5yr: 2.5-5mg/d. 6-12yr: 5-10mg/d. Day Sedation: 5ml 2x/d. &lt;1yr: 1mg/d. 1-5yr: 2.5mg/d. 6-12yr: 5mg/d (1teasp). ¶C. S.E: Drowsiness, paranoia.</td>
    </tr>
    <tr>
      <td>zolpidem</td>
      <td>Stilnox, Zodorm</td>
      <td>C</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>zolpidem (Stilnox, Zodorm)-[Tab 10mg] (Ambien-CR)-[Tab 6.25, 12.5mg] PO Sleep: 10mg at night. ¶C. *L3. S.E: Chest pain, dizziness, depression, influenza-like symptoms, palpitation, pharyngitis, hyperglycemia, infection, diplopia.</td>
    </tr>
    <tr>
      <td>zopiclone</td>
      <td>Imovane</td>
      <td>C</td>
      <td>Anxiolytics/Hypnotics – Other</td>
      <td>PSYCHIATRY</td>
      <td>zopiclone (Imovane)-[Tab 7.5mg]-(Nocturno, Nocturno Forte)-[FC Tab 3.75, 7.5mg] PO Sleep: 3.75-7.5mg at nite. ¶C. *L2. S.E: Anxiety, behavior changes, confusion.</td>
    </tr>
    <tr>
      <td>amitriptyline</td>
      <td>Elatrol</td>
      <td>C</td>
      <td>Antidepressants – Heterocyclics</td>
      <td>PSYCHIATRY</td>
      <td>amitriptyline (Elatrol)-[Tab 25mg] (Elatrolet)-[Tab 10mg] PO Start 25-100mg in divided dose or single dose at night. Usual 50-300mg/d. ¶C. *L2. S.E: Anorexia, arrhythmias, blurred vision, bone marrow depression, coma, edema, hypotension, hypertension, impotence, MI, ECG changes, seizures, syncope, tremors, bone marrow depression.</td>
    </tr>
    <tr>
      <td>clomipramine</td>
      <td>Anafranil</td>
      <td>C</td>
      <td>Antidepressants – Heterocyclics</td>
      <td>PSYCHIATRY</td>
      <td>clomipramine (Anafranil)-[Tab 25mg] (Anafranil, Maronil 75SR)-[SR Tab 75mg] (Maronil)-[Tab 25mg] PO Start 25mg 1x/d at night. Usual 150-250mg/d in divided dose. Max 250mg/d. SR Tab 75mg 1-3x/d. ¶C. *L2. S.E: Arrhythmias, confusion, edema, fever, hyperventilation, paranoia, tremors, libido change, psychosomatic disorder, acne, breast enlargement, ejaculation failure.</td>
    </tr>
    <tr>
      <td>desipramine</td>
      <td>Deprexan</td>
      <td>C</td>
      <td>Antidepressants – Heterocyclics</td>
      <td>PSYCHIATRY</td>
      <td>desipramine (Deprexan)-[Tab 25mg] PO Start 25mg single or divided dose. Gradual increase to usual 100-300mg/d. ¶C. *L2. S.E: Anorexia, suicide risk, edema, bone marrow depressions, hallucinations, hypotension, hypertension, numbness, mydriasis, sudden death, seizures, tachycardia, testicular swelling, tremors.</td>
    </tr>
    <tr>
      <td>dibenzepin</td>
      <td>NaN</td>
      <td>U</td>
      <td>Antidepressants – Heterocyclics</td>
      <td>PSYCHIATRY</td>
      <td>dibenzepin (29 ג') (Noveril)-[Tab 240mg] PO 240mg 1x/d. Max 480-560mg/d. ¶Unsafe. S.E: Anorexia, suicide risk, blurred vision, bone marrow depression, edema, eosinophilia, hallucinations, hypotension, hypertension, jaundice, numbness, photosensitization, seizures, tachycardia, testicular swelling, tremors..</td>
    </tr>
    <tr>
      <td>doxepin</td>
      <td>Gilex</td>
      <td>C</td>
      <td>Antidepressants – Heterocyclics</td>
      <td>PSYCHIATRY</td>
      <td>doxepin (Gilex)-[Cap 10, 25mg] Start 25mg at night. Usual 75-300mg/d in divided dose. ¶C. *L5. S.E: Anorexia, suicide risk, blurred vision, bone marrow depression, edema, eosinophilia, hallucinations, hypotension, hypertension, jaundice, numbness, photosensitization, seizures, tachycardia, testicular swelling, tremors.</td>
    </tr>
    <tr>
      <td>imipramine</td>
      <td>Tofranil</td>
      <td>D</td>
      <td>Antidepressants – Heterocyclics</td>
      <td>PSYCHIATRY</td>
      <td>imipramine (Tofranil)-[Tab 25mg] PO Start 75-100mg/d in divided dose. Gradual increase. Usual 50-300mg/d. ¶D. *L2. S.E: Anorexia, arrhythmias, blurred vision, bone marrow depressions, ECG changes, hallucinations, hypertension, orthostatic hypotension , jaundice, numbness, MI, palpitation, stroke, testicular swelling, tremors.</td>
    </tr>
    <tr>
      <td>opipramol</td>
      <td>Oprimol</td>
      <td>N</td>
      <td>Antidepressants – Heterocyclics</td>
      <td>PSYCHIATRY</td>
      <td>opipramol (Oprimol)-[Tab 50mg] PO 50-100mg 1-3x/d. ¶Not established. S.E: Hypotension, impotence, orthostatic hypotension, stupor, tachycardia, tremors.</td>
    </tr>
    <tr>
      <td>trimipramine</td>
      <td>Surmontil</td>
      <td>C</td>
      <td>Antidepressants – Heterocyclics</td>
      <td>PSYCHIATRY</td>
      <td>trimipramine (Surmontil)-[Tab 25mg] PO Start 75mg in divided doses. Increase gradually. Usual 50-150mg/d. Max 300mg/d. ¶C. S.E: Anorexia, arrhythmias, bone marrow depressions, hallucinations, hypotension, hypertension, impotence, jaundice, numbness, MI, seizures, stroke, testicular swelling, tremors.</td>
    </tr>
    <tr>
      <td>citalopram</td>
      <td>Cipramil, Recital</td>
      <td>C</td>
      <td>Antidepressants – SSRI</td>
      <td>PSYCHIATRY</td>
      <td>citalopram (Cipramil, Recital)-[Tab 20, 40mg] (Citalopram-Teva)-[Tab 20mg] PO Depression: Start 20mg 1x/d. Max 40-60mg/d. ¶C. *L2. S.E: Anorexia, anxiety, CNS depression, fever, hyperglycemia, influenza-like symptoms, insomnia, impotence, jaundice, psychiatric disorders, prolong QT, suicide attempt, syncope, tachycardia, tremors, life-threatening hemorrhage, libido decreased, vision abnormal, amenorrhea.</td>
    </tr>
    <tr>
      <td>escitalopram</td>
      <td>Cipralex</td>
      <td>C</td>
      <td>Antidepressants – SSRI</td>
      <td>PSYCHIATRY</td>
      <td>escitalopram (Cipralex)-[Tab 5, 10, 15, 20mg] (Escitalopram Teva)-[Tab 10, 20mg] (Esto)-[Tab 10, 15, 20mg] PO Initial 10mg 1x/d. Max 20mg 1x/d. ¶C. *L2. S.E: Clinical worsening, mania/hypomania, suicide risk, seizurs, serotonin syndrome, hyponatremia, SIADH, bleeding, angle closure glaucoma, ejaculation disorder, hypertension, increased weight.</td>
    </tr>
    <tr>
      <td>fluoxetine</td>
      <td>Prozac</td>
      <td>C</td>
      <td>Antidepressants – SSRI</td>
      <td>PSYCHIATRY</td>
      <td>fluoxetine (Prozac)-[Cap 20mg] (Flutine)-[Cap 20mg] (Prizma, Prizma Forte)-[FC Tab 20, 60mg] PO Depression, Obsess-Compuls: Start 20mg 1x/d AM. Usual 20-40mg/d. Max 80mg/d. Bulimia: 60mg/d. ¶C. *L2. S.E: Anemia, amnesia, arrhythmias, blurred vision, cerebral embolism andischemia, confusion, edema, fever, hepatitis, hyperventilation, hypothyroidism, hypoxia, influenza-like symptoms, insomnia, photosensitivity, suicide attempt, stridor, syncope, tremors, thrombosis, seizures, weight loss, abnormal bleeding, hyponatremia, libido decreased, serotonin syndrome.</td>
    </tr>
    <tr>
      <td>fluvoxamine</td>
      <td>Favoxil, Fluvoxamine-Teva</td>
      <td>C</td>
      <td>Antidepressants – SSRI</td>
      <td>PSYCHIATRY</td>
      <td>fluvoxamine (Favoxil, Fluvoxamine-Teva)-[Tab 50, 100mg] PO Obsess-Compulsive disorder: Start 50-100mg at night. Usual 100-300mg/d in 2 divided dose. Max 300mg/d. Avoid theophylline and warfarin. ¶C. *L2. S.E: Anorexia, bleeding, hyponatremia, insomnia, impotence, mania/hypomania, palpitations, seizures, upper respiratory infection, serotonin syndrome, angle closure glaucoma.</td>
    </tr>
    <tr>
      <td>paroxetine</td>
      <td>Parotin, Paroxetine-Pfizer, Paxxet</td>
      <td>D</td>
      <td>Antidepressants – SSRI</td>
      <td>PSYCHIATRY</td>
      <td>paroxetine (Parotin, Paroxetine-Pfizer, Paxxet)-[Tab 20, 30mg] (Seroxat)-[Tab 20mg] PO Depression: Start 20mg/d in morning. Usual 20-50mg/d. Max 50mg/d. Obsess-Compuls: Start 20mg/d AM. Usual 20-40mg/d. Max 60mg/d. Panic Disorder: Start 10mg/d. Usual 10-60mg/d. Max 60mg/d. ¶D. *L2. S.E: Blurred vision, insomnia, impotence, libido decreased, myopathy, palpitations, tremors, vasodilation, seizures, hyponatremia, bleeding, bone fracture,.</td>
    </tr>
    <tr>
      <td>sertraline</td>
      <td>Lustral, Serenada</td>
      <td>C</td>
      <td>Antidepressants – SSRI</td>
      <td>PSYCHIATRY</td>
      <td>sertraline (Lustral, Serenada)-[Tab 50, 100mg] PO Start 50mg 1x/d. Usual 50-200mg/d. Max 200mg/d. ¶C. *L2. S.E: Altered platelet function, anorexia, bleeding, dizziness, hyponatremia, insomnia, seizures, suicide risk, tremors, weight loss, ejaculation failure, palpitations, acne.</td>
    </tr>
    <tr>
      <td>nardil</td>
      <td>NaN</td>
      <td>C</td>
      <td>Antidepressants – MAO Inhibitors</td>
      <td>PSYCHIATRY</td>
      <td>nardil (29 ג') (Phenelzine)-[Cap 15mg]. Initial dose: 15mg 3x/d. Early phase treatment: increase to at least 60mg/d for 4wks. Maintenance: reduce slowly over several weeks to 15mg/d a day or every other day. Continue as long as required. Patients should be avoided while taking nardil and for two weeks after discontinuing use: Pickled herring, liver, dry sausage, fava bean pods, sauerkraut, cheese, yogurt, beer and wine, yeast and meat extract, excessive amounts of chocolate and caffeine. ¶C. S.E: Hypertensive crises (occipital headache which may radiate frontally, palpitation, neck stiffness, vomiting, dilated pupils, photophobia, intracranial bleeding), myoclonic movements, weight gain, hypernatremia, postural hypotension, sexual disturbances, glaucoma, blurred vision, edema.</td>
    </tr>
    <tr>
      <td>bupropion</td>
      <td>Wellbutrin</td>
      <td>C</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>bupropion (Wellbutrin)-[Tab 150, 300mg] (Zyban)-[SR Tab 150mg] PO Start 150mg/d in the morning for 3d, then 150mg 2x/d. Max 300-400mg/d. Also used to combat drug dependence. ¶C. *L3. S.E: Anorexia, blurred vision, dyspnea, fever, hemorrhage, hypertension, insomnia, palpitations, Stevens-Johnson syndrome, tremors.</td>
    </tr>
    <tr>
      <td>duloxetine</td>
      <td>Cymbalta</td>
      <td>C</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>duloxetine (Cymbalta)-[Cap 30, 60mg] (Duloxetine DR Teva)-[Cap 20, 30, 60mg] PO &gt;12y: 40-60mg 1x/d. Max 120mg/d. Patienes should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior. For chronic musculoskeletal pain: start 30mg/d up to 60mg/d. ¶C. *L3. S.E: Hepatotoxicity, orthostatic hypotension, serotonin syndrome, seizures, dizziness, diarrhea, constipation.</td>
    </tr>
    <tr>
      <td>hypericum perforatum</td>
      <td>Laif</td>
      <td>N</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>hypericum perforatum (Laif)-[Tab 600mg] PO &gt;12y: 300-400mg 3x/d. ¶Not established. S.E: Photosensitivity, edema, dizziness, GI manifestations.</td>
    </tr>
    <tr>
      <td>maprotiline</td>
      <td>Melodil</td>
      <td>B</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>maprotiline (Melodil)-[FC Tab 25, 50mg] PO Start 25mg/d for 2wks. Adjust gradually to Max 150-225mg/d. ¶B. *L3. S.E: Blurred vision, edema, hallucinations, mania/hypomania, insomnia, impulsivity, suicide risk.</td>
    </tr>
    <tr>
      <td>mianserin</td>
      <td>Bonserin</td>
      <td>N</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>mianserin (Bonserin)-[Tab 30mg] PO Start 30mg/d in divided doses. Max 90mg/d. This treatment is associated with haematological and hepatic reactions, a full blood count is recommended durig treatment. ¶Not established. S.E: Bleeding, blurred vision, bone marrow depressions, dizziness, tremor, postural hypotension, hepatotoxicity, edema, hyponatremia.</td>
    </tr>
    <tr>
      <td>milnacipran</td>
      <td>Ixel</td>
      <td>C</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>milnacipran (Ixel)-[Cap 25, 50mg] PO day 1: 12.5mg/d, day 2-3: 12.5mg 2x/d, day 4-7: 25mg 2x/d, day &gt;7: 50mg 2x/d. ¶C(first trimester);D(second, third trimesters). *L3. S.E: Bleeding, dizziness, insomnia, hypertension, hyponatremia, mania/hypomania, palpitations, seizure, suicide risk, tachycardia, tremors.</td>
    </tr>
    <tr>
      <td>mirtazapine</td>
      <td>Miro, Mirtazapine-Teva</td>
      <td>C</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>mirtazapine (Miro, Mirtazapine-Teva)-[FC Tab 30, 45mg] (Remeron)-[Tab 30mg] PO Start 15mg/d. Increase to 30-45mg at nite in single or divided dose morning/evening. ¶C. *L3. S.E: Anorexia, dizziness, dyspnea, edema, hypertension, mania/hypomania, prolong QT, seizure, suicide risk, tremors.</td>
    </tr>
    <tr>
      <td>reboxetine</td>
      <td>Edronax</td>
      <td>N</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>reboxetine (Edronax)-[Tab 4mg] PO 4mg 2x/d. Increase after 3wks to 10mg/d. Max 12mg/d. ¶Not established. S.E: Blurred vision, dizziness, edema, insomnia, impotence, suicide risk, tachycardia.</td>
    </tr>
    <tr>
      <td>trazodone</td>
      <td>Trazodil</td>
      <td>C</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>trazodone (Trazodil)-[Tab 50, 100mg] (Trittico)-[Tab 100mg] PO Start 150mg/d in divided dose. Increase by 50mg/d every 3-4d. Usual 400-600mg/d. ¶C. *L2. S.E: Aggressiveness, blurred vision, dizziness, hypotension, impulsivity, palpitations, suicide risk, syncope, tachycardia, tremors.</td>
    </tr>
    <tr>
      <td>venlafaxine</td>
      <td>Efexor-XR, Venlafaxine-Teva, Viepax-XR</td>
      <td>C</td>
      <td>Antidepressants – Others</td>
      <td>PSYCHIATRY</td>
      <td>venlafaxine (Efexor-XR, Venlafaxine-Teva, Viepax-XR)-[ER Cap 75, 150mg] (Venla, Viepax)-[Tab 37.5, 75mg] PO Start 37.5mg 2x/d. Usual 150-225mg/d. Max 375mg/d. ¶C. *L3. S.E: Anorexia, bleeding, dizziness, eosinophilic pneumonia, hypertension, hyponatremia, insomnia, seizures, suicide risk, tachycardia, tremors.</td>
    </tr>
    <tr>
      <td>carbamazepine</td>
      <td>Tegretol</td>
      <td>D</td>
      <td>Antimanic</td>
      <td>PSYCHIATRY</td>
      <td>carbamazepine (Tegretol)-[Tab 200mg; Syrup 2%; CR Tab 200, 400mg] (Teril)-[Tab 200mg; CR Tab 200, 400mg] (Timonil)-[SR Tab 300, 600mg] PO 200mg 1-2x/d. Increase by 200mg/d every 2-4d. Usual 800-1200mg/d. ¶D. *L2. S.E: Arrhythmias, aplastic anemia, pancytopenia, bone marrow depression, blurred vision, drug reaction with eosinophilia and systemic symptoms syndrome, CHF, dyspnea, edema, eosinophilia, epilepsy, fever, jaundice, pancreatitis, renal failure, suicide risk, syncope, toxic epidermal necrolysis syndrome, SIADH, hyponatremia, Stevens-Johnson syndrome, agranulocytosis.</td>
    </tr>
    <tr>
      <td>lithium carbonate</td>
      <td>Licarbium</td>
      <td>D</td>
      <td>Antimanic</td>
      <td>PSYCHIATRY</td>
      <td>lithium carbonate (Licarbium)-[Tab 300mg] PO Start 300mg 2x/d. Usual  300mg=8mEq or mmol. Maint level: 0.6-1.2mEq/L. Increase of 300mg raises by approx 0.2mEq/L. Regular monitoring of the patient's clinical state and of serum lithium levels is necessary. Monitor kidney, thyroid. Avoid dehydration, salt restriction, NSAID. Diuretics and ACE inhibitors increase level. ¶D. *L3 (with close observation). S.E: Lithium toxicity, albuminuria, hypothyroidism, anorexia, arrhythmias, blurred vision, coma, ECG changes, seizures, fever, hypotension, tremors, stupor, vertigo neurotoxicity, edema, acne vulgaris, impotence, leukocytosis, GI manifestations.</td>
    </tr>
    <tr>
      <td>valproic acid</td>
      <td>Depalpet, Depalpet-Chrono</td>
      <td>D</td>
      <td>Antimanic</td>
      <td>PSYCHIATRY</td>
      <td>valproic acid (Depalpet, Depalpet-Chrono)-[Tab 200, 500mg; EC Tab/SR 500mg; Soln 200mg/ml; Syrup 200mg/5ml] (Orfiril Inject)-[Amp 300mg/3ml] (Valporal)-[Cap 200mg; Syrup 200mg/5ml] PO 250mg 3x/d. ¶D-When treating epilepsy;X-When treating migraine. *L4. S.E: Anaphylaxis, anorexia, edema, decreased bone density, blurred vision, hearing loss, increased appetite, weight gain, tremor, hepatotoxicity, hypotension, pancreatitis, seizure, hypothermia, thrombocytopenia, pancreatitis, hepatotoxicity, infection, weight loss or gain, cutaneous vasculitis, seborrhea; , drug reaction with eosinophilia and systemic symptoms syndrome.</td>
    </tr>
    <tr>
      <td>topiramate</td>
      <td>Topamax, Topitrim</td>
      <td>D</td>
      <td>Antimanic</td>
      <td>PSYCHIATRY</td>
      <td>topiramate (Topamax, Topitrim)-[Tab 25, 50, 100, 200mg] (Topiramate Teva)-[Tab 25, 50, 100, 200, 300, 400mg] PO Start 25-50mg/d, should be incrased weekly to an effective dose by increments of 25-50mg. Recommended: 200-400mg/day in 2 divided doses. ¶D. *L3. S.E: Anorexia, abnormal vision, fever, hyperthermia, metabolic acidosis, encephalopathy.</td>
    </tr>
    <tr>
      <td>chlorpromazine</td>
      <td>NaN</td>
      <td>C</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>chlorpromazine (29 ג') (Largactil)-[Amp 50mg/2ml] PO IM Start 10-50mg 2-3x/d. Usual 300-800mg/d. ¶C. *L3. S.E: Blood dyscrasia, hypertonia, tardive dyskinesia, tardive dystonia, extrapyramidal syndrome, akathisia, parkinsonism, convulsions, constipation, anxiety, aggravation of schizophrenic symptoms, blurred vision, urinary retention, impotence, contact dermatitis, postural hypotension, ECG changes, hyperprolactinemia, body temperature regulation disorder, respiratory depression, cholestatic jaundice, raised antinuclear antibody titer.</td>
    </tr>
    <tr>
      <td>clothiapine</td>
      <td>Entumin</td>
      <td>N</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>clothiapine (Entumin)-[Tab 40mg] PO 120-160mg/d. Max 360mg/d. ¶Not established. S.E: Blurred vision, dystonia, orthostatic hypotension, neuroleptic malignant syndrome, pseudoparkinsonism, QT prolongation.</td>
    </tr>
    <tr>
      <td>flupentixol</td>
      <td>Fluanxol</td>
      <td>N</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>flupentixol (Fluanxol)-[Tab 3mg] (Fluanxol Depot)-[Amp 20, 100mg/ml] PO Neuroleptic: Start 3-15mg/d in divided doses. Increase if necessary after 1wk. Max 40mg/d in divided dose. IM 0.5-4ml 1x/wk for 4wk. ¶Not established. S.E: Insomnia, fainting, palpitations, pseudo parkinsonism, tremors.</td>
    </tr>
    <tr>
      <td>fluphenazine</td>
      <td>Fludecate</td>
      <td>C</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>fluphenazine (Fludecate)-[Amp 25mg (Depot)] PO Start 0.5-10mg/d in divided doses. Usual 1-20mg/d. Depot: IM SC 12.5-25mg every 3-4wks. Max 100mg. ¶C. *L3. S.E: Drowsiness, edema, hypertension, jaundice, leukopenia, neutropenia, neuroleptic malignant syndrome, tardive dyskinesia, dystonia, akathisia, pseudoparkinsonism, tremors, sudden death.</td>
    </tr>
    <tr>
      <td>haloperidol</td>
      <td>Haldol</td>
      <td>C</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>haloperidol (Haldol)-[Tab 5mg; Amp 5mg/ml; Drops 2mg/ml; Depot 100 mg/ml] (Haloper)-[Tab 0.5, 5, 10mg] (Pericate)-[Amp 100mg/ml (Depot)] IM 2-5mg. PO Start 0.5-5mg 2-3x/d. Usual 6-20mg/d. Therapeutic: 2-15mg/ml. Depot: IM Start 100mg every 4wks. Peds: 3-12yrs: 0.5mg/d. May increase 0.5mg every 5-7d. ¶C. *L2. S.E: Extrapyramidal disorder, hyperkinesia, tardive dyskinesia, dystonia, akathisia, bradykinesia, hypertonia, tremor, parkinsonism, insomnia, constipation, urinary retention, erectile dysfunction, orthostatic hypotension, weight changes, oculogyric crisis, hyperthermia.</td>
    </tr>
    <tr>
      <td>levomepromazine, methotrimeprazine</td>
      <td>Nozinan, Ronexine</td>
      <td>N</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>levomepromazine, methotrimeprazine (Nozinan, Ronexine)-[Tab 25, 100mg] PO Start 25-200mg/d. Max 400mg/d. Pain: 50mg 2-5x/d. ¶Not established.S.E: Blurred vision, confusion, tremors, jaundice, extrapyramidal disorder, akathisia, hyperkinesia, hypertonia, tardive dyskinesia.</td>
    </tr>
    <tr>
      <td>perphenazine</td>
      <td>Perphenan</td>
      <td>C</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>perphenazine (Perphenan)-[Tab 4, 8mg] PO Tranquilizer: 4-8mg 3x/d. Usual 8-40mg/d. Antiemetic: 8-16mg/d 2-3x/d in divided dose. Max 65mg/d. ¶C. *L3. S.E: Parkinsonian symptoms, neuroleptic malignant syndrome, tardive dyskinesia, acute dystonia.</td>
    </tr>
    <tr>
      <td>pimozide</td>
      <td>Orap Forte</td>
      <td>C</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>pimozide (Orap Forte)-[Tab 4mg] PO Start 1-2mg/d. Usual 2-8mg/d. Max 10mg/d. ¶C. *L4. S.E: Somnolence, extrapyramidal disorder, akathisia, lethargy, tremor, hyperkinesia, nocturia, constipation, muscle rigidity, weight changes, abnormal ECG.</td>
    </tr>
    <tr>
      <td>risperidone</td>
      <td>Risperdal, Risperidex, Rispond</td>
      <td>C</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>risperidone (Risperdal, Risperidex, Rispond)-[Tab 1, 2, 3, 4mg] (Risperdal)-[Powdr 25, 37.5, 50mg/vial] (Rispond)-[Soln 1mg/ml] PO Schizophrenia: start 2mg/d, fallowing 4-8mg/d. Max 16mg/d. Bipolar mania: start 2-3mg/d, fallowing 1-6mg/d. IM 25mg/d every 2wks. Max 50mg/d. ¶C. *L3. S.E: Stroke, hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, seizure, parkinsonism, blurred vision, nasopharyngitis</td>
    </tr>
    <tr>
      <td>sulpiride</td>
      <td>Modal, Modal Forte</td>
      <td>N</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>sulpiride (Modal, Modal Forte)-[Cap 50, 200mg] PO Acute schizophrenia: start 200-600mg 2x/d. Max 1200mg 2x/d. Antineuroses, anti-vertigo: 150-300mg/d. ¶Not established. S.E: Aggression, blurred vision, dizziness, edema, fever, jaundice, seizure.</td>
    </tr>
    <tr>
      <td>thioridazine</td>
      <td>Ridazin</td>
      <td>N</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>thioridazine (Ridazin)-[Tab 10, 25, 100mg] PO start 50-100mg 3x/d. Usual 200-800mg/d. Max 800mg/d. Pigmentary retinopathy. ¶Not established. *L2. S.E: Anemia, arrhythmias, blurred vision, edema, jaundice, orthostatic hypotension, neuroleptic malignant syndrome, pigmentary retinopathy, QT-prolongation, sudden death, tremors, blood dyscrasia, infertility, premature ejaculation, dysorgasmia, decreased libido.</td>
    </tr>
    <tr>
      <td>trifluoperazine hydrochloride</td>
      <td>NaN</td>
      <td>C</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>trifluoperazine hydrochloride (29 ג') (Trifluperazine)-[Tab 10mg] PO Schizophrenia: start 2-5mg 2x/d. Maintenance 15-20mg/d. Max 40mg/d. Anxiety: 1-2mg 2x/d. Max 6mg/d. ¶C. *L3. S.E: Extrapyramidal disorder, akathisia, parkinsonism, neuroleptic malignant syndrome, lenticular and corneal deposits, hyperprolactinemia.</td>
    </tr>
    <tr>
      <td>zuclopenthixol</td>
      <td>Clopixol</td>
      <td>C</td>
      <td>Antipsychotics - 1st generation - Typical</td>
      <td>PSYCHIATRY</td>
      <td>zuclopenthixol (Clopixol)-[Tab 2, 10, 25mg; Drops 20mg/ml 1drop=1mg] (Clopixol Acuphase)-[Amp 50mg/ml] (Clopixol Depot)-[Amp 200, 500mg/ml] IM Acute: 50-150mg. Repeat after 2-3d. Maint: PO 10-50mg in divided dose. Usual 20-40mg/d. Max 150mg/d. Depot: 200mg every 2-4wks. Usual 0.5-1mg/ml in 1-4wks. Max 600mg. ¶C. *L3. S.E: Bladder outflow obstruction, blurred vision, hyperglycemia, hyperprolactinemia, hypotension, jaundice, leucopenia, palpitations, parkinsonism, priapism, seizures, tachycardia, thrombocytopenia, tremor, VT, vertigo.</td>
    </tr>
    <tr>
      <td>amisulpride</td>
      <td>Solian</td>
      <td>N</td>
      <td>Antipsychotics – 2nd generation - Atypical</td>
      <td>PSYCHIATRY</td>
      <td>amisulpride (Solian)-[Tab 100, 400mg] PO Start 50-300mg/d in single or divided dose. Usual 400-800mg/d. Negative symptoms: 100mg/d. ¶Not established. S.E: Bradycardia, hyperglycemia, hypokalemia, hypotension, insomnia, leukopenia, neutropenia, QT-prolongation, seizure, stroke, tremors.</td>
    </tr>
    <tr>
      <td>aripiprazole</td>
      <td>Abilify</td>
      <td>C</td>
      <td>Antipsychotics – 2nd generation - Atypical</td>
      <td>PSYCHIATRY</td>
      <td>aripiprazole (Abilify)-[Tab 5, 10, 15, 30mg] PO Schizophrenia: 10-15mg/d. Bipolar disorder: 15mg/d. Depression: start 2-5mg/d. Max 15mg/d. ¶C. *L3. S.E: Agitation, insomnia, suicidal ideation, akathisia, extrapyramidal disorder, weight gain, tachycardia, hypertension, hyperprolactinemia, dysmenorrhea, erectile dysfunction, nephrolithiasis.</td>
    </tr>
    <tr>
      <td>clozapine</td>
      <td>Leponex</td>
      <td>B</td>
      <td>Antipsychotics – 2nd generation - Atypical</td>
      <td>PSYCHIATRY</td>
      <td>clozapine (Leponex)-[Tab 25, 100mg] (Lozapine)-[Tab 25, 100mg] PO Start 12.5-25mg/d. Increase gradually. Usual 300-450mg/d. Max 900mg/d. ¶B. *L3. S.E: Cardiomyopathy, sedation, blood dyscrasia, hypersalivation, hypertension, hypotension, fever, metabolic changes, myocarditis, pulmonary embolism, seizure, tachycardia, QT-prolongation.</td>
    </tr>
    <tr>
      <td>olanzapine</td>
      <td>Olanzapine, Zyprexa</td>
      <td>C</td>
      <td>Antipsychotics – 2nd generation - Atypical</td>
      <td>PSYCHIATRY</td>
      <td>olanzapine (Olanzapine, Zyprexa)-[Tab 5, 7.5, 10mg; Amp 10mg/2ml] (Olanzapine Teva, Zappa)-[Tab 5, 7.5, 10mg] (Zappa ODT)-[Tab orodispersible 5, 10mg] (Zypadhera)-[Amp 210, 300, 405mg] (Zyprexa Velotab)-[Tab 5, 10mg] PO Start 5-10mg 1x/d. Usual 10mg/d. Max 20mg/d. ¶C. *L2. S.E: Bradycardia, leukopenia, metabolic changes, neuroleptic malignant syndrome, neutropenia, orthostatic hypotension, seizures, suicide risk, tachycardia, weight gain.</td>
    </tr>
    <tr>
      <td>paliperidone as palmitate</td>
      <td>Invega</td>
      <td>C</td>
      <td>Antipsychotics – 2nd generation - Atypical</td>
      <td>PSYCHIATRY</td>
      <td>paliperidone as palmitate (Invega)-[Tab ER 3, 6, 9mg] (Trevicta)-[Susp 200mg/1ml] (Xeplion)-[Susp 100mg/1ml] PO 6mg 1x/d; Max 12mg/d. Adolescents 12-17yrs: 3mg 1x/d. Max &lt;51kg:6mg/d. &gt;51kg: 12mg/d. IM Schizophrenia: day 1: 234md/d; day 8:156mg/d. Max monthly dose 234mg. ¶C. *L3. S.E: Stroke, QT prolongation, hyperglycemia, dyslipidemia, weight gain, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, seizures, dizziness.</td>
    </tr>
    <tr>
      <td>quetiapine</td>
      <td>Quenti</td>
      <td>C</td>
      <td>Antipsychotics – 2nd generation - Atypical</td>
      <td>PSYCHIATRY</td>
      <td>quetiapine (Quenti)-[Tab 25mg] (Quetiapine-Teva, Seroquel)-[Tab 25, 100, 200, 300mg; XR 50, 150, 200, 300, 400mg] PO Schizophrenia: Start 25mg 2x/d. Usual 150-750mg/d. ¶C. *L2. S.E: Anorexia, blurred vision, cataract formation, deep thrombophlebitis, dizziness, dyspnea, fever, palpitations, parkinsonism, QT-prolongation, suicide risk, syncope, tachycardia, tremor, vasodilatation.</td>
    </tr>
    <tr>
      <td>risperidone</td>
      <td>Risperdal, Rispond</td>
      <td>C</td>
      <td>Antipsychotics – 2nd generation - Atypical</td>
      <td>PSYCHIATRY</td>
      <td>risperidone (Risperdal, Rispond)-[Tab 1, 2, 3, 4mg; Soln 1mg/ml] (Risperdal Consta)-[Amp 25, 37.5, 50mg] (Risperidex)-[Tab 1, 2, 3, 4mg] PO Start 0.5-1mg 2x/d. Increase weekly interval. Usual 4-8mg/d in single or divided dose. Max 16mg/d. &lt;50kg: start 0.25mg 1x/d. IM 25-50mg every 2wks. ¶C. *L3. S.E: Blurred vision, dizziness, leukopenia, neutropenia, parkinsonism, priapism, seizures, tachycardia, tremor, hyperprolactinemia.</td>
    </tr>
    <tr>
      <td>ziprasidone</td>
      <td>Geodon</td>
      <td>C</td>
      <td>Antipsychotics – 2nd generation - Atypical</td>
      <td>PSYCHIATRY</td>
      <td>ziprasidone (Geodon)-[Cap 20, 40, 60, 80mg; Amp 20mg] PO start 20mg 2x/d. 40mg 2x/d. Max 160mg/d. IM 10-20mg. Max 40mg. ¶C. *L2. S.E: Diabetes mellitus, DRESS, hyperglycemia, leukopenia, neutropenia, orthostatic hypotension, priapism, QT-prolongation, seizures, Steven-Johnson syndrome, suicide risk.</td>
    </tr>
    <tr>
      <td>donepezil</td>
      <td>Aricept, Asenta, Donepezil, Memorit</td>
      <td>C</td>
      <td>Alzheimer’s Disease</td>
      <td>PSYCHIATRY</td>
      <td>donepezil (Aricept, Asenta, Donepezil, Memorit)-[Tab 5, 10mg] PO Start 5mg 1x/d at night. May increase in 4-6wks to 10mg/d. ¶C. *L3. S.E: Anorexia, blurred vision, bradycardia, bone fracture, cataract, dizziness, dyspnea, hallucinations, hypertension, hypotension, GI hemorrhage, muscle cramps, seizures, syncope, tremor, vasodilation, vertigo.</td>
    </tr>
    <tr>
      <td>galantamine</td>
      <td>Reminyl</td>
      <td>B</td>
      <td>Alzheimer’s Disease</td>
      <td>PSYCHIATRY</td>
      <td>galantamine (Reminyl)-[Tab 4, 8mg; PCR 8, 16, 24mg] PO Start 4mg 2x/d 4wks taken with meals. Max 12mg 2x/d. ¶B. S.E: Anemia, anorexia, atrial arrhythmias, bladder outflow obstruction, hematuria, GI hemorrhage, QT-prolongation, palpitation, seizures, syncope, tremor, vertigo.</td>
    </tr>
    <tr>
      <td>rivastigmine</td>
      <td>Alzigmine, Exelon, Rivastigmine-Dexcel</td>
      <td>B</td>
      <td>Alzheimer’s Disease</td>
      <td>PSYCHIATRY</td>
      <td>rivastigmine (Alzigmine, Exelon, Rivastigmine-Dexcel)-[Cap 1.5, 3, 4.5, 6mg; Patches 4.6, 9.5, 27mg] (Rivastigmine-Inovamed)-[Tab 1.5mg] PO Start 1.5mg 2x/d for minimum 2wks. Max 6mg 2x/d. Patch: Only one patch should be worn at a time and the patch should be replaced by a new one after 24h. ¶B. S.E: Anorexia, bradycardia, hallucination, hypersensitivity, hypertension, GI hemorrhage, parkinsonism, seizures, syncope, tremor, worsening Parkinson.</td>
    </tr>
    <tr>
      <td>methylphenidate</td>
      <td>Concerta</td>
      <td>C</td>
      <td>Sympathomimetics / Stimulants</td>
      <td>PSYCHIATRY</td>
      <td>methylphenidate (Concerta)-[ER Tab 18, 27, 36, 54mg] (Medikinet MR)-[Tab 5, 10, 20, 30, 40mg] (Ritalin, Ritalin SR)-[Tab 10mg; SR Tab 20mg; MR Tab 5, 10, 20, 30, 40mg] PO Narcolepsy, ADD, ADHD: Start 5-10mg 2-3x/d or 1ER Tab/d. Avoid night dose. Max 60mg/d. Individualized dosing. ¶C. *L3. S.E: Aggressive behavior, blurred vision, hypertension, tachyarrhythmia, Tourette's syndrome, MI, priapism, Raynaud’s phenomenon, seizure, sudden death, stroke, psychotic disorder with prolonged use.</td>
    </tr>
    <tr>
      <td>modafinil</td>
      <td>Provigil</td>
      <td>C</td>
      <td>Sympathomimetics / Stimulants</td>
      <td>PSYCHIATRY</td>
      <td>modafinil (Provigil)-[Tab 100mg] PO Narcolepsy: 150-250mg/d single dose. ¶C. *L4. S.E: Anorexia, cardiac arrhythmia, dyspnea, hypertension, hypersensitivity, influenza-like illness, Stevens-Johnson syndrome, tremor.</td>
    </tr>
    <tr>
      <td>alfacalcidol</td>
      <td>vitamin D</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>alfacalcidol (vitamin D) (One-Alpha)-[Cap 0.25µg] (Alpha D3)-[Cap 0.25, 0.5, 1µg; Drops 0.25µg/drop] (Tevalfa)-[Cap 0.25, 1µg].PO 1µg/d. Osteoporosis: 0.5µg/d. Peds: &lt;20kg: 0.05µg/kg/d. ¶C. S.E: Hypercalcemia, hyperphosphatemia, urticaria, nephrocalcinosis, renal impairment.</td>
    </tr>
    <tr>
      <td>ascorbic acid+others</td>
      <td>Cernevit</td>
      <td>A</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>ascorbic acid+others (Cernevit)–[Soln 125mg/vial] IV 1vial/d. ¶A(Dose within RDA); C(dose exceeding RDA). *L1(low dose); L5(IV dose). S.E: Anaphylactic shock.</td>
    </tr>
    <tr>
      <td>ascorbic acid+others</td>
      <td>Multi 12/K1 Pediatric</td>
      <td>A</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>ascorbic acid+others (Multi 12/K1 Pediatric)–[Soln 80mg/4ml] IV 1vial/d. ¶A(Dose within RDA); C(dose exceeding RDA). *L1(low dose); L5(IV dose). S.E: Anaphylactoid reactions, headache, dizziness, agitation, anxiety, diplopia.</td>
    </tr>
    <tr>
      <td>ascorbic acid+others</td>
      <td>Soluvit</td>
      <td>A</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>ascorbic acid+others (Soluvit)–[Soln 100mg/vial] IV 1vial/d ¶A(Dose within RDA); C(dose exceeding RDA). *L1(low dose); L5(IV dose). S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>ascorbic acid+others</td>
      <td>Prenatal</td>
      <td>A</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>ascorbic acid+others (Prenatal)–[Tab 100mg] PO 1Tab/d. ¶A(Dose within RDA); C(dose exceeding RDA). *L1(low dose); L5(IV dose). S.E: Allergic reactions.</td>
    </tr>
    <tr>
      <td>calcitriol</td>
      <td>vitamin D</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>calcitriol (vitamin D) (Vitamin D3 1000)-[Tab 1000IU] IV Start 0.5µg or 0.01µg/kg 3x/wk. ¶C. *L3. S.E: Hypercalcemia, hypercalciuria.</td>
    </tr>
    <tr>
      <td>cyanocobalamin</td>
      <td>vitamin B12</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>cyanocobalamin (vitamin B12) (Bedodeka)-[Amp 1000µg/ml] SC IM 100µg/d for 6-7d. ¶C. *L4. S.E: Abdominal pain, bullous eruption, depression ,palpitation, pruritus, syncope, peripheral vascular thrombosis, anaphylaxis, accelerated optic nerve atrophy.</td>
    </tr>
    <tr>
      <td>cyanocobalamin+others</td>
      <td>Shalosh B, Tribemin</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>cyanocobalamin+others (Shalosh B, Tribemin)-[Tab 0.25mg] PO 1-2Tab/d. ¶C. *L4. S.E: Rash.</td>
    </tr>
    <tr>
      <td>fat soluble vitamins</td>
      <td>vitamins A,D,E,K</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>fat soluble vitamins (vitamins A,D,E,K) (Vitamins A, D, E, K+Zinc)-[Tab] PO 2 Tab/d. Peds: 1Tab/d. ¶C. *L3. S.E: None.</td>
    </tr>
    <tr>
      <td>folic acid</td>
      <td>Folic Acid</td>
      <td>A</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>folic acid (Folic Acid)-[Tab 5, 10mg] (Foli 5)-[Tab 5mg] PO 5-10mg/d. ¶A. *L1. S.E: Anaphylactic shock.</td>
    </tr>
    <tr>
      <td>isotretinoin A</td>
      <td>Avipur</td>
      <td>X</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>isotretinoin A (Avipur)-[Tab 50,000IU] PO 1Tab/d for 14d. ¶X. *L5. S.E: Blood dyscrasia, blepharitis, conjunctivitis, mucosal dryness, increased liver enzymes, dermatitis, hyperlipidemia, hyperglycemia.</td>
    </tr>
    <tr>
      <td>leucovorin</td>
      <td>Leucovorin</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>leucovorin (Leucovorin)-[Tab 15mg; Amp 10, 50mg/ml] Folate rescue: PO 15mg 4x/d 2-3d. IM IV individualized dosing. ¶C. *L3. S.E: Leucopenia, thrombocytopenia, Stevens Johnson syndrome, toxic epidermal necrolysis, seizures, syncope.</td>
    </tr>
    <tr>
      <td>niacin</td>
      <td>Niaspan</td>
      <td>A</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>niacin (Niaspan)-[Tab 500, 750, 1000mg] PO 1-4wk: 500mg/d at bedtime. 5-8wk: 1000mg/d at bedtime. After 8wks titrate to patient response. ¶A. *L3. S.E: Hepatotoxicity, hyperuricemia, hyperglycemia, tachycardia, atrial fibrillation, orthostasis, syncope, hypotension, dyspnea.</td>
    </tr>
    <tr>
      <td>multivitamin</td>
      <td>Centrum Junior Advanced+Iron, Gerimax Junior</td>
      <td>N</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>multivitamin (Centrum Junior Advanced+Iron, Gerimax Junior)-[Chew Tab] (Centrum Plus, Centrum Silver, Gerimax NF, Materna, Ocuvite, Optima, Optima Best Years, Optima Junior, Pluviton, Prenatal, Stresstabs 600 with Zinc)-[Tab] (Geriatric)-[Cap] (Polyvit, Polyvit 30 Plus)-[Tab/Cap/Drops] (Supradyn, Supradyn N)-[Tab/Effervesc Tab] (Kiddi, Vi-Daylin Plus Iron, Vitamult)-[Syrp] (Pluviton B)-[Drops] PO Usual 1Tab/Cap/d. Peds: ½-1Tab/d. Soln: 5-15ml/d. Drops: dose varies by age. ¶Not established. S.E: None.</td>
    </tr>
    <tr>
      <td>phytomenadione</td>
      <td>vitamin K</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>phytomenadione (vitamin K) (Konakion)-[Amp 2, 10mg] Mild hemorrhage: IM SC 5-10mg. Severe hemorrhage during anticoagulant therapy: IM SC 10-20mg. Peds: Hypoprothrombinemia Prophylaxis: IM: 0.5-1mg. Vitamin K Deficiency: IM 0.5-1mg. Dose varies by INR and clinical situation. ¶C. *L1. S.E: Anaphylactoid reactions, phlebitis.</td>
    </tr>
    <tr>
      <td>pyridoxine</td>
      <td>vitamin B6</td>
      <td>A</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>pyridoxine (vitamin B6) (B-Six)-[Tab 300mg] PO Sideroblastic anemia: 200-600mg/d, then decrease to 30-50mg/d. Nausea/vomiting of pregnancy: 25mg 3xd. ¶A. *L2. S.E: Sensory neuropathy with axonal degeneration, allergic contact dermatitis.</td>
    </tr>
    <tr>
      <td>tocopherol</td>
      <td>vitamin E</td>
      <td>A</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>tocopherol (vitamin E) (Evitol)-[Tab 100, 200, 400mg] PO 200-400mg/d. Max 800mg/d. ¶A(Dose within RDA); C(dose exceeding RDA) S.E: None.</td>
    </tr>
    <tr>
      <td>vitamin B1+B6+B12</td>
      <td>Tribemin, Shalosh B</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>vitamin B1+B6+B12 (Tribemin, Shalosh B)-[Tab 100mg+250mg+250µg] PO 1-2Tab/d. ¶C. *L2. S.E: Rash.</td>
    </tr>
    <tr>
      <td>water soluble vitamins</td>
      <td>Soluvit-N</td>
      <td>B</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>water soluble vitamins (Soluvit-N)-[Amp] IV vitamin supplementation adults 1Amp/d. Peds 0.1Amp/kg/d. ¶B. *L2. S.E: None.</td>
    </tr>
    <tr>
      <td>zinc as oxide</td>
      <td>Zinc Lotion Vitamed</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>zinc as oxide (Zinc Lotion Vitamed)-[Lotion 20G/100ml] Dermal: Apply to area as often as necessary. ¶C. *L2. S.E: Itching, rash.</td>
    </tr>
    <tr>
      <td>zinc as sulfate</td>
      <td>Zincol Enteric</td>
      <td>C</td>
      <td>Vitamins_2</td>
      <td>NUTRITIONALS</td>
      <td>zinc as sulfate (Zincol Enteric)-[Tab 50mg] PO 1Tab/d. ¶C .S.E: Nausea, vomiting.</td>
    </tr>
    <tr>
      <td>calcium</td>
      <td>NaN</td>
      <td>s</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>calcium () ¶safe, avoid excessive use. *L3. S.E: Hypercalcemia, calcium nephrolithiasis, peripheral vasodilation, hypotension, syncope, vasospastic angina, serious cardiac arrhythmias, AV dissociation, shock, polyuria.</td>
    </tr>
    <tr>
      <td>calcium carbonate</td>
      <td>Calcimore</td>
      <td>s</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>calcium carbonate (Calcimore)-[Chew Tab 600mg] (N-Zarevet)-[Chew Tab 500mg] (Tums, Tums Ex, Tums Ultra Assorted)-[Chew Tab 500, 750, 1000mg] PO Antiacid: 1-2Tab after meals. Calcium supplement: 1200mg 1-3x/d. ¶safe, avoid excessive use.</td>
    </tr>
    <tr>
      <td>calcium carbonate+calcium lactate gluconate+D</td>
      <td>Calcium-D-Sandoz</td>
      <td>C</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>calcium carbonate+calcium lactate gluconate+D (Calcium-D-Sandoz)-[Effervesc Tab 1050+1358+4mg] PO 1Tab 1-2x/d in water. ¶C.</td>
    </tr>
    <tr>
      <td>calcium carbonate+calcium gluconate</td>
      <td>Calcium Sandoz</td>
      <td>C</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>calcium carbonate+calcium gluconate (Calcium Sandoz)-[Effervesc Tab 350.3+149.7mg] 1Tab 1-2x/d in water. ¶C.</td>
    </tr>
    <tr>
      <td>calcium gluconate</td>
      <td>Calcium Gluconate- Fresenius, Calcium Gluconate 10% Injection B.P</td>
      <td>C</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>calcium gluconate (Calcium Gluconate- Fresenius, Calcium Gluconate 10% Injection B.P)-[Amp 10. IV IM 1-2G/d. Peds 6-12yrs: Slow IV 600-1000mg/d. Peds 1-5yrs: Slow IV 300-600mg/d. Peds up to 1yr: Slow IV max 300mg/d. ¶C. *safe.</td>
    </tr>
    <tr>
      <td>fluoride</td>
      <td>Duraphat</td>
      <td>B</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>fluoride (Duraphat)-[Soln 50mg/ml] (Elmex)-[Jelly] (Fluden Forte)-[Tabs 2.2mg] (Fluvium)-[Tab 5, 20mg] (Teeth Tough)-[Drops 0.25mg/2drops] (Zymafluor)-[Tab 2.211mg] Mouth rinse. PO dose should be adjusted to fluoride content of drinking water. ¶B. *L2. S.E: None.</td>
    </tr>
    <tr>
      <td>iron</td>
      <td>NaN</td>
      <td>s</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>iron () ¶safe, avoid excessive use. *L1. S.E: Constipation, diarrhea, melena.</td>
    </tr>
    <tr>
      <td>ferrous citrate+calcium citrate</td>
      <td>Ferrocal</td>
      <td>s</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>ferrous citrate+calcium citrate (Ferrocal)-[Tab 246+249mg] PO Anemia: 1Tab 3-4x/d. Peds: ½-1Tab 2-3x/d. Prophylaxis: 1Tab/d. ¶safe.</td>
    </tr>
    <tr>
      <td>ferrous fumarate+folic acid</td>
      <td>Forol</td>
      <td>s</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>ferrous fumarate+folic acid (Forol)-[Tab 100mg+400µg] PO 1Tab/d. Anemia: 1-3Tab/d. ¶safe. *L2.</td>
    </tr>
    <tr>
      <td>ferrous gluconate</td>
      <td>Ferro 15</td>
      <td>A</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>ferrous gluconate (Ferro 15) [Syr 130mg/5ml (15mg elemental iron)] PO Anemia: max 2mg(0.66ml)/kg/d. Prophylaxis: 1mg(0.33ml)/kg/d. Peds 0-2yrs: Max 15mg/d. ¶A. *L2.</td>
    </tr>
    <tr>
      <td>ferrous polysaccharide</td>
      <td>Ferripel-3</td>
      <td>A</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>ferrous polysaccharide (Ferripel-3)-[Syr 50 mg/5ml] (Tiptipot Ferripel-3)-[Drops 50 mg/ml=20drops (50mg elemental iron)] PO Anemia: Adults: 113-200mg(45-60drops or 10-20ml)/d. Peds: up to 6mg(2drops or 6ml)/kg/d. Prophylaxis: Adults: 38-75mg(15-30drops or 5-10ml)/d. Peds: 1mg/kg/d. ¶A. *L2.</td>
    </tr>
    <tr>
      <td>ferrous polysaccharide+folic acid</td>
      <td>Ferrifol, Foric, Folex</td>
      <td>A</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>ferrous polysaccharide+folic acid (Ferrifol, Foric, Folex)-[Tab 100mg (100mg elemental iron)+0.4mg] Anemia: PO 1Tab 3x/d. Prophylaxis: 1Tab/d. ¶A. *L2.</td>
    </tr>
    <tr>
      <td>ferrous sulfate</td>
      <td>Tardyferon</td>
      <td>A</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>ferrous sulfate (Tardyferon)-[Tab 256.3mg (80mg elemental iron)] PO 1Tab/d before meal. Pregnancy: 75mg/d. ¶A. *L2. S.E: Dyspnea, gastritis.</td>
    </tr>
    <tr>
      <td>ferrous sulfate+folic acid</td>
      <td>Ferrograd Folic</td>
      <td>A</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>ferrous sulfate+folic acid (Ferrograd Folic)-[Tab 325mg (105mg elemental iron)+350µg] PO 1Tab/d. ¶A. *L2. S.E: Anaphylactic shock, bowel obstruction, dyspnea, hematemesis, melena.</td>
    </tr>
    <tr>
      <td>iron sucrose</td>
      <td>Ferrovin</td>
      <td>B</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>iron sucrose (Ferrovin)-[Amp 20mg/ml] IV 20-40mg 1-3x/wk depending on Hb level. Slow infusion, diluted. Infants: 0.15ml/kg/d. ¶B. S.E: Hypotension, phlebitis and vein spasms in the injected area of the punctured vein, dyspnea, bronchospasm, shock.</td>
    </tr>
    <tr>
      <td>magnesium sulfate</td>
      <td>Magnesium Sulfate</td>
      <td>D</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>magnesium sulfate (Magnesium Sulfate)-[Amp 500mg/ml] IM: Hypomagnesemia: 1G 4x/d as needed. IV: Ventricular arrhythmia: Start 1-3g over 2-15min, then 1-2G by continuous IV infusion. ¶D. *L1. S.E: Hypotension, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression proceeding to respiratory paralysis.</td>
    </tr>
    <tr>
      <td>potassium</td>
      <td>Potassium Oral Solution</td>
      <td>C</td>
      <td>Minerals</td>
      <td>NUTRITIONALS</td>
      <td>potassium (Potassium Oral Solution)-[Soln 5ml=10mEq] (Slow-K)-[SR Tab 600mg=8mEq] (Uralyt-U)-[Granules 2.427G/1measuring spoonful] (Potassium Chloride)-[Soln 14.9G/100ml] (Tranxal= Potassium Clorazepate)-[Cap 5, 15mg] Prevention and treatment of hypokalemia: PO 2-3Tab/d. Oral Solution: 10ml 2-4x/d. Peds: 2-3mEq/kg/d in divided doses. IV Solution: Dose and rate should be adjusted according to ECG and serum electrolyte determinations. Max daily dose 2-3mmol/kg/d. Max infusion rate up to 20mmol/h. Granules dissolution of uric acid stones: 4 measuring spoonful divided in 3 doses, after meals. Metaphylaxis of calcium containing renal calculi: 2-3 measuring spoonful as single dose in the evening. Anxiety and alcohol withdrawal relief: PO Cap 5-90mg/d. ¶C. S.E: Severe allergic reactions, severe muscle weakness, arrhythmia, acidosis, hyperkalemia.</td>
    </tr>
    <tr>
      <td>alfentanil</td>
      <td>Rapifen</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>alfentanil (Rapifen)-[Amp 0.5mg/ml] IV adjunct. Specialized dosing. ¶C. *L2. S.E: Hypertension, arrhythmias, bradycardia, tachycardia, hypotension, asystole, sinus arrest, apnea, postoperative respiratory depression, bronchospasm, hypercarbia, laryngospasm, anaphylaxis.</td>
    </tr>
    <tr>
      <td>desflurane</td>
      <td>Sulorane</td>
      <td>B</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>desflurane (Sulorane)-[Liq 100%] Inhalation anesthetic. ¶B. S.E: Apnea, laryngospasm, oxyhemoglobin desaturation, pharyngitis, respiratory failure, respiratory distress, hemoptysis, hypoxia, acute pancreatitis, hypertension, arrhythmia, myocardial ischemia, hemorrhage, cardiac arrest, Torsade de pointes, ventricular failure, ventricular hypokinesia, hypotension, convulsion, hepatic failure, hepatic necrosis, cytolytic hepatitis, cholestasis, shock, malignant hyperthermia, conjunctivitis, hyperkalemia, hypokalemia, metabolic acidosis, rhabdomyolysis, coagulopathy.</td>
    </tr>
    <tr>
      <td>diazepam</td>
      <td>Assival</td>
      <td>D</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>diazepam (Assival)-[Amp 10mg/2ml] IM 10mg before surgery. ¶D. *L3. S.E: Drowsiness, ataxia, fatigue, muscle weakness.</td>
    </tr>
    <tr>
      <td>enflurane</td>
      <td>Enflurane, Ethrane</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>enflurane (Enflurane, Ethrane)-[Liq 100%] Inhalation anesthetic. ¶C. S.E: Malignant hyperthermia, hypotension, respiratory depression, arrhythmia, leukocytosis, liver injury, seizures.</td>
    </tr>
    <tr>
      <td>etomidate</td>
      <td>Etomidate-Lipuro</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>etomidate (Etomidate-Lipuro)-[Amp 20mg/10ml] IV induction 0.15-0.3mg/kg. ¶C. S.E: Myoclonus, hypotension, respiratory depression.</td>
    </tr>
    <tr>
      <td>fentanyl</td>
      <td>Fentanyl Janseen, Fentanyl Panpharma, Fenta Injection</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>fentanyl (Fentanyl Janseen, Fentanyl Panpharma, Fenta Injection)-[Amp 0.05mg/ml] IM 0.05-0.1mg as adjunct to regional anesthesia, 30-60min before procedure. Epidural adjunct: 100µg. ¶C. *L2. S.E: Tremor, anxiety, tachycardia, hypertension, hypotension, constipation, application site reactions, blood dyscrasia, lymphadenopathy, hyperglycemia, hypoalbuminemia, peripheral edema, electrolyte disturbances, myoclonus, hallucinations, dyspnea, respiratory distress, respiratory depression.</td>
    </tr>
    <tr>
      <td>halothane</td>
      <td>Halothane</td>
      <td>N</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>halothane (Halothane)-[Liq 100%] Inhalation anesthetic. ¶Not established. Teratogenic in first trimester. *L2. S.E: Hepatic necrosis, cardiac arrest, hypotension, respiratory arrest, cardiac arrhythmias, emesis.</td>
    </tr>
    <tr>
      <td>isoflurane</td>
      <td>Aerrane, Forane, Isoflurane</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>isoflurane (Aerrane, Forane, Isoflurane)-[Liq 100%] Inhalation anesthetic. ¶C. S.E: Malignant hyperthermia, respiratory depression, hypotension, arrhythmias, postoperative hepatic dysfunction, hepatitis, elevated levels of carboxyhemoglobin, hyperkalemia.</td>
    </tr>
    <tr>
      <td>ketamine</td>
      <td>Ketalar</td>
      <td>N</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>ketamine (Ketalar)-[Amp 10, 50mg/ml] (Ketamine Hameln)-[Amp 50mg/ml] Induction IV 1-2mg/kg at a rate of 0.5mg/kg/min or IM 6.5-13mg/kg. ¶Not established. *L3. S.E: Hypertension, hypotension, tachycardia, bradycardia, arrhythmia, respiratory depression, laryngospasm, obstructive airway disorder, nystagmus, diplopia, elevated ICP, tonic clonic movements, hallucinations, delirium, psychotic episodes, cystitis, anaphylactic reaction.</td>
    </tr>
    <tr>
      <td>midazolam</td>
      <td>Midolam</td>
      <td>D</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>midazolam (Midolam)-[Amp 1, 5mg/ml] IV. Induction of Anesthesia: under the age of 55y- 0.3-0.6mg/kg over 20-30min. over the age of 55y- 0.15-0.25mg/kg. Maintenance- up to 25% of the induction dose as necessary. ¶D. *L2. S.E: Respiratory depression, apnea, desaturation in peds, agitation.</td>
    </tr>
    <tr>
      <td>nitrous oxide</td>
      <td>Maxicool</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>nitrous oxide (Maxicool)-[Gas] Surgical sedation and analgesia: Concentrations of 25%- 50% with oxygen. General anesthesia: concentrations of 40%-70% via mask or endotracheal tube. When administered at 70%, reduces the MAC (Minimal alveolar concentration) of other anesthetics by half. Dental: Sedation and analgesia: Concentrations of 25%-50% with oxygen. ¶C. *L3. S.E: Hypotension, sepsis, infections, atelectasis, stridor, hematuria, hyperglycemia.</td>
    </tr>
    <tr>
      <td>propofol</td>
      <td>Propofol Fresenius</td>
      <td>B</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>propofol (Propofol Fresenius)-[Amp 1G/100ml] (Diprofol, Propofol-Lipuro)-[Amp 10, 20mg/ml] IV Induction: 5µg/kg/min. The infusion rate should be increased by increments of 5 to 10µg/kg/min until the desired level of sedation is achieved. Maintenance: 5 to 50µg/kg/min. ¶B. *L2. S.E: Cardiovascular and respiratory depression.</td>
    </tr>
    <tr>
      <td>remifentanil</td>
      <td>Ultiva, Remifentanil Bioavenir, Remifenranil Teva</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>remifentanil (Ultiva, Remifentanil Bioavenir, Remifenranil Teva)-[Amp 1, 2, 5mg] IV adjunct. Not recommended as the sole agent in general anesthesia. Induction: 0.5-1mcg/kg/min, maintenance dose varies according to the second agent used. ¶C. *L3. S.E: Respiratory depression, hypotension, confusion, muscle rigidity.</td>
    </tr>
    <tr>
      <td>scopolamine</td>
      <td>NaN</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>scopolamine (29 ג') (Scopolamine Hydrobromide, Scopoderm TTS)-[Patch 1.5mg] 1patch 5-6h before traveling. ¶C. *L3. S.E: Increased intraoccular pressure, dizziness, impairment of memory or concentration, hallucinations.</td>
    </tr>
    <tr>
      <td>sevoflurane</td>
      <td>Sevorane</td>
      <td>B</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>sevoflurane (Sevorane)-[Liq] Inhalation anesthetic. 0.5-3% with or without the concomitant use of NO. ¶B. *L3. S.E: Cardiovascular and respiratory depression, arrhythmias, malignant hyperthermia, seizures.</td>
    </tr>
    <tr>
      <td>thiopental</td>
      <td>Thiopental</td>
      <td>C</td>
      <td>General Anesthetics / Adjuncts</td>
      <td>ANESTHESIA</td>
      <td>thiopental (Thiopental)-[Pwdr 0.5,1G] IV Induction: 100-150mg over 10-15seconds. ¶C. *L3. S.E: Steven-Johnson syndrome, bone marrow suppression, hepatotoxicity, osteopenia, cardiovascular and respiratory depression, injection-site reaction, laryngeal spasm, hemolytic anemia, radial neuropathy.</td>
    </tr>
    <tr>
      <td>atracurium</td>
      <td>Tracrium</td>
      <td>C</td>
      <td>Neuromuscular Blockers</td>
      <td>ANESTHESIA</td>
      <td>atracurium (Tracrium)-[Amp 10mg/ml] IV 0.4-0.5mg/kg. Duration: 30-45min (25% recovery). ¶C. S.E: Inadequate musculoskeletal block, prolonged block, hypotension, vasodilatation, tachycardia, bradycardia, dyspnea, bronchospasm, laryngospasm.</td>
    </tr>
    <tr>
      <td>pancuronium</td>
      <td>Pavulon</td>
      <td>C</td>
      <td>Neuromuscular Blockers</td>
      <td>ANESTHESIA</td>
      <td>pancuronium (Pavulon)-[Amp 4mg] IV 0.04-0.1mg/kg. Duration: 45min. ¶C. S.E: Hypertension, tachyarrhythmia, apnea, bronchospasm, respiratory failure.</td>
    </tr>
    <tr>
      <td>rocuronium</td>
      <td>Esmeron, Rocuronium Teva</td>
      <td>C</td>
      <td>Neuromuscular Blockers</td>
      <td>ANESTHESIA</td>
      <td>rocuronium (Esmeron, Rocuronium Teva)-[Amp 10mg/ml] IV 0.6mg/kg. Duration 30min. ¶C. S.E: Hypertension, tachyarrhythmia, apnea, bronchospasm, respiratory failure.</td>
    </tr>
    <tr>
      <td>suxamethonium, succinylcholine</td>
      <td>Suxamethonium, Suxametonio</td>
      <td>C</td>
      <td>Neuromuscular Blockers</td>
      <td>ANESTHESIA</td>
      <td>suxamethonium, succinylcholine (Suxamethonium, Suxametonio)-[Amp 100mg/2ml] IV Prolonged muscular relaxation: start 0.3-1.1mg/kg then 0.04-0.07mg/kg at appropriate intervals to maintain the required degree of relaxation. ¶C. S.E: Respiratory depression, arrhythmia, hypertension, malignant hyperthermia, hyperkalemia, myoglobinuria.</td>
    </tr>
    <tr>
      <td>vecuronium</td>
      <td>Norcuron</td>
      <td>C</td>
      <td>Neuromuscular Blockers</td>
      <td>ANESTHESIA</td>
      <td>vecuronium (Norcuron)-[Amp 4, 10mg] IV 0.08-0.1mg/kg. Duration 15-30min. ¶C. S.E: Hypertension, tachyarrhythmia, apnea, bronchospasm, respiratory failure.</td>
    </tr>
    <tr>
      <td>bupivacaine</td>
      <td>Marcaine, Marcaine Spinal, Marcaine Spinal Heavy (+glucose</td>
      <td>C</td>
      <td>Local Anesthetics</td>
      <td>ANESTHESIA</td>
      <td>bupivacaine (Marcaine, Marcaine Spinal, Marcaine Spinal Heavy (+glucose))-[Amp 5mg/ml] (Kamacaine 0.5%)-[Amp 100mg/20ml] Spinal. Inject 0.25-0.5% usually. ¶C. *L2. S.E: Cardiac and respiratory arrest, arrhythmias, decreased myocardial contractility, methemoglobinemia, seizure, cardiotoxicity at higher concentrations.</td>
    </tr>
    <tr>
      <td>lidocaine</td>
      <td>Esracain</td>
      <td>B</td>
      <td>Local Anesthetics</td>
      <td>ANESTHESIA</td>
      <td>lidocaine (Esracain)-[Amp 1, 2%; cream 5%; Gel 2%] (Xylocaine)-[Soln 10mg/0.1ml]. (Stud 100)-[Spray 9.6%] Local injection. Dose varies by procedure. Max 4.5mg/kg or 300mg. ¶B. *L2. S.E: Cardiac and respiratory arrest, arrhythmias, decreased myocardial contractility, methemoglobinemia, seizure, asystole, bradycardia, respiratory depression, anaphylaxis, status asthmaticus.</td>
    </tr>
    <tr>
      <td>lidocaine+epinephrine</td>
      <td>Lidocadren Teva, Lignospan Special, Xylonor</td>
      <td>C</td>
      <td>Local Anesthetics</td>
      <td>ANESTHESIA</td>
      <td>lidocaine+epinephrine (Lidocadren Teva, Lignospan Special, Xylonor)-[Soln 36mg/1.8ml+22.5mcg/1.8ml] (Lidocaine HCl and Epinephrine, Octocaine 100, Cambridge)-[20mg/ml +10mcg/ml]. Dental infiltration. Up to 7mg/kg. ¶C. *L2. S.E: Cardiac and respiratory arrest, arrhythmias, decreased myocardial contractility, methemoglobinemia, seizure, asystole, bradycardia, respiratory depression, anaphylaxis, status asthmaticus.</td>
    </tr>
    <tr>
      <td>ropivacaine</td>
      <td>Naropin</td>
      <td>B</td>
      <td>Local Anesthetics</td>
      <td>ANESTHESIA</td>
      <td>ropivacaine (Naropin)-[Soln 2, 10mg/ml] (Ropivacaine Bioavenir)-[Soln 2, 7.5, 10mg/ml] Epidural/nerve block: 2-10mg/ml, individualized dosing according to procedure. ¶B. *L2. S.E: Hypotension, bradycardia, urinary retention.</td>
    </tr>
    <tr>
      <td>epinephrine</td>
      <td>Epipen, Epipen Junior</td>
      <td>C</td>
      <td>Antidotes</td>
      <td>TOXICOLOGY</td>
      <td>epinephrine (Epipen, Epipen Junior)-[Auto Inject 0.3mg/0.3ml, 0.15mg/0.3ml] (Adrenaline)-[Soln 1mg/ml] IM SC anaphylaxis: autoinject. Peds: Patients greater than or equal to 30kg-0.3mg, Patients 15 to 30kg -0.15mg. ¶C. *L1. S.E: Arrhythmias including ventricular fibrillation, cerebral hemorrhage, severe hypertension, pulmonary edema.</td>
    </tr>
    <tr>
      <td>charcoal</td>
      <td>Charcodote</td>
      <td>A</td>
      <td>Antidotes</td>
      <td>TOXICOLOGY</td>
      <td>charcoal (Charcodote)-[Susp 200mg/ml] PO Single dose: 25-100mg. Multi dose: Initial dose: 50-100mg followed by 25-50mg every 4h. Pediatric: Infants &lt;1 year: 10-25mg. Children 1-12 years: 25-50mg. ¶A. S.E: Severe hypernatremic dehydration, GI obstruction, aspiration, respiratory failure, corneal abrasion.</td>
    </tr>
    <tr>
      <td>deferoxamine</td>
      <td>Desferal</td>
      <td>C</td>
      <td>Antidotes</td>
      <td>TOXICOLOGY</td>
      <td>deferoxamine (Desferal)-[Amp 0.5] IM IV SC Initial dose-500mg followed by 2 dose of 500mg every 4h, subsequent doses may be administered every 4-12h. ¶C. *L3. S.E: Allergic Reactions, Infections with Yersinia and Mucormycosis, tachycardia, hypotension, shock, hepatic dysfunction.</td>
    </tr>
    <tr>
      <td>flumazenil</td>
      <td>Flumazenil Mylan, Fulmasenil Teva</td>
      <td>C</td>
      <td>Antidotes</td>
      <td>TOXICOLOGY</td>
      <td>flumazenil (Flumazenil Mylan, Fulmasenil Teva)-[Soln 0.1mg/ml] IV Reversal of benzodiazepine sedation: 0.2mg over 15sec, then 0.2mg every min as needed up to 1mg total. Acute overdose reversal: 0.2mg over 30sec, then 0.3-0.5mg every 30sec up to 3mg total. ¶C. S.E: Seizures, cardiac arrhythmias.</td>
    </tr>
    <tr>
      <td>fomepizole</td>
      <td>Antizol</td>
      <td>C</td>
      <td>Antidotes</td>
      <td>TOXICOLOGY</td>
      <td>fomepizole (Antizol)-[Amp 1.5ml] Loading dose: of 15mg/kg, followed by doses of 10mg/kg every 12h for 4 doses, then 15mg/kg every 12h thereafter until ethylene glycol or methanol concentrations are undetectable or have been reduced below 20mg/dL. ¶C. S.E: Multiorgan system failure, shock, hypotension, DIC.</td>
    </tr>
    <tr>
      <td>naloxone</td>
      <td>Narcan</td>
      <td>B</td>
      <td>Antidotes</td>
      <td>TOXICOLOGY</td>
      <td>naloxone (Narcan)-[Amp 0.02, 0.4 mg/ml] IV IM SC ET Opioid overdose: 0.4-2mg. Post-op: 0.1-0.2mg. Peds: 5-10µg/kg. Repeat every few min as required. ¶B. *L3. S.E: Tachycardia, hypotension, hypertension, hallucination, anaphylactic shock, pulmonary edema, arrhythmia, convulsions.</td>
    </tr>
    <tr>
      <td>methadone hydrochloride</td>
      <td>Methadone</td>
      <td>C</td>
      <td>Drug Dependence</td>
      <td>TOXICOLOGY</td>
      <td>methadone hydrochloride (Methadone)-[Soln 50mg/ml] PO Opiate withdrawl: start 20-30mg, after 2-4h if withdrawl symptoms reappear, add 5-10mg. Max day 1 dose 40mg. Target range 80-120mg/d. Cessation of therapy: reduce less than 10% every 10-14d. ¶C. *L3. S.E: Sedation, edema, constipation, vertigo, hallucinations, weight gain.</td>
    </tr>
    <tr>
      <td>nicotine gum</td>
      <td>Nicorette, Nicotinell</td>
      <td>C</td>
      <td>Drug Dependence</td>
      <td>TOXICOLOGY</td>
      <td>nicotine gum (Nicorette, Nicotinell)-[Chewing Gum 2, 4mg] Smoking cessation: start 8-12 pieces/d of 2mg, may increase to 4mg for 12wks. Max 25 pieces/d of 2mg or 15 pieces/d of 4mg. Gradually taper. ¶C. *L2. S.E: Allergic reaction, arrhythmia.</td>
    </tr>
    <tr>
      <td>nicotine patch</td>
      <td>Nicotinell TTS</td>
      <td>D</td>
      <td>Drug Dependence</td>
      <td>TOXICOLOGY</td>
      <td>nicotine patch (Nicotinell TTS)-[Patch 17.5, 35, 52.5mg] Smoking cessation: 1 patch/d and taper after 6wks. Heavy smoker: start 21mg/d. Confirm effectiveness. ¶D. *L2. S.E: Allergic reaction, arrhythmia</td>
    </tr>
    <tr>
      <td>nicotine lozenges</td>
      <td>Nicotinel</td>
      <td>C</td>
      <td>Drug Dependence</td>
      <td>TOXICOLOGY</td>
      <td>nicotine lozenges (Nicotinel)-[Loz 1, 2mg]. wk 1-6: 1Tab every 1-2h. wk 7-9: 1Tab every 2-4h. wk 10-12: 1Tab every 4-8h. ¶C. S.E: Allergic reaction, arrhythmia.</td>
    </tr>
  </tbody>
</table>
    </body>
    </html>
    